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Abstract 
 
Bipolar Disorder is primarily treated with medication which can be effective in reducing relapse 
risk, however, treatment is complex and adherence is sub-optimal. People can face significant 
challenges in self-managing the condition. The aim of this thesis was to better understand 
patients’ perspectives of BD and its treatment. Then, to use both this knowledge and self-
regulation and behaviour change theory to develop and test a novel intervention entitled 
Improving information for people with Bipolar Disorder (IBiD). Intervention mapping, a 
stepwise process was followed to develop intervention content, delivery and evaluation. 
A systematic review with meta-analysis (k=18) was conducted and revealed that interventions 
are effective in improving adherence, effects are durable and brief interventions may be more 
effective than longer programmes (Chapter 3). A qualitative study (Chapter 4) (n=12) revealed 
patients insights into the burden of illness, unmet information needs and also how to live well 
with BD. These findings informed the IBiD intervention, which was tested in a feasibility RCT in 
a sample of patients in an acute mental health setting (Chapters 5-7). The intervention can 
feasibly be delivered in this setting and was acceptable to patients. Aspects of the intervention 
and the study itself had self-reported positive outcomes, however a more targeted, longer 
intervention may be required to actually modify specific medication beliefs and adherence. 
In order to explore additional factors raised during these studies a cross-sectional study (n=57) 
into the associations between perceptions, adherence and involvement in treatment decisions 
was conducted. Experiences of involvement and preferences for this were high. Involvement 
was significantly associated with satisfaction with information and illness perceptions. 
Associations between involvement and adherence were inconsistent. 
The results of this research programme have important implications for both mental health 
services and the application of health and illness theory to mental health. 
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Introduction 
Bipolar disorder (BD) is a serious, long-term mood disorder which is characterised by episodes 
of mania, hypomania and depression. It is estimated that around 1.3% of the UK population 
have this condition (Smith et al., 2013). One of the main treatments for by BD is medication 
which aims to reduce relapse risk, however, treatment is complex and is not always effective 
for everyone. However the potential for treatment effectiveness can be helped by ensuring 
appropriate adherence to medication. People with a BD diagnosis can face multiple challenges 
in living with the condition, from accepting and understanding the diagnosis, managing 
treatment and dealing with the stigma of being given a mental health diagnosis. 
Self-regulatory theories of illness focus on the dynamic relationships between external factors 
and personal schemas influencing perceptions of illness and treatment, coping responses and 
subsequent beliefs. Models of health and illness and health behaviour change have been 
widely applied to physical health, but are in their early stages in application to mental health 
conditions. It is hoped that by exploring patients’ perceptions of BD and its treatment in the 
context of these models, it will lead to a greater understanding. By understanding perceptions 
and behaviour in this area, it will in turn inform development of the models. The nature of BD, 
as a potentially life-long, complex and fluctuating condition with treatment reflecting these 
characteristics, provides unique challenges for the application of health psychology models. 
Given the challenges faced by many people with BD and the personal and societal costs 
associated with the condition, effective interventions which can be integrated into clinical care 
are needed. The overarching aim of the research is to utilise current understanding of illness 
perceptions, behaviour change theory and direct consultation with individuals with a BD 
diagnosis to develop an intervention which will help people to manage BD more effectively in a 
way which empowers them. 
 
Thesis aims 
The specific aims of this thesis were to: 
 Understand patients’ perceptions of the challenges in dealing with a diagnosis of BD and 
engaging in self-management. (Chapters 1, 4, 6, 7, 8) 
 Uncover the unmet information and support needs of people with BD. (Chapters 4, 6, 7, 8) 
 Investigate how current understanding of determinants of health behaviour and behaviour 
change theory can be applied to adherence and self-management. (Chapters 2, 5) 
23 
 Determine the effectiveness of existing interventions which exist to address adherence in 
BD. (Chapter 3) 
 Develop a novel intervention to target adherence to medication through proximal 
determinants of perceptions, understanding, satisfaction with information and internalised 
stigma by using the step-wise method of Intervention Mapping (IM) involving behaviour 
change theory and service-user consultation. (Chapter 5) 
 Test the feasibility and acceptability of conducting an RCT of the intervention in an acute 
adult mental health setting. (Chapters 6, 7) 
 Investigate the extent to which patients with BD wish to be involved in treatment decisions, 
the extent to which they are involved, the association of these two factors with their illness 
and treatment perceptions and their adherence to medication. (Chapter 8) 
 
Structure of the thesis 
The opening chapter of this thesis provides the background to the empirical work included in 
the thesis. The nature of BD and its treatment are described as well as the costs and 
consequences which can be associated with the condition and, particularly with non-
adherence to treatment. The challenges with defining and measuring adherence are outlined, 
before a summary of the research evidence on the demographic, clinical, social and perceptual 
factors associated with adherence behaviour in BD. Chapter 1 also describes the difficulties 
many individuals face in living with BD, their understanding the nature of the condition, how to 
manage it, and the stigma associated with a mental health diagnosis. 
In Chapter 2, the theoretical foundation of this programme of research is described, the 
Common Sense Model of self-regulation (CSM) (Leventhal, Nerenz, & Steele, 1984) , leading 
onto the Necessity-Concerns Framework (NCF) (Horne, 2003b) which encapsulates the 
perceptual determinants of adherence and the Perceptions and Practicalities Approach (PAPA) 
(Horne, 2001) which additionally incorporates practical barriers to adherence. Together with 
current evidence on behaviour change theory, in particular the use of Behaviour Change 
Techniques (BCTs), these frameworks provide the theoretical grounding for intervention 
development described in later chapters. Chapter 2 also outlines the approach used to guide 
and structure the research in this thesis, the Medical Research Council (MRC) framework for 
the development of complex interventions in healthcare (Craig et al., 2008) from evidence 
synthesis and modelling to intervention development and testing. 
Chapter 3 comprises a key part of evidence synthesis in a systematic review and meta-analysis 
of 30 years of interventions to improve adherence to medication in BD. The aim was to review 
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randomised-controlled trials of interventions incorporating medication adherence for people 
with a diagnosis of BD. Specifically to: describe the interventions characteristics using 
published guidelines, evaluate the quality of reporting and design, quantitatively synthesise 
evidence for effectiveness of interventions and identify moderating factors associated with 
intervention effectiveness. Twenty-four trials were included in the review, with 18 having 
sufficient data available for meta-analysis. 
Having reviewed evidence on existing interventions, it was vital to generate rich data from 
patients’ perspectives on being diagnosed with, living with, and taking medication for BD. 
Qualitative interviews were conducted with 12 adults with a BD diagnosis who had been 
prescribed medication for BD (Chapter 4). The interviews explored perceptions of BD and its 
treatment as well as providing data on unmet information and support needs and preferences 
for meeting these needs. Primary qualitative research is a key component of both research and 
policy development and is recommended by both the MRC, the NIHR as well as in local NHS 
Research policies (Craig et al., 2008; NIHR n.d.; Sussex Partnership NHS Foundation Trust, 
2012). 
These preceding chapters comprise the groundwork for the development of a novel 
intervention. Chapter 5 describes the development process using an Intervention Mapping 
(IM) approach, which is a stepwise process for systematically developing the content, 
techniques, delivery and evaluation of an intervention (Bartholomew, Parcel, Kok, Gottlieb, & 
Fernandez, 2011; Kok, Schaalma, Ruiter, Van Empelen, & Brug, 2004). This chapter draws 
together the findings from Chapters 1 to 4, and uses this to generate the intervention aims, 
behavioural and cognitive outcomes and the determinants of change to reach these outcomes. 
Appropriate theory-based methods and practical strategies were selected using theory and 
research evidence. The chapter also described the process of service-user and stakeholder 
consultation which was undertaken to ensure that the intervention was appropriate and 
adoptable. This process produced the Improving Information for people with Bipolar Disorder 
(IBiD) intervention (Appendix K). This comprises a written information resource tailored to 
individuals’ perceptions of BD, its treatment and their information needs. The intervention 
aimed to target adherence to medication through proximal determinants of perceptions, 
understanding, satisfaction with information and internalised stigma. 
Chapter 6 describes the ‘Feasibility & Piloting’ stage of the MRC process for the development 
of complex interventions (Craig et al., 2008). In this chapter, a feasibility RCT was designed and 
conducted with 30 individuals in an acute mental health setting which randomised participants 
(1:1) to receive the intervention or care as usual. Baseline and follow-up assessments at 8 
weeks used validated and adapted measures of illness and treatment perceptions, adherence, 
25 
satisfaction, and internalised stigma. The study aimed to explore a number of feasibility 
objectives: the number of eligible patients in the population; recruitment and retention rates; 
acceptability of the RCT protocol, instruments and intervention; and intervention need. In 
addition, changes in the outcome measures were explored in both groups. 
To provide additional insight on study acceptability from participants taking part in the 
feasibility RCT, a qualitative study was conducted with seven participants, from both the 
intervention and control group (Chapter 7). This aimed to explore the experience of 
participants taking part in the IBiD study including: participants’ reflection on their decisions to 
enter the study, views on the questionnaires and practical arrangements, the acceptability and 
their use of the IBiD intervention and more generally their experience of information provision 
and support in mental health services. 
It was clear from the findings of the empirical work and by reviewing current literature on 
adherence and self-management in BD that additional factors may be important to consider in 
both understanding individuals’ perspectives on BD and its treatment and also for intervention 
development. In particular, factors around patient choice, empowerment and involvement in 
making informed decisions around treatment. To this end, a cross-sectional study was 
conducted (Chapter 8). The sample comprised 57 adults with BD who were prescribed 
medication. Validated measures of illness and treatment perceptions, adherence, satisfaction 
and experiences and preferences for shared-decision making (SDM) were completed. The aims 
of this study were to investigate the extent of SDM and preferences for this and the 
relationship between these variables with the hypothesis that greater involvement in 
medication decisions would be associated with more positive perceptions and increased 
adherence. 
Chapter 9 concludes this thesis by summarising the key findings from each piece of research 
and examining these outcomes in the context of published studies. The strengths and 
contribution of these findings are discussed in relation to health psychology theory and mental 
health care. The chapter includes a discussion of the wider issues around mental health which 
were uncovered through the research process, including the application of current health 
psychology models to mental health and in terms of practical aspects, areas of mental health 
care which are currently not meeting the needs of people with a BD diagnosis. Limitations of 
the research in terms of areas of bias and threats to validity are highlighted and finally the 
theoretical implications and future research directions are discussed. 
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Chapter 1 Bipolar Disorder 
 
1.1 Bipolar Disorder 
1.1.1 Diagnosis & Epidemiology 
Bipolar disorder (BD) is an often, long-term mood disorder which usually appears in early 
adulthood and is, for many people, characterised by episodes of mania, hypomania and 
depression. Although the specific nature and experience of the condition for each person 
varies widely. To meet current Diagnostic and Statistical Manual of Mental Disorders, Fourth 
edition (DSM-IV) criteria a person must have experienced an episode of mania during their 
lifetime (American Psychiatric Association, 2000). 
A manic episode can be characterised by persistent elevated mood over a period of more than 
one week and symptoms may include grandiosity, decreased need for sleep, pressure of 
speech, racing thoughts and risk-taking. A depressive episode can be characterised by 
symptoms such as diminished interest or anhedonia, sleep and appetite disturbance, low self-
esteem and suicide ideation. Some people experience ‘mixed episodes’ where aspects of 
mania may be experienced along with symptoms of depression (The British Psychological 
Society, 2010). Multiple recurrence of episodes is common (Pallaskorpi et al., 2015) and for 
most people, the period of time spent in depressive episodes is longer than that in manic 
episodes, with one study indicating that three times more days are spent depressed than in 
manic states (Kupka et al., 2007). Assessments of time spent in euthymic or normal mood 
indicate that this accounts of half of the time (Kupka et al., 2007; Pallaskorpi et al., 2015). 
BD affects approximately one person in every hundred (Fajutrao, Locklear, Priaulx, & Heyes, 
2009). However this may be an underestimation of the true prevalence due to difficulties with 
diagnosis (Fagiolini et al., 2013). There is a wide range in the presentation of BD, the course of 
illness and resulting impairment (Judd et al., 2002). Most people with BD will experience 
recurrent relapses, although some individuals will have few episodes and experience long 
periods in remission. De Dios and colleagues (2012) found that just under a quarter of people 
had at least one recurrence during a 12 month period. However, the remaining 76% remained 
free of recurrence for the 12 month follow-up. 
Misdiagnosis or delay in diagnosis can occur in BD due to unreported or non-recognition of 
manic or hypomanic symptoms. Most often people present with a first episode of depression 
and therefore may receive a diagnosis of unipolar depression or major depressive episode (M. 
Berk et al., 2007; Morselli & Elgie, 2003). Indeed the large-scale, cross-cultural BRIDGE (Bipolar 
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Disorders: Improving Diagnosis, Guidance and Education) study identified that an additional 
31% of patients diagnosed with a major depressive disorder met the criteria for bipolarity 
(Angst et al., 2011). As a result of misdiagnosis, inappropriate treatment decisions and 
prescriptions can be made, with antidepressants potentially leading to worsening of the 
condition. In the BRIDGE study almost a quarter of the sample had experienced episodes of 
elevated or irritable mood triggered by antidepressants (Angst et al., 2011). There may also be 
psychiatric co-morbidity such as substance misuse which can impact on reaching a diagnosis. 
The diagnosis of BD is often an ongoing process with multiple diagnoses and treatments along 
the way. The time taken from onset of illness to reaching a correct diagnosis is approximately 
six years (M. Berk et al., 2007; Drancourt et al., 2013; Morselli & Elgie, 2003). 
 
1.1.2 Costs associated with BD 
BD can result in significant physical, functional and cognitive impairment, having a severe 
impact on individuals’ quality of life and the people around them (Conus, Macneil, & McGorry, 
2013; J. Goldberg, Harrow, & Grossman, 1995). Participants reported the impacts which BD 
had for them in the GAMIAN-Europe/ BEAM survey (Global Alliance of Mental Illness Advocacy 
Networks-Europe/ Bipolar Education Awareness Materials). Over half reported problems with 
relationships within the family (53.9%) and over a quarter reported difficulties in obtaining 
(33.8%) or retaining (34.4%) employment (Morselli & Elgie, 2003). People with BD are also at a 
higher risk of suicide, 10-15% of those admitted to hospital will eventually die by suicide 
(Hawton, Sutton, Haw, Sinclair, & Harriss, 2005). A recent systematic review concluded that 
people with BD are at an elevated risk of mortality in all of the causes studied (Hayes, Miles, 
Walters, King, & Osborn, 2015). BD is also associated with drug and alcohol misuse, with 
approximately half of people with the diagnoses being dependent at some point in their lives 
(Cassidy, Ahearn, & Carroll, 2001). In addition, those with substance use problems do not 
benefit as much from available treatment compared to those without these problems (Salloum 
& Thase, 2000). 
BD is also connected with significant economic costs and loss of productivity. Recent estimates 
of the annual cost of managing BD to the UK healthcare system at £342 million, with 
hospitalisations accounting for 60% of this (A. Young, Rigney, Shaw, Emmas, & Thompson, 
2011). 
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1.1.3 Management 
Recommendations by the National Institute for Clinical Excellence (NICE) for the management 
of BD include both psychological therapies and medication. In 2006, the emphasis was placed 
on medication stating the ‘treatment of bipolar disorder is based primarily on psychotropic 
medication to reduce the severity of symptoms, stabilise mood and prevent relapse’ (2006: pg 
20). The guidelines recommend specific treatment options for mania, hypomania, depressive 
episodes and for long-term maintenance (NICE, 2006). The place of psychological therapy was, 
however, acknowledged as having an important role. With the revision of the guidelines in 
2014, there was a greater emphasis placed on psychological therapy with the recommendation 
that all people should be offered this, both in primary and secondary care as well as for longer-
term management (NICE, 2014). Existing programmes include psychoeducation and Cognitive 
Behavioural Therapy. However, these are not routinely used in practice in the UK (Basco & 
Rush, 2005; Colom & Lam, 2005). 
The importance of collaborative treatment planning and informed decision making is 
emphasised in both guidelines in accordance with recovery-focused care, ‘treatment and care 
should take into account people’s individual needs and preferences. People with bipolar 
disorder should have the opportunity to make informed decisions about their care and 
treatment’ and ‘Written, evidence-based information about the condition and its treatment 
should also be provided. All information should be tailored to the needs of the individual 
patient’ (2006: pg 4) (NICE, 2006). Management, in line with the recovery model, is explicit in 
the 2014 guidelines with the recommendation that ‘care must promote a positive recovery 
message from the point of diagnosis and throughout care’ and building supportive and 
empathic relationships is an essential part of care (2014: pg 14) (NICE, 2014). This reflects a 
movement within mental health policy towards care which focuses on helping patients to 
become empowered and being able to gain control, not solely managing symptoms but 
working together to build resilience and set personal goals (for more details on recovery see 
Section 1.2.6) (Jacob, 2015). 
Psychological therapy can include lifestyle-focussed self-management which refers to activities 
which patients carry out separately from their healthcare professional (HCP) which aim to 
maintain wellness even in chronic conditions (Lorig & Holman, 2003). In BD this includes: 
regular and sufficient sleep, appropriate exercise and nutrition, monitoring mood and activity 
changes and understanding personal behavioural patterns and warning signs, creating and 
using informal or formal plans for dealing with episodes and maintaining social connections 
and seeking professional support (NICE, 2006; Suto, Murray, Hale, Amari, & Michalak, 2010). 
Carers can support people with BD by listening, providing affirmation, empowering people to 
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develop and use coping strategies and supporting them to detect early warning signs 
(Billsborough et al., 2014). 
In the UK, individuals may be managed in primary care through their GP, secondary care 
through their psychiatrist and also through a care-coordinator from Community Mental Health 
Teams (CMHT). At times of crisis, individuals may be admitted to acute inpatient units, have 
their care managed through the Crisis Resolution and Home Treatment teams (CRHT) or by 
Assertive Outreach Teams (AOT) which work with people experiencing frequent relapse or 
social difficulties (NICE, 2006). 
It is clear that maintaining wellness with a diagnosis of BD can be a complex and ongoing 
process. The challenges faced by many people with BD, include adhering to their medication, 
understanding and coming to terms with the diagnosis, accessing and understanding 
appropriate information and support and dealing with societal issues such as the experience of 
stigma. Adherence to medication is one key aspect of staying well. 
 
1.2 Adherence 
1.2.1 Rates and consequences of poor adherence 
Like other long-term conditions, treatment non-adherence in BD is a concern as it affects the 
chances of medication being successful. A recent prospective study found that after 18 
months, one-quarter of patients had discontinued medication and one-third were not using it 
regularly (Arvilommi et al., 2014). Research indicates that lithium is only maintained 
continuously for around 70 days (R. E. Johnson & McFarland, 1996) and Keck and colleagues 
found that after 1 year, half of patients were non-compliant with maintenance treatment 
(Keck, McElroy, Strakowski, Bourne, & West, 1997). Non-adherence is associated with 
substantial costs both financial and human including hospitalisation, suicide and loss of 
productivity (Baldessarini et al., 2006; Hong, Reed, Novick, Haro, & Aguado, 2011; Keck et al., 
1996; Scott & Pope, 2002b). 
 
1.2.2 Defining adherence 
Adherence is defined as the extent to which a person’s behaviour corresponds with agreed 
recommendations from a health care professional (World Health Organisation, 2003). Within a 
recovery model, this should be a care plan as agreed collaboratively between a patient and 
clinician, taking into account the patients preferences and goals (NICE, 2014). In order to 
adhere to a treatment plan, individuals must perceive some need for treatment, be able to 
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access it, understand and follow instructions on how and when to take the medication and 
remember to take it. Non-adherence can occur at any of these steps. Non-adherence can be 
both intentional by deciding not to take medication as prescribed and unintentional, by 
forgetting or not having the resources to take it (Arvilommi et al., 2014; Horne, Weinman, 
Barber, Elliott, & Morgan, 2005). Unintentional non-adherence may be a problem in BD 
particularly when becoming manic and also through confusion with regimen changes 
(Clatworthy, Bowskill, Rank, Parham, & Horne, 2007). 
Different patterns of adherence have been observed, for example partial adherence by 
patients modifying their regimens without advice or irregularity ,for example, taking 
medication holidays or not taking them when using alcohol or drugs (L. Berk et al., 2010). 
Adherence is a dynamic process which can change through the course of illness. There is no 
consensus on what constitutes adequate adherence levels in BD. A level of 80% has been 
recommended (Velligan et al., 2009), but an actual level for positive clinical outcomes has not 
been determined. 
 
1.2.3 Measuring adherence 
The measurement of treatment adherence is complex and precise assessment is a challenge 
given the need to take account of full, partial, irregular and selective adherence. 
Measurements can be broadly classified into: objective, such as pill counts, serum level 
measurement and electronic monitoring or subjective such as self or clinician report (Sajatovic, 
Velligan, Weiden, Valenstein, & Ogedegbe, 2010). 
 
1.2.3.1 Objective adherence measurement 
Pill counts estimate the percentage of medications taken by determining how many pills are 
missing from a container and comparing this with the number which should have been taken 
within a specified time. Random, unscheduled visits serve to increase reliability, however, the 
problem remains that patients may not consume all medications removed from containers and 
the act of monitoring may undermine the therapeutic relationship if conducted by the patients 
clinical care team (Velligan et al., 2008). However, pill counts have been found to be correlated 
with other adherence measures in psychiatric populations (Velligan et al., 2006). 
Measurement of the presence of medications taken in blood serum may be monitored as part 
of routine clinical care, such as in the case of monitoring Lithium levels to ensure correct 
dosing and data may therefore be more easily obtained. However, this does not apply to some 
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newer atypical antipsychotics and it would rely on patients attending for samples to be taken. 
Differences in medication half-life, metabolism and variability both within and between 
individuals’ means that determining levels of medication or when medication was taken is 
difficult. Biological measurements may not fully capture partial adherence behaviour (Sajatovic 
et al., 2010). 
Data from pharmacy records can be used to estimate adherence, for example, Medication 
Possession Ratios (MPR) i.e the number of days of medication supplied against the number of 
days prescribed. However, there are numerous problems with this method, including how to 
take account of clinical advice to change doses (but not with a corresponding prescription 
change) and like other methods, filled prescriptions will not necessarily mean medications are 
actually taken (Sajatovic et al., 2010). 
Electronic monitoring involves the use of devices to record when pill containers are opened, 
this data is used to estimate the timing of medication doses and calculate adherence rates. 
Despite offering benefits such as being able to monitor remotely and monitoring multiple 
medications which patients may be prescribed, this method has a number of drawbacks. The 
method is expensive to purchase and a large amount of data cleaning is necessary prior to 
analysis. Patients may open containers to check how many doses are left or take more than 
one out at a time. Frequently in published reports using electronic monitoring, the detail of the 
data is reduced to percentage of doses taken, therefore the expense of this method may have 
been unnecessary (Sajatovic et al., 2010). In patients with schizophrenia, studies have shown 
that electronic monitoring was correlated with self-report and pill counts (Byerly, Nakonezny, 
& Rush, 2008; Velligan et al., 2006). However, these methods of measurements may over-
estimate actual adherence levels as those taking part in these intensive studies might be more 
likely to be adherent. 
 
1.2.3.2 Subjective adherence measurement 
Self-report measures ask patients to estimate the number of doses taken or number of days 
where medication was taken as prescribed or they are asked to rate or endorse items relating 
to general medication taking behaviour, such as I sometimes forget to take my medication. 
Self-report is a frequently used measure of adherence. However, it may be subject to social 
desirability and recall bias. While reports of non-adherence may be accurate, adherence may 
be overestimated by patients (Sajatovic et al., 2010). However, there is evidence that self-
report and serum levels are well correlated (Jónsdóttir et al., 2010; Lam et al., 2003; Scott & 
Pope, 2002b). Despite their limitations, self-report questionnaires provide more information 
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on how and why a patient is non-adherent, helping to identify types of non-adherence and 
providing information which can be used to try and improve adherence. In addition, people’s 
representation of their own adherence can be a precursor to how they choose to act in the 
future. Asking people about their adherence may result in greater contemplation of the 
behaviour and influence subsequent decisions. This should be acknowledged when considering 
self-report data (McClatchley, Shorter & Chalmers, 2014). 
Self-report measures of adherence used in BD research are described in detail in Chapter 6. 
These include the Medication Adherence Report Scale (MARS) (Horne & Weinman, 2002), the 
Morisky Adherence Scale (Morisky, Green, & Levine, 1986), the Brief Adherence Rating Scale 
(BARS) (Dolder et al., 2004), and the Tablets Routine Questionnaire (TRQ) (Scott & Pope, 
2002b). 
Self-report measures of adherence also use proximal factors such as attitudes to medication, 
barriers and insight into illness. These include the Beliefs about Medicine Questionnaire (BMQ) 
(Horne & Weinman, 1999), Rating of Medication Influences (ROMI) (Weiden et al., 1994), 
Medication Adherence Rating Scale (MARS) (K. Thompson, Kulkarni, & Sergejew, 2000) and the 
Drug Attitude Inventory (DAI) (Awad, 1993; Hogan, Awad, & Eastwood, 1983). They provide 
useful information on factors associated with adherence but a careful distinction is needed as 
attitudes may not translate into behaviour. However, an association has been demonstrated 
between attitudes and both self-report adherence and blood measures in BD and 
schizophrenia (Clatworthy et al., 2009; K. Thompson et al., 2000; Weiden et al., 1994). 
A number of studies have used clinician estimated adherence levels, however these appear to 
be limited as clinicians could not reliably identify non-adherent patients (de las Cuevas, 
Peñate, & Sanz, 2013; Stephenson et al., 2012; Velligan et al., 2007). Velligan and colleagues 
(2007) highlight that this difficulty in clinicians identifying patients medication taking behaviour 
may have important consequences for patient care as there may be incorrect assumptions of 
patient response to prescriptions. 
Informant report where patients caregivers or significant others provide an assessment of 
adherence have also been used. However, patients may not have someone who is able to 
provide this data as they may not have anyone who is involved in their care to that degree 
(Velligan et al., 2006). Also there has been poor compliance with completing these 
assessments in trials (Cochran, 1984). 
 
33 
1.2.3.3 Composite measures 
Researchers have attempted to mitigate the limitations of single methods of adherence 
measures by using a combination of methods which may be examined separately or combined 
into a composite measure (Velligan et al., 2006) and this is recommended as the best way to 
measure adherence (Horne et al., 2005; Sajatovic et al., 2010; Velligan et al., 2009). Despite 
this, there are still challenges with deciding how to combine the measures, ascertaining what 
weight to give to each measure and defining what actually constitutes adequate adherence 
(Sajatovic et al., 2010). 
 
1.2.4 Factors associated with non-adherence/ antecedents of adherence 
Identifying the factors associated with non-adherence can help identify where risk is highest. A 
number of reviews have investigated these factors in BD (L. Berk et al., 2010; Busby & 
Sajatovic, 2010; Colom & Lam, 2005; Crowe, Wilson, & Inder, 2011; Leclerc, Mansur, & 
Brietzke, 2013). Factors can be grouped into demographic and clinical, attitudes, beliefs and 
knowledge and interpersonal (Figure 1.1). 
 
1.2.4.1 Demographic & clinical factors 
With regard to demographic factors, a recent review concluded there is mixed evidence for 
gender differences in adherence (Leclerc et al., 2013). The evidence is generally in favour of 
younger age being a risk factor for non-adherence. Two studies found the OR to be 1.03 for 
younger patients having poor adherence over older patients (Baldessarini, Perry, & Pike, 2008; 
Montes, Maurino, de Dios, & Medina, 2012) and evidence contributing to this comes from 
large, prospective studies so more likely reflects a true association. Other factors not found to 
be consistently linked in BD are relationship status and education (Colom & Lam, 2005). 
One consistently reported clinical risk-factor for non-adherence is the presence of co-morbid 
substance use (Colom et al., 2000; Gonzalez-Pinto et al., 2010; Keck et al., 1997; Montes et al., 
2012; Sajatovic et al., 2007). Where the magnitude of effect was reported, this was OR=1.98 
(Montes et al., 2012) and OR=0.31 (Gonzalez-Pinto et al., 2010). With substance use, patients 
may use these in place of medication and may derive some symptom relief. In addition, it 
could be possible that use of substances may contribute to cognitive difficulties in 
remembering to take medication or having the motivation to do so. The evidence of the link 
between other co-morbidities and adherence is limited, but studies have found lower 
adherence linked with a comorbid diagnosis of obsessive compulsive disorder (OCD), OR=7.24 
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(Baldessarini et al., 2008) and personality disorders (Colom et al., 2000). It should be noted 
that patients with co-morbidities can also successfully manage BD and achieve personal goals 
of recovery. 
Systematic reviews have found that disorder-related factors associated with poorer 
medication adherence specific to BD include elevated mood states (L. Berk et al., 2010; Busby 
& Sajatovic, 2010), mixed episodes or rapid cycling (Leclerc et al., 2013). The experience of 
psychotic symptoms has also been shown to be related to non-adherence, OR=0.91 (Gonzalez-
Pinto et al., 2010), OR=0.523 (Moon et al., 2012) where the was a decreased odds in being 
adherent with the experience of psychotic symptoms. Other factors where there is 
inconclusive evidence are; age of illness onset and cognitive impairments (Jonsdottir et al., 
2012; Leclerc et al., 2013). 
 
1.2.4.2 Treatment-related factors 
With regard to treatment-related factors, some studies find similar rates of non-adherence 
between different medications (Arvilommi et al., 2014; Baldessarini et al., 2008) and evidence 
from a large systematic review demonstrated that the introduction of new types does not 
appear to have affected adherence rates (Lingam & Scott, 2002). Keck and colleagues (1997) 
found that adherence to a combination of medications (a mood stabiliser, anti-convulsant and 
an antipsychotic) was higher over one year than to any of the monotherapies. The reasons are 
unclear but could be related to higher effectiveness of these combination therapies. However, 
other studies have not demonstrated a significant effect of the number of medications taken 
on adherence (de las Cuevas et al., 2013), and there is also inconsistent evidence on the effect 
of how long individuals had been taking mood stabilisers (Moon et al., 2012; Scott & Pope, 
2002a). 
Actual experience of side-effects has not been consistently related to non-adherence 
(Baldessarini et al., 2008; Sajatovic, Bauer, Kilbourne, Vertrees, & Williford, 2006). Fear of side-
effects or subjective experience appears to be more important (Scott & Pope, 2002a). Despite 
this, in a large European survey, almost one-fifth of respondents said that side-effects were the 
main reason for discontinuation (Morselli, Elgie, & Cesana, 2004). However, participants may 
be adherent despite experiencing side-effects (Rosa et al., 2007) and those reporting side-
effects as a reason for non-adherence also frequently report other reasons contributing to it 
(Arvilommi et al., 2014). It is clear that the relationship between fears and experience of side-
effects is a complex one and warrants further exploration. Qualitative research is needed to 
35 
understand people’s motivations and decision making around medication, weighing up costs 
and benefits. 
 
1.2.4.3 Interpersonal & cognitive factors 
The factors related to non-adherence described above relate to the condition and treatment 
itself. Individual psychological or interpersonal factors are also related to adherence and can 
be selected for interventions to target non-adherence. 
 
1.2.4.3.1  Knowledge of illness and treatment 
Knowledge about bipolar and treatment has been associated with adherence in a large review 
of the evidence (L. Berk et al., 2010). Although knowledge in itself is not necessarily the 
primary determinant of adherence (Horne et al., 2005), the importance of patients being 
informed about illness and treatment provides strong support for the recovery-model of 
mental illness which emphasises the importance of providing information (NICE, 2014). 
Knowledge has been identified as a tool for empowerment for mental health service-users by 
enabling them to act autonomously (Jacobson & Greenley, 2001). 
 
1.2.4.3.2 Interpersonal factors 
Relationships and interactions with family have been shown to have an association with 
adherence, for example caregiver's emotional over-involvement was associated with non-
adherence (OR=0.24) (Perlick et al., 2004). Positive therapeutic alliance (a collaborative 
partnership between professional and patient) has been shown to be associated with 
adherence in a systematic review (L. Thompson & McCabe, 2012). This provides support for 
recovery-oriented care where patients are experts in the experience of their condition and 
relationships involve shared expertise (Davidson, 2005). However, it is important to recognise 
that, as much of the evidence comes from cross-sectional research, the direction of association 
is unknown. It may be that positive relationships result in good adherence or that by adhering 
to medication, and therefore remaining stable this may result in better relationships with 
caregivers and clinicians. This goes for much of the evidence around factors associated with 
adherence. 
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1.2.4.3.3 Beliefs about treatment 
Non-adherence has been shown to be associated with people’s beliefs about their illness and 
treatment. Doubts about the personal necessity of medication have been shown to be 
associated with poorer adherence (OR=0.5) (Clatworthy et al., 2009) (Devulapalli et al., 2010). 
These doubts may also relate to perceptions of the disorder, for example, that it is not 
controllable or is not a chronic condition (Clatworthy et al., 2007). Due to the fluctuating 
nature of the condition, it is clear as to why at times people may choose to stop their 
medication. Low perceived need has been shown to be a key barrier for seeking mental health 
treatment and reasons for dropping-out of treatment include patients wanting to handle 
problems themselves and perceived or actual treatment ineffectiveness (Andrade et al., 2014). 
Another study found that the main reasons for dropping-out of maintenance treatment were 
denial of therapeutic need during stable mood and perceptions of a lack of treatment efficacy 
during illness (Moon et al., 2012). This study did not take account of the different types of 
treatments participants were prescribed however, a strength of this study was that it included 
people no longer engaged with treatment therefore providing insights from a population who 
are often not assessed due to the fact that they have dropped out of treatment. 
Patients with BD have reported concerns about dependency on medication and long-term 
side-effects (Morselli & Elgie, 2003). A qualitative investigation of treatment perceptions in 
individuals with BD revealed many perceived medication as providing mood-stabilising 
benefits, however, there were concerns about long-term adverse effects (Sajatovic, Ignacio, et 
al., 2009). Concerns about adverse effects have been associated with non-adherence in 
qualitative (Clatworthy et al., 2007) and quantitative research (OR=2.0, with stronger concerns 
being associated with poorer adherence) (Clatworthy et al., 2009). Linked with this, concerns 
about harm of medicine as opposed to worry about too many medicines impacts negatively on 
adherence (de las Cuevas et al., 2013). These concerns can be understood as they may reflect 
quite reasonable fears. The long-term effects of many medications have not been established 
and the documented side-effects in patient medication information could lead to people being 
very concerned about taking these treatments. 
 
1.2.4.3.4 Beliefs about illness 
Poor insight has been linked to poor adherence in a large prospective study, with good insight 
at the start of maintenance treatment being a protective factor (OR=1.98) (Gonzalez-Pinto et 
al., 2010). This was also found in an earlier review in BD (Látalová, 2011). Adams and Scott 
(2000) found that in patients with severe mental illness (schizophrenia and affective disorders) 
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there was a significant difference between high adherers and partial adherers in their 
perception of illness severity and their control over the disorder (high adherence being 
associated with a belief in external control of health), and concerns about further 
hospitalization. Partially adherent patients (as identified through a structured clinical 
interview) have been shown to have greater denial of severity of illness (Scott & Pope, 2002a). 
Stronger beliefs that their own behaviour controlled their health status were associated with 
adherence in BD in an interview-survey study with 100 patients (Darling, Olmstead, Lund, & 
Fairclough, 2008). Adherent participants in the same study also had more resources for coping 
with stress (Darling et al., 2008). 
 
 
Figure 1.1: A summary of the factors associated with adherence in BD 
 
1.2.5 Challenges associated with being diagnosed with and living with BD 
It is clear that adherence is a major challenge in effective self-management, which is 
associated with a number of modifiable and non-modifiable factors. However, managing 
bipolar involves much more than adhering to medication, there are additional factors which 
affect individuals’ ability to live well. These include the impact of receiving the diagnosis and 
associated stigma, accessing and understanding information about the condition and 
treatment and being actively involved in their own care. 
 
Factors associated with adherence in BD 
Demographic & clinical 
Gender (mixed) 
Age (younger) 
Comorbid substance use 
Obsessive compulsive 
disorder 
Personality disorders 
Mood states (mania, mixed 
episodes, rapid cycling, 
psychotic symptoms) 
Duration of mood stabiliser 
treatment (mixed) 
Attitudes, beliefs & 
Knowledge 
Knowledge about bipolar and 
treatment 
Medication necessity beliefs 
Concerns about medication 
Fear of side effects 
Beliefs about illness 
Insight into illness 
Perception of illness severity, 
Personal control beliefs 
Interpersonal 
Significant others 
influence/ 
relationships with 
caregivers 
Patient-professional 
therapeutic alliance 
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1.2.5.1 Impact of receiving a BD diagnosis 
Receiving a diagnosis for a mental health condition can have profound effects on an individual. 
Diagnosis, is for some, associated with reactions of shock and distress (Bilderbeck, Saunders, 
Price, & Goodwin, 2014; S. G. Goldberg, 2012) and a challenge to a person’s identity or sense 
of self (Inder et al., 2008; Mansell, Powell, Pedley, Thomas, & Jones, 2010; Michalak et al., 
2011; Proudfoot et al., 2009). Patients report feelings of internalised stigma from actual and 
perceived discrimination (Michalak et al., 2011). However, the diagnosis has also been 
reported as a useful way of explaining experiences and allowing individuals to separate their 
sense of self from the illness (Michalak, Yatham, Kolesar, & Lam, 2006; Proudfoot et al., 2009). 
The impact of bipolar itself may include the feeling of not being in control of moods or actions 
and this affects how people feel about the future (Crowe, Inder, et al., 2012; Lim, Nathan, 
O'Brien-Malone, & Williams, 2004). The studies about the impact of BD are often from small, 
qualitative studies, however the rich descriptions provided and the consensus across different 
pieces of research demonstrate how it actually is for people living with a BD diagnosis. 
 
1.2.5.2 Understanding BD – Illness perceptions 
In addition to their association with medication adherence, the relationship between both 
illness perceptions and treatment-seeking behaviour and subsequent outcomes has been 
investigated (Petrie, Broadbent, & Kydd, 2008). Illness beliefs have been demonstrated to have 
moderate to substantial stability over 12 months (Lobban, Solis-Trapala, et al., 2012). Using an 
illness cognitions measure (incorporating sick role, illness acceptance, dissatisfaction with 
treatment and support), Berk and colleagues (2013) investigated associations with outcomes 
(e.g. illness outcomes, functioning and self-esteem). More negative cognitions were associated 
with poorer outcomes. Lobban and colleagues (2012) investigated the impact of illness beliefs 
in BD, using a self-regulation model (described in Chapter 2) (Leventhal et al., 1984), on 
outcomes (mood and length of time before illness relapse). Stronger beliefs about the severity 
of the consequences of bipolar were associated with higher relapse risk and likelihood of 
becoming depressed. Stronger identity scores (more symptoms experienced) were associated 
with lower risk of relapse. Stronger beliefs in personal control were associated with lower risk 
of becoming depressed. This study followed up patients for 24 months, but did not investigate 
how beliefs may have changed over the course of illness. In addition to understanding how 
beliefs might change, a greater understanding of how beliefs originate and how they can be 
affected by care providers’ views and what information they give to people with a BD 
diagnosis. A clinician using a disease-based model of mental health may not promote beliefs 
and feelings of personal control and help people towards a view of personal recovery and 
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living a fulfilled life despite the diagnosis. In patients with psychosis, illness perceptions 
(cognitive and emotional) have been found to mediate the relationship between illness course 
and quality of life (Gómez-de-Regil, Kwapil, & Barrantes-Vidal, 2014). In a South African 
sample, spiritual attribution of cause was associated with longer duration of untreated 
psychosis (Burns, Jhazbhay, & Emsley, 2011). Illness perceptions have also been shown to be 
related to negative expectations about returning to work in a population of mental health 
service users, specifically, more severe illness consequences, lower personal control over 
illness, greater illness identity and concern about their illness. (Løvvik, Øverland, Hysing, 
Broadbent, & Reme, 2014). Given the body of evidence, illness perceptions have been 
identified as an important area in developing interventions in mental health (Petrie et al., 
2008). 
 
1.2.5.3 Satisfaction with information & involvement in care 
Dissatisfaction with information about medicines is commonplace and has been associated 
with poorer adherence (Bowskill, Clatworthy, Parham, Rank, & Horne, 2007). A number of 
studies have identified specific areas of dissatisfaction. Bowskill and colleagues (2007) found 
that the areas of information which participants with BD in a community sample were most 
dissatisfied with were ‘the risks of getting side effects’ and whether the medication would 
affect their sex lives. A large scale European survey of individuals with mood disorders 
identified the information which respondents would find helpful in dealing with BD were: 
managing the condition both day to day and in the long term, the range of treatments 
available and their efficacy and safety, the nature of the condition and where to obtain help 
(Morselli & Elgie, 2003). In a study by Perreault and colleagues (2006) the most endorsed items 
in terms of importance of information were confidentiality and access to medical information, 
followed by the type and side-effects of medication. However this was a small study (n=86) 
and did not include participants over 65 years of age. An online survey in Germany revealed 
that respondents searched for information about BD, in particular treatment options, because 
the information they received from their clinicians was insufficient (Liebherz, Tlach, Harter, & 
Dirmaier, 2015). 
In the 2011 Care Quality Commission (CQC) survey of users of community mental health 
services in England over one-quarter of patients reported that they were not given information 
about possible side-effects of new medication and 15% were not provided with information in 
a way that they could understand (2011a). Findings for the inpatient setting have also 
indicated dissatisfaction in receiving explanations about medication (Care Quality Commission, 
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2009b). Almost half of patients reported that they were not provided with information on side-
effects of medication in a way that they could understand (Care Quality Commission, 2009b).  
As well as specific information needs, more general unanswered questions exist after patients 
receive a diagnosis of BD. Patients have reported uncertainty about what the diagnosis means 
for their future in terms of employment, relationships and family due to the chronic nature of 
the condition (Proudfoot et al., 2009). Participants have reported wanting practical help in 
managing their condition, not just explanations of it (Bilderbeck et al., 2014). 
There is an increasing emphasis on involving patients in their own care in mental health and it 
has been recommended that information given in psychiatric care should enhance choice and 
reflect patients’ values, this will promote informed decisions (Deegan & Drake, 2006; Hope, 
2002). Shared decision making (SDM) involves patients actively in planning treatment and 
setting goals. It is important for both ethical reasons and for patient outcomes and has been 
addressed as part of the Toronto consensus statement for healthcare since 1991 (Simpson et 
al., 1991). A recent review found that having involvement in decisions, or receiving preferred 
treatment was associated with higher satisfaction with treatment, adherence and better 
clinical outcomes than where patient involvement or preference was not taken into account 
(Lindhiem, Bennett, Trentacosta, & McLear, 2014). The benefits of patient participation in 
medication choice are highlighted by Wilder and colleagues (2010) who found that patients 
were more likely to adhere to medications which they had requested in advance directives. 
Patients wish to be informed about their diagnosis and involved in decisions about their 
treatment (Bilderbeck et al., 2014; de las Cuevas, Rivero-Santana, Perestelo-Perez, Perez-
Ramos, & Serrano-Aguilar, 2012). However, in practice, national surveys conducted by the CQC 
have identified that there are a substantial proportion of patients who do not feel involved in 
decisions about their care and treatment. In the inpatient setting more than one-quarter (27%) 
of patient were not involved as much as they wanted to be (Care Quality Commission, 2009a). 
In terms of medication decisions in a community sample, only 13% did not feel their views 
were taken into account (Care Quality Commission, 2011a). However, in the local NHS trust in 
this programme of research, there was poor performance compared to national figures in 
patients’ opinions of having their views taken into account during decisions and patients did 
not feel they had enough time to discuss their condition and treatment (Care Quality 
Commission, 2011b). The local figures for the inpatient setting show poor levels of satisfaction 
for being involved in care and treatment compared to those nationally (Care Quality 
Commission, 2009a). In the CQC Annual report of the provision of care for patients detained 
under the Mental Health Act, more than half of patients were not given a copy of their care 
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plan and one-third did not have their own views recorded on this (Care Quality Commission, 
2013). 
 
1.2.5.4 Stigma associated with mental illness 
National surveys indicate movement towards increased understanding and tolerance of 
mental illness. However, in 2010, 87% of the public agreed that people with mental illness 
experience stigma and discrimination (TNS UK for the National Mental Health Development 
Unit, 2010). A large Europe-wide survey of people with BD and depression revealed 22% 
reported moderate or high levels of self-stigma (Brohan, Gauci, Sartorius, & Thornicroft, 2011). 
Many people with BD describe negative opinions and reactions from the public as well as 
people they are close to (Michalak et al., 2011; Michalak et al., 2006; Proudfoot et al., 2009; 
Todd, Jones, & Lobban, 2012). Stigma can serve as a barrier to accepting a mental illness 
diagnosis (Mizock, Russinova, & Millner, 2014). 
A review of the factors associated with stigma in mental illness identified a number of 
psychosocial variables being negatively associated with internalised stigma, in particular, low 
levels of hope and empowerment, self-esteem, self-efficacy, quality of life, and social support. 
In terms of outcomes (from longitudinal studies) high levels of stigma were associated with a 
negative impact on self-esteem, coercion and experiencing symptoms of psychosis (Livingston 
& Boyd, 2010). A strong therapeutic alliance with HCPs had been shown to be associated with 
less negative feelings of stigma about BD (Strauss & Johnson, 2006). 
 
1.2.6 Recovery, self-management and living well with BD 
There are many definitions of recovery in mental health including syndrome recovery, i.e. no 
longer meeting the criteria for BD, symptomatic recovery i.e. the absence of symptoms and 
functional recovery in social, educational, occupational areas (P. Harvey, 2005). The absence of 
symptoms perspective represents a more traditional medical model of mental health, where 
recovery is externally defined according to criteria imposed by care providers/ organisations 
(Jacob, 2015). Recovery in mental health in the UK is moving towards a conceptualisation of 
living well with a chronic condition and staying in control of their life, as opposed to the 
complete absence of symptoms (Jacob, 2015). There has been policy shift towards making 
services more ‘recovery-orientated’ and encouraging personalisation of care and self-directed 
support (Perkins & Slade, 2012). Personal goals of recovery and staying well reported by 
participants included acknowledging the condition, having a good quality of life, being free 
from symptoms and being in control of their own lives (Michalak et al., 2006; S. Russell & 
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Browne, 2005; Todd et al., 2012). The most important consideration is that recovery must 
represent what is important to each individual (Davidson, 2005). 
Reports from patients on what may have been helpful in reaching acceptance of the condition 
sooner included increased awareness in society, less stigmatisation, greater support from 
family and friends, more information and education immediately following the diagnosis and 
earlier access to treatment (Delmas, Proudfoot, Parker, & Manicavasagar, 2011). 
In terms of what helps people move towards recovery or living well with BD, strategies for 
staying well identified by patients include being proactive and finding out information, 
maintaining and strengthening their support network, monitoring mood and behaviour and 
implementing strategies to counteract these, managing sleep and daily routines, engaging with 
treatment and creating and implementing wellness plans (Mansell et al., 2010; Michalak et al., 
2006; Mizock et al., 2014; S. Russell & Browne, 2005; Todd et al., 2012; Van den Heuvel, 
Goossens, Terlouw, Van Achterberg, & Schoonhoven, 2015). 
The process of monitoring personal warning signs, or prodromes, has been identified as a key 
aspect of self-management to reduce relapse risk and stay well (S. Russell & Browne, 2005). It 
had been demonstrated that patients are able to report prodromes reliably in a prospective 
study assessing relapse. Common prodromes for mania include reduced need for sleep and 
more goal directed behaviour and for depression, loss of interest in activity or people, worries 
and anxieties and interrupted sleep. The use of behavioural coping strategies for mania and 
depression prodromes reduced risk of relapse (Lam, Wong, & Sham, 2001). 
In addition to the increasing literature on living well with BD, there has been a recent growing 
interest in looking at the positives the diagnosis can be associated with for people. A review 
identified that the diagnosis was associated with positive factors including spirituality, 
empathy, creativity, realism and resilience (Galvez, Thommi, & Ghaemi, 2011). Qualitative 
research identified positives associated with BD, including amplifying experiences like focus 
and creativity (not only associated with mania or hypomania by patients). Participants 
reported that BD gave them an increased range of feelings and experiences and the ability to 
learn from these (but with acknowledgement that with these positives come challenges and 
difficulties) (Lobban, Taylor, Murray, & Jones, 2012). Some patients have also reported that the 
diagnosis opened doors and allowed them to explore new opportunities such as different 
career paths and new social networks (Michalak et al., 2006). 
Qualitative research by Russell and colleagues (2013) focussed on the differences between 
happiness and the highs of mania. Patients identified that happiness was more associated with 
acceptance and peace and mania was more chaotic and disruptive. Happiness was associated 
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with a sense of community and connecting with others whereas highs were associated with 
the disruption of social relationships. The authors conclude it is important a discussion is 
opened up where clinicians and patients are able to see that positive states aren’t always a 
sign of ‘illness’ (L. Russell & Moss, 2013). 
 
1.3 Conclusions 
BD can be a chronic condition which is often associated with negative consequences for both 
the individual, their significant others and more widely in terms of economic and social costs. 
Medication can be effective in reducing the risk of relapse and potentially destructive 
consequences associated with this. However, medication is often not taken as prescribed or 
discontinued prematurely. Factors associated with non-adherence to prescribed treatment 
have been identified and include demographic and clinical characteristics as well as factors 
related to treatment. Psycho-social factors have also been identified including perceptions of 
both illness and treatment, satisfaction with information and interpersonal relationships with 
healthcare providers. 
To manage BD, it is important for many to adjust to the diagnosis, be able to access 
information about their condition and treatment, feel involved in their care and work 
collaboratively with their HCPs, who in turn should acknowledge the patient’s own unique, 
experiences. However, a number of issues exist which mean that staying well can be a 
challenge including unhelpful perceptions of treatment, practical barriers to taking medication, 
lack of support and understanding from healthcare providers, lack of access to information and 
public perceptions of mental illness. 
Effective interventions are needed to address these issues in order to help people live well 
with BD. Chapter 2 first outlines the recommended process for development of interventions 
in health which is appropriate to use in developing an intervention to address outcomes for 
people with BD (Craig et al., 2008). A key first stage in this development process is to identify 
evidence to inform intervention development. This includes the evidence presented in this 
chapter concerning the identified areas of need for people with BD, the factors associated with 
adherence to treatment and the challenges for many people living with the diagnosis. Chapter 
2 goes on to describe how current theories of behaviour and behaviour change relate to this 
area and can be used to inform an evidence-based intervention.   
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Chapter 2 Theoretical context 
 
The evidence presented in Chapter 1 demonstrates that in bipolar disorder (BD) there are 
perceptual factors, such as beliefs about treatment, as well as practical factors, such as 
memory or physically being able to access treatment which are associated with adherence to 
medication and other self-management behaviours. In order to both understand and develop 
strategies to attempt to modify perceptions and behaviours, it is imperative to utilise an 
evidence-based theoretical framework. 
In order to understand and modify behaviour, it is necessary to consider models and theories 
which attempt to describe relationships between, for example, cognitions and behaviours. 
These provide explanations as to why behaviours are enacted or not. It is also vital in 
developing strategies to modify these cognitions and behaviours to draw on the increasing 
evidence on theory-based behaviour change techniques. These are considered in this chapter 
in a context of how they can be applied to adherence and self-management in BD. The models 
are selected for their appropriateness to this programme of research. Specifically these are 
models which describe illness and treatment perceptions and the influence of these 
perceptions on health behaviours and outcomes. These are presented first to provide the 
context of the current theoretical framework, before leading into a discussion of how current 
models and research in health psychology and behavioural science uses the knowledge of 
determinants of behaviour and uses this to attempt to modify it. 
Prior to describing these models and how they apply to the area of BD, the recommended 
process of developing complex interventions in this area is described (Craig et al., 2008). A first 
key stage of this process is to identify the theoretical basis on which to base the intervention 
development. Theories of behaviour and behaviour change are essential in designing and 
delivering an intervention to improve outcomes for people with BD. This chapter describes 
these processes as applied generally to health behaviour and healthcare interventions 
generally, Chapter 5 describes the detailed process of applying this framework and identifying 
the evidence-base for improving adherence and outcomes in BD. 
 
2.1 Using the MRC Framework for the development of complex interventions 
This programme of research applies the approach recommended by the MRC framework for 
the development of complex interventions in healthcare (Craig et al., 2008) (Figure 2.1). The 
aim of this guidance is to provide researchers with a systematic process for designing, testing, 
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evaluating and implementing interventions which are based on the best available evidence and 
tested using rigorous methods. 
The process comprises four stages (which may or may not follow in a linear or cyclical 
sequence): development, feasibility/ piloting, evaluation, and dissemination. Firstly it outlines 
best practice in using evidence and theory for intervention development. Secondly it explains 
the process of establishing feasibility and undertakes piloting. Thirdly the effectiveness of the 
intervention is evaluated and finally, the intervention is implemented into practice. Despite 
being prescriptive, the authors acknowledge that intervention development must also be 
pragmatic. In practice, development is likely to take place under constraints, conditions or pre-
existing service delivery, for example, the setting in which the intervention can practically take 
place is already specified and there may be  time restrictions on delivery of an intervention. 
Each of these stages is described below in more detail. 
Development phase: This comprises identifying the evidence base and involves systematic 
reviews and identifying or developing theory and potential mechanisms of behaviour change. 
This process should use published research as well as conducting new primary research. It aims 
to develop an intervention to the point where it could be expected, given the evidence 
available, that it would have the potential to have an effect. An intervention can then be 
developed and ‘modelled’ (more detail on how this process is conducted as applied to the BD 
intervention in this thesis is described in Chapter 5). This phase should also incorporate the 
selection and/ or development of outcome measures for the intervention evaluation. The 
development phase should also incorporate practical aspects such as considering how it might 
be possible to implement any future intervention, where, how and by whom this would be 
delivered. A recently developed checklist provides a framework on which to ensure that 
interventions are comprehensively described and replicable. The Template for Intervention 
Description and Replication (TIDieR) checklist comprises 12 items to fully describe the 
intervention; Brief name; Why (rationale, theory or goal); What (materials used); What 
(procedures used); Who provided; How (mode of delivery); Where (location); When and how 
much; Tailoring; Modifications; How well (planned); and How well (actual) (Hoffmann et al., 
2014). 
Feasibility/ piloting: This phase involves establishing the acceptability of the intervention and 
designing the processes to evaluate it. This may involve a number of stages, often involving 
both qualitative and quantitative methods and allows estimation of recruitment, retention, 
provides data on the fidelity of intervention delivery and methods to assess this. It also 
provides the opportunity to identify any other problems in order to anticipate and mitigate 
these prior to a full-scale trial. This is a crucial step to ensure that resources are not wasted in 
46 
the long-term (the distinction between pilot and feasibility studies are outlined in Chapter 6, 
Section 6.3). From feasibility and piloting studies, information can be gained to inform a 
sample size calculation and cautious estimation of the potential intervention effects. 
Evaluation: After establishing that an intervention is feasible, it is then subject to a formal 
evaluation (and cost evaluation where possible) where an appropriate study design is chosen. 
This could be the individually randomised controlled trial, as the most robust option as it 
reduces elements of bias. However, there may be factors which mean that this is not 
appropriate or feasible to randomise. Other methods such as cluster trials, stepped-wedge, n 
of 1 design, quasi-experimental or non-experimental methods can be used. Important aspects 
of evaluation, as well as assessing outcomes, are in looking at process variables, or why 
interventions work, and what aspects might be most important or what factors the result is 
dependent upon or influenced by. 
Dissemination: Once an intervention has been evaluated it is crucial to ensure that this 
learning is disseminated, used to inform further research or translated into clinical practice or 
policy. This could be using peer-reviewed journals, but importantly to disseminate to planners, 
policy makers and clinical teams to ensure translation into practice. The intervention 
evaluation may be short-term, however, it is important to follow-up outcomes of interventions 
in the longer-term and conduct surveillance to assess effects not covered in the evaluation. 
 
 
 
Feasibility and piloting 
Testing procedures 
Estimating recruitment and retention 
Determining sample size 
Development 
Identifying the evidence base 
Identifying or developing theory 
Modelling process and outcomes 
Evaluation 
Assessing effectiveness 
Understanding change process 
Assessing cost effectiveness 
Implementation 
Dissemination 
Surveillance and monitoring 
Long term follow-up 
Figure 2.1: Medical Research Council framework for the development of complex interventions 
(Adapted from (Craig et al., 2008)) 
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2.2 Understanding illness behaviour 
Models, theories and frameworks of illness behaviour incorporate multiple and complex 
factors. These include individual factors as well as society and environmental influences. It is 
important to make the distinction between models and frameworks and theories. Frameworks 
serve to represent the structure of and potential relationships between relevant factors and 
behaviours. However, a theory takes this further by comprising empirically validated 
relationships between concepts and allowing testable hypotheses (Michie, West, & Spring, 
2013). A good theory has been defined, in addition to these characteristics, as using clearly 
defined concepts that are parsimonious and coherent (Michie, West, et al., 2013). 
Although some of the variance of illness behaviours such as adherence can be explained 
through disease characteristics, demographics and individual differences, these factors do not 
consistently account for behaviour. In addition, these factors are difficult to modify, thus their 
utility in attempting to change behaviour is severely limited. Individual, modifiable factors such 
as a person’s beliefs about illness are an important factor in explaining health behaviour, 
including adherence, in both physical illness and in mental ill-health (Petrie et al., 2008). 
Research into physical illness has demonstrated the association between beliefs or 
perceptions, motivation and behaviour leading to the development of a number of theories, 
models and frameworks. One such model is the Common Sense Model of self-regulation of 
illness behaviour (CSM), described below (Leventhal et al., 1984). 
 
2.2.1 Leventhal’s Common Sense Model (CSM) of self-regulation of illness behaviour 
The CSM provides a framework for understanding people’s perceptions and responses to 
health threats and the cognitive proceses underlying them (Leventhal et al., 1984). The model 
is dynamic in that people’s representations of threats are updated by actions and behaviours 
(Leventhal, Leventhal, & Breland, 2011). Central to the model are illness representations, 
which are beliefs or expectations about an illness or symptom. In the original CSM, illness 
represenations are comprised of five key components: 1. identity, beliefs associated with the 
label or name of the illness, diagnosis or symptoms, 2. timeline, beliefs concerning acute, cyclic 
or chronic, 3. cause, beliefs concerning the factors causing the illness, 4. consequences, beliefs 
concerning the expected effects of the illness, and 5. control/cure, beliefs associated with the 
extent to which treatment or behaviour can control or cure the illness. 
The model describes the dynamic self-regulatory processing which takes place when 
symptoms are perceived or other stimuli are experienced, such as being informed of a 
diagnosis (particularly in asymptomatic conditions). Illness representations are activated 
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through symptoms perception by the individual themselves and also messages from society 
(including family and media, for example recommendation to seek help for a cough). The 
illness representations activated then motivate the individual to generate, select and utilise 
coping strategies, these can be behavioural and cognitive. Taking medication and engaging in 
other self-management strategies are examples of coping methods. The outcomes of coping 
strategies are appraised as either effective or ineffective. Outcome appraisals in turn lead to 
refinements of illness representation and subsequent selection of coping strategies. In 
conjunction with this cognitive processing, stimuli trigger emotional responses which result in 
the generation of emotion coping strategies which are appraised and processed (Leventhal, 
Diefenbach, & Leventhal, 1992). 
The importance of illness representations on peoples’ illness behaviour has been 
demonstrated in a number of studies over the previous 30 years (e.g. (Lobban, Solis-Trapala, et 
al., 2012; Løvvik et al., 2014; Petrie, Weinman, Sharpe, & Buckley, 1996)). For example, 
stronger beliefs that an illness could be controlled as associated with increased likelihood to 
attend a cardiac rehabilitation course (Petrie et al., 1996). A strength of this study was that 
patients were followed up over the course of six months so it is more likely that the direction 
of causality of cognitions and behaviour can be inferred. In mental health, even after adjusting 
for clinical and demographic differences, participants beliefs that their mental health problems 
had severe consequences was related to uncertain or negative return to work expectations. 
However there were limitations in measuring return to work expectations with a single item 
and this study was cross-sectional (Løvvik et al., 2014). In a prospective study in BD, illness 
beliefs (greater consequences, more symptoms, emotional concern) predicted illness relapse 
and symptom experience over 24 weeks. On the positive side, perceptions of personal effort to 
get well was associated with less symptom experience (Lobban, Solis-Trapala, et al., 2012). 
Overall a systematic review of the CSM as applied to mental illness concluded that illness 
perceptions are associated with a number of behavioural measures such as coping, help-
seeking and treatment adherence. These in turn will be related to clinical outcomes (Baines & 
Wittkowski, 2013). However the review authors acknowledge that much of the research is 
cross-sectional. 
The practical utility of the model is demonstrated by studies showing that changes to illness 
perceptions can improve disease outcomes, for example in increasing perceptions of the 
chronic nature of myocardial infarction, the severity of consequences as well as that the illness 
was controllable, was associated with return to work and symptom experience (Petrie, 
Broadbent, & Meechan, 2003; Petrie, Cameron, Ellis, Buick, & Weinman, 2002). However, this 
was a small trial with a limited follow-up time (3 months). 
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2.2.1.1 Operationalising the CSM 
The original method used to elicit patient’s illness representations were in-depth semi-
structured interviews which focussed on their illness experiences. In order to provide a 
psychometrically verifiable method of assessing representations a theoretically derived 
questionnaire was developed which was based on patients own representations in a range of 
conditions. The original Illness Perception Questionnaire (IPQ) (Weinman, Petrie, Moss-Morris, 
& Horne, 1996) assessed the five key components of the CSM; identity, timeline, cause, 
consequences and control/cure, described above using 5 sub-scales. The ‘identity’ subscale 
comprises 12 core symptoms which can be tailored to specific illnesses. Patients rate the 
symptoms for frequency on a four point scale (all of the time, frequently, occasionally, never) 
and a sum score of those experienced at least occasionally is generated. Items in the additional 
four subscales are rated on a five point scale of levels of agreement and are scored according 
to guidelines (Weinman et al., 1996). 
In 2002, a revision to the original IPQ was published (IPQ-R) (Moss-Morris et al., 2002) which 
due to problems with internal consistency added a cyclical timeline beliefs subscale in addition 
to the acute and chronic subscales of the timeline scale The control scale was split into two 
subscales of personal control and treatment control which accounted for growing evidence of 
outcome expectancies the importance of treatment beliefs (Horne, Weinman, & Hankins, 
1999). The original IPQ did not include emotional representations which are a key part of the 
CSM, the IPQ-R includes a six item subscale assessing affective responses to illness. An illness 
coherence subscale was also added in order to assess whether an individuals’ illness 
representations provide a coherent understanding of the illness (Moss-Morris et al., 2002). 
On account of the length of the IPQ-R (over 80 items), in 2006, the Brief-IPQ was developed 
which contains only one-single item to measure each component (Broadbent, Petrie, Main, & 
Weinman, 2006). Both the IPQ-R and B-IPQ demonstrate good reliability and construct validity 
(Broadbent et al., 2006). However, some authors have identified problems with the content 
validity of the B-IPQ, for example respondents misinterpreting items about personal control 
and cause, therefore further validation is warranted (van Oort, Schröder, & French, 2011). 
The utility of the use of illness perceptions in mental health has been advocated (Petrie et al., 
2008) and recently the IPQ has been used or adapted for use in this area (Fortune, 
Barrowclough, & Lobban, 2004; Lobban, Solis-Trapala, et al., 2012; Witteman, Bolks, & 
Hutschemaekers, 2011). 
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2.2.2 An extended model of self-regulation (e-SRM) for treatment behaviours 
In order to understand behaviour such as treatment adherence, it is important to have a 
detailed understanding of the coping procedures specific to the behaviour. Namely, ‘how do 
representations of treatments relate to adherence?’. The orginal CSM was extended to 
explicitly incorporate treatment representations into the extended self-regulation model (e-
SRM) (Horne, 2003b) (Figure 2.2). According to the model, perceptions of treatment are 
influenced by general beliefs about medications as well as by a persons experiences and 
perceptions of social norms. Clinician’s input can also impact on these perceptions by 
providing or witholding information and their own viewpoint on the condition (ie. using a 
diseased-based model to understand and communicate to patients or a more recovery-
focused model). Studies in physical illnesses have shown that negative perceptions of 
treatment are linked to perceptions of illness and the degree of ‘fit’ between patients belief 
about the problem (illness) and preferred solution (the treatment) (Horne & Weinman, 2002). 
A common-sense model in which an individual has a recognition of their condition, a perceived 
need for medication, and their concerns about the prescribed treatment have been 
acknowledged would be likely to lead to engagement in positive self-management, including 
adherence (Horne, 2003b). In the converse, conditions which are asymptomatic may result in a 
person doubting the need for treatment (Horne, 2003b). 
 
Health Threat 
e.g. Symptoms 
Perceptions of treatment e.g. Necessity and 
concerns 
Contextual factors e.g. Self-efficacy, social 
norms 
Illness 
Representation 
Emotional 
response to 
illness 
Coping procedure Appraisal 
Coping procedure Appraisal 
Emotional response to treatment e.g. worry 
Figure 2.2: The extended model of self-regulation (adapted from (Horne, 2003b)) 
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2.2.3 Necessity and Concerns Framework 
Research has identified that treatment beliefs can be divided into beliefs about the personal 
necessity of treatment and individual’s concerns about medication. People have higher-order 
beliefs about medication in general, i.e. pharmaceuticals as a specific class of treatment, these 
are influenced by more specific beliefs about particular medications. The Necessity and 
Concerns Framework (NCF) (Horne, 2003b) provides a model for understanding specific beliefs 
about medications. Necessity beliefs incorporate a person’s perceptions of how much they feel 
they need a treatment, and related to this, their perception of a treatments efficacy. However 
a person could for example have high perceptions of a treatments necessity as it is the only 
option available, while not believing it is very effective. One limitation of the framework is that 
it is not clear exactly how necessity and efficacy beliefs interact. Concerns incorporate both 
cognitive and emotional representations and include the personal impact of treatment such as 
side-effects as well concerns about future effects and possible dependence on treatment. 
These beliefs will influence a person’s motivation to commence and continue with treatment. 
Beliefs about treatment necessity and concerns about potential negative consequences about 
taking it are often judged relatively to each other and subsequent behaviour will be a response 
to these judgements. There is a cost-benefit analysis where beliefs are weighed up against 
each other (Horne & Weinman, 1999). Individuals can also hold ambivalent or apparently 
contradictory beliefs about taking medication, for example they may feel that they need to 
take the medication to get better, however, they have strong concerns about the effects of 
taking the medication (Laakso, 2012). In this way, non-adherence to treatment can be 
regarded as a ‘common-sense’ response to weighing up these beliefs. There is a large body of 
evidence demonstrating the utility of the framework in explaining adherence. A meta-analysis 
of 94 studies demonstrated that better adherence was associated with stronger necessity 
beliefs and fewer concerns (Horne et al., 2013). A strength of this evidence is that the effect 
persisted when small, underpowered studies were excluded. Many studies were cross-
sectional in design so the direction of causation cannot be implied, however, the association 
between beliefs and adherence remained when including only longitudinal and prospective 
studies. Further work is, however, needed to establish the relationship between beliefs and 
different ways of administering treatments other than oral medications, such as depot 
injections. 
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2.2.3.1 Operationalising the Necessity and Concerns Framework 
The dimensions identified above have formed the content for a tool to assess treatment 
representations; the Beliefs about Medicines Questionnaire (BMQ) (Horne et al., 1999). The 
BMQ contains three scales, one relating to general beliefs about medicines which assesses the 
extent to which a person views medications as harmful and overused by doctors (General 
Harm and Overuse scale). The remaining two scales assess beliefs about specific medications 
and assess necessity beliefs (Specific Necessity scale) and concerns about that medication 
(Specific Concerns scale). An example of items on the necessity scale is ‘My health at present 
depends on my medicines’. Concerns items relate to worries about side-effects, long-term 
effects, and worries about dependence, e.g. ‘I sometimes worry about becoming too 
dependent on my medication’ and ‘Having to take this medication worries me’. 
The BMQ has been widely used in physical health and more recently in mental health research, 
where it has shown utility in predicting adherence behaviour (Clatworthy et al., 2009; de las 
Cuevas, Peñate & Sanz, 2013; Horne & Weinman, 2002). Jonsdottir and colleagues (2009) 
measured adherence using both subjective self-report and objective serum levels in 285 
psychiatric patients and demonstrated that high necessity and low concerns was associated 
with better adherence. However, the study was cross-sectional and there were high levels of 
adherence in the sample meaning that the size of the non-adherent group was very small. 
 
2.2.4 Perceptions and Practicalities Approach (PAPA) 
The frameworks outlined above describe clearly how adherence is influenced by volitional 
factors, and non-adherent behaviour can be described as ‘intentional’. Non-volitional factors 
also account for non-adherence (Chambers et al., 2011; Clatworthy et al., 2007) and these are 
also influenced by illness and treatment representations. ‘Unintentional’ non-adherence 
occurs where a patient may wish to adhere but is prevented from doing so due to barriers in 
capacity and resources. These barriers can include financial costs, difficulties with recall and 
comprehension of instructions on how to take the treatment, and physical barriers to 
administering treatment. Volitional and non-volitional factors may overlap, for example 
patients might be highly motivated to take medication and therefore explore ways to 
overcome practical barriers (Horne & Clatworthy, 2010). 
Unintentional and intentional non-adherence are incorporated in the Perceptions and 
Practicalities Approach (PAPA) (Horne, 2001) (Figure 2.3). The approach describes factors at an 
individual level which influence adherence, but also acknowledges that these individual factors 
are influenced by wider context, environmental and social factors. The perceptual barriers are 
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those specified in the NCF and the practical barriers are those capacity and resource barriers 
specified above. The two circles in Figure 2.3 overlap which represents the concept that 
perceptual factors may influence practical factors as specified above. 
It is proposed that the PAPA can be used to provide a framework for the development of 
interventions (Horne & Clatworthy, 2010). The approach does not specify how interventions 
should be delivered beyond the fact that interventions need to be tailored to a person’s 
specific barriers. However, a number of studies incorporate PAPA principles in interventions 
(Glattacker, Heyduck, & Meffert, 2012; O'Carroll, Dennis, Johnston, & Sudlow, 2010). 
Specifically, Glattacker and colleagues (2012) used these constructs to guide discussions with 
patients about lower back pain, these discussions were tailored to the patients individual 
illness and treatment beliefs and information needs. They found that those receiving this 
intervention perceived their pain as more controllable than those in a control group. However, 
the quasi-experimental, under-powered study also had a high dropout rate meaning that the 
intervention may not be effective in a real-world setting. The use of the principles of the PAPA 
approach in the development of the intervention in this thesis is described in Chapter 5 
including how the actual methods of delivery was arrived at.
 
Figure 2.3: The Perceptions and Practicalities Approach (adapted from (Horne, 2001)) 
 
2.3 Behaviour change 
The theories and frameworks described explain, predict and measure behaviours. In the 
development of theory-based interventions, they provide evidence-based causal pathways by 
which the mechanisms for behaviour change and behavioural determinants can be identified 
and targeted (Michie, Johnston, Francis, Hardeman, & Eccles, 2008). In order to develop 
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interventions to modify behaviour, it is necessary to map specific techniques and strategies 
onto these pathways. There is an increasing body of work devoted to the development of 
frameworks linking theory and evidence-based techniques for use in practice (Michie & 
Johnston, 2012). Connected with this is the creation of a taxonomy to ensure that the 
language used to describe active components of interventions is consistent and there is a 
common understanding of evidence-based techniques for modifying health behaviour (Michie, 
Johnston, Abraham, Francis, & Eccles, 2013). 
 
2.3.1 Theories of behaviour 
A range of constructs which influence behaviour have been identified and synthesised in a 
number of theories known collectively as social cognition models (SCM) which attempt to 
explain behaviour using predictors. The ‘social’ aspect of cognition refers to how people 
perceive the social environment as opposed how it might actually exist and it is those 
perceptions of reality which actually guide behaviour (Conner & Norman, 2005). Armitage and 
Connor (2000) provide an overview of these which include motivational models where the 
premise is that intentions predict behaviour including the Health Belief Model (Rosenstock, 
1974), Social Cognitive Theory (Bandura, 1986), the Theory of Planned Behaviour (Ajzen & 
Madden, 1986). Behavioural enaction models include an action component between 
intentions and behaviour, for example Implementation Intentions (Gollwitzer, 1993) and finally 
multi-stage models which incorporate behaviour maintenance such as the Health Action 
Process Approach (HAPA) (Schwarzer, 1992). 
In reviewing these theories it is apparent that many of the behavioural determinants they 
describe, overlap (French et al., 2012). Michie and colleagues identify problems with 
attempting to choose between the numerous theories of behaviour and instead it would be 
more useful if a definitive set of theoretical explanations of behaviour change were available 
and researchers had the means to identify those relevant to the context of their work (Michie, 
Johnston, et al., 2008). In addition, theories themselves do not provide guidance on 
intervening to improve health behaviours. By using one theory on its own, key determinants 
may be missed, particularly in complex health behaviours. Work conducted by Michie and 
colleagues (2005) draws together the key determinants of behaviour change into the 
Theoretical Domains Framework (TDF) which was subject to refinement and validation and has 
been widely used (Cane, O’Connor, & Michie, 2012; Francis, O'Connor, & Curran, 2012). In 
addition, an approach for using the TDF to actually develop an intervention has been 
developed (French et al., 2012), thus allowing researchers to meet the MRC guidelines and 
incorporate theory into the development phase of complex interventions (Craig et al., 2008). 
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As a further development to this work, Michie and colleagues (2011) have brought together, 
through expert consensus, the range of frameworks of behaviour change into the Behaviour 
Change Wheel (BCW). The ‘hub’ of the wheel comprises what the authors term the COM-B 
system (Capability, Motivation and Opportunity), this incorporates the physical, psychological 
and social elements of behaviour. Around the COM-B system, the BCW includes Intervention 
functions which can act on the COM-B elements, for example persuasion by using 
communication to increase motivation for a behaviour, and education by providing 
information to increase understanding. Finally, the BCW includes the policy context in which 
these functions would occur, for example published treatment guidelines for a condition and 
legislation. The BCW thus incorporates the environmental context in which behaviour change 
is attempted. 
The COM-B elements of motivation and capability or capacity tie in with the Perception and 
Practicalities components of PAPA in that the elements they comprise refer to the same 
behavioural determinants. The perceptual factors are comparable to the motivation 
component which contains automatic and reflective processes, and the practicality factors 
compares to the capability components (psychological and physical). In addition, the 
Opportunity component of COM-B comprises the social and physical factors outside of the 
individual which allow behaviour to take place such as having a pharmacy in the local 
environment to be able to access medication. In the PAPA, these are comparable to practical 
barriers and resource limitations which comprise the practicalities factor. The BCW allows the 
systematic selection of intervention functions in order to develop an appropriate means of 
changing behaviour. This leads into the selection of the exact techniques which are likely to 
have an effect on the determinants of the behaviour. 
 
2.3.2 Behaviour Change Techniques 
The constructs and intervention functions which have been identified as influencing behaviour 
can be mapped on to specific behaviour change techniques (BCTs) in order to ensure that 
interventions are theory-based and evidence-driven (Michie, Atkins, & West, 2014). BCTs are 
the active, observable, irreducible components of an intervention (Michie, West, et al., 2013). 
A substantial body of work has been conducted in recent years by Michie and colleagues 
(2010; 2011) in order to provide a framework for this. This enables researchers to not only 
identify behavioural determinants to target, to select appropriate BCTs to use in interventions 
but also to use their research to further develop the theories themselves. In addition, it 
facilitates accurate replication of interventions as standardized definitions are available 
(Michie, Johnston, et al., 2013). 
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BCTs are numerous and have been listed by a number of pieces of work, with a taxonomy 
approach of these techniques still developing (Abraham & Michie, 2008; Dixon & Johnston, 
2010). A recent example of which is the BCT Taxonomy (v1) which consists of 93 hierarchically 
clustered behaviour change techniques (Michie, Johnston, et al., 2013). Agreement on these 
were reached through a Delphi-type exercise involving experts in behaviour change and coding 
existing interventions using the taxonomy. The taxonomy has been applied to a range of 
health behaviours and also provides clear definitions of each BCT and examples of how this 
would translate to practical use. Research continues to apply the BCT taxonomy across 
different behaviours and populations including medication adherence (Bobrow et al., 2014; 
Dombrowski et al., 2012; Hartmann‐Boyce, Johns, Jebb, & Aveyard, 2014). However, there has 
been criticism that the original purpose of BCT taxonomies was to describe the content of 
interventions, and use of the taxonomies to develop interventions should be cautioned (Kok et 
al, 2015). This is due to the fact that they do not list effective interventions or provide 
information on what parameters need to be in place for them to be applied. 
 
2.3.2.1 Mapping BCTs to theory 
In order to have a potential impact on behaviour, e.g. adherence, BCTs must be selected which 
relate to changing cognitions or emotions, or by addressing practical or environmental barriers 
connected with the relevant frameworks (e-SRM, NCF and PAPA). The exact selection of the 
methods used in the novel intervention developed in this thesis are specified in Chapter 5 
(section 5.2.3) as part of the Intervention Mapping process. An example is included below to 
illustrate how BCTs can be mapped onto the frameworks and the constructs targeted by an 
intervention. 
The NCF consists of concerns about taking treatment, for example fear of side-effects, worries 
about dependence and necessity beliefs such as needing the treatment to stay well and to 
avoid hospitalisation. These NCF constructs have been shown to be related to adherence as 
described in Section 2.2.3. The BCT Taxonomy (v1) (Michie, Johnston, et al., 2013) item 9.2 
‘Pros and cons’ is relevant here as cost-benefit analysis is a method of helping patients 
consider making a behaviour change (Basco & Rush, 2005; Michie, Rumsey, et al., 2008; 
Rollnick, Mason, & Butler, 1999). Patients can weigh up the personal benefits and costs of both 
taking their medication and not taking it. Connected with this is that patients feelings of 
ambivalence towards treatment can be identified and addressed. 
It is important to remember, as this research into BCTs is still very much in development, 
particularly in relation to adherence behaviour, there may not be an evidence-based technique 
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related exactly to the construct in the specified health area. Recently, researchers have 
discussed the application of COM-B to adherence, with a view to understanding how to change 
adherence (Jackson, Eliasson, Barber, & Weinman, 2014). The authors applied adherence 
behaviour determinants to the model then suggest the application of suitable BCTs to each 
component. BCTs, as applied to health behaviours such as smoking or engaging in physical 
activity can also be adapted and applied to adherence (Michie, Johnston, et al., 2008). This 
process of mapping determinants onto a model which then provides guidance on BCT selection 
is the process conducted in the development of then intervention in this thesis. 
However, it has been noted that BCTs selected must target the specific beliefs in question, for 
example, not just personal control beliefs but specifically the technique needs to target 
perceptions of low personal control (Kok et al, 2015). The practical application of BCTs must be 
appropriate for the target population and the context in which they are being implemented. 
There may not be sufficient evidence to say with whom, where and when a BCT might 
expected to have a positive effect. Although by conducting qualitative research we can gain 
insights into the variability of the population and context. 
 
2.4 Limitations of health behaviour theories and approaches 
The models and approaches presented above provide useful evidence for understanding 
behaviour, relating constructs to behaviour and providing techniques in order to facilitate 
change. However, there are a number of limitations which apply to some or all of these. 
Multiple terms for what is essentially the same construct have been identified in the range of 
theories in health psychology, for example, in a review, Skinner identifies over 100 ways of 
conceptualising perceived control (Skinner, 1996). In addition, outcome expectancies in social 
cognitive theory (Bandura, 1986) i.e. the expectation that a behaviour will lead to particular 
outcomes, overlap with the behavioural beliefs and attitudes in the Theory of Planned 
Behaviour (TPB) (Ajzen & Madden, 1986) and may also relate to Necessity beliefs in the NCF in 
that a patient will see a treatment as needed if they believe it to be effective, i.e. It is likely to 
result in a relief of symptoms. There is, therefore, much overlap between models. The 
synthesis of frameworks to define these constructs serves to move forward from relying on the 
range of theories in order to develop evidence based interventions (Michie et al., 2005). 
However, TDF serves as a descriptive framework but does not specify relationships between 
constructs. (Francis et al., 2012) 
Some models focus on the motivational aspects of behaviour, through intentions to perform 
that behaviour, for example the TPB (Ajzen & Madden, 1986). However, intentions may not 
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translate into behaviour and indeed research has identified a considerable gap between 
prediction of intentions and subsequent behaviour, coined the intention-behaviour gap (Orbell 
& Sheeran, 1998; Sniehotta, Presseau, & Araújo-Soares, 2014). Models may lack an account of 
how the action actually occurs and specifically we need to understand volition in order to bring 
about behaviour change. 
Some SCMs, such as the TPB do not include a specific role for emotions, thus ignoring the idea 
that factors such as anxiety or fear could influence behaviour, newer models do include these 
factors (McEachan, Conner, Taylor, & Lawton, 2011; Sniehotta et al., 2014). Models may not 
include the role of past behaviour and of wider influences on heath such as the perceptions 
and behaviours of health professionals, society and the environment. This is where newer 
frameworks do attempt to include not only the individual psychosocial determinants, but also 
those influencing an individual from the wider context such as the BCW incorporating COM-B 
(Michie et al., 2011) and the PAPA (Horne, 2001). These later frameworks however, still may 
need development, both in ensuring their comprehensiveness and in ensuring they are 
operationalised appropriately. With COM-B, a strength of the model is in its breadth in 
including wider influences on behaviour. However, some of the definition may be difficult to 
apply to the specific behaviour in question. Some aspects of illness models aren’t clearer 
explicitly represented, such as symptom interpretation and that is where the e-SRM provides a 
useful model for this programme of research as symptom interpretation may impact on coping 
behaviours including adherence. 
Social cognition models do not account for habitual behaviour, they focus on rational decisions 
based on considerations of the factors in the model and this is not appropriate for prediction 
of behaviours once they become habitual (Horne & Weinman, 1998; Jackson et al., 2014; 
Sheeran, Gollwitzer, & Bargh, 2013). However, the COM-B model and NCF both incorporate a 
role for automatic processes (Horne, 2003b; Michie et al., 2011). Initiation of a behaviour and 
maintenance might be influenced differently, so the dynamic, self-regulation models better 
account for behaviours which are not performed ‘one-off’, as in medication adherence (Horne, 
2003a; Leventhal et al., 1984). 
Recognising that the current testable models do not account for all of the necessary 
determinants of behaviour, the frameworks COM-B (Michie et al., 2011) and the PAPA (Horne, 
2001) provide important tools for developing interventions. However, the next step might be 
to move back to conducting research to test the causal processes behind the constructs. This 
would aid in the development of interventions as a better understanding of the process of 
change could be gained, in accordance with MRC modelling process. 
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Further work is needed to ensure that validated tools are available to measure all of the 
constructs in order that empirical evidence can be obtained on the effectiveness of 
interventions which have been derived from theory. The original BMQ has undergone 
validation and further work on translations and extension to different conditions and 
treatment is underway (de las Cuevas et al., 2011; Komninis, Micheli, Roumeliotaki, & Horne, 
2013). Validated tools to measure the practical barriers to adherence are needed, and there 
has been work to develop these (Jackson, 2011). However, as it currently stands the BMQ may 
be subject to limitations. Although it is acknowledged that necessity and efficacy beliefs may 
be different, it is not clear how they interact and it would be worthwhile to conduct analysis to 
determine this. The BMQ-specific is quite absolute in the way it is worded, e.g. ‘Without this 
medicine I would be very ill’. In mental health, there are multiple factors contributing to 
staying well and the wording of the BMQ may not account for the perceptions of viewing a 
medication as one part of what helps someone to stay well. Side effect experience is measured 
but not fear of side effects which we know is an important factor in BD adherence. Also people 
might not interpret the wording of the side-effects item as including the effects on how they 
feel, they may just think of physical side effects and therefore miss a reason why people may 
not take their treatment. It is clear that adaptations are needed to make the BMQ relevant to 
mental health diagnosis. 
Further research into the measurement of illness perception in mental health is warranted. 
There may be subjective judgements made by the wording of the IPQ, in that it characterises 
the mental health experiences people have as an illness or problem. People may not agree 
with the diagnosis, but agree that they experience difficulties and this doesn’t seem to be fully 
accounted for in the way the SRM is operationalised. The emotional impact measurement is 
one single item and implies that all emotional consequences are negative. There may be a 
whole range of emotional impacts of the condition. In addition, the IPQ doesn’t fully take into 
account the recovery model in that people may understand that the diagnosis may be chronic 
but they also forsee that they may recover and live a fulfilling life. 
In relation to the area covered by this programme of research, there are still questions about 
whether or not these models as they currently stand are applicable to the area of mental 
health and in particular adherence to medication in mental health (Petrie et al., 2008). Do they 
include the constructs which may be relevant to this area, or miss key aspects of the influences 
particularly on behaviour in a mental health context? People’s reports of their own BD 
experiences, perceptions of treatment and goals for recovery could lead to the development of 
these models and increase their applicability to mental health. These additional aspects could 
include perceptions of the medicalisation of mental health experiences, identity as being part 
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of or separate from the illness and hopes and fears around recovery. This thesis aims to 
identify and further understand some of these issues and contribute towards the development 
and application of the work of social cognition, self-regulation and behaviour change in mental 
health. 
 
2.5 Chapter summary 
In formulating an intervention to improve outcomes for people with BD, the MRC framework 
for complex intervention development is a systematic process which can be applied. As health 
behaviours, adherence and other activities such as self-monitoring are behaviours in 
themselves and as such, are covered by health behaviour theories such as social cognition 
models and theories of behaviour change such as COM-B. In addition, as this area relates to 
illness, treatment and coping, self-regulation theories including the e-SRM are most applicable. 
The NCF provides a way of conceptualising and understanding patients’ perceptions about 
treatment and the PAPA approach allows us to formulate ways of intervening in adherence by 
understanding both the perceptual and practical barriers. 
These frameworks and theories allow us to conceptualise and link the beliefs, cognitions and 
other factors which relate to the behaviours associated with managing treatment and living 
with the condition of BD. Additional models, frameworks and theories relating to mechanisms 
of behaviour change complement these and assist in selecting and using techniques to attempt 
to modify these perceptual and practical factors associated with the health behaviours in 
question. However, there are likely to be unknown limitations to applying the models in BD 
and therefore qualitative research is needed to explore this. 
This chapter has outlined the selection of appropriate theories and techniques which the 
evidence suggests may be of use in taking forward for a novel intervention. This forms a crucial 
first stage in the MRC framework. The first stage also includes conducting a systematic review 
if no high quality, up to date review already exists in the area. Chapter 3 firstly describes an 
assessment of the availability of existing reviews, before then presenting a systematic review 
and meta-analysis of interventions to improve adherence in BD. 
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Chapter 3 Improving medication adherence in bipolar disorder: A 
systematic review and meta-analysis of 30 years of intervention trials. 
 
3.1 Background 
In assessing the need for a novel intervention, it is essential to review the existing literature on 
interventions in this field. From this, it is possible to identify whether high-quality, effective 
interventions have been conducted within the population in question. It can also identify 
which intervention content and delivery methods are worthwhile of development in order that 
previous work is built upon as opposed to developing new interventions from scratch each 
time (Campbell et al., 2000; Coyne, Thombs, & Hagedoorn, 2010; Liberati et al., 2009). In 
addition, important information can be obtained on how best to target interventions and 
whether there is evidence to suggest who might benefit most and who might be unlikely to 
respond. 
Reviewing the existing evidence prior to developing an intervention is recommended by MRC 
guidelines for developing complex interventions (Craig et al., 2008) and the more detailed, 
Intervention Mapping (IM) process which is described in Chapter 5 (Bartholomew et al., 2011). 
This systematic review forms part of the first stage of the process of conducting a needs 
assessment to identify what methods have been used to attempt to improve outcomes, what 
has worked in terms of population samples and contexts, and what gaps need to be addressed 
by conducting new empirical research. 
Systematic reviews should also provide an assessment of the quality of studies included, 
therefore whether the findings concerning the intervention effectiveness is likely to be subject 
to bias (Petticrew & Gilbody, 2004). In addition to assessing intervention effectiveness, it is 
crucial also to examine the reporting of interventions in order to identify whether potentially 
promising interventions could be replicated (Hoffmann et al., 2014). 
In the same way that a novel intervention would not be conducted if an effective, appropriate 
high quality one existed, prior to conducting a review, it is necessary to conduct a scoping 
review in order to determine if a high-quality, up to date review had already been published. 
This identifies firstly if a review is necessary and secondly to identify areas which may not be 
covered either by the scope of previous reviews, specificity of inclusion criteria and whether an 
adequate assessment of intervention and study quality has been conducted. 
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3.1.1 Limitations of previous reviews 
Systematic reviews of trials of programmes to improve outcomes in the area of severe mental 
health have been conducted however, they have limitations which reduce their use in 
identifying effective techniques to improve medication adherence. Some focussed only on 
psychoeducational or psychosocial interventions (Batista, Baes, & Juruena, 2011; L. Berk et al., 
2010; Crowe, Porter, et al., 2012; C. Depp, Moore, Patterson, Lebowitz, & Jeste, 2008; 
Gaudiano, Weinstock, & Miller, 2008). Others did not examine adherence outcomes (Lolich, 
Vazquez, Alvarez, & Tamayo, 2012), provide only a narrative review (Busby & Sajatovic, 2010; 
Colom & Lam, 2005; Miklowitz, 2006), or were not specific to BD (Desplenter, Simoens, & 
Laekeman, 2006; Fernandez, Evans, Griffiths, & Mostacchi, 2006). Together these provide a 
limited picture of the adherence intervention literature in BD, as they do not systematically 
quantify the magnitude of intervention effects across studies, or test what components of 
study and intervention design may be most effective. The effects of inadequately powered 
studies may also be over-estimated in narrative reviews. Meta-analysis provides a 
quantification of effect and we can test whether particular components may significantly 
contribute to the effect. Reviews are also limited by the fact that they investigate what is 
ostensibly a single illness, but what is in reality a highly variable condition, with different ways 
of characterising the diagnosis and different experiences and beliefs held by participants. In 
the same way, they group together ‘adherence’ as a behaviour, which is in reality a highly 
variable behaviour, measured using different techniques and different cut-offs are applied. 
 
3.1.2 Need for a comprehensive review in BD 
It is important to systematically synthesise the evidence and conduct meta-analysis, where 
appropriate, to quantify the effect of interventions. In addition, this method can test whether 
particular components of the study design or intervention may significantly contribute to 
effects and whether effects depend on study quality, which is not possible in narrative reviews. 
Interventions which are taken forward and used in clinical practice need to be clinically 
effective, but also cost and time efficient for providers and patients. As such, they should 
include only the necessary components and be delivered only for as long as needed. They need 
to be appropriately targeted to ensure they are delivered to participants who might benefit 
and not suffer unwanted effects. The intervention and study components tested in this review 
reflect current thinking of what may be useful in improving adherence and by conducting a 
meta-analysis, this allows for confident recommendations to be made on what makes for an 
effective intervention. 
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Certain interventions components may be important, for example; tailoring (L. Berk et al., 
2010; Crowe, Porter, et al., 2012; Desplenter et al., 2006; Horne et al., 2005), content and 
delivery (ABC Project Team, 2013) specifically the focus given to adherence, the length of the 
programme (Batista et al., 2011; Gaudiano et al., 2008; Rouget & Aubry, 2007), whether it is 
educational, includes a focus on beliefs and cognitions (Desplenter et al., 2006; Fernandez et 
al., 2006; Gaudiano et al., 2008; Horne et al., 2005; Leclerc et al., 2013; Sajatovic, Davies, & 
Hrouda, 2004). Targeting and delivery variables which are explored include involving partners 
and family members (Gaudiano et al., 2008), stage of illness, whether patients were euthymic 
and also whether they were inpatients or outpatients (L. Berk et al., 2010; Lolich et al., 2012; 
Rouget & Aubry, 2007). In addition to content and delivery, certain process variables are key to 
assessing how interventions were implemented such as fidelity (Craig et al., 2008) and what 
comprises standard clinical care (de Bruin, Viechtbauer, Hospers, Schaalma, & Kok, 2009; 
Gaudiano et al., 2008). 
 
3.1.3 Use of Systematic review, Intervention reporting and Quality assessment guidelines 
This review follows the guidelines set out for reporting systematic reviews and meta-analysis 
of studies that evaluate healthcare interventions, the PRISMA statement (Preferred Reporting 
Items for Systematic reviews and Meta-analyses) (Moher, Liberati, Tetzlaff, & Altman, 2009). 
This ensures that it is transparent and complete in that it contains all of the details necessary 
for replication (see Appendix A for completed PRISMA checklist). 
Published guidelines on reporting behavioural interventions were used to systematically 
describe content and delivery of the studies included in the review (Davidson et al., 2003) as 
well as guidance from the Consolidated Standards of Reporting Trials (CONSORT) (Boutron, 
Moher, Altman, Schulz, & Ravaud, 2008; Schulz, Altman, & Moher, 2010). 
This review provides an assessment of the methodological quality and reporting of studies 
(Higgins et al., 2011). The problems of inconsistent and inadequate reporting have recently 
begun to be addressed. CONSORT guidelines state that interventions must be reported with 
‘sufficient details to allow replication, including how, and when they were actually 
administered’ (Schulz et al., 2010). A recent study of intervention reporting in non-
pharmacological trials concluded that 61% of interventions were reported inadequately 
(Hoffmann, Erueti, & Glasziou, 2013). To address this issue the Template for Intervention 
Description and Replication (TIDieR) checklist and guide has been published (Hoffmann et al., 
2014). TIDieR is intended as a tool for study authors and systematic reviewers to describe 
interventions accurately and consistently, with enough detail to allow replication. In the 
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present review all interventions were assessed for the quality of intervention descriptions 
provided in published reports using TIDieR. 
 
3.2 Aims and Objectives 
3.2.1 Aim 
To undertake a systematic review of randomised-controlled trials of interventions 
incorporating medication adherence for people with a diagnosis of BD. 
 
3.2.2 Objectives 
 To describe intervention design, delivery and study characteristics. 
 To evaluate quality of reporting and trial design. 
 To quantitatively synthesise evidence for the effectiveness of interventions relative to 
control conditions. 
 To identify moderating factors associated with intervention effectiveness. 
 To assess the likelihood of publication bias in the available literature. 
 
3.3 Methods 
We conducted a comprehensive search of published literature until the end of October 2012 
through abstract databases, clinical trial registers, hand-searching of citations in previous 
reviews and included studies and by contacting researchers directly. In order to ensure the 
review was as up to date as possible, the original search criteria were re-run in August 2014 to 
identify additional studies. 
 
3.3.1 Eligibility criteria 
Type of studies: Randomised controlled trials of interventions incorporating medication 
adherence either directly or indirectly and comparing the intervention/s to an active or passive 
control (including trials where patients were described as being randomly allocated to 
condition). 
Participants: Adults over 18 years of age with a diagnosis of bipolar disorder (all types), or with 
general psychiatric populations when subgroup analysis was provided for bipolar disorder. 
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Types of outcome measures: Medication adherence as either a primary, secondary outcome or 
mediator, measured by subjective or objective methods. 
Excluded: Studies focussing exclusively on individuals with psychosis, schizoaffective disorders 
or a diagnosed substance misuse problem, or undergoing compulsory treatment. 
 
3.3.2 Identification of studies 
Studies were identified by searching the following databases; CINAHL, EMBASE, PsychInfo, 
PubMed, Sociological abstracts and Cochrane trials. No date or language restrictions were 
imposed and the search included studies added to the databases until end of October 2012, 
and updated to include studies published until the end of August 2014. Search strategies were 
designed and tested with the assistance of a research librarian. 
Search terms to identify studies were as follows; Adheren*, complian*, medicat*, medicine, 
drug, clinical trial, random*, control*. For the Cochrane trials database the following terms 
were also included; pharmacotherapy or regimen* or educat*. Consequently we combined 
this with search terms; Bipolar disorder (MESH), Manic depressi* (Box 3.1). Subsequently the 
trials registers Clinicaltrials.gov and (Health Technology Assessments (HTA) were searched for 
trials including ‘bipolar disorder’. The reference lists of previous reviews in the area and 
studies included in this review were examined for additional qualifying articles. 
 
(patient compliance[MeSH Terms]) OR ("Medication Adherence"[Mesh])) OR (compliance 
OR adherence[Title/Abstract])) OR (complian* OR adheren*) OR ("treatment refusal") AND 
(drug therapy) OR (regimen[Text Word]) OR (medicat*[Text Word])) OR ("Drug 
Therapy"[Mesh]) AND (clinical[Title/Abstract] AND trial[Title/Abstract]) OR clinical 
trials[MeSH Terms] OR clinical trial[Publication Type] OR random*[Title/Abstract] OR 
random allocation[MeSH Terms] OR therapeutic use[MeSH Subheading]) AND 
(intervention[Title/Abstract])) OR ("Causality"[Mesh:noexp])) OR ("Outcome and Process 
Assessment (Health Care)"[Mesh]) OR "Health Services Research"[Mesh]) OR ("Treatment 
Outcome"[Mesh]) OR ("Outcome Assessment (Health Care)"[Mesh])) OR ("Intervention 
Studies"[Mesh]) AND (bipolar disorder[MeSH Terms]) OR (bipolar disorder) OR (manic 
depressi*) 
Box 3.1: Example of search strategy from PubMed 
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3.3.3 Data collection 
3.3.3.1 Selection of trials 
The results of the search strategies were downloaded into Endnote x3 before removing 
duplicate studies and conducting and cross-checking the additional searches with the 
downloaded citations. 
Two investigators (the author and SC) carried out title and abstract review on the 671 studies 
retrieved and excluded studies if they did not meet the inclusion criteria. Inter-rater 
agreement was high, with a kappa value of 0.986. Four potentially relevant papers, identified 
by SC were subsequently excluded after discussion (Colom, Vieta, Sanchez-Moreno, Goikolea, 
et al., 2009; Frank et al., 2008; G. Simon, Ludman, Bauer, Unutzer, & Operskalski, 2006; 
Valenstein et al., 2011). Papers for the remaining 116 studies were retrieved and the full texts 
of these articles were reviewed (Figure 3.1) (Moher et al., 2009). Twenty-three studies met the 
criteria for inclusion in the systematic review (Tables 3.8 and 3.9). Data was extracted from 26 
papers as four studies reported methods and results across two papers each (accounting for 
where the number of references cited in the text is higher than the number of studies 
mentioned). 
The search update in August 2014 retrieved an additional 125 studies which were reviewed by 
the same investigators and five potentially relevant articles were retrieved. One additional 
study was included in the systematic review (Javadpour, Hedayati, Dehbozorgi, & Azizi, 2013). 
The remaining four were excluded as they either comprised conference abstracts where the 
data was not available from authors or studies with mixed psychiatric sample for which 
sufficient detail for inclusion in the review was not available. 
 
3.3.3.2 Data extraction and assessment of methodological quality 
A data extraction template was designed and piloted before making refinements (Appendix B) 
and data was extracted on intervention design and delivery, study characteristics, quality of 
reporting and trial design and adherence outcomes. 
Intervention content: The term ‘Psychoeducation’ was applied to heterogeneous 
interventions. Colom provides a broad definition; including empowering patients and give 
them the tools to manage, cope and live with bipolar disorder, involving adherence 
enhancement, early warning sign identification, lifestyle, crisis management and 
communication. It involves changing behaviour and attitudes in addition to simply providing 
information (Colom, 2011). We coded interventions in terms of whether they used the term 
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psychoeducation and whether the description of the programme included all of these 
elements of psychoeducation. Interventions were coded into whether adherence was the 
primary focus of the intervention, or whether the intervention was multi-focus. 
Intervention tailoring: categorised (‘yes’, ‘no’ or ‘unclear’) according to inclusion of different 
forms of tailoring based on guidelines described by de Bruin and colleagues (2009) in the 
‘Coding manual for Behaviour change techniques’: Individualization (content individualised to 
reflect participants’ questions or individual progress), Macro-tailoring (intervention depends 
on pre-tested characteristics e.g. motivational stage or adherence level ), Attention/Meso-
tailoring (amount of intervention contacts depends on participant need), Micro-tailoring 
(intervention components are tailored to the participant e.g. specific action plans generated) 
and Participation (the participant is actively involved by providing input or making decisions) 
(de Bruin et al., 2009). 
Intervention delivery: coded for provider, format (i.e. group, individual, family), delivery 
setting (e.g. specialist affective disorder/ bipolar clinic or unit, university), recipient, number of 
intervention contacts, total intervention contact time, duration of intervention delivery, 
intensity of intervention contacts. Guidelines on reporting behavioural intervention trials were 
used to summarise the descriptions of interventions (Davidson et al., 2003; Hoffmann et al., 
2014). Where the number of intervention contacts, time or duration varied (as specified by 
protocol), we used the average. In coding intervention duration in months, one-contact 
interventions were classified as 0.03 months, in order that they had a quantifiable duration for 
computation of medians. 
Control group: Due to differences in the intensity of standard care, treatment as usual (TAU) 
was coded as either 1. General care- outpatient psychiatry or GP appointments/ medication 
management usual (no specific education or psychological support mentioned) or 2. Intensive 
support- structured specialist support. Additional components were also coded as being 
included or not; additional GP training, additional education/ psychoeducation, additional 
sessions (not educational but attention matched) and receiving feedback on adherence. 
Study and sample characteristics: date of publication, number of participants randomised 
(intervention and control groups), length of follow-up assessment (both from baseline and last 
intervention contact point), primary outcome (whether adherence was specified as a primary 
outcome or not), country of study, diagnostic assessment of bipolar (which assessment 
measure or criteria was used to determine the diagnosis), participants’ illness state at the 
point of recruitment (depression, mania, euthymia or mixed), gender, ethnicity. 
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Adherence outcome: Primary outcome included adherence (Yes/ No). Mode of measurement - 
1. subjective (self-report, physician report, informant report), 2. objective (e.g. electronic 
monitoring, pill counts), 3. biological (e.g. lithium serum levels) and 4. composite. Target 
medication– 1. Lithium only, 2. Multiple medications reported/analysed together, 3. Multiple 
medications – reported/analysed separately. Data was extracted on every reported adherence 
assessment at each time point. Eighteen studies provided sufficient data in the published 
report in order to compute standardised effect sizes for the meta-analysis. For six studies, 
authors were contacted for additional data and this was provided for one study (Eker & Harkin, 
2012), data was unavailable for four (Frank et al., 2005; Frank et al., 1999; Gilbert, 2000; N. S. 
Harvey & Peet, 1991; Javadpour et al., 2013; Peet & Harvey, 1991) and in one study the data 
were medication continuation months (Bordbar, Soltanifar, & Talaei, 2009) which was not 
comparable with the other studies and was not included in the meta-analysis. 
Intervention retention: the proportion of participants who took part in intervention sessions, 
completed the programme, or were classed as adhering to the protocol according to cut-offs 
specified in the study. 
Fidelity: coded as formal assessment using coding systems by independent raters, informal 
assessment (where fidelity was reported to have been conducted, but formal scoring or rating 
was not used), or no evidence of fidelity assessment. 
Quality of intervention reporting: coded using the Template for Intervention Description and 
Replication (TIDieR) checklist (Hoffmann et al., 2014). This comprises 12 intervention items; 
Brief name; Why (rationale, theory or goal); What (materials used); What (procedures used); 
Who provided; How (mode of delivery); Where (location); When and how much; Tailoring; 
Modifications; How well (planned); and How well (actual). For each intervention, each item 
was coded as being either adequately reported, inadequately reported, not reported or not 
applicable to the intervention. Data was extracted for each study to demonstrate where in the 
paper the information could be found, or in the case of inadequate reporting, details on what 
information was lacking. As per TIDieR guidelines, details were sought from not only the 
published paper, but also papers referenced by the authors, available protocols and manuals, 
online supplementary material, and websites. Following independent coding, the two 
reviewers met to reach agreement on any coding discrepancies (seeking advice from a third 
reviewer where agreement could not be reached). To provide a simple assessment of quality 
for each study items were coded as adequately described, inadequately described, not 
reported or not applicable. This process was similar to that used by Hoffamn et al (2013) 
where items were rated as either clearly described, or not reported or not clearly described. 
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Quality of trial design: assessed using the Cochrane collaboration tool for assessing risk of bias 
in; selection, performance, detection, attrition and reporting (Higgins et al., 2011). Each study 
was classified into ‘low risk of bias’, ‘high risk of bias’ or ‘unclear’ for; Random sequence 
generation, Allocation concealment, Blinding of participants, Blinding of personnel, Blinding of 
adherence outcome assessments, Incomplete adherence outcome data, and Selective 
adherence outcome reporting. As studies frequently used more than one outcome measure, 
for the purposes of the narrative summary, the risk of bias in; blinding of outcome assessment, 
incomplete outcome data and selective reporting categorised studies according to the lowest 
risk of bias. For the meta-analysis, the risk of bias was assessed for the outcome measure and 
timepoint specified in each sub-analysis. 
Data extraction for all studies was conducted by the author, with a second data extraction by 
two investigators (SC & another independent researcher). Inter-rater reliability was assessed 
for 15 items by calculating Cohens Kappa values. Kappa values were; target medications 
(k=0.91), intervention focus (k=0.66), setting (k=0.49), intervention tailoring (5 items, k= 0.11 
to 0.78), control group (1 item, k=0.66) risk of bias (6 items, k=0.13 to 0.83). There was good 
agreement except for the TIDieR tailoring item (54%), for two items on intervention tailoring 
(Individualisation 38%, Micro-tailoring 50%) and for two risk of bias items (Personnel blinding 
42%, Selective reporting 54%). Disagreements in coding were resolved through discussions 
between the three investigators. 
 
3.4 Data analysis 
Extracted data was organised and processed using IBM SPSS statistics (v21) and 
Comprehensive Meta Analysis (v2) software. Studies were included in the meta-analysis where 
it was possible to pool the adherence data and compute standardised effect sizes. Studies 
reported different statistics including t-tests, chi squares, ANOVAs, means, sd and p values. In 
order to compare data, standardised odds ratios with 95% confidence intervals were 
computed from the proportions of participants classified as adherent in the control and 
interventions groups at follow-up. A random effects model was selected as it is more 
conservative than a fixed effects model and should be used when analysing real world data 
(Field, 2003; Hunter & Schmidt, 2000). 
Where data was reported on multiple outcome measures and time points, effect sizes were 
computed for each. The order of preference for selecting outcomes was, in descending order 
of priority; composite measure, serum lithium, self-report, informant report, based on papers 
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recommending that a combination is the most valid measure for adherence in psychiatric 
research (Sajatovic et al., 2010). 
The chi-squared statistic (Q) was used to test for the presence of heterogeneity across studies 
with the level expressed using the I2 statistic, describing the percentage of variation due to 
heterogeneity as opposed to by chance. Cochrane guidance provides cut-offs for interpretation 
of the magnitude of heterogeneity, where 30-60% represents potentially moderate 
heterogeneity, 50-90% represents substantial heterogeneity (Higgins et al., 2011). 
Moderation analysis was conducted to assess if adherence outcome varied according to study 
characteristics (where possible i.e. where sub-categories contained two or more studies). This 
was conducted for the following categorical potential moderators; intervention focus 
(adherence primary vs Multi-focus interventions), content (all elements of psychoeducation vs 
other interventions), delivery setting (specialist clinic/ department vs other settings), delivery 
format (individual vs group), adherence as a primary outcome, adherence – what was 
measured (mixed medications assessed globally vs Lithium only) intervention tailoring, use of 
manual, assessment of fidelity, baseline illness state and study comparison group. Meta-
regression analysis was conducted for the following continuous moderator variables: date of 
publication, intervention contacts (as per protocol) intervention duration (months), total 
intervention contact time, and follow-up duration, both from baseline and last intervention 
contact. Random effects models were used in this analysis as we have no reason to assume 
systematically different variance between groups of studies by moderator variable and there 
are a small number of studies within each category (Borenstein, Hedges, Higgins, & Rothstein, 
2011). 
Sensitivity analysis was performed to detect whether the overall effect was affected by the 
inclusion of; small studies, outliers, type of outcome and timepoint of follow-up, evidence 
quality and participant retention at follow-up. Studies with small sample sizes were excluded 
for the first sensitivity analysis (using a recommended cut-off of n<70 for either intervention or 
control group (Coyne et al., 2010)), resulting in the inclusion of only five studies (Colom et al., 
2003; Eker & Harkin, 2012; Lenz, 2010; Reinares et al., 2008; Sajatovic, Davies, et al., 2009). For 
the second sensitivity analysis, one study was excluded due to its extremely large effect size 
(outlier) (Dogan & Sabanciogullari, 2003). Next, the longest follow-up outcome was selected 
for; serum levels, composite measures and self-report and computed effect sizes for each. 
Effect sizes were computed for study outcomes grouped into 1-3 months post-intervention, ~6 
months and ~12 months. Then only those studies with satisfactory retention at follow-up using 
a slightly less stringent cut-off than in a previous review of adherence interventions (80%) 
(Haynes, Ackloo, Sahota, McDonald, & Yao, 2008) of >75% in both intervention and control 
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groups were selected. Finally sensitivity analysis was conducted to detect if outcome was 
affected by evidence quality (including studies judged to have low risk of bias). 
Risk of publication bias analysis was performed as it is possible that studies reporting a 
statistically significant result may be more likely to be published and therefore a meta-analysis 
may over-estimate the real effect of all studies conducted (published or unpublished) 
(Rothstein, Sutton, & Borenstein, 2006). A funnel plot was examined for symmetry which 
displays the effect size of the published studies against the variance; this would be 
asymmetrical if fewer studies with a large variance (typical of smaller studies) and large effect 
size were published, suggesting that small studies are more likely to be published if consistent 
with the intervention being effective. However, as funnel plots can be misleading, particularly 
when the number of studies is small or the studies are heterogeneous (Walker, Hernandez, & 
Kattan, 2008), a trim and fill method was applied (Duval & Tweedie, 2000), a classic fail safe 
analysis to compute the number of studies needed to produce a null result (Rosenthal, 1979) 
and Egger’s test to measure funnel plot asymmetry (Egger, Smith, Schneider, & Minder, 1997). 
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Figure 3.1: Flow of studies in the systematic review 
 
Records identified through electronic 
database search 
(k= 983) 
Records identified through other sources 
(Trials registers & Systematic review 
abstracts) (k=78) 
Duplicates excluded (k= 390) 
Records after duplicates removed (k=671) 
Studies remaining after title/ abstract 
review (k=116) 
Excluded - title/ abstract (k=555) 
No adherence intervention (k=198) 
Review papers (k=176) 
Medication based intervention (k=63) 
Children <18 (k=37) 
Not bipolar (k=29) 
Substance misuse (k=24) 
Case study/ series (k=11) 
Not an RCT (k=8) 
Regimen based intervention (k=8) 
Not human study (k=1) 
Excluded - full text (k=81) 
Review papers (k=14) 
Not an RCT (k=14) 
No adherence measure (k=11) 
Mixed psychiatric sample (k=11) 
No adherence intervention (k=11) 
Intervention development (k=6) 
Medication based intervention (k=6) 
Letter/ responses – no intervention 
(k=3) 
Not bipolar (k=3) 
Post-hoc analysis (k=2) 
Qualitative review, included studies 
(k=24) 
(from k=27 published papers) 
Unable to access paper/ results (k=8) 
Quantitative review (meta-analysis) 
(k=18) 
Studies identified from search update 
August 2014 (k=125) 
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3.5 Results 
3.5.1 Description of studies 
Studies are described in Tables 3.9 and 3.9 and intervention characteristics across all studies 
are summarised in Table 3.1 and Table 3.2. 
 
3.5.1.1 Intervention content & tailoring 
Five interventions had adherence as the primary focus of the intervention content (Cochran, 
1984; Dogan & Sabanciogullari, 2003; Elixhauser, Eisen, Romeis, & Homan, 1990; N. S. Harvey 
& Peet, 1991; Peet & Harvey, 1991; Sajatovic, Davies, et al., 2009), 18 were multi-focus 
programmes, (Ball et al., 2006; D. Castle et al., 2007; Clarkin, Carpenter, Hull, Wilner, & Glick, 
1998; Colom et al., 2003; D'Souza, Piskulic, & Sundram, 2010; Eker & Harkin, 2012; Frank et al., 
2005; Frank et al., 1999; Gilbert, 2000; Javadpour et al., 2013; Lam et al., 2000; Lam, Hayward, 
Watkins, Wright, & Sham, 2005; Lam et al., 2003; Lenz, 2010; Miklowitz, George, Richards, 
Simoneau, & Suddath, 2003; Miklowitz et al., 2000; Rea et al., 2003; Reinares et al., 2008; van 
Gent & Zwart, 1991; Zaretsky, Lancee, Miller, Harris, & Parikh, 2008). We were unable to 
classify one study due to the limited information provided in the paper (Bordbar et al., 2009). 
Fifteen interventions were described as being or including psychoeducation (Ball et al., 2006; 
Bordbar et al., 2009; Clarkin et al., 1998; Colom et al., 2003; D'Souza et al., 2010; Eker & 
Harkin, 2012; Gilbert, 2000; Javadpour et al., 2013; Lenz, 2010; Miklowitz et al., 2003; 
Miklowitz et al., 2000; Rea et al., 2003; Reinares et al., 2008; Sajatovic, Davies, et al., 2009; van 
Gent & Zwart, 1991; Zaretsky et al., 2008). Five classified themselves as cognitive-behavioural 
therapy (CBT) or cognitive therapy (Ball et al., 2006; Cochran, 1984; Lam et al., 2000; Lam et 
al., 2005; Lam et al., 2003; Zaretsky et al., 2008). When coding interventions based on the 
content described in the paper, 13 clearly included all elements of psychoeducation (Ball et al., 
2006; D. Castle et al., 2007; Clarkin et al., 1998; Colom et al., 2003; D'Souza et al., 2010; Eker & 
Harkin, 2012; Gilbert, 2000; Javadpour et al., 2013; Lam et al., 2000; Lam et al., 2005; Lam et 
al., 2003; Lenz, 2010; Miklowitz et al., 2003; Miklowitz et al., 2000; Rea et al., 2003; Sajatovic, 
Davies, et al., 2009). 
As described, four interventions appeared to be information provision only without a specific 
behavioural or psychosocial element (Bordbar et al., 2009; Dogan & Sabanciogullari, 2003; N. 
S. Harvey & Peet, 1991; Javadpour et al., 2013; Peet & Harvey, 1991). Three had a specific 
focus on family communication (Gilbert, 2000; Miklowitz et al., 2003; Miklowitz et al., 2000; 
Rea et al., 2003). Elixhauser and colleagues (1990) used an electronic adherence monitoring 
device, adherence feedback and education. 
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Fifteen interventions included more than one type of tailoring. Sixteen interventions used 
micro-tailoring of components of the intervention such as action planning in relation to 
participants lifestyle and goals or information on risk tailored to individual characteristics or 
history (Ball et al., 2006; D. Castle et al., 2007; Cochran, 1984; Colom et al., 2003; D'Souza et 
al., 2010; Eker & Harkin, 2012; Frank et al., 1999; Gilbert, 2000; Lam et al., 2000; Lam et al., 
2005; Lam et al., 2003; Miklowitz et al., 2003; Miklowitz et al., 2000; Rea et al., 2003; Reinares 
et al., 2008; Sajatovic, Davies, et al., 2009; van Gent & Zwart, 1991; Zaretsky et al., 2008). 
Sixteen studies involved participation where the participants had active input, for example 
own difficulties with adherence, deciding on strategies and evaluating the outcomes of 
strategies used (Ball et al., 2006; D. Castle et al., 2007; Cochran, 1984; Colom et al., 2003; 
D'Souza et al., 2010; Eker & Harkin, 2012; Frank et al., 1999; Gilbert, 2000; Javadpour et al., 
2013; Lam et al., 2000; Lam et al., 2005; Lam et al., 2003; Miklowitz et al., 2003; Miklowitz et 
al., 2000; Rea et al., 2003; Reinares et al., 2008; Sajatovic, Davies, et al., 2009; van Gent & 
Zwart, 1991; Zaretsky et al., 2008). 
Six interventions used individualization, where the content of sessions was individualised in 
response to participants’ needs, their questions or queries (Ball et al., 2006; Dogan & 
Sabanciogullari, 2003; Eker & Harkin, 2012; Gilbert, 2000; N. S. Harvey & Peet, 1991; Peet & 
Harvey, 1991; Rea et al., 2003). 
Five interventions were tailored by varying the level of intervention contacts depending on 
participants’ needs or preferences (Frank et al., 2005; Frank et al., 1999; Gilbert, 2000; Lam et 
al., 2000; Lam et al., 2005; Lam et al., 2003) with the decisions either based on participant 
choice (k=1) (Gilbert, 2000), HCP/ clinical need (k=2) (Lam et al., 2000; Lam et al., 2003) or both 
patient and practitioner choice (k=2) (Frank et al., 2005; Frank et al., 1999). 
One intervention used tailoring at a macro-level, i.e. determining the intervention to be 
received by pre-tested characteristics, in this case the levels of symptoms, where participants 
must be classed as asymptomatic before proceeding (Frank et al., 1999) and one tailored 
feedback according to a mid-point assessment of adherence (Elixhauser et al., 1990). 
 
3.5.1.2 Delivery (provider, setting, target, duration, frequency of sessions) 
A range of providers were involved in intervention delivery; most commonly psychologists 
(k=5) and psychiatrists (k=6), but also mental health nurses (k=3), social workers (k=3) and 
‘therapists’ (k=3) (Table 3.1). 
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Five interventions were delivered through specialist affective, mood or bipolar disorder clinics 
(Cochran, 1984; Colom et al., 2003; Eker & Harkin, 2012; N. Harvey & Peet, 1991; Reinares et 
al., 2008). Other settings included hospital outpatient mental health departments and 
University psychology or psychiatry departments (not specifying specialism in affective 
disorders) (Table 3.1). In six cases, the exact location of delivery of the intervention was not 
specified (David Castle et al., 2010; Clarkin et al., 1998; D'Souza et al., 2010; Lenz, 2010; van 
Gent & Zwart, 1991; Zaretsky et al., 2008), however it might be assumed that they were 
conducted at the outpatient clinics or University departments where authors were based. 
Most interventions targeted either the patient alone (k=11) or the patient and their family 
(k=10), three interventions targeted the family or patients significant others only (Bordbar et 
al., 2009; Reinares et al., 2008; van Gent & Zwart, 1991) (Table 3.1). Interventions were 
delivered to only groups (k=8), solely to individuals (k=9), or delivered to the patient and family 
members or as a couple (k=4). 
The median number of intervention contacts as per protocol was 17 (range 1-56), with a mean 
contact time (estimated from data available for 16 studies) of 19.7 (sd 11.67) hours. The 
median duration of interventions was 6 months (IQR=0.5-12), ranging from a single 
intervention to 2 ½ years. 
The spacing of intervention contacts was highly variable including, single-sessions (Bordbar et 
al., 2009) or two contacts (Elixhauser et al., 1990; Peet & Harvey, 1991), but most were 
delivered as a weekly programme for at least 6 sessions (k=17). Seven interventions started 
with regular weekly sessions, and before reducing the frequency. The family-focussed therapy 
programmes were conducted for 12 weekly sessions, reducing to bi-weekly, then 3 monthly 
(Miklowitz et al., 2000; Rea et al., 2003). Clarkin and colleagues (1998) psychoeducation for 
couples ran weekly for 10 sessions, then bi-monthly for remaining 15 sessions. Javadpour and 
colleagues (2013) conducted weekly face to face sessions for eight weeks then monthly 
telephone follow-up until 18 months. Booster sessions after the main intervention were a 
feature of three studies (Lam et al., 2000; Lam et al., 2003; Lenz, 2010). 
 
3.5.1.3 Control group 
Thirteen studies compared the intervention to TAU or standard care only (low or high 
intensity), eight compared standard care plus an additional component and four described the 
comparison group as another form of therapy. TAU was classified into low intensity general 
care or intensive support (structured specialist support). 
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The comparison group comprised only low intensity general care in six studies (Clarkin et al., 
1998; Harvey & Peet, 1991; Javadpour et al., 2013; Lam et al., 2000; Lam et al., 2005; Lam et 
al., 2003; Peet & Harvey, 1991; Reinares et al., 2008) and only high intensity in three studies 
(Bordbar et al., 2009; D'Souza et al., 2010; Sajatovic, Davies, et al., 2009). Two studies did not 
provide detail on what TAU constituted (Dogan & Sabanciogullari, 2003; van Gent & Zwart, 
1991). 
Where the comparison group received additional components, these included additional 
clinician training (Ball et al., 2006), very brief medication training (Eker & Harkin, 2012) and 
attention matched group therapy sessions or phone calls to control for contact time (D. Castle 
et al., 2007; Cochran, 1984; Colom et al., 2003). Additional education or psychoeducation 
sessions were provided to control groups, for example seven sessions of psychoeducation (the 
IG received the same and the addition of 13 sessions of CBT) (Zaretsky et al., 2008), individual 
patient treatment sessions with a therapist and medication management sessions with a 
psychiatrist for a year (Rea et al., 2003), the provision of a self-help book and additional group 
sessions (Lenz, 2010). 
The electronic monitoring device intervention provided by Elixhauser and colleagues (1990) 
was compared against TAU and individual compliance feedback based on lithium levels and 
suggestions for improving compliance. 
For the four studies where the comparison group received an alternative intervention, this 
took the form of a programme of therapy differing in content or focus: Intensive Clinical 
Management (ICM), Interpersonal and Social Rhythm Therapy (IPSRT), ‘Crisis management’, 
Family Focussed Therapy and ‘Individual patient management’ (FFT) (Frank et al., 2005; Frank 
et al., 1999; Gilbert, 2000; Miklowitz et al., 2003; Miklowitz et al., 2000). 
 
3.5.1.4 Study & sample characteristics 
The median number of participants in the studies was n=66 (IQR=45-102) and participants 
randomised to intervention groups was n=31 (IQR=19-54). The length of time of follow-up 
varied across studies, participants were followed up for a median of 6 months (IQR=0.5-12) 
after last intervention contact (Table3.2). 
Over one-third of studies (k=9) were based in the United States, three in the UK, three in 
Australia, two in Spain, two in Turkey and Iran and one each in Canada, Austria and the 
Netherlands (Tables 3.8 and 3.9). Data was available in 21 studies for the proportion of males 
and females recruited to the study. Overall there was a mean of 55.72% (sd=12.21) females in 
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the sample, ranging from 25% to 82%. Seventeen studies did not specify the ethnicity of 
participants. 
To determine diagnosis eligibility different criteria were use; DSM (k=17); Research Diagnostic 
criteria (k=2); MINI (k=2); Schedule for Affective Disorders and Schizophrenia (SADS (k=2); 
unspecified (k=1). In 11 studies researchers recruited patients who were euthymic, 5 during 
episodes, 3 during manic episodes only, 1 recruited participants in all states, 4 studies did not 
report this (Table 3.2). 
 
3.5.1.5 Adherence assessment and primary outcome 
Thirteen studies reported the use of more than one assessment method, of which seven 
combined these into one adherence score or categorisation. Seven studies used a composite 
measure of adherence, combining a number of assessment methods which were then either 
rated for the level of adherence, or defined by pre-set criteria (Table 3.2). Subjective 
techniques included self-report (k=11), informant report (k=3) and physician report (k=4). 
Objective techniques (other than biological measures) were used in two studies (D'Souza et al., 
2010; Elixhauser et al., 1990), nine studies used biological measures for example serum 
medication levels. 
Seventeen studies either assessed and reported adherence overall for all medications 
participants were prescribed (Ball et al., 2006; Bordbar et al., 2009; D. Castle et al., 2007; 
Clarkin et al., 1998; D'Souza et al., 2010; Eker & Harkin, 2012; Gilbert, 2000; Javadpour et al., 
2013; Lam et al., 2000; Lam et al., 2003; Lenz, 2010; Sajatovic, Davies, et al., 2009), or assessed 
them separately and then reported an overall adherence result (Frank et al., 2005; Miklowitz 
et al., 2000; Rea et al., 2003; Reinares et al., 2008; Zaretsky et al., 2008). Within these 17 
studies, data was collected and reported for mood stabilisers only in four (Ball et al., 2006; 
Frank et al., 2005; Gilbert, 2000; Lenz, 2010), for mixed medications such as mood stabilisers, 
anti-depressants and benzodiazepines in nine studies (Bordbar et al., 2009; Clarkin et al., 1998; 
D'Souza et al., 2010; Lam et al., 2000; Lam et al., 2003; Miklowitz et al., 2000; Rea et al., 2003; 
Reinares et al., 2008; Zaretsky et al., 2008). Four studies did not report what medications were 
assessed (D. Castle et al., 2007; Eker & Harkin, 2012; Javadpour et al., 2013; Sajatovic, Davies, 
et al., 2009). Only one study measured and reported results individually for different mood 
stabilisers, and this was only at the two year follow-up paper (Colom et al., 2005). Six studies 
only reported on lithium prescriptions (Cochran, 1984; Dogan & Sabanciogullari, 2003; 
Elixhauser et al., 1990; Frank et al., 1999; N. S. Harvey & Peet, 1991; van Gent & Zwart, 1991). 
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The primary outcome included adherence (k=8) (three studies had adherence as the only 
primary outcome and five had multiple primary outcomes including adherence), relapse/ 
recurrence, symptoms (k=14), wellbeing/ functioning (k=7), coping with prodromes (k=1) and 
attitudes towards treatment (k=1), and was not specified for two studies (Clarkin et al., 1998; 
Lenz, 2010). 
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Table 3.1: Intervention components/ delivery 
Intervention Component Number of 
studies (k) 
Content 
All elements of Psychoeducation 
CBT/ CBT-type techniques 
Social/ family therapy 
Communication skills training 
Education 
Psychotherapy 
Medication packaging 
technology 
 
13 
9 
6 
4 
3 
2 
1 
Tailoring 
Micro-tailoring 
Participation 
Individualisation 
Attention tailoring 
Macro-tailoring 
 
16 
16 
6 
5 
1 
Intervention focus 
Multi-focus 
Adherence as primary focus 
Unclear 
 
18 
5 
1 
Provider 
Psychologists 
Psychiatrist 
Mental health nurses 
Social workers 
‘Therapists’ 
Other (research assistants/ 
trainees/ psychiatric counsellor) 
 
5 
6 
3 
3 
3 
4 
Format 
Groups 
Individual 
Family/ couples-based 
Group and individual 
Electronic device, phone & mail 
Group & telephone 
 
8 
9 
4 
1 
1 
1 
Delivery setting 
Hospital outpatient psychology/ 
psychiatry department 
Specialist affective disorder/ 
bipolar clinic/ unit 
University psychology/ 
psychiatry department (not 
specialist BD) 
Other 
Actual delivery location unclear 
 
5 
 
5 
 
5 
 
 
3 
6 
Recipient 
Patient only 
Family/significant others & 
patient 
Family/significant others only 
 
11 
10 
 
3 
Table 3.2: Study design 
Study Component Number of 
studies (k) 
Eligibility assessment 
DSMa 
Research Diagnostic criteria 
MINIb 
SADSc 
Not specified 
 
17 
2 
2 
3 
1 
Control/ Comparison group 
TAUd only (general care) 
TAU only (intensive support) 
TAU+ additional content 
(sessions or materials) 
TAU+ attention matched 
sessions 
TAU+ clinician training 
TAU+  brief medication 
training 
TAU+ compliance feedback 
Alternative intervention 
Unclear 
 
6 
3 
3 
 
3 
 
1 
1 
 
1 
4 
2 
Adherence assessment mode 
Self-report 
Caregiver report 
Physician report 
Objective (pill counts/ MPR) 
Biological measures 
Composite measure 
 
11 
3 
4 
2 
9 
7 
Adherence – medications analysed 
Mixed medications – reported 
globally 
Lithium only 
Mixed medications – reported 
separately 
 
17 
 
6 
1 
Primary outcome 
Relapse/ recurrence/ 
Symptoms 
Adherence 
Wellbeing/ functioning 
Coping with prodromes 
Attitudes towards treatment 
Not specified 
 
14 
8 
7 
1 
1 
2 
n. participants, median (IQR) 
n. participants IG, median (IQR) 
Follow-up from last intervention 
contact, median (IQR) mths 
66 (45-102) 
31 (19-54) 
6 (0.5--12) 
a Diagnostic and Statistical Manual of Mental 
Disorders 
b MINI International Neuropsychiatric Inventory 
c Schedule for Affective Disorders and 
Schizophrenia 
d Treatment as usual 
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3.5.1.6 Quality Indicators (Retention, Fidelity, Intervention description, Study design – risk of 
bias) 
Many studies reported a good participant retention rate in multi-session programmes, for 
example, 76% completing the full programme of nine months of treatment (Rea et al., 2003), 
73% of the intervention group adhering to the programme (missed no more than five out of 21 
sessions) (Colom et al., 2003), 97% taking part in the two session intervention sessions (Harvey 
& Peet, 1991; Peet & Harvey, 1991), 89% participating in at least four psychoeducation 
sessions (average 7 sessions) (Javadpour et al., 2013). Sajatovic and colleagues (2009) found 
that 37% never participated in the sessions, 49% did complete at least four of the six sessions. 
This data was not reported for nine studies (Table 1). Where the programme was delivered to 
caregivers, a good retention rate was reported, for example, 100% of families agreeing to 
participate completing the intervention (Bordbar et al., 2009), 95% of caregivers attending at 
least eight out of 12 sessions (Reinares et al., 2008). 
Eighteen studies specified that the intervention was manualised although only nine studies 
mentioned some form of fidelity assessment. For five studies this was formal assessment by 
independent raters using published or adapted coding systems or scales (Ball et al., 2006; 
Frank et al., 2005; Miklowitz et al., 2003; Miklowitz et al., 2000; Rea et al., 2003). The fidelity 
assessments reported good adherence to the manuals, compliance with the principles of the 
therapy and competent delivery. Fidelity assessments which were not formally scored or rated 
were used in four studies (Clarkin et al., 1998; Lam et al., 2000; Lam et al., 2003; Sajatovic, 
Davies, et al., 2009) for example, Sajatovic and colleagues (2009) reported that fidelity was 
assessed by the co-principle investigator delivering feedback at the end of each session. 
Using the TIDieR checklist and guidelines, only two studies provided all detail required to allow 
replication (items 1-9) (Colom et al., 2003; Miklowitz et al., 2000). Adequate reporting was 
most common in; Brief name (100%), Why (rationale, theory or goal) (92%) and What 
(procedures used) (88%). Less well described items were Where (location) (54%), When and 
how much (58%) and What (materials used) (58%) (Figure 3.2). Reasons for coding items as 
‘inadequately described are reported in Table 3.3. 
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Figure 3.2: TiDier reporting 
 
Table 3.3: Summary of reasons for inadequate reporting of interventions 
TIDieR Item Studies adequately 
reporting (%) 
Example reasons for ‘inadequate reporting’ coding 
1. Brief name 100.0 n/a 
2. Why (rationale, 
theory or goal) 
91.7 
Paper doesn’t link theory or rationale with actual intervention 
content or techniques. 
3. What (materials 
used) 
58.3 
No information was provided on where or how to access 
intervention content or materials, or manuals not referenced. 
4. What 
(procedures used) 87.5 
Paper doesn’t provide sufficient detail to replicate the procedure, 
key details on timing, or how to actually carry out the 
intervention is unclear. 
5. Who provided 
54.2 
Information is required on who delivered the intervention, i.e. 
job role, training or expertise and background. Papers often 
reported only job title. 
6. How (mode of 
delivery) 
79.2 
The descriptions provided did not report the size of the groups in 
group delivered interventions. 
7. Where 
(location) 
54.2 
Either the context of the research (to provide information on the 
country and healthcare context) or the exact location of delivery 
of the intervention was not reported (for example in an 
outpatient clinic, hospital or research setting). 
8. When and how 
much 
58.3 
The duration of intervention sessions or the spacing of contacts 
was not reported. 
9. Tailoring 
66.7 
Tailoring techniques are mentioned as being part of the therapy, 
but unclear how they were used or personalised or whether 
there was a two-way dialogue. 
10. Modifications 8.3 n/a 
11. How well 
(planned) 
50.0 The study was manualised but no actual assessment of fidelity, or 
sessions were recorded, but no mention of whether or not an 
assessment of recordings was conducted. 
12. How well 
(actual) 
20.8 The information provided was not specific, ie ‘adherence to 
manual was high’ or the outcome of any fidelity checks was not 
reported. 
 
0 5 10 15 20
1 Brief name
2 Why
3 What (Materials)
4 What (Procedures)
5 Who provided
6 How
7 Where
8 When and How Much
9 Tailoring
10 Modifications
11 How well (Planned)
12 How well (actual)
Number of studies
Adequately reported
Inadequately reported
Not reported
n/a
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The method of randomisation was judged to have low risk of bias in nine studies, high risk in 
one study (Dogan & Sabanciogullari, 2003) but was inadequately described to make an 
assessment in 14 studies. Three studies demonstrated low risk of bias in allocation 
concealment, (Frank et al., 2005; Lam et al., 2003; Miklowitz et al., 2000), one demonstrated 
high risk of bias (Dogan & Sabanciogullari, 2003), in 20 studies and was judged to be unclear. 
Descriptions of blinding of study personnel was inadequately described to judge risk of bias in 
nine studies and in 14 studies there was high risk of bias. Studies were judged to have a high 
risk of bias in participant blinding in 10 cases. Only one study each were judged to have low 
risk of bias for personnel blinding (Castle et al., 2007) and participant blinding (Reinares et al., 
2008) (Figure 3.3). In terms of adherence outcome assessment, 10 studies included an 
outcome measure with low risk of bias, however, 12 studies only included measures where 
there was a high risk of bias (for example self-report). 
Figure 3.3: Risk of bias in included studies (k=23). 
 
3.6 Meta-analysis results 
3.6.1 Primary analysis 
Across 18 studies, there was a significant effect of interventions versus control on adherence, 
OR 2.27, 95% CI [1.45, 3.56], p<0.001). Outcomes were better in the intervention group than 
the control group in 15 studies, as indicated by positive effect sizes, while in 3 studies 
adherence outcomes were not improved relative to control (Table 3.4, Figure 3.4). There was 
substantial heterogeneity between the studies Q(17)=36.96 (p=0.003) I2=54.00. 
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Table 3.4: Primary meta-analysis 
Comparison k OR 95% CI p I2 Heterogeneity 
      Q (df) p 
Composite measures> serum 
levels> self-report > informant 
report & longest follow-up 
assessment. 
18 2.27 1.45,3.56 <0.001 54.00 36.96(17) 0.003 
 
3.6.2 Moderation analysis 
Moderation analysis was conducted to assess whether intervention and study characteristics 
(intervention focus, content, delivery, setting, tailoring, fidelity, primary outcome and target 
medication, baseline illness state, control group, publication year and follow-up time) 
contributed to the variability in effect sizes (Tables 3.5 & 3.6). Intervention contact time 
(hours) had a significant impact with increasing contact time being associated with a reduction 
in effect B=-0.08 (-0.14, 0.02); Q= 6.12 p=.013 (Tables 4 and 5). If TAU was supplemented with 
an additional component for the control group, the intervention effect was smaller (p=0.034) 
(Table 3.6). None of the other variables significantly moderated the intervention effect. 
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Figure 3.4: Forest plot of odds ratios of studies included in primary meta-analysis 
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Table 3.5: Moderation analysis - Intervention characteristics 
Intervention characteristics k OR (95%CI) Heterogeneity (within 
group) 
Q(df), p, I2 
Heterogeneity 
(between 
group) 
Q(df), p 
Intervention focus 
Multi-focus 
Adherence as primary focus 
 
14 
4 
 
2.09 (1.23,3.54) 
3.12 (1.18,8.25) 
 
30.43(13), 0.004, 57.27% 
6.02(3), 0.111, 50.17% 
0.50(1), 0.479 
Content 
Psychoeducation – all elements 
Other 
 
11 
4 
 
2.14 (1.18,3.89) 
3.03 (0.89,10.23) 
 
27.82(10), 0.002, 64.06% 
5.59(3), 0.133, 46.35% 
0.25(1), 0.617 
Delivery setting 
Specialist 
General 
 
4 
11 
 
3.17 (1.09, 9.21) 
1.65 (0.94, 2.92) 
 
9.28(3), 0.026, 67.66 
18.80(10), 0.043, 46.79 
1.12(1), 0.289 
Delivered to partner/family only 
Delivered to partner/family & pt 
2 
4 
1.31 (0.20,8.55) 
1.98 (0.57,6.93) 
0.73(1), 0.400, 0.00% 
16.60(3), 0.001, 81.93% 
0.13(1), 0.719 
Individual and/or group only 
Family/partner & pt involved 
12 
4 
2.66 (1.45,4.85) 
1.94(0.75,5.06) 
17.89(11), 0.084, 38.49% 
16.60(3), 0.001, 81.93% 
0.29(1) 0.588 
Group & individual 
Group only 
Individual 
2 
4 
6 
1.75 (0.29,10.41) 
2.77 (1.23,6.23) 
2.69 (1.23,5.90) 
3.99(1), 0.046, 74.95% 
8.13(3), 0.043, 63.12% 
4.98(5), 0.418, 0.00% 
0.22(2) 0.896 
Tailoring – Individualisation 
Yes 
No/ Unclear 
 
4 
14 
 
3.56 (1.84,6.89) 
1.95 (1.41,2.69) 
 
7.44(3), 0.059, 59.68% 
26.94(13), 0.013, 51.75% 
1.06(1) 0.303 
Tailoring – Attention (individual 
level) 
Yes 
No/ Unclear 
 
 
2 
16 
 
 
4.58 (1.43,14.66) 
2.08 (1.54,2.81) 
 
 
0.09(1), 0.763, 0.00% 
35.22(15), 0.002, 57.41% 
 
0.89(1) 0.346 
Tailoring – Micro (individual 
level) 
Yes 
No/ Unclear 
 
 
14 
4 
 
 
2.18 (1.57,3.01) 
2.24 (1.17,4.30) 
 
 
30.78(13), 0.004, 57.77% 
6.17(3), 0.104, 51.37% 
 
0.14(1) 0.714 
Tailoring – Participation 
Yes 
No/ Unclear 
 
13 
5 
 
1.97 (1.64,2.93) 
2.89 (1.67, 5.00) 
 
27.44(12), 0.007, 56.27% 
8.17(4), 0.086, 51.05% 
0.82(1) 0.365 
Manualised 
Yes 
No 
 
13 
5 
 
2.03 (1.21,3.42) 
3.26 (1.29,8.27) 
 
23.86(12), 0.021, 49.70% 
11.58(4), 0.021, 65.45% 
0.76(1), 0.384 
Intervention fidelity assessed 
Formal 
Informal 
No fidelity assessment 
reported 
 
3 
4 
11 
 
0.98 (0.397,2.425) 
4.25 (1.825,9.903) 
2.34 (1.372,3.976) 
 
4.80(2), 0.091, 58.32% 
0.82(3), 0.844, 0.00% 
20.17(10), 0.028, 50.42% 
5.424(2), 0.066 
 k B, (95% CI) Q; p  
Intervention contacts (per 
protocol) Range 2- 27 
18 -0.04 (-0.10,0.01) 2.21; 0.137 
 
Intervention duration (months) 
Range 1.4- 12 
17 -0.11 (-0.24,0.02) 2.86; 0.091 
 
Intervention contact time 
(hours) 
Range 6- 31.5 
12 -0.08 (-0.14,0.02) 6.12; 0.013 
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Table 3.6: Moderation analysis – Study characteristics 
Study characteristics k OR (95%CI) Heterogeneity (within 
group) Q(df), p, I2 
Heterogeneity 
(between 
group) Q(df), p 
Adherence a primary outcome 
No (including ‘missing’) 
Yes 
 
12 
6 
 
1.91 (1.12,3.27) 
3.34 (1.40,7.45) 
 
21.79(11), 0.026, 49.53% 
12.07(5), 0.034, 58.58% 
1.29(1), 0.256 
Target medication 
Mixed medication – reported/ 
assessed together 
Lithium only 
 
13 
 
4 
 
2.43 (1.45,4.01) 
 
2.51 (0.65,9.63) 
 
28.13(12), 0.005, 57.34% 
 
6.54(3), 0.008, 54.14% 
0.002(1), 0.968 
Baseline state 
Episodic included 
Euthymia only 
 
5 
10 
 
2.05 (0.88,4.75) 
2.62 (1.38,4.96) 
 
15.95(4), 0.003, 74.93% 
15.21(9), 0.085, 40.81% 
0.21(1), 0.649 
TAU type 
General care 
Intensive care 
 
11 
5 
 
2.46 (1.66,3.65) 
2.02 (1.25,3.26) 
 
17.82(10), 0.058, 43.87% 
17.42(4), 0.002, 77.03% 
0.14(1) 0.710 
TAU + education/ 
psychoeducation 
Yes 
No/ Unclear 
 
4 
14 
 
0.92 (0.50,1.70) 
2.81 (2.02,3.90) 
 
4.42(3), 0.220, 32.11% 
22.75(13), 0.045, 42.86% 
4.47(1) 0.034 
 K B, (95% CI);  Heterogeneity Q; p  
Publication year 
 
18 -39.88 (-160.74,80.98) 0.44, 0.509 
 
Follow-up duration (mths since 
last intervention contact) Range 0 
to 60 
18 -0.02 (-0.05,0.01) 1.66; 0.197 
 
Follow-up duration(mths from 
baseline (excluding van Gent) 
Range 1.4 to 65 
17 -0.03 (-0.05,0.00)  3.06; 0.080 
 
 
3.6.3 Sensitivity analysis 
The effect of interventions on adherence remained similar when small studies, studies with 
low retention and outliers were excluded, and across all follow-up points (Table 3.7). When 
only studies using serum levels were included there was no significant effect of intervention 
however the effect size was similar to the overall analysis. Highest OR were found by including 
those reporting outcomes from composite measures (2.50) followed by serum levels (1.91) 
and self-report (1.71). Significant heterogeneity was present when including ORs from studies 
using composite measures (Q(7)= 27.35, p<.001). Study ORs were not significantly 
heterogeneous within the serum level or self-report outcome measures. 
The overall OR was reduced for those studies with low risk of bias in outcome measure 
blinding OR=1.49 (0.60,3.70) and selective reporting OR=1.66 (0.60,4.91). However, a higher 
effect was seen where studies had low risk of bias in incomplete outcome data OR=2.99 
(1.44.6.21). 
87 
Table 3.7: Sensitivity analysis 
      Heterogeneity 
Comparison k OR 95% CI p I2 Q (df) p 
Small studies excluded 5 2.57 1.31,5.06 0.006 53.72 8.64(4) 0.071 
Outlier excluded 
17 2.18 1.39,3.41 0.001 53.98 
34.77(16
) 
0.004 
Follow-up assessment retention 
< 75% excluded 
9 3.16 1.67,5.96 <.001 50.78 16.25(8), 0.039 
Adherence measure (final 
timepoint assessed is used) 
       
Serum levels 6 1.91 1.10,3.32 0.021 1.78 5.09(5) 0.405 
Serum levels a 5 1.77 1.03,3.05 0.040 0.00 2.58(4) 0.631 
Composite measures a 8 2.50 1.11,5.66 0.028 74.41 27.35(7) <0.001 
Self report a 9 1.71 1.05,2.14 0.033 40.43 13.43(8) 0.098 
Timepoint assessed        
~1-3 mths 7 1.87 0.86,4.08 0.117 69.80 19.87(6) 0.003 
~1-3 mths a 6 1.63 0.76,3.51 0.213 70.39 16.89(5) 0.005 
~ 6 mths a 7 1.91 1.15,3.19 0.013 24.59 7.96(6) 0.241 
~ 12 mths a 
11 1.97 1.23,3.16 0.005 52.16 
20.90(10
) 
0.022 
Low risk of biasb        
Blinding of outcome measure 7 1.49 0.60,3.70 0.393 57.39 14.08(6) 0.029 
Incomplete outcome data 9 2.99 1.44,6.21 0.003 54.82 17.71(8) 0.024 
Selective reporting 2 1.66 0.56,4.91 0.362 25.60 1.34(1) 0.246 
a  Dogan et al (2003) excluded or not present in analysis (Dogan & Sabanciogullari, 2003) 
b Risk of bias analysis for risk measures where at least 2 studies were in low risk category (where risk was unclear, 
studies were excluded) 
 
3.6.4 Publication bias 
The funnel plot was symmetrical suggesting the absence of publication bias (Figure 3.5). Duval 
and Tweedie’s ‘trim and fill’ method suggested that one study would need to be added or 
removed for the funnel plot to be symmetrical. The imputed OR after this procedure was 2.181 
(1.389, 3.422) i.e. very similar to our original estimate of the effect of interventions on 
adherence (Figure 4 for funnel plot with imputed study). Egger’s test for asymmetry was not 
significant indicating no evidence for publication bias, the B0(bias) = 0.86213, 95% CI (-
1.74167, 3.46594), with t=0.70191, df=16., p=0.24641. The fail-safe N was calculated and 117 
studies would need to be included, i.e. 6.5 missing studies for every observed study, for the 
intervention effect to be nullified. The results of these tests indicate that publication bias does 
not present a threat to the results of this meta-analysis. 
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Figure 3.5: Funnel plot with one imputed study 
 
3.7 Discussion 
3.7.1 Intervention effects and moderators of effects 
This review brings together the published literature on RCTs of interventions to enhance 
medication adherence in bipolar disorder. There is strong evidence that interventions can 
improve adherence. The pooled OR was 2.27 (95% CI 1.45, 3.56) equivalent to a two-fold 
increase in the odds of adherence in the intervention group relative to control. The effects 
appear to be durable, as there was no significant change in effect of the interventions when 
patients were followed up at longer post-intervention intervals. Studies with a two-year 
follow-up still reported positive effects on adherence. 
Interventions which involved more contact were less effective than less intense interventions. 
Smaller intervention effects were found when the comparison group received additional 
therapy sessions compared to those receiving just TAU. When analysing only studies with low 
risk of bias, i.e. higher quality studies, interventions remained effective, indicating that 
effectiveness was not as a result of only poor quality studies. No other significant moderator 
variables were associated with intervention effectiveness. However, both intervention and 
study design were often poorly reported, limiting the extent of moderation and sensitivity 
analysis which could be conducted. 
Most interventions involved psychoeducational techniques which appear to be effective; these 
take into account an individuals’ knowledge, beliefs and attitudes. These are promising areas 
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of focus for interventions (Gaudiano et al., 2008; Leclerc et al., 2013; Sajatovic et al., 2004) and 
are included in recommendations for improving adherence in the UK National Health Service 
(Horne et al., 2005). Taking into account participants’ own beliefs and opinions about bipolar 
and its treatment may foster better engagement (L. Berk et al., 2010; Clatworthy et al., 2009). 
However, additional evidence is needed to tease out the mechanisms behind how these 
interventions might have an effect because description of intervention content was often 
poor. The way psychoeducation or CBT were operationalised varied across studies, therefore 
accurate moderation analysis comparing intervention types is challenging. In this review the 
information provided on intervention content was scrutinised, rather than relying on the broad 
title or name given to each intervention. 
Many of the interventions are complex and resource intensive and further identification of the 
active components, mechanisms of action and effective dose of intervention will be needed 
before they could be integrated into clinical care (Batista et al., 2011; Rouget & Aubry, 2007). It 
is recommended that future trials use published taxonomies of evidence-based BCTs in 
planning, delivery and reporting (Michie, Johnston, et al., 2013; Michie et al., 2011). Many 
studies used multiple methods to measure adherence conforming to the recommendation that 
studies should use more than one type of measure (Horne et al., 2005; Sajatovic et al., 2010). 
Sensitivity analysis demonstrated that a positive effect of the interventions was present 
regardless of type of measure used. 
Smaller intervention effects were found when the comparison group received additional 
therapy sessions than when this group received only TAU. This confirms empirically the 
conclusion by Guadiano and colleagues (2008) that interventions compared to TAU, 
predominantly CBT and psychoeducation, had greater evidence for effectiveness than for 
those using an active control, which tended to be Family-focussed Therapy and Interpersonal 
and Social Rhythm Therapy interventions. Comparing groups receiving different ‘active’ 
interventions e.g. in factorial designs, is essential to identify the effective components of the 
intervention (Collins, Murphy, & Strecher, 2007) and if the intervention is effective beyond 
attentional ‘Hawthorne’ effects. However, TAU comparison groups are also extremely useful 
as, in practice, the content and attention participants’ receive are components of the 
intervention and using TAU can establish whether the intervention can improve outcomes over 
and above current standard care (Freedland, Mohr, Davidson, & Schwartz, 2011). 
Smaller effects on adherence were found in longer interventions. But these were typically 
multi-focused interventions that did not have adherence as the primary outcome and aimed to 
improve clinical outcomes through a range of determinants. Sessions may have focussed 
initially on medication, but then moved on to other aspects of self-management. The three 
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shortest interventions all had adherence as a primary outcome, the focus was firmly on 
adherence (Cochran, 1984; Eker & Harkin, 2012; Sajatovic, Davies, et al., 2009). These findings 
are consistent with Gaudiano and colleagues (2008) suggestion that making an intervention's 
primary focus adherence tends to increase effects on adherence, and suggests that resource 
intensive interventions may be unnecessary for adherence improvement. In clinical care, the 
briefest interventions may be more easily adopted. However, we recognise that many of the 
longer interventions also had impacts on adherence, and that these more complex 
interventions may address other determinants clinical outcomes in bipolar disorder not 
explored in this review. 
There was a great deal of heterogeneity between the studies, in terms of setting, content, 
adherence outcome, follow-up and quality, concurring with previous narrative reviews (Crowe, 
Porter, et al., 2012; Desplenter et al., 2006; Leclerc et al., 2013; Reinares, Sánchez-Moreno, & 
Fountoulakis, 2014). We found no intervention, study design or delivery moderator variables 
except those mentioned above, significantly distinguished between the effectiveness of 
studies. 
 
3.7.2 Limitations of studies included in the review 
The conclusions which can be drawn from the review are limited by both the quality of the 
RCTs themselves and in the reporting of both the trials and the interventions tested. As stated, 
it was not possible to include a number of studies in the moderation analyses as data items 
were inadequately reported. 
Although some intervention description items were consistently reported, overall only two out 
of 24 studies provided sufficient information for replication. Other assessments of inadequate 
reporting of trials have been conducted, although not using the TIDieR checklist. An 
assessment of reporting in National Institute of Health Research (NIHR) Health Technology 
Assessment (HTA) funded RCTs demonstrated that components necessary for replication were 
missing in 73% of published psychological interventions (Douet et al., 2014). Hoffman et al 
(2013) found that only 39% of non-pharmacological interventions published in 2009 had 
adequate reporting. Items poorly reported in the present review included Item 3 (Materials), 
concurring with previous studies (Glasziou et al., 2010; Hoffmann et al., 2013). However, in 
previous studies authors were able to increase the proportion of studies classed as having 
adequate information available by contacting authors for this information (not conducted in 
the present review). Item 7. Where (location) and Item 5 Who provided were also poorly 
reported, in specifying both the healthcare context and the actual delivery setting of the 
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intervention and in specifying the training and experience of staff members respectively. 
Hoffman and colleagues (2014) note that these details are important as they can affect the 
feasibility of replicating the intervention. If interventions were described consistently it would 
allow for more thorough moderation analysis to be conducted. It is recommended that authors 
make use of TIDieR guidelines to ensure consistency of reporting (Hoffmann et al., 2014). 
The publication of reporting guidelines is relatively recent compared to the timescale of 
included studies in the review. The CONSORT extension for non-pharmacological interventions 
was published in 2008 (Boutron et al., 2008), however, in the present review eight studies 
were published in 2008 or later and the two studies reporting all items adequately were 
published prior to this. It is appreciated that due to journal restrictions it may be difficult to 
provide the necessary information succinctly. It is recommended that this information should 
be published in trial protocols, in supplementary journal information or linked to from trial 
register websites. 
Study quality was assessed using published guidelines (Higgins et al., 2011) and sensitivity 
analysis was used to assess its impact on the conclusions. The quality of the studies varied and 
randomisation and allocation concealment methods were often not adequately reported to 
judge risk of bias. Blinding of personnel and participants may be difficult or impossible in the 
delivery of psychosocial interventions (Davidson et al., 2003). Blinding of outcome assessment 
of the studies in the meta-analysis was classified as having a high risk of bias in half of the 
studies as they included self-report. When we included only studies where the outcome 
assessments were blinded and where studies did not selectively report outcomes, the 
effectiveness of these interventions was lower than when all studies were included. This fits 
with the hypothesis that poor quality may inflate effects. However, interventions remained 
effective over control when only high quality studies were included. Researchers need to 
adopt consistent standards of reporting so that risk of bias can be reliably judged such as 
CONSORT statements (Boutron et al., 2008). 
For the effect sizes selected for comparison, half (9/18) were based on results where over 25% 
of follow-up data was not available for one or both groups. Exclusion of these studies resulted 
in an increase in overall OR, indicating that studies with poorer follow-up rate were not biased 
to reporting better results. Sensitivity analysis also demonstrated that the effects did not arise 
purely from studies with small samples. However using a recommended cut-off of n<70 for 
either intervention or control group (Coyne et al., 2010), only five studies remained indicating 
that recruitment to these trials may be challenging. It is striking that many of the studies in this 
review were not sufficiently powered to detect moderate to large effects. The meta-analysis 
process, in pooling results, increases the statistical power overall (Petticrew & Gilbody, 2004; 
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Walker et al., 2008). However, the fact that the meta-analysis is based on a large proportion of 
small studies may affect the results as they may be more prone to methodological issues which 
may increase the risk of bias. These include that groups may be dissimilar at baseline, may be 
more influenced by outliers and recruitment may have stopped once statistically significant 
intervention effects are found (Coyne et al., 2010). Published protocols and clear sample size 
calculations are needed to assess the likelihood of this bias. It is clear that larger, more 
adequately powered trials are needed.  
In terms of retention to the interventions themselves, data on this was not reported for nine 
studies so it is impossible to tell whether those assigned to receive it actually received did so or 
for researchers to conduct sensitivity analysis to detect whether effects were related to 
intervention exposure. 
 
3.7.3 Strengths & Limitations of the review 
There are a number of strengths to the present review which increase its validity and 
reliability. The review is reported in accordance with guidelines in the PRISMA statement 
(Moher et al., 2009). This helped minimise selection bias and ensure reporting transparency in 
order that the review could be replicated. Published guidelines for conducting reviews as well 
as assessing quality of studies and reporting of interventions were used (Boutron et al., 2008; 
Davidson et al., 2003; Higgins et al., 2011; Hoffmann et al., 2013; Schulz et al., 2010). An 
experienced librarian assisted with the design of the search strategy and search terms from a 
previous adherence review were incorporated (Haynes et al., 2008). 
Registered trials, conference abstracts and published doctoral theses were included to reduce 
selection bias caused by including only studies published in peer-reviewed journals. Study 
selection was performed independently by two researchers to also minimise bias in selection. 
Two investigators coded and extracted data for each study, increasing reliability and 
disagreements were resolved through discussion and seeking input from a third researcher 
when needed. 
Limitations of the published studies are reflected in the limitations of this review, i.e. poor 
reporting and quality limiting the conclusions which can be drawn. Included studies were not 
homogeneous, with regard to population, type of interventions and outcome measures, 
assessment timepoints and adherence definitions. It could be argued that studies which are 
too disparate cannot be compared. However, inclusion criteria were broad in order that the 
study characteristics could be examined using moderation analysis. 
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Lack of evidence on interventions for specific clinical groups limits our ability to establish what 
works for whom. The majority of the interventions in this and previous reviews have focussed 
on euthymic patients and are therefore not generalizable to those in acute phases (Colom & 
Lam, 2005; Crowe et al., 2010). Patients who have experienced greater number of bipolar 
episodes may be less likely to benefit from long duration CBT (Scott et al., 2006). In this review, 
data was not available on number of previous episodes for us to test this as a hypothesis. In 
addition, it is important to further investigate the effects on individuals who are inpatients, or 
who have comorbidities (L. Berk et al., 2010; Desplenter et al., 2006; Lolich et al., 2012; Rouget 
& Aubry, 2007). 
The measurement of treatment adherence in psychiatry is complex (Sajatovic et al., 2010) and 
this review is affected by the heterogeneity of adherence outcomes. To compute an overall 
effect, odds ratios were used as most studies reported the proportion of participants who 
were classified as adherent/ non-adherent and this produced the most comparable results 
across studies, even though adherence cut-offs differed. There is no agreed clinical adherence 
level for BD and further research is needed to determine whether a clinically appropriate 
standard can be identified (Velligan et al., 2010). An improvement in adherence in one study 
may not equate to the same clinical outcome as the same magnitude of improvement in 
another. Sensitivity analysis demonstrated that a positive effect of the interventions was 
present regardless of type of measure used. 
More broadly than the difficulties in measuring adherence, is the individual variability in BD 
itself, the symptom profile differs between individuals and within individuals over time. This 
means that it is challenging to draw conclusions about effectiveness of interventions, not just 
because of the different ways trialists might select participants, but also in the fact that the 
participants will have their own unique views and characteristics which may affect how they 
experience the intervention. 
Using the TIDieR checklist interventions were coded from the published paper included in the 
review as well as any referenced protocols, papers and available manuals. Contacting authors 
for additional information as conducted by Hoffman et al (2013) was not carried out in this 
review which would be recommended for future reviews and intervention development. 
However, that the information is not readily available is itself an important finding as pursuing 
this extra information is time consuming and may not be feasible for clinicians looking to 
assess potential interventions. The checklist was only applied to the intervention group and 
not to the control or comparison group. In the present review the comparison group was 
coded using basic criteria for its content, however, a full assessment of reporting of all trial 
arms would add to the picture of reporting adequacy. 
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The present review is based on published data only. Registered trials were searched and 
investigators were contacted in order to obtain results of registered trials which were not 
found through the bibliographic database searches, but this did not yield additional results. In 
addition, the full text or sufficient results for meta-analysis were not available for eight studies 
despite numerous attempts to obtain these. However, we found no evidence of publication 
bias, and as adherence interventions are resource intensive, it would be unlikely that there 
would be the number of unpublished studies (k=117) needed to nullify the overall effect of 
interventions found in this review. 
 
3.7.4 Other interventions of note 
A number of relevant interventions were not included in the review due to either not utilising 
an RCT design or including a mixed psychiatric sample without sub analysis. It is worthwhile 
considering these briefly as they provide some useful points for consideration for the 
development of adherence interventions. 
An adherence intervention for people with serious mental illness developed by Valenstein et al 
(2011) was tested in an RCT. Delivered by pharmacists or technicians, this comprised of ‘unit of 
use packaging’, an educational session about medication, refill reminders and clinician 
reminders in cases of failure to refill prescriptions. This intervention significantly increased 
adherence as assessed by medication possession ratios in comparison to the usual care group. 
This intervention is of note due to novel delivery by pharmacists. Additional research would be 
needed to establish its effectiveness in a statistically powered sample of patients with BD. 
A pilot multi-component adherence intervention for older adults with BD, the Medication 
Adherence Skills Training for Bipolar Disorder (MAST-BD) used a quasi-experimental 
methodology (Depp, Lebowitz, Patterson, Lacro, & Jeste, 2007). The intervention comprised 
education, motivational training, medication management and symptom management and 
incorporated specific issues facing older adults, namely cognitive impairment and medical 
comorbidity and showed a decline in non-adherence. Feasibility and acceptability evaluation 
revealed that participants felt the intervention should be more individually tailored and future 
interventions should address this. 
An intervention of psychiatric Advance Directives on adherence in people with severe mental 
illness comprised a guided discussion of choices for planning of mental healthcare to be 
received during future periods of illness and completion of advanced directives (Wilder et al., 
2010). After 12 months, those who had requested a particular medication were more likely to 
be taking it and being prescribed at least one medication which had been requested in the 
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advance directive significantly predicted higher medication adherence. This study 
demonstrates the importance of involving participants in medication decisions. 
Customised adherence enhancement (CAE) was designed to address the need for a short-term, 
lower intensity psychosocial intervention which focuses specifically on adherence and 
incorporates a ‘needs-based approach’ (Sajatovic et al., 2012). The intervention was delivered 
flexibly according to participant need and was tested in a prospective non-controlled trial with 
poorly adherent patients with bipolar disorder. The intervention was associated with improved 
adherence at three and six month follow-up, in addition, there was good attendance at 
intervention sessions. A larger, controlled study is needed to confirm the results from this 
study. 
 
3.7.5 Conclusions & Implications for intervention development 
This review quantitatively synthesises evidence for adherence interventions in BD, including 
psycho-educative approaches and other techniques and therapies. Strong evidence was found 
for the effectiveness of interventions to improve adherence. Brief adherence interventions 
should be incorporated in routine clinical practice as it would be likely to lead to improved and 
sustained adherence outcomes for patients. Adherence interventions could positively impact 
on outcomes for people with a diagnosis of BD through reducing relapse and risk of 
hospitalisation. 
Identification of the active components, mechanisms of action and effective dose of 
intervention is needed to allow for easier integration into clinical care in that interventions 
only use the minimum resources necessary (Batista et al., 2011; Rouget & Aubry, 2007). It is 
recommended that future reviews and trials conducted make use of published taxonomies of 
evidence-based behaviour change techniques in planning and delivery as well as in reporting 
(Michie, Johnston, et al., 2013; Michie et al., 2011). However, we can be confident that 
prolonged, resource intensive interventions may not be necessary. 
The capacity to draw conclusions about exactly what works and for whom is limited by the 
strength of reporting specifically the descriptions of the intervention content and delivery. The 
growing body of evidence and improved trial and intervention reporting will allow us to draw 
more conclusive recommendations as to whether these results can be generalised to more 
naturalistic clinical settings. However, with the evidence available, we can be confident that 
conducting a brief intervention incorporating psychoeducation or CBT skills can be effective in 
improving adherence outcomes in bipolar disorder. 
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Conducting this review comprises a crucial step in the process of developing a novel 
intervention (Craig et al., 2008) and forms part of the needs assessment stage of IM 
(Bartholomew et al., 2011). The results of the review therefore provide confirmation of the 
types of intervention which can be effective and has identified gaps where further research 
and deeper understanding of the specific needs of people is required. Chapter 4 comprises the 
next stage of this development process and needs assessment by exploring factors associated 
with adherence and self-management including illness and treatment perceptions and unmet 
information needs of people with BD. As well as seeking their perspectives on information and 
support to further inform intervention development. 
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Table 3.8: Summary of included studies –Adherence specific interventions 
Study Country Intervention Control 
description 
Intervention 
retention 
Participants Follow-up 
after last 
intervention 
contact 
Adherence 
a primary 
outcome? 
Adherence 
measurement 
Adherence Results 
Cochran 
(1984). 
US Modified CBT 
delivered 
individually by 
Psychologists 
weekly for 6 weeks. 
TAU (affective 
disorders clinic, 
inc. brief 
medication visits 
weekly or 
bimonthly) 
86% 
participants 
completed 
full 6 weeks. 
38 pts (IG=20, CG= 
18) with current 
lithium 
prescription. Mean 
age 32, 61% 
female, 21% 
married. 
6 mths Yes Author designed 
self report, 
informant report, 
and Physician 
report scales. 
Serum lithium 
levels. 
Compliance index 
Self & Informant report: no 
sig. differences between IG 
and CG at post, 3 mths or 6 
mths. 
Physician report: Sig. 
difference between IG and 
CG at post-intervention 
and 6 mths (n/s at 3 mths). 
Serum levels: n/s at post-
intervention and 3 mths. 
Levels mostly unavailable 
at 6 mths. 
Compliance index: Sig. 
difference between IG and 
CG at post-intervention 
and 6 mths (n/s at 3 mths). 
IG less likely to have major 
compliance problems. 
Dogan & 
Sabanciogullari 
(2003). 
Turkey Education sessions 
delivered 
individually by 
Psychiatric nurses 
for 2 sessions 
followed by one 
group session. 
TAU (no details 
specified) 
Not 
specified 
32 pts (IG=14, 
CG=12) long-term 
lithium users. Mean 
age 38, 35% 
female, 73% 
married. 
2 mths Yes Serum lithium 
levels 
Sig. difference between IG 
and CG in baseline to 3 
mth change in proportion 
of pts low to normal serum 
levels. Higher proportion in 
IG moving to ‘normal’ 
range levels than in CG. 
Elixhauser et 
al. (1990). 
US Use of an electronic 
adherence 
monitoring device 
and feedback for 
individuals on 
adherence. 
TAU (psychiatric 
outpatient clinic, 
usual mail refill 
of lithium 
prescriptions) 
+ 
Not 
specified 
93 pts (IG=42, 
CG=51) with 
current lithium 
prescription. Mean 
age 49, gender 
3 mths Yes Self-report 
(Morisky) 
Serum lithium 
levels. 
Prescription refills 
(% obtained). 
Self report scale mean & % 
reporting no missed doses 
– n/s effect of intervention 
(monitoring or feedback).  
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Provision of 
adherence 
education for non-
adherent individuals 
by phone or mail. 
Feedback on 
compliance 
(from lithium 
levels) and 
suggestions for 
improving 
compliance at 
visit 2. 
breakdown not 
reported. 
Medication taking 
patterns - Daily 
and period pill 
counts (% 
prescribed doses) 
Serum lithium – n/s effect 
of intervention (monitoring 
or feedback). 
Prescription refills (%) – 
significant effect of 
monitoring with higher & 
refill in intervention group. 
n/s effect of feedback. 
Harvey & Peet 
(1991). 
Peet & Harvey 
(1991) 
UK Educational video 
on lithium with 
illustrated transcript 
viewed by 
participants 
followed by 
individual home visit 
after 2 weeks for 
discussion with 
Psychiatrists. 
TAU (not 
specified) 
+ 
Educational 
intervention at 
12 weeks. 
97% 
attended IG 
sessions 
60 pts (IG=30, 
CG=30) in remission 
attending lithium 
clinic. Mean age 
55m 67% female. 
5 mths Yes Red blood cell 
lithium levels 
during fixed-dose 
regimen. 
Estimate of 
missed doses/ 
days in each 6 
week period, 
checked without 
warning with 
spouse or other. 
Lithium RBC, serum levels 
and lithium ratio: No sig. 
difference between change 
scores for IG and CG. 
Lithium missed days: sig. 
difference in change scores 
with a greater reduction in 
missed doses in the IG 
compared to CG 
Sajatovic et al. 
(2009). 
US Life Goals Program 
(LGP) – Group 
psychoeducation 
sessions delivered 
by a mental health 
nurse and 
‘psychiatric 
counsellor’ in 6 
weekly sessions. 
Followed by 
optional monthly 
unstructured group 
sessions. 
TAU (community 
mental health 
centre care, 
typically 
medication 
management, 
psychosocial 
therapy, 
counselling, 
access to 
intensive 
assistance. 
49% 
completed 
at least 4 
sessions. 
37% 
completed 
no sessions, 
less than 
10% 
participated 
in optional 
sessions. 
164 pts (IG=84, 
CG=80) in remission 
or episodic. Mean 
age 40, 68% 
female, 13% 
married. 
10 ½ mths Yes Adherence 
behaviours SRTAB 
- self-report over 
past 30 days, 0%, 
25%, 50%, 75% 
100%. 
SRTAB 3 months IG (n=62) 
83.87(28.66), CG (n=61) 
81.15(32.49) 6 months I 
(n=51) 90.20(22.40), C 
(n=55) 77.27(35.12) 12 
months I (n=41) 
95.73(11.04), C (n=39) 
81.08(30.85) p=.41. 
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Table 3.9: Summary of included studies - Multi-focus interventions 
Study Country Intervention Control description Intervention 
retention 
Participants Follow-up 
after last 
intervention 
contact 
Adherence 
a primary 
outcome? 
Adherence 
measurement 
Adherence Results 
Multi-focus interventions (Individual/ couples/ family) 
Ball et al. 
(2006). 
Australia Modular cognitive 
therapy 
programme 
incorporating 
Psychoeducation 
and CBT 
techniques. 
Delivered by 
Psychologists 20 
weekly, individual 
sessions. 
TAU (sessions as 
required with GP/ 
psychiatrist. 
+ 
Clinicians provided 
with educational 
package on BD & 
mood monitoring. 
Not specified 52 pts (IG=25, 
CG=27) with at 
least 1 bipolar 
episode in last 
18mths. Mean age 
42, 58% female. 
12 mths No Serum 
concentration. 
Self-report 
(reporting 
occasions of 
missing 
medication) 
Self-report; n/s between 
proportion with adequate 
compliance in IG and CG, 
either post-treatment or 
12 mths. 
Serum levels not reported 
due to low attendance for 
measurement. 
Clarkin et 
al. 
(1998). 
US Structured 
Psychoeducation 
intervention for 
patients and their 
spouses delivered 
by Social workers 
in 25 sessions, 11 
months. 
TAU (medication 
management as part 
of usual inpatient and 
outpatient care) 
Not specified 42 pts (IG= 19, 
CG= 23) married 
or living with sig 
other > 6mths. 
Mean age 47, 46% 
female. 
0 (post-
intervention) 
Not 
specified 
Author 
developed 
adherence 
scale 
Sig. difference between 
IG and CG in adherence 
scores at post-
intervention follow-up. 
(nb missing data for 1/3 
CG) 
Frank et 
al (1999). 
US Interpersonal and 
social rhythm 
therapy (IPSRT) – 
Psychotherapy 
and 
psychoeducation 
with a focus on 
life events and 
social rhythms. 
Individually 
delivered with 
Intensive clinical 
management 
(sessions focus on 
education, adherence 
& side-effects), 
delivered weekly for 
min 12 weeks, then 
monthly for 2 years. 
Not reported for 
each treatment. 
65% overall 
entered 
preventative 
phase. 
82 pts (IG=60, 
CG=22) in at least 
3rd discrete 
affective episode. 
Mean age 36, 66% 
female, 37% 
married. 
0 (post-
intervention) 
No Adherence – 
ratio of blood 
level to dose 
prescribed. 
n/s difference between 
four different treatment 
strategies in blood levels 
and no effect of changing 
treatment strategy. 
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Study Country Intervention Control description Intervention 
retention 
Participants Follow-up 
after last 
intervention 
contact 
Adherence 
a primary 
outcome? 
Adherence 
measurement 
Adherence Results 
ancillary family 
education 
sessions. IPSRT 
delivered by 
'therapist' and 
physician weekly 
for min 12 weeks, 
then monthly for 
2 years. 
Frank et 
al. 
(2005). 
US IPSRT delivered by 
non-physician 
clinician (social 
worker, nurse, or 
psychologist) and 
a psychiatrist. 
Sessions delivered 
weekly until 
stabilisation, 
every other week 
for 12 weeks 
(preventative 
phase) and 
monthly until the 
end of the 2-year 
(maintenance 
phase). 
Intensive clinical 
management 
(sessions focus on 
education, adherence 
& side-effects), 
delivered weekly for 
min 12 weeks, then 
monthly for 2 years. 
Not reported for 
each treatment. 
70% retention 
rate at end of 
stabilisation. 
53% of originally 
randomised 
completed 2 
year 
maintenance. 
175 pts (IG=132, 
CG=43) in at least 
3rd discrete 
affective episode. 
Mean age 35, 57% 
female, 35% 
married. 
0 (post-
intervention) 
No Serum levels - 
coefficient of 
variation of 
mood 
stabilizer 
medication. 
No significant difference 
between four different 
treatment strategies in 
coefficient of variation of 
mood stabilizer serum 
levels. 
Gilbert 
(2000). 
US Family Focussed 
Therapy (FFT) 
involving 
psychoeducation, 
communication 
enhancement 
training and 
Individual patient 
management (30 min 
sessions inc support, 
problem solving and 
education, 1-2 family 
education sessions & 
Not specified 53 pts (IG=19, 
CG=18) with 
manic episodes 
with consenting 
family member. 
Mean age 25, 57% 
12 mths No Adherence 
scale (7 point), 
psychiatrist 
rated for first 
12 mths, then 
self report at 
24 mths. 
No significant effect of 
group for any time point. 
Study reported that there 
was lower adherence at 2 
years than at 1 year 
follow-up. 
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Study Country Intervention Control description Intervention 
retention 
Participants Follow-up 
after last 
intervention 
contact 
Adherence 
a primary 
outcome? 
Adherence 
measurement 
Adherence Results 
problem-solving 
skills training. 
Sessions delivered 
to families by 
therapists in 22 
sessions delivered 
over 12 months 
Weekly for first 3 
mths, bi-weekly 
for 3 mths, 
monthly for 3 
mths. 
crisis intervention as 
needed. 
female, 14% 
married. 
Lam et al. 
(2000). 
UK Cognitive Therapy 
(CT) including 
Psychoeducation 
and CBT delivered 
by psychologists 
to individuals over 
12-20 sessions 
over 6 months. 
TAU (routine 
outpatient and 
appropriate MDT 
input judged by 
clinical team.) 
Flexible number 
of sessions - 
average sessions 
16.3(3.2). 92% 
completed at 
least 4 sessions. 
25 pts (IG=13, 
CG=12) 
experiencing at 
least 2 episodes in 
previous 2 yrs, or 
3 episodes in 5 
yrs, but not 
currently episodic. 
Mean age 39, 52% 
female, 32% 
married/ 
cohabiting. 
6 mths No Medication 
Compliance 
Questionnaire 
(MCQ) – self 
report over 
previous 
month. Never 
misses, missed 
once or twice, 
missed 3-7 
times, missed 
more than 7, 
stopped 
altogether. 
Sig. difference between 
mean scores over 12 
mths with better 
adherence in IG. 
Lam et al. 
(2003). 
Lam et al. 
(2005). 
UK Cognitive Therapy 
(CT) including 
Psychoeducation 
and CBT delivered 
to individuals by 
Psychologists over 
12-18 sessions for 
TAU 
(psychopharmacology 
& regular psychiatric 
outpatient 
appointments). 
Flexible number 
of sessions. 84% 
retention rate to 
6 sessions. 
Average sessions 
completed 13.9 
(5.5). 
103 pts (IG=51, 
CG=52) 
experiencing at 
least 2 episodes in 
previous 2 yrs, or 
3 episodes in 5 
yrs, but not 
2 yrs No Medication 
Compliance 
Questionnaire 
(MCQ) 
Medication 
serum levels 
Self report (MCQ): 
significant difference at 6 
mths between IG and CG 
with higher proportion of 
IG categorised as having 
‘good compliance’. 
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Study Country Intervention Control description Intervention 
retention 
Participants Follow-up 
after last 
intervention 
contact 
Adherence 
a primary 
outcome? 
Adherence 
measurement 
Adherence Results 
the first 6 months 
and 2 booster 
sessions in the 
second 6 months. 
currently episodic. 
Mean age 44, 56% 
female. 
Self report (MCQ mean): 
sig. difference between 
IG and CG at 24mths and 
30 mths with IG group 
reporting better 
adherence (n/s difference 
at 18 mth follow-up). 
Serum levels: n/s 
difference between 
proportion classified as 
adequate in IG and CG at 
6 mths (p= .06). 
Javadpur 
et al. 
(2013) 
Iran Psychoeducation 
involving 8 
individually 
delivered by 
psychiatrists in 
weekly sessions 
and follow-up 
phone calls for 18 
months. 
TAU (standard 
pharmacotherapy 
with own 
psychiatrist) 
89% participated 
in at least 4 
sessions. 
Average 7.3 
sessions and 
15.3 telephone 
sessions 
108 pts (IG=54, 
CG=54) currently 
euthymic. Mean 
age not specified, 
41% female, 20% 
married. 
0 months 
(post final 
telephone 
follow-up) 
Yes Medication 
Adherence 
Rating Scale 
(MARS) 
(Thompson 
2000) 10 items 
at 6, 12 and 
18mths 
Sig. difference between 
IG and CG over follow-up 
period (p=0.008) with 
higher adherence in the 
IG. 
Miklowitz 
et al. 
(2000). 
Miklowitz 
et al. 
(2003). 
US Family Focussed 
Therapy (FFT) 
involving 
psychoeducation, 
communication 
enhancement 
training and 
problem-solving 
skills training. 
Sessions delivered 
at home to 
families by 
Crisis management (2 
x 1hr home-based 
family education 
sessions, crisis 
intervention as 
needed (9 months), 
relapse prevention 
and resolution of 
family conflicts, 
telephone support/ 
monitoring contact 
once per month. 
10% of IG 
withdrew before 
6 mths. 
101 pts (IG=31, 
CG=70) with 
recent bipolar 
episode (within 3 
mths). Mean age 
36, 63% female, 
60% married/ 
cohabiting. 
15 mths No Patient 
reported 
compliance -
Checked 
against 
physician and 
family report. 
Serum levels. 
Compliance 
(composite) 3 
point rating 
from other 
Compliance score - n/s 
group, time or interaction 
effects at 12 mths. 
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Study Country Intervention Control description Intervention 
retention 
Participants Follow-up 
after last 
intervention 
contact 
Adherence 
a primary 
outcome? 
Adherence 
measurement 
Adherence Results 
therapists in 21 
sessions delivered 
over 9 months 12 
weekly, then bi-
weekly, then 3 
monthly. 
reports; fully 
nonadherent, 
partially 
nonadherent, 
fully adherent. 
Rea et al. 
(2003). 
US Family Focussed 
Therapy (FFT) 
involving 
psychoeducation, 
communication 
enhancement 
training and 
problem-solving 
skills training. 
Sessions delivered 
to families by 
therapists in 21 
sessions delivered 
over 9 months 12 
weekly, then bi-
weekly, then 3 
monthly. 
TAU (Weekly 
medication 
management 
sessions with 
psychiatrist for 1 
year, then every two 
weeks then monthly. 
+ 
Individual medication 
management 
sessions with 
psychiatrist for 1 year 
+ 
Individually focussed 
patient treatment. 30 
min sessions x 21 
over 9 months. 
79% of IG 
completed full 9 
mths of 
treatment. 
53 pts (IG=28, 
CG=25) recently 
hospitalised for 
mania episode. 
Mean age 26, 57% 
female, 15% 
married. 
15 mths No Medication 
compliance - 
Psychiatrist 
rating using 
standardised 
form 7 point 
scale 1(full 
compliance 
7(discontinued 
against 
medical 
advice). 
Composed of 
pt report, 
psychiatrist 
observation, 
medication 
blood levels. 
Compliance score - n/s 
group, time or interaction 
effects at 12 mths. n/s 
difference between 
groups in mean 
compliance during post-
treatment follow-up or 
any time points. 
Zaretsky, 
et al. 
(2008). 
Canada Psychoeducation 
(7 sessions) 
followed by CBT 
(13 sessions) 
delivered 
individually by 
psychiatrists over 
a period of 20 
weeks. 
TAU (standard 
outpatient care usual 
pharmacotherapy, 
and naturalistic 
monitoring, no 
additional CBT) 
+ 
7 PE sessions. 
72% of IG 
completed at 
least 6 sessions 
of 
psychoeducation 
and 9 sessions of 
CBT. 
79 pts (IG=40, 
CG=39) currently 
euthymic. Mean 
age 41, gender 
breakdown not 
specified. 
7 ½ mths No Number of 
missed doses 
per month (pt 
interview) 
At follow-up there was 
high adherence in both 
the IG and CG, but no 
difference between 
groups. 
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Study Country Intervention Control description Intervention 
retention 
Participants Follow-up 
after last 
intervention 
contact 
Adherence 
a primary 
outcome? 
Adherence 
measurement 
Adherence Results 
Multi-focus interventions (Group interventions) 
Study Country Intervention Control description Intervention 
retention 
Participants Follow-up 
after last 
intervention 
contact 
Adherence 
a primary 
outcome? 
Adherence 
measurement 
Adherence Results 
Bordbar 
et al 
(2009). 
Iran One session of 
group 
psychoeducation 
for family 
members prior to 
patient discharge. 
TAU (routine psycho-
education & 
pharmacotherapy for 
pts from own 
psychiatrist. 
100% of families 
assigned to IG 
completed the 
intervention. 
60 pts (IG30, 
CG=30) in acute 
manic episode, 
<5yrs onset. Mean 
age 30, 25% 
female, 42% 
married 
12 mths No Mths using 
medication, 
questionnaire 
by blinded 
home visit 
team. 
Sig. difference in time 
using medication at 6, 9 
and 12 mths with IG 
continuing for longer. 
Castle et 
al. 
(2007). 
Australia Psychoeducation 
and CBT-type 
group therapy 
delivered weekly 
for 12 weeks by 
Research 
Assistants. 
Personalised 
Collaborative 
Therapy Journal 
workbook, 
homework 
exercises and 
phone calls. 
TAU (Own GP/ 
psychiatrist care) & 
weekly phone calls 
controlling for extra 
contact time. 
90% retention. 20 pts (IG=10, 
CG=10) without 
current severe 
symptoms. Mean 
age 44, 82% 
female, 82% 
married/ with 
partner. 
0 (post-
intervention) 
No MARS n/s difference between 
pre- and post 
intervention change 
scores. 
Colom et 
al. 
(2003). 
Colom et 
al. 
(2009).  
Spain Group 
psychoeducation 
(Barcelona Bipolar 
Disorders 
Program) 
education, 
exercises and 
TAU (4 weekly 
psychiatrist 
appointments with 
mood support, 
standard 
psychopharmacology. 
+ 
73% adhered to 
psychoeducation 
(did not miss 
more than 5 
sessions). 
120 pts (IG=60, 
CG=60) in 
remission. Mean 
age 34, 63% 
female. 
5 yrs No Composite 
measure 
Plasma lithium 
concentrations: 
Significant difference 
between IG and CG at 2 
ys. 
Combined measure: 
Significant difference 
105 
Study Country Intervention Control description Intervention 
retention 
Participants Follow-up 
after last 
intervention 
contact 
Adherence 
a primary 
outcome? 
Adherence 
measurement 
Adherence Results 
discussion. 
Delivered by 
psychologists. 21 
weekly sessions. 
Weekly group 
meetings without 
instruction (control 
for supportive effects 
of group meetings) 
between IG and CG at 5 
yrs, fewer IG classified as 
poorly adherent. 
Eker & 
Harkin 
(2012). 
Turkey Group 
psychoeducation 
delivered weekly 
over 6 weeks by 
mental health 
nurses. 
TAU (outpatient 
mood disorders 
clinic) 
+ 
10-15 min medication 
training from doctor. 
4 pts did not 
attend regularly 
(retention detail 
not provided) 
71 pts (IG=36, 
CG=35) in 
remission. Mean 
age 36, 54% 
female, 49% 
married. 
0 (post-
intervention) 
Yes Composite. 
Medication 
Adherence 
Rating Scale 
(MARS). 
McEvoy 
treatment 
observation 
form. 
Combined measure: 
significant difference in 
proportion of pts 
classified as adherent 
from baseline to 6 weeks, 
with greater proportion 
of IG pts classified as 
adherent at 6 weeks. 
Lenz. 
(2010). 
Austria Cognitive 
Psychoeducative 
therapy (CPT) – 
psychoeducation 
and CBT-type 
techniques 
delivered in 14 
weekly group 
sessions. 8 hours 
of group sessions 
with significant 
others, booster 
sessions 6 and 9 
mths after 
baseline. 
TAU (not specified) 
+ 
Self-help book, 3 
group sessions & 
booster sessions 6 
and 9 mths. 
Not specified 100 pts (IG=52, 
CG=48) with 
minimum 2 
episodes in last 3 
years or 3 
episodes in last 5 
years, but not 
currently episodic. 
Mean age 40, 59% 
female. 
3 mths Not 
specified 
Medication 
Compliance 
Questionnaire 
(self-report) 
Significant decrease after 
12 months for control 
group in % reporting 
good compliance (no 
change in intervention 
group. 
D'Souza 
et al. 
(2010). 
Australia Systematic Illness 
Management 
Skills 
Enhancement 
TAU (community 
based case 
management; 45 min 
weekly review with 
Not specified 58 pts (IG=27, 
CG=31) recently in 
remission. Mean 
11 mths No Medication 
Adherence 
Scale (ARS) 
(pill count and 
Significant difference in 
mean adherence scores 
with better adherence in 
IG at follow-up. 
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Study Country Intervention Control description Intervention 
retention 
Participants Follow-up 
after last 
intervention 
contact 
Adherence 
a primary 
outcome? 
Adherence 
measurement 
Adherence Results 
Programme-
Bipolar Disorder 
(SIMSEP-BD). 
Group 
psychoeducation 
sessions with 
companion-
patient dyads 
delivered weekly 
over 12 sessions. 
clinician & monthly 
medical review). 
age 40, 52% 
female. 
need for 
repeat 
prescription) 
Reinares 
et al. 
(2008). 
Spain Psychoeducation 
group delivered to 
caregivers (not 
patients) including 
communication 
skills. Delivered by 
psychologists in 
weekly over 12 
weeks. 
TAU (standard 
psychiatric care; 
outpatient follow-up, 
pharmacotherapy, 
advice to contact 
clinician as needed, 
no systematic 
psychotherapy. 
95% attended at 
least 8 out of 12 
sessions. 
113 pts (IG=57, 
CG=56) euthymic 
for at least 3 
mths. Mean age 
34, 54% female, 
40% married. 
12 mths No Medication 
compliance - 
pt report, 
caregiver 
report, plasma 
concentrations 
(described in 
Colom 2000) 
n/s within-group 
comparisons between the 
baseline and final 
assessment. 
van Gent 
& Zwart 
(1991). 
Netherlands Group 
psychoeducation 
for partners 
delivered by a 
Psychiatrist and 
Social Worker 
over 5 sessions 
(unspecified 
duration). 
TAU (not specified, 
but referred from 
university outpatient 
clinic.) 
Not specified 39 pts (IG=19, 
CG=20) with a 
partner (no other 
criteria specified). 
Mean age 50, 
gender 
breakdown not 
specified. 
6 mths Yes Serum lithium 
levels. Non 
compliance = 
difference 
between tests 
of more than 
0.3 mmol/l 
No significant difference 
between IG and CG in 
terms of proportion of 
patients categorised as 
non-adherent before and 
after the study. 
Note: TAU=Treatment as usual, CBT= Cognitive Behaviour Therapy, IG= Intervention group, CG= Control group, RBC= Red blood count, SRTAB = Self-reported treatment adherence behaviours. 
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Chapter 4 Patients’ common-sense understanding of bipolar disorder 
and its treatment: a qualitative study 
 
4.1 Background 
A key step in addressing the issues of poor adherence and difficulties in self-management 
through the development of an intervention, in accordance with the MRC framework, is 
conducting primary research (Craig et al., 2008). It is recommended that this research, where 
appropriate, consists of interviews with individuals who would be targeted by the intervention 
and who are involved in its development (Craig et al., 2008). The detailed process of 
Intervention Mapping, described in Chapter 5 includes as its first stage, a needs assessment. 
Conducting qualitative research contributes to this stage by identifying issues which may need 
addressing by an intervention and also factors associated with the intended outcomes 
(Bartholomew et al., 2011; Kok et al., 2004). In addition to providing evidence on which to base 
the intervention, this process constitutes stakeholder engagement and patient and public 
involvement. This is an integral part of research and policy development and is recommended 
by both the MRC, the NIHR as well as in local NHS Research policies (Craig et al., 2008; NIHR 
n.d; Sussex Partnership NHS Foundation Trust, 2012). The MRC advises that ‘Qualitative 
research, as well as providing important insights into processes of change, can be a good way 
to involve users. It can complement user involvement in steering groups, and allows for a 
wider range of views to be canvassed and systematically incorporated into the design of an 
evaluation.’ (Craig et al., 2008 p6) (Lewin, Glenton, & Oxman, 2009). 
To this end, a series of semi-structured interviews were conducted with people with a 
diagnosis of BD recruited through Consultant Psychiatrists in Sussex Partnership NHS 
Foundation Trust. This study incorporates patient and public involvement through the input of 
a service-user representative who advised on research design and analysis and by seeking 
participants’ views directly in the development of an intervention. 
The study was undertaken to gain a greater understanding of the perceptual factors (e.g. 
beliefs about illness and treatment) and practical factors (capacity and resources) associated 
with taking medication for BD. In addition, it aimed to explore peoples’ reactions to the 
diagnosis and experiences with their prescribed medication. In order to better understand 
levels of dissatisfaction with care and treatment reported locally in Care Quality Commission 
reports (2009b, 2011b), the research explored exactly what information needs were not being 
met and the impact of this on participants. By exploring these issues it was aimed that a 
greater understanding would help the subsequently developed intervention facilitate informed 
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choice and adherence to treatment. This study is reported following the guidelines set out for 
reporting qualitative research set out in the Consolidated criteria for Reporting Qualitative 
research (COREQ) checklist (Tong, Sainsbury, & Craig, 2007), this ensures that it is transparent 
and complete (see Appendix C for completed COREQ checklist). 
 
4.2 Aims & Objectives 
4.2.1 Aims 
To explore the beliefs and lived-experience of people with BD in relation to their diagnosis and 
treatment. 
 
4.2.2 Objectives 
To explore participants’ 
 perceptions of BD, their reactions and adjustment to the diagnosis, 
 perception of medication and how this relates to their perspectives of BD, 
 unmet information and support needs, 
 preferences in terms of content, delivery and context of sources of information and 
support. 
 
4.3 Design 
This research employed a qualitative design involving semi-structured interviews to investigate 
the beliefs and experiences of a group of individuals with BD. The choice of a research method 
should come from the particular research questions posed (Dootson, 1995). Qualitative 
methods are appropriate as the research question aimed to gain a greater understanding of 
the perspectives and lived-experiences of people with a common feature, in this case a 
diagnosis of BD (Elliott, Fischer, & Rennie, 1999). These methods allow us to take into account 
a person’s own account and interpretation of their attitudes, motivations and behaviour 
(Hakim, 2000). As stated, qualitative methods are of use prior to testing interventions to 
explore the issues related to the research questions and inform intervention development 
(Lewin et al., 2009). 
In designing a qualitative study a number of considerations are important, these include the 
method of data collection, participant sampling and data analysis techniques. In this study two 
data collection methods were considered; individual interviews and focus groups. A limitation 
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of focus groups is that when describing behaviour or attitudes, there may be a tendency for 
less typical views or experiences to be under reported (Bloor, Frankland, Thomas, Thomas, & 
Robson, 2001). Individual interviews were selected over focus group methods as we would be 
able to gain an in-depth perspective on an individuals’ experience reducing the potential for 
under-reporting experiences. Due to the sensitive nature of the topic, participants may be less 
likely to share their thoughts and experiences with a group. In addition, it was practically easier 
to arrange interviews with participants as opposed to trying arrange a mutually convenient 
time and location for participants to attend a focus group. This was confirmed by advice from 
the service-user representative involved in the study who recommended that by using 
individual interviews participants would be more likely to share their experiences and we 
would gain a deeper perspective on an individuals’ lived experience. 
Conducting face-to-face interviews as opposed to over the telephone allows the researcher to 
pick up respondent’s nonverbal cues, and they tend to provide a greater quantity of 
information (Holbrook, Green, & Krosnick, 2003). In addition, a rapport can be built up, helping 
the participant to feel open and comfortable with talking about their experiences. 
A semi-structured interview schedule was used to guide the interviews (Appendix D). This was 
designed to explore participants’ experience of diagnosis, their perceptions of BD and its 
treatment. In addition, participants were asked about their satisfaction with any information 
received and outstanding information needs about BD and treatment. An interview schedule 
allows for researchers to ensure that there is consistency in addressing subjects across all 
interviews and provide a framework for the interview. The sequence and emphasis of the 
questions can be altered according to each participant’s experiences (Arthur & Nazroo, 2003). 
Open questions were used with probes being used to obtain greater clarity, detail or depth of 
understanding of participants’ responses. The semi-structured nature of the interview allowed 
for sufficient flexibility to be adaptable to the issues pertinent to each individual. The design 
considerations related to participant sampling and data analysis techniques are described 
below. 
 
4.4 Methods 
4.4.1 Participants 
Twelve people with a diagnosis of BD were recruited through their Consultant Psychiatrists in 
Sussex Partnership NHS Foundation Trust. All participants met the inclusion criteria of: having 
a diagnosis of BD according to ICD-10/ DSM-IV, having capacity to provide written, informed 
consent, currently being prescribed medication for BD and aged between 18 and 65 years. 
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Participants who suffered from organic brain syndrome or had active suicidal ideation were 
excluded from the study. Active suicidal ideation was assessed by researchers using the Beck 
Depression Inventory (A. Beck, Steer, & Carbin, 1988). 
 
4.4.2 Sampling 
Due to the focus of the study being an in-depth exploration of the experiences of individuals a 
small sample size is adequate. A large sample is unnecessary due to the fact that in qualitative 
methodology a phenomenon only needs to occur once to be of value and there is no 
requirement for statements about prevalence (Ritchie & Lewis, 2003). A process of sampling to 
thematic saturation was used, whereby new participants were recruited and interviewed until 
no new themes were identified. Purposive sampling by Psychiatrists was used to recruit from 
this potentially hard to reach population and to ensure there was variation in age, gender, 
degree of severity of BD, length of time since diagnosis and medication regimen complexity. 
Using a flexible, iterative approach, the number of participants required was assessed by 
transcribing and coding the interviews during the course of the study. 
 
4.4.3 Ethics 
Ethical approval for this study was granted by the Brighton & Sussex Research Ethics 
Committee (09/H1107/110) and by Sussex partnership NHS Foundation Trust Research & 
Development Department (CSP 25387) (Appendix E). In developing and conducting the study a 
number of ethical considerations were taken into account. Participants were ensured of the 
confidentiality of their disclosures and that their responses would not be shared with anyone 
outside the research team. It was important to give participants the confidence to discuss their 
thoughts and feelings about their diagnosis, to disclose their medication taking experience 
including non-adherence, as well as their opinions of care they have received. To ensure 
participants felt able to disclose personal information a non-judgemental interview approach 
was maintained. In the event of disclosure of information relating to severe risk of the health 
and safety of themselves and others, participants were informed that their care coordinators 
would be contacted. Participants were informed that they were free to withdraw at any time. 
 
4.4.4 Recruitment 
Potentially eligible participants were sent an information pack introducing the study (Appendix 
F). Participants were asked to contact the researchers if they were interested in participating. 
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The researchers responded to any questions potential participants had and if appropriate, 
arrangements were made for the interview to be conducted. 
 
4.4.5 Procedure 
Interviews were conducted, according to participants’ preference either at a hospital or in 
their home and lasted between 45 and 90 minutes. Consent was obtained according to CGP 
guidelines (International Conference on Harmonisation of Technical Requirements for 
Registration of Pharmaceuticals for Human Use, 1996) (Appendix G). Interviews were audio-
recorded with consent of the participants and transcribed verbatim. Two experienced PhD 
level, female, qualitative researchers (MK & GG) conducted the interviews. 
Demographic information was obtained from participants to allow for description of the 
sample as although not intended to be representative it was important to understand the 
demographic and clinical characteristics of the sample. This consisted of participants’ age, 
ethnicity, education, time since diagnosis and current medications. 
 
4.4.6 Analysis 
Thematic analysis was used to identify, analyse and report themes within the transcribed data 
(Braun & Clarke, 2006). All personal details such as names were removed from transcripts and 
replaced with generic text e.g. ‘Dr name’. Transcripts were read a number of times to gain 
familiarity and understanding of each interview before coding individual portions of text which 
represented ideas, concepts or experiences. These codes were grouped into sub-themes 
representing common meanings in the data. The themes were then reviewed by a further two 
members of the research team. Following re-reading all coded extracts and returning to the 
original transcripts a number of refinements were made, these were then reviewed by one of 
the original coders. A constant comparison method was used, as new codes and themes 
emerged, earlier transcripts were subject to re-coding (Pope, Ziebland, & Mays, 2000). A 
consensus was reached between researchers on the hierarchy of sub-themes and super-
ordinate themes. 
The primary analysis conducted and presented first in the results (Section 4.5.2) focussed on 
lived-experience accounts of adjustment to diagnosis, perceptions of BD and treatment and a 
summary of unmet needs. As a second analysis, all interviews were re-read and coded by the 
author in order to identify specific features for the practical development of the intervention. 
The results of this analysis are presented in the second section of results (Section 4.5.3). 
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In undertaking qualitative research is it crucial that authors acknowledge their own 
experiences and theoretical orientations (Elliott et al., 1999). The theoretical perspective of the 
Necessity Concerns Framework (NCF) (Horne, 2003b) guided the design and analysis of this 
research; therefore it is acknowledged that the research did not take a grounded theory 
approach (Glaser, Strauss, & Strutzel, 1968). The research aimed to build on existing evidence, 
to further refine theories and inform intervention development (Bowskill et al., 2007; 
Clatworthy et al., 2009; Clatworthy et al., 2007). Key components of intervention development 
were used as a coding structure in the secondary analysis, specifically intervention content, 
delivery and context (Horne, 2012). The semi-structured nature of the interviews and multiple 
researchers coding and discussing themes ensured that where ideas and themes arose, there 
was the scope for inclusion of those which are not currently part of the original theoretical 
perspectives. The results were also scrutinised by the service-user representative involved in 
the study, a Consultant Psychiatrist and a Health Psychologist, independent from the data 
collection and analysis (AC) which added additional credibility checks (Elliott et al., 1999). 
 
4.5 Results 
4.5.1 Sample description 
The sample consisted of 12 participants, nine were female and all were White British. The 
mean age was 43 years (range 24–55 years). In terms of clinical characteristics, the length of 
time since diagnosis ranged between three months and 26 years (mean 10 years). All were 
taking medication for BD, most commonly antipsychotics (n=10) (Table 4.1). 
 
Table 4.1: Sample demographics and clinical information 
Sample characteristic  
Gender Female n=9 
Mean age (sd) (range) 43 years (11.21) (24-55) 
Ethnicity White British (n=12) 
Mean years since diagnosis (range) 10 (3 months-26 years) 
Medications (n taking currently) 
Antipsychotic 
Anticonvulsant 
Antidepressants 
Mood stabilisers 
Hypnotics - Anti-anxiety Tranquillizers/ Sleeping pills 
Beta blocker 
Information not provided 
 
10 
5 
5 
4 
4 
1 
1 
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4.5.2 Primary Thematic analysis 
The data from the primary analysis of the interviews were organised into three superordinate 
themes, each subdivided into a number of subthemes as illustrated in the Table 4.2 with 
example coded text. The themes are described below and illustrated with verbatim quotes 
from participants. 
 
Table 4.2: Themes and example codes from Primary Thematic analysis 
Superordinate 
themes 
Subthemes Example coded text 
The impact of illness 
and treatment on 
sense of self 
Impact of the Illness 
the achievements what it would have 
been like if I hadn’t been mentally ill 
Stigma augmenting the negative impact of 
illness on sense of self 
The rejection from society 
Medication as a symbol and reminder of 
illness identity 
I don’t like what the medication 
represents 
Concerns about treatment I just felt like a vegetable 
A disconnect between the illness and the 
need for medication 
as soon as I start feeling well, I start 
thinking I can come off it 
Positive Interpretation 
of illness and 
treatment 
Diagnosis as a helpful process I knew then I could get proper treatment 
Medication as part of the solution Just being able to live normally 
A gradual process of medication 
acceptance (involving trial and error) 
I’ve come to terms with that now and I’m 
happy to do that to stay well 
Unmet information 
and support needs 
and the impact on 
informed choice. 
Information on the disorder 
When I first got diagnosed I had no 
information. 
Information on action of medications, 
side-effects and long term effects 
you’ve got to know the side effects and 
the benefits of it 
Information on finding the right treatment you’re just one big experiment 
Involvement in decisions about 
medication 
if the doctor said “Take this” I guess I 
would take it, don’t really question it 
 
4.5.2.1 The impact of illness and treatment on sense of self 
4.5.2.1.1 Impact of the Illness 
Participants reflected on what the diagnosis of BD meant to them, how it had affected them 
and how they had adjusted to this diagnosis. Receiving a diagnosis was often associated with 
difficulties and challenges to their sense of self. Some participants chose not to identify with 
the label of BD, or perceive their condition in an alternative way, for example, not as an illness. 
This highlights aspects of the recovery model where people’s own definitions of their 
experience should be acknowledged and supported as for some people this can be one part of 
gaining control and moving towards recovery. 
114 
P: “I hate, I can’t bear saying, Manic Depression. I cringe whenever I hear it. I find it very, 
very difficult mostly to accept that I’ve got it. It’s just something that other people have 
and I don’t. I don’t like admitting that I’ve got something wrong with me [...] I don’t want 
to be in that sort of category that I was always ill.” (P11: Female, 52yrs, 25yrs since 
diagnosis) 
P: “since I’ve been diagnosed I’ve found that all I ever really get from organisations or 
where I work and that is sympathy. You don’t need sympathy, I’m not [expletive] sick.” 
(P2: Male, 36yrs, 4 mths since diagnosis) 
An individual’s sense of self can affect how they interact with the world. A diagnosis of BD was 
often regarded as a threat to fulfilment and therefore to an individual’s achievement of a 
positive identity.  
P: “It means that I’ve achieved a lot less than I’ve wanted to. I’ve lost a lot of confidence.” 
(P9: Female, 33yrs, 10yrs since diagnosis) 
Related to the challenges associated with the illness, some participants described that they 
could not control how they felt, they described having no control over the periods of highs and 
lows or their actions during these periods. Gaining a sense of personal control is an essential 
component of recovery and care that people are provided with should foster this sense of 
control which it is clear that some people feel they have lost. 
P: “...bipolar for me is a lack of self control. There is this lack of self control. I can’t control 
when I’m going to be sleepy. I can’t control the suicidal thoughts...” (P9: Female, 33yrs, 
10yrs since diagnosis) 
 
4.5.2.1.2 Stigma augmenting the negative impact of illness on sense of self 
Perceived stigma of BD compounded the burden that the illness had on participants’ sense of 
self. Participants perceived negative reactions from others in society and, experienced the use 
of stigmatising language. The language used endorsed the stereotype of a distinction between 
mental illness and sanity or ‘normality’. 
P: “Just by not being in psychosis and not being paranoid and being able to function 
in the day and being similar to normal people...” (P5: Male, 47yrs, 8yrs since 
diagnosis) 
P: “The rejection from society and you’ve got the embarrassment about your condition, 
especially if you were well before. You lose family that don’t understand you [...] They 
think you are mad.” (P8: Female, 30yrs, 10yrs since diagnosis) 
This stigma was identified as a contributing factor to difficulties with accepting the diagnosis of 
BD. Participants’ displayed a reluctance to label themselves as mentally ill. 
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P: “I didn’t really accept the diagnosis until probably a couple of years ago... There is such 
a lot of stigma about giving yourself a label or mental illness in general that it’s a hard 
thing to accept, really.” (P9: Female, 33yrs, 10yrs since diagnosis) 
Having disclosed a diagnosis, one participant felt that normal mood changes were interpreted 
as symptoms by people close to them. People’s attitudes and the way they reacted to him 
were influenced by his diagnosis. He wanted his everyday experience of emotions to just be 
interpreted the same as others without a BD diagnosis. 
P: “...what I found is that people tread softly around you. If you happen to get slightly 
emotional or angry about something you automatically get the feeling that “That’s how he 
does things” kind of thing whereas you could be angry, you could be pissed off about 
something. So yes, attitudes have changed around me.” (P2: Male, 36yrs, 4 mths since 
diagnosis) 
 
4.5.2.1.3 Medication as a symbol and reminder of illness identity 
Medication and what medication represents also had a negative impact on some participants’ 
sense of self. In an illness with no apparent outward differences and from time to time, no 
symptoms, medication was a reminder and a symbol of this fundamental difference. The 
stigma which was associated with mental illness also related to participants readiness to 
accept medication. For some participants, taking medication reinforced the stigmatising label 
of mental illness. 
P: “I don’t like what the medication represents...It says, you know, you are taking that 
because you’ve got [that] and I hate that. I really hate that.” (P11: Female, 52yrs, 25yrs 
since diagnosis) 
P: “It’s if I take these drugs I’m mentally ill, if I leave them then I’m fine you know, there’s 
nothing wrong with me.” (P1: Female, 54yrs, 26yrs since diagnosis) 
 
4.5.2.1.4 Concerns about treatment 
A number of concerns about treatment were described and how medication could have a 
negative impact on quality of life. These concerns included; the sedative effects of medication, 
reductions in positive emotions and enthusiasm as well as a reduction in daily functioning due 
to fatigue. 
P: “...Lithium...it gave me more side effects than effects... blurred vision and tiredness and 
feeling dead and I just felt like a vegetable to be honest...” (P9: Female, 33yrs, 10yrs since 
diagnosis) 
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P: “...somewhat flat [...] it’s just sort of less joy and less excitement and less colour in life 
[...] it’s just not getting as much pleasure out of things and as much joy out of things than 
if I wasn’t taking medication I think.” (P3: Female, 55yrs, 4 ½yrs since diagnosis) 
There were also concerns about the long-term effects of medication and participants 
expressed a feeling of dependence in that they would have to stay on the medication 
indefinitely for fear of experiencing another episode. These questions had not been answered 
by clinicians and therefore were the subject of fear and uncertainty. 
P: “Will it cause Alzheimer’s? Will it cause dementia? Will it cause short term memory loss 
and will it cause—it worries me that I don’t know what the long term effects are and it 
appears that other people don’t either. That frightens me.” (P9: Female, 33yrs, 10yrs since 
diagnosis) 
P: “It does scare me that I feel that I can’t come off it or I can’t miss three days without 
starting to feel more suicidal than I did before. That scares me. I find that frightening. 
What if I was in a position where I was somewhere in the world and I couldn’t get that 
medication.” (P9: Female, 33yrs, 10yrs since diagnosis) 
 
4.5.2.1.5 A disconnect between the illness and the need for medication 
For some participants there was a clear disconnect between their illness and the need for 
medication. The illness and the symptoms they experienced did not correspond to the 
treatment which they were prescribed. The implicit understanding of an illness is related to 
the experience of symptoms. It is therefore difficult to see that medication may be needed 
when participants are free of symptoms as the illness is episodic. 
P: “...for whatever reason I need the medication and it makes me feel well. But the trouble 
is, as soon as I start feeling well, I start thinking I can come off it...It’s about confidence, 
isn’t it, because you think there is nothing wrong with me and I haven’t got this label and I 
haven’t got this condition and I’m not mentally ill. I was just going through a rough time.” 
(P9: Female, 33yrs, 10yrs since diagnosis) 
 
4.5.2.2 Positive Interpretation of illness and treatment 
4.5.2.2.1 Diagnosis as a helpful process 
When adjusting to the diagnosis, some participants made an effort to detach the diagnosis 
from their sense of self, perceived in this way, it no longer represented a threat. 
P: “I may have a diagnosis of bipolar, but I’m [name] and I’m not my illness or the illness 
that I’ve been delivered from. And then I stopped introducing myself as [name] with 
bipolar, because I felt like this bipolar attached to me.” (P8: Female, 30yrs, 10yrs since 
diagnosis) 
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For some, receiving a diagnosis helped them, by providing an explanation for their 
experiences. By having this diagnosis, they were able to move forward, take control and seek 
treatment. 
P: “In a way, it was quite helpful. I don’t know if I felt this at the time, but quite helpful 
because I knew then I could get proper treatment, whereas I’d been bumbling along and 
not been too great for years.” (P7: Female, 30yrs, 1 ½yrs since diagnosis) 
 
4.5.2.2.2 Medication as part of the solution 
Leading on from the observations above, that after a diagnosis, there was an inevitable need 
for medication. Medication was then not regarded as a threat but part of the solution of 
regaining control and maintaining a positive sense of self. 
P: “I think that’s something that I’ve realised since being given a diagnosis and then you 
think, okay, I’m someone that needs medication, as opposed to just being depressed when 
there is a very big question over whether or not you need medication, if you are bipolar 
then you need medication.” (P7: Female, 30yrs, 1 ½yrs since diagnosis) 
P: “[I] had my own business and everything, and I realised that the only way I was going to 
maintain a life like that, and to live my life like that, was through drugs, through drug 
therapy…” (P1: Female, 54yrs, 26yrs since diagnosis) 
Some participants regarded their medicated ‘self’ as positive and normalised compared to 
their non-medicated ‘self’. Medication helped provide a more stable future where otherwise 
BD could be associated with a loss of a positive view of the future. The medication served to 
control the symptoms and enable them to have a better quality of life. 
P: “I’m much calmer, I’m less impulsive in terms of particularly around things like swearing 
[...] I have more control over my impulsivity [...] I’m quite confrontational, I’ve been quite 
confrontational with my boss, this is pre-medication, and that’s only just begun to settle 
down so that’s better [...] my quality of life has improved massively [...] life is much 
calmer...” (P2: Male, 36yrs, 4 mths since diagnosis) 
P: “At the moment, I’ve got a nine year old daughter and there is no way I could parent 
and not be on meds...I think the medication has probably saved me and my daughter’s 
relationship as well...[medication is] vital at the moment...” (P9: Female, 33yrs, 10yrs since 
diagnosis) 
 
4.5.2.2.3 A gradual process of medication acceptance (involving trial and error) 
Acceptance of the diagnosis and medication as part of an individual’s life was achieved by 
participants, however, this level of acceptance could take years to achieve. 
P: “I’ve accepted it and I’ve also accepted that the bipolar it will be for the rest of my life 
and I most certainly will have to take medication for the rest of my life and I’ve now come, 
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it’s taken me nearly 20 years or over 20 years, but I’ve come to terms with that now and 
I’m happy to do that to stay well.” (P10: Female, 45yrs, 7yrs since diagnosis) 
P: “It is vital [...] at some point I think I would have another period of being high and the 
last time I was ill I spent a lot of money and got myself into debt and it was quite scary 
when I came to reality and realised what I’d done and was dealing with the debt problem, 
so I would be quite terrified of getting ill again [...] yes so I’ve made the decision to stay on 
it for life.” (P3: Female, 55yrs, 4 ½yrs since diagnosis) 
The control of medication over their symptoms was learned through experience of either 
intentionally or unintentionally not taking their medication. These experiences gave those 
participants greater belief in the necessity of their treatment. 
P: “...it was only in July I stopped taking one of my meds. I wouldn’t stop taking my 
antidepressant, because I can see quite quickly that I became suicidal.” (P9: Female, 
33yrs, 10yrs since diagnosis) 
 
4.5.2.3 Unmet information and support needs and the impact on informed choice. 
Participants in the study were at differing stages in their adjustment to diagnosis and 
subsequent acceptance of treatment. However, there was a commonality in their 
dissatisfaction with information and support which they had been provided around diagnosis 
and treatment. Even for those who, over time had found a positive adjustment, there were 
unmet needs. 
 
4.5.2.3.1 Information on the disorder 
A lack of information about BD made it difficult for participants to accept the diagnosis and to 
know what it meant for themselves and their future. This deficit seemed to exist at the time of 
diagnosis but could persist for many years. 
P: “When I first got diagnosed I had no information. No information whatsoever. It was 
pathetic. It was just, you know, what am I meant to do with this label? I had no idea.” (P9: 
Female, 33yrs, 10yrs since diagnosis) 
P: “I’d like to know more about it. I never ever remember somebody saying to me, 
well, you’ve got bipolar and you know you’ve got bipolar and here is some 
information on it.” (P10: Female, 45yrs, 7yrs since diagnosis) 
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4.5.2.3.2 Information on action of medication, side-effects and long terms effects 
There was a clear lack of satisfaction with information provided about medication with regard 
to; how they worked, what the side-effects were and any implications of taking them in the 
long term. 
P: “...even when the psychiatrist has recommended the medication, in my 
experience it is not explained that well. What the medication does and why you are 
taking it etc.” (P5: Male, 47 yrs, 8yrs since diagnosis) 
P: “One of the things that I think is vital is the side effects, knowing what the side 
effects are likely to be and if there is anything you can do about them I think.” (P3: 
Female, 55yrs, 4 ½yrs since diagnosis) 
In order to make informed choices, participants felt that information about the benefits and 
positive effects of medication was also essential. 
P: “The truth [...] you’ve got to know the side effects and the benefits of it, maybe 
you’ve got to take the side effects, like I had to do [...] the side effects outweigh 
them, they outweigh them with the good things...” (P1: Female, 54yrs, 26yrs since 
diagnosis) 
 
4.5.2.3.3 Information on finding the right treatment 
The lack of understanding of both BD and prescribed medication was reflected in the lack of 
understanding of the process of finding the right treatment programme. Instead of 
understanding the need for individualisation of treatment, participants perceived changes to 
medication as a lack of correct management of their condition on the part of the health 
professional. 
P: “I don’t think they’ve got a clue what they’re doing, some of the doctors, all 
they’ve got is what they see on paper and then you’re just one big experiment.” (P1: 
Female, 54yrs, 26yrs since diagnosis) 
P: “I think it’s trial and error as well. So I’ve never seen a bipolar person and keep 
them on the same meds. I’ve seen it go on for years and years and years, it took all 
these years just to get me right. And they were just throwing stuff down me. They 
couldn’t care.” (P1: Female, 54yrs, 26yrs since diagnosis) 
 
4.5.2.3.4 Involvement in decisions about medication 
A lack of specific information was compounded by participants feeling like they were not able 
to work in collaboration with their healthcare professionals and had very little input or 
knowledge of how they were being cared for. Their reflections on these issues seemed to 
indicate a lack of trust in the decisions about their care. 
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P: “I suppose it’s almost a traditional doctor-patient relationship in some respects, 
the doctor says do this and, even though I’ve just said I haven’t got much trust in 
them, I go ahead and do it anyway [...] if the doctor said “Take this” I guess I would 
take it, don’t really question it.” (P2: Male, 36yrs, 4 mths since diagnosis) 
P: “So the collective medical profession missed the elephant in the room for what is 
probably all of my life. So I have a limited respect in some respects I would suggest, 
and therefore there is a natural scepticism I guess, particularly when it comes to any 
medication, because fundamentally when you chose, whether it was deliberate or 
not, you gave me something that made me worse.” (P2: Male, 36yrs, 4 mths since 
diagnosis) 
Collaboration and the importance of their relationships with health professionals was key and 
participants reported that they learned through experience that they did not need to passively 
accept treatment and could collaborate to find the most beneficial options. 
P: “...I think maybe if the doctor had been able to say to me, even my GP had said, look, I 
will try you on this medication and it might not be suitable for you. I think a lot of people 
get thrown on medication like Citalopram, which makes a lot of people feel absolutely 
awful and then they try it and they think, I feel awful, but the doctor said I might feel awful 
and then they persevere with it, when, actually, when you find the right medication it’s 
really helpful. I never really was given the information that it would take quite a long time 
to find a medication that suited me.” (P9: Female, 33yrs, 10yrs since diagnosis) 
P: “You go and see your GP and it’s more useful if you kind of have a rough idea what’s 
wrong with you and then you can talk it through and then you can explore it together. I 
don’t think doctors necessarily have the definitive answer. They need your input. [...]. I’m 
an intelligent girl. I don’t need to just blindly say, just do whatever you want to me. I know 
my mind. I know my brain. I know how I can feel and how I want to feel.” (P9: Female, 
33yrs, 10yrs since diagnosis) 
 
4.5.3 Secondary Thematic analysis - IBiD Development 
The data from the secondary thematic analysis of the interviews were organised into three 
themes which comprise key components identified for intervention development (Horne, 
2012). These consist of recommendations for; 
- Content - The specific information people diagnosed and prescribed treatment for BD 
should be provided with. 
- Delivery - How the information should be provided, the mode or format of delivery 
including the providers of information or support. 
- Context - Where and when information or support should be provided. 
These components and the subthemes within them are illustrated in Table 4.3 with example 
coded text. 
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Table 4.3: Themes and example extracts from Primary Thematic analysis 
Intervention 
component 
Subthemes Example coded text 
Content 
Information on bipolar, 
symptoms and positive 
reassurance 
When I first got diagnosed I had no information. 
if you take medications you can be controlled and you can live a 
healthy life 
Information on 
medications, side-effects 
and medication choices 
I think maybe if the doctor had been able to say to me, even my 
GP had said, look, I will try you on this medication and it might 
not be suitable for you. 
One of the things that I think is vital is the side effects, knowing 
what the side effects are likely to be and if there is anything you 
can do about them I think 
Sources of further 
information 
And also with a number to contact to speak to somebody if they 
had any other questions, speak to somebody knowledgeable.  
Delivery 
Opinions of written 
information 
I think writing would actually be nice and I might consider 
speaking to maybe my support worker or even my key worker. 
I think that there should be almost like a booklet 
Support groups 
It makes me think I have thought of going sometime ago and 
maybe it would be helpful to go and see what other people say. 
I found that they were more people who was really ill and I 
couldn’t relate to them 
Internet 
If I were looking on the internet then I would know that some 
sites, you can tell which sites are rubbish and which sites have 
good information. I would trust things like MIND and NHS 
websites. 
Trusted sources of 
information 
I would go to the AOT for anything like that to the Outreach 
team. I’d use them rather than my own GP 
I do trust what psychiatrists tell me and what CPNs tell me 
Context 
Readiness and desire to 
take in information can go 
up and down 
Information provision 
must be sensitive to 
illness state, but illness 
shouldn’t preclude it 
at the moment I’m kind of on a holiday, I don’t want to know 
anything more about it at the moment. 
later on, to know, later on is to know, the best thing to do is 
stabilise somebody first 
I mean I wouldn’t take in a leaflet when I was in psychosis, so 
only afterwards. 
So even though I was high it was still good to be receiving 
information. 
Tailoring to level of 
understanding and desire 
for detail 
Some people will be bright take it [information about 
medication] and automatically and they’ll do what I done with.  
I think I feel that although I haven’t been told much, I’m quite 
happy with that. 
 
4.5.3.1 Content 
4.5.3.1.1 Information on bipolar, symptoms and positive reassurance 
Some participants reported having received no information about the condition itself. It would 
have been useful to receive this information and participants reported needing more 
information even years after diagnosis. 
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P: “… if somebody was saying to me, you’ve got bipolar and this is a little bit about your 
illness. It’s never come across to me as far as I can remember.” 
I: “Would it have been helpful to have…” 
P: “Very. I’d like to know more about it.” (P10: Female, 45yrs, 7yrs since diagnosis) 
P: “I’d say I understand my illness, but I don’t know if I know enough about it. Are there bits 
that I don’t know? Are you with me?” (P10: Female, 45yrs, 7yrs since diagnosis) 
The different signs and symptoms of episodes (the variety and not just typical signs) were 
crucial pieces of information allowing participants to begin to learn and recognise personal 
signs and symptoms. 
P: “You get the classic people saying, you know, ‘do you spend a lot?’ and ‘do you 
whatever?’ and go through the questionnaire. ‘Do you make rash decisions?’ Yeah, yeah, 
yeah, definitely, definitely, definitely. It isn’t, it doesn’t really sum it up. […] I remember 
picking up after my recent manic episode, picking up my bipolar disorder survival guide and 
it said, what people are in mania they usually say, oh, I’m in control and I’m really 
confident at the moment. I found myself saying that exact phrase to my mate the week 
previous. It’s with hindsight and experience that I can, it’s almost like I need the 
information now but the information helps me to understand my past.” (P9: Female, 33 yrs, 
10yrs since diagnosis) 
Information on the long-term nature of BD were seen as important for people to know, 
however, it was also important to emphasise positives for people diagnosed with BD, that they 
can live well, cope with the condition and lead a worthwhile life. 
P: “And also realising it can go on for life as well. I can’t see, I can’t see them ever taking 
me off them.” (P1: Female, 54yrs, 26yrs since diagnosis) 
P: “I guess it was just the idea that erm, it’s very difficult to predict what’s going to happen, 
but that if you take medications you can be controlled and you can live a healthy life, as 
long as you take the medication, I guess.” (P7: Female, 30yrs, 1 ½yrs since diagnosis) 
 
4.5.3.1.2 Information on medications, side-effects and medication choices 
Participants lacked information about their medication and recalled being prescribed 
treatment but not being informed fully about this or about different options which might be 
available. 
P: “Obviously Dr [name] is my consultant Psychiatrist here and I do respect him and what 
he’s doing is clearly having benefits kind of thing, but he hasn’t directly told me a great 
deal about, we haven’t sat down for example and had a conversation about ‘[name], 
you’re on Seroxyl and Seroxyl does this and these are the biochemical implications and this 
is the’ we haven’t had that discussion. It’s been very much kind of ‘You’ll go onto this 
medication’.” (P2: Male, 36yrs, 4mths since diagnosis) 
Specific information seen as essential was; possible side effects, the risk of these occurring, 
medications you can take to alleviate these and the possibility of trying different medications 
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to find those with the least side-effects. One participant noted that experiencing unexpected 
side-effects could lead to treatment non-adherence. However, some participants found that 
detailed side-effect information can be overwhelming, confusing or contradictory. 
P: “Yeah, going back to the first medication that I tried. I would like to have known, like 
suddenly I felt quite dulled down and quite like flat, and no one sort of said to me, well 
there are alternatives, you shouldn’t be feeling like this, you can try other things.” (P6: 
Female, 24yrs, 4yrs since diagnosis) 
P: “What I didn’t realise until my friend was a psychiatric nurse told me was that there is a 
drug that’s available that you can use for the side effects. I didn’t know that either. I feel 
like I’m learning all the time. “(P9: Female, 33yrs, 10yrs since diagnosis) 
P: “I didn’t know about the weight gain with the Sodium Valproate until I went on the 
internet and I was like, why am I putting on so much weight.” 
I: “If you’d had that sort of information, what difference would that have made?” 
P: “I wouldn’t have gone on that one. I would have chosen something else. I wouldn’t have 
gone on it. I’m sure I’ve got a bit of body dysmorphia so there is no way I would have gone 
on that one. As soon as I started putting on weight, the likelihood is I’m going to come off it 
and then I’m likely to go manic or depressed.” (P9: Female, 33yrs, 10yrs since diagnosis) 
P: “I just find them [leaflets in the medication box] strange with possible side effects 
contradict each other, you know. They say it causes dizziness and another one says it 
doesn’t. A lot of them are contradictory.” (P1: Female, 54yrs, 26 yrs since diagnosis not 
reported) 
Information should be straightforward, accurate and also realistic about the potential benefits 
of medication. Recognising that there were pros and cons of medication for BD was key in 
allowing people to make informed decisions around treatment. 
P: “But maybe, side effects definitely. Especially life threatening and long term side effects. 
I’d like to know the good things. I really would like to know the good things [benefits of 
medication].” (P1: Female, 54yrs, 26yrs since diagnosis) 
P: “That it does something very good for you if you take it and you can weigh up the side 
effects against the benefits.” (P8: Female, 30yrs, 10yrs since diagnosis) 
Other information which participants thought was important included; reassurance that it 
could take time to find the right treatment, information about medication and alcohol; what 
the medications do and how to take them, drug interactions and instructions not to stop 
medication without advice. 
P: “To actually tell someone that they will go through a period of time and they will go 
through and not they might, they will go through a time where they might—they will have 
to try different medications and find which one suits them.” (P9: Female, 33 yrs, 10yrs since 
diagnosis) 
P: “I think it’s a little bit ambitious with these products to say, do not drink alcohol. A lot of 
people will drink alcohol. I’ve learned that I can’t drink wine. I can drink beer, but I can’t 
drink wine. I can’t drink too much.” (P9: Female, 33yrs, 10yrs since diagnosis) 
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I: “What was good about the booklet and the DVD [participant had previously received].” 
P: “Informative. It explained everything about the drug and how to take it etc, etc.[..] it and 
what you’ve got to be careful of blah, blah.” (P11: Female, 52 yrs, 25yrs since diagnosis) 
P: “Maybe where to find out more, if you need. Other things you shouldn’t take with it. 
That’s about it, really.” (P7: Female, 30yrs, 1 ½yrs since diagnosis) 
P: “Not to just take themselves off medication and always ring this helpline or this number 
or whatever before you do it on that day.” (P9: Female, 33yrs, 10yrs since diagnosis) 
 
4.5.3.1.3 Sources of further information 
Participants identified the importance of being signposted to sources of additional information 
or support so they are informed and empowered to find the information they need and also 
what to do in an emergency and where to go for help. 
P: “…and also with a number to contact to speak to somebody if they had any other 
questions, speak to somebody knowledgeable.” (P7: Female, 30yrs, 1 ½yrs since diagnosis) 
P: “If you could have a bipolar survival pack from the hospital with numbers and sources 
that they thought were good and a way of recommending other sources back to them. That 
would be great.” (P9: Female, 33yrs, 10yrs since diagnosis) 
 
4.5.3.2 Delivery mode 
4.5.3.2.1 Opinions of written information 
Many participants were positive about written information either that they had received or 
that they thought would be useful to convey the information people might need. However, it 
was important that information was concise and presented in language that was easy to 
understand. 
I: “Would it be something that you’d want in writing or would you want somebody to talk 
to you?” 
P: “I don’t know. I think writing would actually be nice and I might consider speaking to 
maybe my support worker or even my key worker.” (P10: Female, 45yrs, 7yrs since 
diagnosis) 
P: “I think that there should be almost like a booklet, not a pamphlet but a booklet where 
you just you know describing, basically the symptoms and the help group, Manic 
Depression Fellowship.” (P11: Female, 52yrs, 25yrs since diagnosis) 
P: “I’m not a genius but I’ve got a reasonable brain and frankly some of the information in 
the [medication] boxes baffles me. Why use long complicated words when you can just put 
stuff in plain English? And that frankly is where charities and stuff tend to be much more 
helpful in that they make the subject both understandable but relevant to the reader, or 
the audience, that they’re targeting.” (P2: Male, 36yrs, 4mths since diagnosis) 
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Participants reflected that it is useful to have a combination of written information and the 
opportunity to speak with someone and have questions answered. A personalised, tailored 
approach is important and when they are prescribed medication, it is important to be able to 
speak with someone about their treatment. 
P: “I’d probably keep a copy. I’d read It [a leaflet], it would probably prompt some 
questions and I would go back to Dr [name] and I would ask him what his opinion and 
answers were kind of thing.” (P2: Male, 36yrs, 4mths since diagnosis) 
P: “I read the leaflet whenever I’m given any new medication, so I read the leaflet, the 
pharmacy leaflet inside. I also talk to the psychiatrist, my GP, to the, I haven’t got a care 
co-ordinator at the moment. My care co-ordinator left and they thought I’d be fine without 
one, so but I would have talked this over with the care co-ordinator.” (P3: Female, 55yrs, 4 
½yrs since diagnosis) 
P: “I guess it would be written information that you are given, because you, if you are 
depressed you are not going to be keen to find out much or read at that time, but you 
would have it for a time when you could or when you are able to take in information. […] 
And also with a number to contact to speak to somebody if they had any other questions, 
speak to somebody knowledgeable.” (P7: Female, 30yrs, 1 ½yrs since diagnosis) 
 
4.5.3.2.2 Support groups 
Support groups were discussed by a number of participants and there were mixed opinions of 
these. Some participants found they could not relate to other members of the group or did not 
want to speak about their diagnosis. One participant had found sharing her experiences with a 
trusted group of people was useful and felt now that attending a support group might be 
something to consider. 
P: “But then I found that I actually went to some MDF meetings and I found them awful. I 
hated it. I felt that I wasn’t one of them. That was my problem and it wasn’t theirs. They 
were lovely. I hated it. I was sitting in a room with a friend of mine who took me and I was 
listening to all these people and I just thought, I’ve got nothing in common with them, 
absolutely nothing.” (P11: Female, 52yrs, 25yrs since diagnosis) 
P: “I’ve never gone along to the bipolar group. I know it exists and where to go but I’ve just, 
to begin with I never plucked up the courage and then since then I’ve sort of not felt the 
need but you saying it, it might be beneficial. I’ve got two or three friends now who also 
have mental health problems that I’ve met through the hospital being an in-patient or 
going to [community centre] which is one of the first help forums in the community and you 
know we can support each other and that’s nice, so there are other people that I’ve met or 
who have problems. We’ve got a sort of mini little support group.” 
I: “You share experiences.” 
P: “Yes, as it were there. But I haven’t joined formal support groups and you know you 
bringing it up it makes me think maybe I would like to go.” (P3: Female, 55yrs, 4 ½yrs since 
diagnosis) 
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4.5.3.2.3 Internet 
Participants discussed their experience of and perceptions of the internet as a source of 
information about BD and medication. They were aware that caution was needed to identify 
trustworthy information sources. Participants had used the internet to find information about 
their medication and to share this with others. Personal stories featured on the internet had 
helped one participant as they were experiences he could relate to and found it reduced 
feelings of isolation. The advantage of information on the internet was that you could refer to 
it at any time and go back to useful information. 
P: “In terms of the internet I think I really principally went on there because I had to try and 
explain to people at work what the hell was going on and I needed some background in 
terms of the medication. [..] But the internet was probably the most useful and immediate 
source and tool. Now, I think I ticked in there that I do trust it, which, am I that gullible? No, 
but generally I think I do. There are a number of sources on there, you’ve obviously got the 
NHS, as I recall there was some information on the NHS site about it. You can go to the, I 
think I went to the actual, some drug company information on it as well which, whilst I 
know that they’re obviously very happy to sell their tablets and all that sort of stuff and 
they’re private companies, the information on there was reasonably useful as I remember.” 
(P2: Male, 36yrs, 4mths since diagnosis) 
P: “I found that useful [web videos about bipolar], yes, both in terms of people’s experience 
of bipolar and how it affects them but also actually of the medication that they’re on [..] 
But they are informative because they’re human basically, and just listening to somebody, 
he asks her questions about what was life like beforehand and it’s like the usual sort of shit, 
disorganised, confused, frustrated, describing and then he says “Explain to me what 
hypermania is like” and it’s just like oh my God, I can completely relate to that, when your 
to-do list becomes longer than 24 hours in a day, it’s like yes, it gets like that. And it’s very 
informative because not only do you learn something about bipolar and you learn 
something about how the medication works but you also realise that you’re not the only 
one who’s thinking and feeling like that, which so often, more so at the depressive end of a 
manic episode than the hyper end, it’s a very isolating, intensively individual experience.” 
(P2: Male, 36yrs, 4mths since diagnosis) 
 
4.5.3.2.4 Trusted sources of information 
When discussing trusted sources of information, participants frequently mentioned their own 
care team (specifically their mental health team) as being their point of contact. Health 
professionals were trusted sources of information as were mental health charities. 
P: “You want to feel that someone has empathy and understands what it is, rather than 
just having the medical knowledge. [I] Trust psychiatrists, CPNs, I trust my psychotherapist 
because I think she’s very experienced and my friend who has had experience of similar 
problems and is a psychiatrist herself.” (P7: Female, 30yrs, 1 ½yrs since diagnosis) 
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P: “I suppose a psychiatrist is a bit more objective where they have a feel for people’s 
uncertainties, they are a bit more objective about it.” (P6: Female, 24yrs, 4yrs since 
diagnosis) 
P: “Basically they [MIND charity] went to their drawers and got the information and said, if 
there is anything that I want to talk about that I could sit and talk about it with them. […] 
MIND are absolutely out of this world.” (P8: Female, 30yrs, 10yrs since diagnosis) 
Other people with lived experience of BD were not consistently viewed as useful or trusted 
sources of information. Some found it reassuring to hear from the experiences of others, 
whereas some found it difficult to relate to other peoples’ bipolar experiences. 
I: ”So what is it about speaking to other patients?” 
P: “Well it is just refreshing that first of all I can relate to them and relate to their 
medications, but you know what funnily enough is a lot of people don’t like talking about it 
and so it is quite frustrating from that point of view.” (P5: Male, 47yrs, 8yrs since diagnosis) 
P: “I am actually on a [online] forum. I joined that when I started kind of panicking really, 
just to meet other people with it really, because I had never met anyone in my real life 
who’s ever had it, so it is not to feel alone, that is not very cheesy isn’t it? You know it has 
really been just a source of information for chatting to other people, yeah, you know what 
they have experienced and things like that.” (P6: Female, 24yrs, 4yrs since diagnosis) 
P: “That is the frustrating thing about finding out information through others. It is that 
there’s people who are really ill, I can’t really, you can’t, I can’t relate to them and they 
can’t relate to me and then the people in the middle, probably like me, don’t really want to 
talk about it too much.” (P5: Male, 47yrs, 8yrs since diagnosis) 
 
4.5.3.3 Context 
Issues surrounding the context of providing information and support have been described in 
above. These include the finding that beliefs about illness and the necessity of treatment may 
change during someone’s experience from diagnosis onwards and these are highly individual. 
This demonstrates that information needs to be tailored. Participants may not feel involved in 
decisions around their care or feel confident or empowered to engage with health 
professionals and there may be a lack of understanding around decisions that are made. In 
addition, the wider societal context of stigma can affect acceptance of illness and engagement 
with treatment. 
 
4.5.3.3.1 Readiness and desire to take in information can go up and down 
The context of individuals’ readiness to take in information is important to consider, and 
participants reflected that their desire to seek information themselves or be ready to hear 
about BD did change, going up and down. 
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P: “I went through phases when I sort of looked up things all about it. I suppose I sort of 
went into denial, really. I sort of got books about it and I read about it and I thought, no, 
that’s not me. At times I went, yes, I suppose it is me.” (P11: Female, 52yrs, 25yrs since 
diagnosis) 
P: “I could about bipolar and ADD [attention deficit disorder] and at the moment I’m kind 
of on a holiday, I don’t want to know anything more about it at the moment.” (P2: Male, 
36yrs, 4 mths since diagnosis) 
P: “If it gets to a point where I start to get depressed again and suddenly think “I’m not 
really being able to cope with this very well” then I would probably go and look for sources 
of help from those kind of places.” (P2: Male, 36yrs, 4 mths since diagnosis) 
I: “Is it for example important that you could know what the side effects of a particular 
drug were or perhaps not.” 
P: “Yeah now, yeah now, I think in the early days I wasn’t really interested. I just wanted to 
get well, but yeah, now.” 
I: “So that kind of links back to what you were saying about your information needs may be 
changing.” 
P: “Yeah.” (P5: Male, 47yrs, 8yrs since diagnosis) 
P: “I think generally I have started to get more information about medications, yeah, it has 
been a gradual process really.” 
I: “Has that come about because you sought more information or because it’s been given to 
you.” 
P: “I think a bit of both really.” (P6: Female, 24yrs, 4yrs since diagnosis) 
 
4.5.3.3.2 Information provision must be sensitive to illness state, but illness shouldn’t preclude 
it 
Participants discussed when they thought were the most appropriate times to receive 
information during their illness and care. Some participants felt that it was important that any 
information provision should wait until the person is stabilised and so better able to take the 
information in. 
P: “I mean I wouldn’t take in a leaflet when I was in psychosis, so only afterwards, does 
that answer your question?” (P5: Male, 47yrs, 8yrs since diagnosis) 
P: “It’s got numbers to contact that you can speak to so that’s very helpful. There is a lot to 
read [Rethink booklet]. I think if I was very depressed, I wouldn’t...” (P7: Female, 30yrs,1 
½yrs since diagnosis) 
P: “Yeah, I mean I remember when I was in psychosis and I was being sectioned and these 
two nurses came into the room and they said you are being sectioned and they gave me a 
form. I didn’t even know what was on the form, I couldn’t even read it. So it wouldn’t make 
any difference. I mean I wouldn’t take in a leaflet when I was in psychosis, so only 
afterwards.” (P5: Male, 47yrs, 8yrs since diagnosis) 
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I: “...are you saying that there might be, it might be later on that information is more 
helpful?” 
P: “Yeah, later on, to know, later on is to know, the best thing to do is stabilise somebody 
first and by that, that’s quite nasty, people get the shakes.” 
I: “So once someone is stabilised then providing more information at that point would be 
helpful?” 
P: “Yeah, even just stabilising them. Let them know what you’re trying to do for them.” (P1: 
Female, 54yrs, 26yrs since diagnosis) 
P: “Yeah, I mean I remember when I was in psychosis and I was being sectioned and these 
two nurses came into the room and they said you are being sectioned and they gave me a 
form. I didn’t even know what was on the form, I couldn’t even read it. So it wouldn’t make 
any difference. I mean I wouldn’t take in a leaflet when I was in psychosis, so only 
afterwards.” (P5: Male, 47yrs, 8yrs since diagnosis) 
P: “I think I need to be stabilised on the drugs to be able to look back on things with 
hindsight to be able to understand my condition, because when you are in it you cannot 
understand it. It’s only once stabilised I would say that you can then look back and go, do 
you know what, they are right.” (P9: Female, 33yrs, 10yrs since diagnosis) 
 
However, participants also felt that information should be provided from the start even if a 
person is not quite ready. They may be able to take some information from it, or feel that they 
are being involved in their care and they can return to it as and when they feel able or need 
more information. It is clear that in an illness like BD, information needs will be highly variable 
depending on a person’s illness and also their level of acceptance at the time. 
P: “Yes I found it quite helpful when in hospital, even though I might not be my normal self, 
I still find it helpful when I’m high to be told about what drugs I’m being put on and how 
they working and why they’re working that way and what side effects I might be 
experiencing. I found that very helpful. When I was less ill I was here at [hospital name] and 
one of the nurses who tended to work nights was very, very helpful and he would look up 
things on the internet for me and give me, print it out and I found that very helpful. So even 
though I was high it was still good to be receiving information.” (P3: Female, 55yrs, 4 ½yrs 
since diagnosis) 
P: “I guess it would be written information that you are given, because you, if you are 
depressed you are not going to be keen to find out much or read at that time, but you 
would have it for a time when you could or when you are able to take in information.” (P7: 
Female, 30yrs, 1 ½yrs since diagnosis) 
I: “So the timing is about when people get the information is quite important.” 
P: “I would say. When I first got diagnosed I had no information. No information 
whatsoever. It was pathetic. It was just, you know, what am I meant to do with this label? I 
had no idea. I’ve ticked a few boxes and yes I’ve got bipolar and it really didn’t do 
anything.” (P9: Female, 33yrs, 10yrs since diagnosis) 
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4.5.3.3.3 Tailoring to level of understanding and desire for detail 
Participants commented on how information needs to be provided in the context of peoples 
own level of understanding and intelligence. 
P: “Medication. Depends how bright people are. Some people will be bright take it 
[information about medication] and automatically and they’ll do what I done with.” (P1: 
Female, 54yrs, 26yrs since diagnosis) 
P: “Exactly what I’m saying, you know. I need to be able to know what’s right. I’m an 
intelligent girl. I don’t need to just blindly say, just do whatever you want to me. I know my 
mind. I know my brain. I know how I can feel and how I want to feel. No-one can say that 
for me. I need the information out there.” (P9: Female, 33yrs, 10yrs since diagnosis) 
P: “…what information do you really need? It comes back to the point I was saying earlier 
on, do I need a pharmalogical breakdown of all the chemicals? Well, actually, no, not 
unless I’m going off and doing a degree and then understand how those interact with me 
physiologically kind of thing.” (P2: Male, 36yrs, 4 mths since diagnosis) 
P: “I think I feel that although I haven’t been told much, I’m quite happy with that. I’m quite 
content with that.” (P7: Female, 30yrs, 1 ½yrs since diagnosis) 
In participants’ narratives there was the running theme that in what is by name, the same 
illness, individuals with this diagnosis may be very different and their illness and treatment 
experiences are unique to them. This has a bearing on information provision as it needs to be 
appropriately tailored. 
P: “I do also know people that suffer with bipolar can be as different as anything even 
when they are ill by just by what others have told me how members of their family they’ve 
seen their members of their family and how they have been towards them and also been in 
hospital a lot of times when you see others with the same illness and condition and 
whatever and how they are.” (P10: Female, 45yrs, 7yrs since diagnosis) 
P: “It does take a long time to sink in, only it just depends what sort of person to be able to 
deal with all, or was also uniquely individual.” (P1: Female, 54yrs, 26yrs since diagnosis) 
 
4.6 Discussion 
The findings from this study highlight the importance of the interplay between the burden of 
the illness, participants representations of illness and medication and their subsequent 
responses through engagement with the management of their condition. As well as providing 
insights on living with and managing BD, the study provides vital learning on the components 
necessary for intervention development, what the information should be included and how 
this should be framed or communicated (Content), how information and support could best be 
provided and by whom (Delivery vehicle) and the wider factors around receiving information 
including timing and locations of support (Context) (Horne, 2012). 
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Challenges associated with the diagnosis included threats to participants’ sense of self and the 
impact on how they interacted with the world and felt about the future. These challenges 
were compounded by experience of stigma. The views and behaviour of people around them, 
including views consistent with the medical model, added to the burden of the illness. 
Participants reflected on changes in how others viewed them, for example, normal behaviour 
or emotions being seen as an indication of illness. This fear of being defined by the illness by 
others and the imposition of an illness identity is supported by previous research (Inder et al., 
2008; Mansell et al., 2010; Michalak et al., 2011). 
The lack of appropriate information on the disorder itself made it difficult for participants to 
accept the diagnosis, to understand what it meant and the implications for their future. 
Difficulty in making sense of the diagnosis has also been reported in more recent studies (Van 
den Heuvel et al., 2015). Unanswered questions after a diagnosis of BD have been shown to be 
related to uncertainty about the future in a qualitative study (Proudfoot et al., 2009). 
Individuals should be provided with information to meet these unmet needs to facilitate 
understanding and acceptance of BD. 
Medication was a symbol of the illness which could provide an unwelcome reminder of the 
condition and an outward indication of fundamental difference from ‘normality’. In this regard 
it compounded the impact of the illness on sense of self. Taking medication reinforced the 
stigma of mental illness. There was a strong desire for some to be ‘drug-free’ in the future as 
this would represent a return to normality. This concurs with descriptions in the recovery 
focussed literature (Mansell et al., 2010). 
In the present study participants often described that medicated ‘self’ was a return to their 
true self, and a return to normality. This is in contrast to other work where participants 
reflected that when taking medication, they were not their true self. However participants in 
the study by Mansell and colleagues (2010) had remained relapse free for two years and so 
were more distant from acute episodes and how it felt to be on medication at this time and 
three of the participants were not currently taking medication. 
The present research provides descriptions of how, for participants, medication was a tool for 
taking back control which enabled improved functioning and enhanced quality of life. The 
necessity of adherence to medication was reinforced by participants’ experiences of the 
consequences of non-adherence. 
This study confirms the links between views of treatment and beliefs about and experience of 
the illness (Horne, 2003b). Perceptions of treatment are linked to perceptions of illness and 
the degree of ‘fit’ between patients’ belief about the problem (illness) and preferred solution 
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(the treatment) (Horne & Weinman, 2002). The episodic experience of the illness did not fit 
with a need for continuing maintenance treatment. When there were no symptoms, it was 
difficult for participants to see themselves as having an illness which necessitated treatment. 
People’s beliefs about the necessity of medication have an impact on adherence, as do their 
concerns about medication (Horne, 2003b). Participants in the present study described their 
concerns about the medication. For many, medication was described as having a sedative 
effect, daily functioning was reduced and they reported getting less enjoyment out of life. 
There were also reports of feeling dependent on medication, including a fear of missing doses. 
The medication concerns identified by participants and dissatisfaction with information on 
medications and side-effects resulted in many patients not effectively engaging with 
treatment. For example, knowing what to do in the event of side-effects occurring was a key 
unmet information need. Indeed, research with HCPs in the UK identified that professionals 
working with people with schizophrenia reported withholding information on side-effects for 
fear of providing too much information and fear of putting people off (E. Brown & Gray, 2015). 
Previous research identified widespread dissatisfaction with information about medication in 
BD and lower levels of satisfaction were associated with low adherence (Bowskill et al., 2007). 
These findings concerning beliefs about illness and treatment and their impact on treatment 
engagement add further support to the importance of focusing on beliefs in mental health 
research and practice (Clatworthy et al., 2009; Clatworthy et al., 2007; Hou, Cleak, & Peveler, 
2010; Jonsdottir et al., 2009; Lobban, Barrowclough, & Jones, 2003; Petrie et al., 2008). 
This study provides important insights from individuals who have come to a positive resolution 
with their illness. It is critical to note, that this took time and experience to regain a positive 
sense of self where the diagnosis was acknowledged and treatment seen as part of the 
solution and was not without its challenges. Participants described re-evaluating and re-
ascribing meaning to the diagnosis and treatment, separating their sense of self from their 
illness. For others, the diagnosis gave meaning to, explained and legitimised their experiences, 
and help them to regain control. This concurs with other qualitative research around 
adjustment and experiences with the BD diagnosis (Inder et al., 2008; Michalak et al., 2011; 
Proudfoot et al., 2009). Recent qualitative research also identified that being well enough to 
regain social roles and responsibilities such as looking after children was an important part of 
regaining autonomy and control (Van den Heuvel et al., 2015). 
Challenges or difficulties associated with accepting a diagnosis of BD the need for medication 
may be tackled by providing information which is relevant for the individual’s needs and 
beliefs and helps them with developing a helpful, common-sense understanding of their 
condition and treatment. Primarily this needs to focus on developing necessity beliefs and 
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addressing concerns about medication. However, the current research indicates, in addition, 
that successful engagement with treatment requires individuals to feel actively involved in 
their condition management. 
Dissatisfaction with both information and care was compounded by a lack of participants’ 
involvement in decisions about their own care and treatment and a sense that they were not 
working in collaboration with healthcare professionals. A key issue in the current study was a 
lack of understanding about the need for therapeutic individualisation through experiment. 
This was reflected in some participants’ lack of confidence in HCPs. Other qualitative research 
in this area has also identified difficulties with relationships between patients and 
professionals, issues of trust relating to concerns about medication and frustration with 
trialling medications to find the right combination (Inder et al., 2010; Proudfoot et al., 2009). 
Shared-decision making which involves patients actively in their treatment has been 
addressed as part of the Toronto consensus statement for healthcare since 1991 (Simpson et 
al., 1991). However, it is clear that this not always achieved in psychiatric care. 
It is encouraging that participants in the current study had learned to successfully engage with 
HCPs and collaborate to find treatments which suited them, minimising side-effects and 
providing the best effectiveness. This should be the goal for professionals and patients 
working together to manage BD. The importance of collaboration and encouraging medication 
alliance in adherence has been demonstrated in a large cross-sectional study (Zeber et al., 
2008). Although a large sample (n=435), the cross-sectional nature of the study means that 
causation cannot be implied. However, an intervention study showed that clinician training to 
enhance therapeutic alliance can lead to increased adherence in mental health patients, 
suggesting that alliance does affect adherence (M. Byrne & Deane, 2011). 
 
4.6.1 Limitations 
Qualitative methods were appropriate to meet the aims of this study due to the need to 
explore participants’ subjective beliefs and experiences and gain an understanding of the 
meaning of these and to provide participants recommendations for how to improve 
information and support. In addition, the study is reported in accordance with the COREQ 
guidelines this ensures that it is transparent and complete (Appendix C). However, the findings 
should be interpreted in the light of a number of limitations. This approach explores the 
experiences and views of this small sample and results should not be generalised to all people 
with a diagnosis of BD, however it provides an in-depth and rich description. All of the sample 
were of white British ethic origin so do not include insights from other cultures. However, 
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subsequent intervention development and trialling was conducted in the same geographical 
and healthcare context. The study being locally-based is advantageous and the MRC 
Framework recommends that primary research is conducted with those to be targeted by the 
intervention (Craig et al., 2008). 
Recruitment methods comprised of purposive selection of participants by their psychiatrist, 
followed by self-selection. We cannot be sure that the findings from this study would be 
representative of those who have disengaged from formal care. However, participants did 
reflect on previous experiences of disengagement and non-adherence to medication. 
A limitation of the interview method is that participants may not accurately report their 
experiences or behaviour, it relies on them being able to articulate their thoughts, and is 
dependent on memory. We aimed to mitigate this by the interviewers being non-medical 
staff, unconnected with participants’ healthcare team or local NHS Trust and assuring 
participants of confidentiality. In addition, participants were not in an acute episode of illness 
where any deficits in cognitive functioning may be more severe (Quraishi & Frangou, 2002). 
As with all qualitative research the themes generated are influenced by the experience and 
theoretical viewpoint of the researchers. However, the use of multiple researchers to analyse 
the data gives increased credibility to the analysis (Elliott et al., 1999). 
 
4.6.2 Implications for intervention development 
The findings from this research indicate the need for interventions to support patients through 
diagnosis and treatment management. Illness and treatment beliefs serve as a framework for 
people to make sense of information they receive, including that from healthcare 
professionals. To meet people’s information needs it is imperative to link information to 
beliefs. The utility of illness and treatment beliefs in interventions has been discussed in a 
number of studies (Wearden & Peters, 2008). The findings have clear implications for informed 
choice in treatment as many participants have not received satisfactory information about 
their condition and medication, concurring with previous research (Bowskill et al., 2007). It has 
been recommended that information given in psychiatric care should enhance choice and 
reflect patients’ values, this will promote informed decisions (Hope, 2002). It is clear that this 
had not happened in the experience of participants in this study. 
A full description of how the intervention was developed based on the findings from the 
qualitative study and additional formulation work is presented in Chapter 5. The intervention 
content must include the most basic information about BD and treatment (due to reports of a 
complete lack of information). This information must address the necessity of ongoing 
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treatment especially during periods of euthymia. Concerns about medications should be 
elicited and addressed including information about medication switching, trialling treatment 
to find the most suitable and the alleviation of side-effects. 
Written information is a valued delivery vehicle, however, participants need access to trusted 
sources of support to ask questions and these may be their own care team or mental health 
charities. This finding concurs with a review of the role and value of written information for 
patients where patients valued tailored information, however it should not be a substitute for 
information delivered verbally from their HCP (Grime, Blenkinsopp, Raynor, Pollock, & Knapp, 
2007). Aspects of information delivery via the internet which were valued were the lived-
experience of others with BD through forums or personal stories. 
Information provision must take into account the context that participants can be impacted by 
stigma of the illness and the stigma around medication. It is crucial that information does not 
focus completely around negative aspects of illness and treatment, but provides a supportive 
and encouraging view of life with BD. The relationship with HCPs is important in feeling 
confident and able to engage in conversations about treatment. In terms of the temporal 
context of support, it appears to be important to allow someone to be stabilised after a severe 
mood episode. However, this should not preclude the provision of simple information about 
diagnosis and treatment. Van den Heuval and colleagues (2015) found that individuals with BD 
reported that information provided too early could be overwhelming when they were 
struggling to cope with the impact of BD. Difficulties in concentration also affected the ability 
to take on board information. Ongoing support and information is needed and participants 
must have this available to take up as and when needed. Participants’ readiness to accept 
information and their desire for it increased and decreased during their illness. The finding 
that information needs vary over time is supported by a systematic review of patient 
information preferences (Grime et al., 2007). The individual context of someone’s stage of 
acceptance and engagement as well as their level of understanding and desire for detail must 
be taken into account in any intervention or information provision. 
These three components of interventions (content, delivery vehicle and context) all 
demonstrate the importance of tailoring information to both individual needs and to their 
stage of illness. The next chapter describes fully the process of developing an intervention to 
target illness and treatment perceptions with the aim of improving adherence and enhancing 
self-management. This takes into account the concepts and recommendations for this 
qualitative study, as well as the findings from the systematic review and meta-analysis in 
Chapter 3 and the research evidence presented in Chapters 1 and 2. 
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Chapter 5 Development of the IBiD intervention 
 
5.1  Introduction to Intervention development 
This chapter describes the development of the Improving Information for people with Bipolar 
Disorder (IBiD) intervention, specifically the content, delivery mechanism and context. As 
described in Chapter 2, the MRC Framework for the development and evaluation of complex 
interventions was applied (Craig et al., 2008). The framework specifies that both identifying 
and developing appropriate theory and modelling the processes and outcomes is a crucial 
stage. The processes of change are identified using existing theory and research evidence. 
However, the framework does not specify exactly how to undertake the process of using 
evidence and theory to model mechanisms for behaviour change (Hardeman et al., 2005). 
Intervention mapping (IM) provides a detailed description of the systematic process and 
decisions behind intervention content, techniques and delivery (Bartholomew et al., 2011; Kok 
et al., 2004). The process has been used in a range of public health intervention trials including 
in adherence and in mental health (Balfour et al., 2006; Koekkoek, van Meijel, Schene, & 
Hutschemaekers, 2010; Lloyd, Logan, Greaves, & Wyatt, 2011; Pyne et al., 2014). IM provides a 
process for mapping objectives onto determinants or mediators of behaviour and selecting the 
techniques or strategies to attempt to modify these. It involves six steps (Bartholomew et al., 
2011; Kok et al., 2004): 
Step 1) Needs assessment -Defining the problem (including the behaviour and population 
at risk), the identification of outcomes and change objectives. Identify if previous 
interventions have worked and what the gaps are. This can involve systematic 
reviews as well as primary research. 
Step 2) Generation of matrices of change objectives - Defining the aims of the 
intervention, the behavioural or cognitive outcomes and the determinants of 
change. The matrices link the outcomes and their determinants using previous 
research to generate hypotheses. 
Step 3) Selection of theory based methods and practical strategies – Using appropriate 
theory and research evidence to select BCTs. 
Step 4) The development of a programme plan - Ensuring that the intervention is fit for 
purpose i.e. correctly translates the BCTs, is deliverable and appealing to potential 
participants. This step involves creation of the intervention protocol and materials. 
Step 5) Generation of adoption and implementation plan – Involving potential 
stakeholders to ensure that the intervention is designed for potential future 
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adoption. Considerations include potential adopters, capacity and ability to deliver, 
and required resources.  
Step 6) Generation of an evaluation plan – Producing an evaluation protocol specifying 
appropriate study design, comparison group, outcome measures, analysis plan, 
process evaluation and fidelity assessment. 
This chapter summarises the evidence and primary research contributing to intervention 
development (described in Chapters 1-4). It describes evidence-based decisions which 
determined the design, content and delivery of IBID. The chapter describes the detailed 
process of developing matrices and specifying methods and practical strategies selected for 
IBiD. This chapter also describes the process of development and subsequent refinement of 
IBiD through stakeholder and service-user consultation. Figure 5.1 illustrates the processes 
undertaken to produce the intervention. The chapter concludes with a description of the final 
intervention which is tested in a feasibility RCT (Chapter 6-7). 
 
5.2 Developing the IBiD Intervention - Intervention mapping 
The intervention was developed from the psycho-social constructs identified in Chapters 1-4 
related to adherence and self-management in bipolar and retrospectively mapped onto 
techniques from the, then unpublished, BCT Taxonomy (v1) of 93 techniques (described in 
Chapter 2) (Michie, Johnston, et al., 2013). The processes informing the intervention 
development were; a review of behaviour change theory and techniques (Chapter 2), a 
systematic review of adherence interventions in BD (Chapter 3), the qualitative study with 
people with a bipolar diagnosis (Chapter 4), development work by the Project Management 
group (PMG), a review of existing resources and manuals, a review of illness and treatment 
beliefs in severe mental illness and consultation with service-user representatives. This process 
is illustrated in Figure 5.1. 
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Figure 5.1: Illustration of the development of IBiD (Intervention mapping) 
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5.2.1 Step 1: Needs assessment 
The needs assessment step ties in with the MRC’s development phase comprising the 
identification of the evidence base using published research and new primary research 
(Bartholomew et al., 2011; Craig et al., 2008). The aim is to understand the population 
concerned, the extent or risk of potential problems and to identify the capacity for conducting 
an intervention. This was conducted by systematically evaluating the literature, theories and 
models and by conducting primary qualitative research. 
A needs assessment can involve the use of the PRECEDE model (Green, 1974), the principles of 
this approach informed the IBiD development process. PRECEDE involves the identification of 
the determinants (both personal and environmental) of the behaviour or problem in question, 
this helps to focus the areas to be targeted through intervention. This can be equated to the 
establishment of a medical diagnosis before developing a treatment plan. Factors include 
predisposing factors (e.g. knowledge and beliefs), reinforcing factors (e.g. social support, 
economic reward), and enabling factors (e.g. skills, availability of resources). The model 
became the PRECEDE-PROCEED model in the 1990’s in order to incorporate health 
determinants of policy and environmental factors (Green & Kreuter, 1999). 
The needs assessment identified the problem to be addressed, namely non-adherence and 
potential consequences of this as well as dissatisfaction with information about BD and 
treatment and lack of involvement in decisions about care (Arvilommi et al., 2014; Baldessarini 
et al., 2006; Bowskill et al., 2007; Care Quality Commission, 2009b, 2011b; Clatworthy et al., 
2009; Clatworthy et al., 2007; Hong et al., 2011; MacDonald et al., 2014; Morselli & Elgie, 
2003) (covered in Chapters 1 & 4). An intervention was required to address these issues and 
the factors associated with non-adherence informed the intervention content. 
A needs assessment also investigates ‘community capacity’ (Bartholomew et al., 2011). The 
establishment of a Project Management Group (PMG) is key in collaborative planning. In this 
programme of research the PMG comprised local HCPs, research and development staff and a 
service-user representative. Consultation with PMG members contributed to the assessment 
of need and in understanding the population and setting. 
 
5.2.2 Step 2: Proximal Programme Objective Matrices 
The evidence outlined in Chapter 1, 3 and 4 identified determinants of non-adherence which 
could potentially be amenable to change and were therefore of interest for intervention 
development. Programme objectives were selected in consultation with the PMG to ensure 
that they were valid, and would be potentially useable targets for future intervention delivery. 
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The target behaviour of adherence was tackled through a focus on the selected, potentially 
modifiable determinants; illness and treatment perceptions, satisfaction with information and 
feelings of stigma. Using IM terminology, these comprise performance objectives, i.e. the 
targets which the intervention aims to change (Bartholomew et al., 2011).  
The behavioural outcome was identified as adherence to medication. However, for this 
feasibility study, the focus for outcome measurement was on cognitive outcomes as they are 
proximal to adherence and illness outcomes. In addition, needs assessment and consultation 
with stakeholders and patients demonstrated that it was important to consider the broader 
aspects of staying well with BD, and not just adherence. The intervention content therefore 
targeted self-management strategies previously identified by research with people with BD 
(Mansell et al., 2010; Michalak et al., 2006; Mizock et al., 2014; S. J. Russell & Browne, 2005; 
Suto et al., 2010; Todd et al., 2012). The effective management of BD requires, not just 
adherence to prescribed medications, but also appropriate dose adjustments and changes to 
different types of medication as agreed with patients’ health professionals, therefore content 
included advice on finding the right treatment. 
Table 5.1 comprises a Change Matrix specifying the performance objectives to improve 
behavioural and cognitive outcomes and their determinants. As described in Chapter 2, self-
regulation theories of health behaviour are applicable, specifically the CSM (for understanding 
illness perceptions and coping strategies) (Leventhal et al., 1984), the e-SRM (incorporating 
treatment perceptions and the PAPA (understanding medication taking behaviour) (Horne, 
2003b). Indeed, Bartholomew and colleagues (2011) recommend that in the self-management 
of chronic illness, self-regulatory processes are important to consider when selecting 
programme objectives and designing the intervention. 
As illness and treatment perceptions and practical barriers to adherence are specific to each 
individual, it was important that the intervention reflected this. The process of self-managing 
chronic illness also includes the importance of taking into account the skills or knowledge of 
the individual, and tailoring intervention to these (Lorig & Holman, 2003). Hoffmann and 
colleagues (Hoffmann et al., 2014) highlight the importance of accurate reporting when 
individual participants do not all receive the same intervention. This can involve different 
doses, or the rules on which participant assessments affect the formulation of the intervention 
for each person. In IBiD, baseline assessments were used to ensure that the information 
presented to participants was adapted to their particular concerns and needs. The exact 
methods and rules of tailoring for IBiD are specified in Section 5.3. 
The intervention development work also identified that it was important to address other 
concepts and factors associated with acceptance and engagement with treatment and ongoing 
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management of BD, these included the need for medication trial and error, lifestyle self-
management and stigma and discrimination (Identified in Chapters 1 & 4). 
The process of selecting programme objectives informs Step 6, the evaluation, in particular, 
the operationalization of the outcomes. Objectives need to be measurable and therefore 
consideration is given to the selection of outcomes where valid, reliable measures exist or a 
plan is put in place to develop novel measurement, this is covered in Chapter 6, Section 6.3. 
In the IM process, environmental conditions are important considerations for full intervention 
development, these comprise social and physical including organisational and community 
conditions which impact the health problem (Bartholomew et al., 2011). However, in the 
present intervention, the research focused on psycho-behavioural aspects. 
 
Table 5.1: Change Matrix of Behavioural and cognitive outcome and determinants. 
Performance (behavioural) 
Objective 
Determinants/ Proximal objectives Model framework/ construct 
Intentional Medication 
adherence – 
Take medication as agreed 
with HCP 
Medication concerns 
Long term effects concerns 
Dependence concerns 
Side-effects concerns 
NCF – Concerns 
 Necessity beliefs 
Adherence and risk of relapse 
Long-term necessity of medication 
NCF – necessity beliefs 
 Satisfaction with medication information PAPA Practicalities 
e-SRM (appraisal of coping 
strategy, Contextual factors) 
 Feelings of stigma 
Medication related 
Disorder related 
e-SRM (affective emotional 
response to illness and 
treatment) 
COM-B (motivation) 
 Therapeutic alliance 
Effective communication with HCPs 
COM-B (all components) 
e-SRM (contextual factors) 
 Illness beliefs 
Acceptance of BD diagnosis 
Stronger bipolar identity 
Severity perception 
Timeline beliefs (BD as a long-term 
condition) 
Control perception 
e-SRM (illness representations) 
 Symptom monitoring 
Personal triggers of episodes 
Prodrome recognition 
Self-management in response to changes 
e-SRM (illness representations - 
identity) 
 Therapeutic alliance 
Effective communication with HCPs 
COM-B (all components) 
Unintentional Medication 
adherence 
Practical barriers 
Medication understanding 
Forgetting, dealing with routine changes 
etc 
PAPA 
& COM-B (opportunity & 
capability) 
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5.2.3 Step 3: Theory-based methods and practical strategies 
Theory-based methods are the processes which are anticipated to have an effect on the 
behavioural determinants specified in Step 2. In addition, practical strategies are required in 
order to actually deliver the methods in the intervention (Bartholomew et al., 2011). A useful 
way of explaining this is provided by Bartholomew and colleagues (2011) ‘Models and practical 
applications form a continuum that extends from abstract theoretical methods through 
practical applications to organised programs with specified scope, sequence and support 
materials’ (p.310). 
In order to ensure that the techniques used in IBiD are specified and described using the most 
up to date and comprehensive taxonomy, and a ‘common language’, the intervention content 
and delivery has been mapped onto BCTs from the Taxonomy (v1) of 93 techniques (described 
in Chapter 2) (Michie, Johnston, et al., 2013). This taxonomy had not been published when the 
intervention was being developed. Previously published resources were used in order to select 
BCTs and practical strategies (content and delivery) to operationalise these. These included 
Abraham and Michie’s taxonomy of 26 BCTs (2008), a framework of health behaviour change 
competencies (Dixon & Johnston, 2010), existing therapeutic manuals for BD (Basco & Rush, 
2005; Colom & Vieta, 2006) and CBT guides and workbooks (Centre for Clinical Interventions, 
2008). Table 5.2 specifies how each determinant was addressed by specific intervention 
content and which BCTs this maps onto. 
The concept of self-management in chronic illness also aids the formulation of IBiD. Five 
components of self-management have been defined and inform the application of BCTs to the 
intervention; problem solving, decision making, resource utilisation, forming of a 
patient/health care provider partnership, and taking action (Lorig & Holman, 2003). 
There is growing evidence for specific techniques in improving medication adherence, for 
example, Implementation Intentions (I. Brown, Sheeran, & Reuber, 2009), eliciting and 
targeting beliefs about illness and medication and practical barriers (O’Carroll, Chambers, 
Dennis, Sudlow, & Johnston, 2013) and in improving outcomes in BD (Lolich et al., 2012).It has 
also been recommended that BCTs applied to other health behaviours such as smoking or 
engaging in physical activity can be adapted and applied to adherence (Michie, Rumsey, et al., 
2008). 
A number of techniques were used in the overall intervention delivery, for example, 
Motivational Interviewing (MI) (Miller & Rollnick, 1991). MI is classified as one BCT in the 
Taxonomy (under BCT code 3.3 Social support, emotional) (Michie, Johnston, et al., 2013), 
however the approach encompasses a variety of techniques for motivating change (Hagger & 
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Hardcastle, 2014), most frequently involving goal setting, provision of social support and 
feedback and comparing possible outcomes using a pros and cons discussion (Morton et al., 
2014). In IBiD, as well as these specific techniques, the client-centered focus of MI guided how 
the intervention was delivered. Participants were encouraged to make choices which were 
appropriate for them, to feel in control of these decisions and feel they have the ability to 
carry out any changes. The approach used was non-judgemental, made use of open questions, 
affirmations and reflective listening. In the face to face discussions with participants they were 
provided with encouragement that they could successfully manage their medication and 
condition. This corresponds to the BCT Verbal persuasion about capacity (code 15.1). The 
discussions also covered past successes in adherence and self-management, and therefore 
covered ‘Focus on past successes’ (code 15.3). 
This ethos of MI ties in with self-management as opposed to more traditional patient 
education, whereby patients are active participants tailoring and applying the skills and 
knowledge gained to their particular needs and circumstances (Lorig & Holman, 2003). 
Tailoring was a key aspect of the intervention and this is described fully in Section 5.3. In brief, 
information was presented to participants reflecting their individual beliefs and concerns 
about BD and treatment. 
Therapeutic models have been applied to BD for example, Cognitive Behaviour Therapy (CBT) 
e.g. (Basco & Rush, 2005) and Psychoeducation e.g.(Colom & Lam, 2005) (see Chapter 3). 
Psycho-education, in the context of BD refers to a therapeutic model focussing on adherence 
enhancement, early identification of prodromes (personal early warning signs preceding 
episodes), the importance of lifestyle regularity, exploring individuals' health beliefs and 
illness-awareness, and enabling the individual to understand the relationship between 
symptoms, personality, interpersonal environment, and medication side-effects.(Colom & Lam, 
2005). CBT as a therapy aims to identify and challenge negative thoughts and emotions. In 
mental health the aims include managing symptoms and preventing relapse and learning 
effective coping techniques for managing stress and mood and dealing with negative thoughts 
(J. S. Beck, 1995). 
In the Taxonomy (Michie, Johnston, et al., 2013), the authors specify that encouraging 
adherence to medication in order to facilitate behaviour change (BCT code 11.1 
Pharmacological support) is a technique in itself. However this related to, for example, using 
nicotine replacement therapy to aid smoking cessation. In the case of IBiD, the behavioural 
objective is adherence so therefore this is not a specific technique used in this intervention. If 
the measured behaviour outcome was illness relapse then the intervention would be using this 
technique to encourage adherence. 
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The remainder of this section describes the process of targeting specific determinants and 
proximal objectives through the development of practical strategies including the intervention 
content. Table 5.2 summarises each determinant from the matrix above and the practical 
strategy, IBiD section and relevant BCTs which this maps onto.  
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Table 5.2: Matrix of Determinants/ Proximal objectives, implementation in the IBiD intervention and BCTs these mapped onto. 
Determinants/ Proximal 
objectives 
Implementation strategies in IBiD IBiD section/ exercise BCTs (Michie, Johnston, et al., 2013) 
Medication concerns Prompt participant to identify and compare reasons for adherence and 
non-adherence (medication concerns), then prompt them to weigh up 
the concerns vs the benefits of medication. 
Balancing pros and cons – information and decisional balance 
exercise 
9. Comparison of outcomes - 9.2 
Pros and cons 
Medication concerns - Side-
effects 
Provide information to allow participant to identify which physical 
symptoms are side-effects. 
Prompt them to generate or select strategies to help manage these, 
minimise the impact, or find alternative treatments. 
Advise participant to seek practical support from HCPs on managing side-
effects and finding the right medications. 
I’m worried about the side effects from these medications 
Common side effects and strategies to manage them 
Taking this medication affects my daily life 
‘What should I do if I am having problems..’ 
I dislike the way these medications make me feel 
Medications prescribed for bipolar disorder 
Sussex Partnership NHS Trust leaflets 
Link to Choice and Medication website 
1. Goals and Planning - 1.2 Problem 
solving 
3. Social support - 3.2 Social support 
(practical) 
5. Natural consequences - 5.6 
Information about emotional 
consequences 
9. Comparison of outcomes - 9.1 
Credible source 
Medication concerns – 
Dependence 
Provide information on dependence, what constitutes addiction and 
withdrawal symptoms. Acknowledge concerns about dependence. 
‘I sometimes worry that I might become addicted to or 
dependent on the medication I’m taking’ 
5. Natural consequences - 5.1, 
Information about health 
consequences 
Medication concerns - Long term 
effects 
Provide information on risk of long-term effects and how to reduce risks. 
Prompt participant to identify and compare reasons for adherence and 
non-adherence (long-term effects concerns), then prompt them to weigh 
up the risk of long-term effects vs the benefits of medication. 
‘I sometimes worry whether there might be long-term effects...’ 
Link to Choice and Medication website 
Balancing pros and cons – information and decisional balance 
exercise 
5. Natural consequences - 5.1, 
Information about health 
consequences 
9. Comparison of outcomes - 9.1 
Credible source, 9.2 Pros and cons 
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Determinants/ Proximal 
objectives 
Implementation strategies in IBiD IBiD section/ exercise BCTs (Michie, Johnston, et al., 2013) 
Necessity beliefs - Adherence and 
risk of relapse 
Provide information about non-adherence and relapse risk. 
Prompt participant to imagine and compare the outcomes of adherence 
and non-adherence for them in the future and the pros and cons of 
adherence and non-adherence (relapse risk). 
Provide information about the challenges with managing bipolar and 
factors which precipitate non-adherence (antecedents). 
Emphasise the emotional, social and environmental consequences of 
adherence and non-adherence and the specific impact which these could 
have on participants’ lives (relapse/ hospitalisation/ employment etc). 
Prompt participants reflect on the consequences of previous adherence/ 
non-adherence. Provide information to stimulate future regret about 
non-adherence (based on previous experience). 
Provide ways in which others have viewed BD and taking medication 
more positively. 
Your thoughts and feelings about taking medication 
Exercise - What does taking medication for bipolar mean to you? 
Taking control: 3 steps to effective management - Challenges 
exercise 
Balancing pros and cons – info and exercise (taking and not 
taking medication) 
Exercise – impact of stopping or taking medication differently 
Making sense of the diagnosis: Does taking medication mean I 
have to accept I am ill? 
13. Identity- 13.2 Framing/reframing 
4. Shaping knowledge - 4.2 
Information about antecedents 
5. Natural consequences - 5.1 
Information about health 
consequences, 5.2 Salience of 
consequences, 5.3 Information 
about social and environmental 
consequences, 5.4 Monitoring of 
emotional consequences, 5.5 
Anticipated regret 
9. Comparison of outcomes - 9.2 
Pros and cons, 9.3 Comparative 
imagining of future outcomes 
Necessity beliefs - Long-term 
necessity of medication (health in 
the future depends on 
medication) 
Provide information that medication is a preventative treatment to 
reduce relapse risk and framing BD as a long-term condition with ongoing 
susceptibility to episodes. 
I don’t feel ill so why should I continue to take my medication? 
Will I always have bipolar? 
13. Identity - 13.2 Framing/reframing 
Satisfaction with medication 
information 
Provide information on medications for BD and the specific medications 
participants are prescribed. 
Provide links to where to access additional information from credible 
sources. 
Medications prescribed for bipolar disorder 
Sussex Partnership NHS Trust leaflets 
Link to Choice and Medication website 
Useful resources. 
9. Comparison of outcomes - 9.1 
Credible source 
Feelings of stigma - medication 
related 
Provide information (quotes from people with lived experience) on 
positive ways to perceive medication. 
Encourage participant to build a positive identity of having a BD diagnosis 
and taking medication. 
Taking medication is an unwelcome reminder of my condition 
(quotes) 
‘I tend to hide the fact that I am taking these medications...’ 
9. Comparison of outcomes - 9.1 
Credible source 
13. Identity - 13.5 Identity associated 
with changed behaviour 
Feelings of stigma - disorder 
related 
Provide information on public perceptions of mental health (national 
survey) and prompt participant to compare with their own perceptions to 
attempt order to change cognitions about stigma. 
There’s such a lot of stigma about giving yourself a label – 
Information & exercise 
Public views about mental illness 
9. Comparison of outcomes - 9.1 
Credible source 
13. Identity - 13.2 Framing/reframing 
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Determinants/ Proximal 
objectives 
Implementation strategies in IBiD IBiD section/ exercise BCTs (Michie, Johnston, et al., 2013) 
Therapeutic alliance 
Effective communication with 
HCPs 
Advise participant to seek support and practical advice from HCP on 
adherence and managing BD. 
Provide suggestions on how to communicate effectively with HCP and get 
the most benefit from consultations. 
Taking control: 3 steps to effective management Challenges 
exercise (advice to use with HCP) 
‘What should I do if I am having problems..’ 
Getting the most from your consultations 
3. Social support - 3.1 Social support 
(unspecified), 3.2 Social support 
(practical) 
Illness beliefs - Bipolar identity 
(acceptance of BD diagnosis) 
Encourage participant to build a positive identity of having a BD diagnosis 
and taking medication. 
Recommendation of where to seek more information on BD from 
credible sources. 
Making sense of the diagnosis: Does taking medication mean I 
have to accept I am ill? 
Exercise – What does bipolar mean to you? 
Useful resources 
13. Identity - 13.5 Identity associated 
with changed behaviour 
9. Comparison of outcomes - 9.1 
Credible source 
Illness beliefs - Severity 
perception 
Provide information on the consequences of mood episodes and why 
bipolar is treated as an illness 
Understanding bipolar, Highs & Lows (Q&A) 9. Comparison of outcomes - 9.1 
Credible source 
 
Illness beliefs – Timeline beliefs 
(BD as a long-term condition) 
Framing BD as a long-term condition with ongoing susceptibility to 
episodes. 
Encourage participant to build a positive identity of having a BD diagnosis 
and taking medication. 
Will I always have bipolar? 13. Identity - 13.2 
Framing/reframing, 13.5 Identity 
associated with changed behaviour 
Illness beliefs - Control perception Provide information that medication and self-management can help 
control BD. 
Taking control: 3 steps to effective management 13. Identity - 13.2 Framing/reframing 
Practical barriers - Forgetting, 
dealing with routine changes etc. 
Prompt participant to identify own practical barriers to adherence then 
generate or select strategies to help overcome barriers. 
Suggest environmental or social stimulus which prompt medication 
taking, advise participant of ways of minimising demands on mental 
resources (e.g. use of alarms, reminders, linking medication with another 
activity, requesting assistance from friends/ family), advise to change the 
physical environment to facilitate adherence (e.g. dosette boxes, location 
of medication storage), prompt detailed planning of daily medication 
taking (e.g. context, frequency, duration, intensity), advise to seek 
support from friends/ family and let them know their treatment plan and 
to contact HCPs for practical support on difficulties with medication. 
 
 
Sometimes I find it difficult to take my medication 
‘What should I do if I am having problems..’ 
Implementation Intentions exercise 
1. Goals and Planning - 1.2 Problem 
solving, 1.4 Action Planning 
3. Social support - 3.2 Social support 
(practical) 
7. Associations - 7.1 Prompts/cues 
11. Regulation - 11.3 Conserving 
mental resources 
12. Antecedents - 12.1 Restructuring 
the physical environment 
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Determinants/ Proximal 
objectives 
Implementation strategies in IBiD IBiD section/ exercise BCTs (Michie, Johnston, et al., 2013) 
Practical barriers - Understanding 
how to get and take medication, 
and how and why changes may be 
needed. 
Presentation of information on specific medications prescribed to each 
participant. 
Provide advice to participant to seek practical support from HCPs on 
finding the right medications. 
Medications prescribed for bipolar disorder 
Sussex Partnership NHS Trust leaflets 
Link to Choice and Medication website 
Useful resources 
I’ve been on the same medication for years, do I need to 
change? 
Why does the medication I am given keep changing? 
3. Social support - 3.2 Social support 
(practical) 
9. Comparison of outcomes - 9.1 
Credible source 
Symptom monitoring - Identifying 
personal triggers of episodes. 
Provide information on potential triggers and prompt participant to 
identify previous triggers to enable identification of future ones (i.e. 
define stimulus which cue self-management). 
Is there a cause of bipolar (triggers information & exercise) 7. Associations - 7.1 Prompts/cues 
Symptom monitoring 
Prodrome recognition 
Provide advice to participant to identify personal prodromes of episodes. 
Prompt participant to track triggers (e.g. life events) prodromes (e.g. 
sleep, spending), behaviour (including adherence) and outcomes.  
Monitoring your symptoms and looking after yourself 
Completing your own mood chart 
Taking control: 3 steps to effective management 
1. Goals and Planning - 1.2 Problem 
solving 
2. Feedback and monitoring - 2.3 
Self-monitoring of behaviour, 2.4 
Self-monitoring of outcome(s) of 
behaviour 
Symptom monitoring 
Self-management in response to 
changes 
Prompt participant to identify barriers to effective self-management. 
Presentation of information on practical strategies to try in the event of 
mood changes.  
Prompt participant to generate or select strategies to put into place in 
the event of noticing prodromes. 
Advise participant to work with HCP to help generate or select strategies. 
Instruct and advise participant to use mood charting exercise to monitor 
prodromes, behaviour and outcomes and advise to use this with HCP to 
problem solve. 
Taking control: 3 steps to effective management – Challenges 
exercise 
Monitoring your symptoms and looking after yourself 
Completing your own mood chart 
1. Goals and Planning - 1.2 Problem 
solving 
2. Feedback and monitoring - 2.3 
Self-monitoring of behaviour, 2.4 
Self-monitoring of outcome(s) of 
behaviour 
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5.2.3.1 Treatment perceptions – Necessity & Concerns beliefs 
As previously discussed, medication perceptions have been linked to adherence in BD 
(Clatworthy et al., 2009). Therefore the intervention needed to use techniques to attempt to 
help participants come to a view of medication that is consistent with adherent behaviour i.e. 
reduce concerns and increase perceptions of need. 
Persuasive communication involves guiding people towards an attitude or behaviour using 
persuasive arguments. A theoretical model of persuasive communication is the Elaboration 
Likelihood Model (ELM) (Petty & Cacioppo, 1986). The ELM involves two processing routines 
for persuasion; central and peripheral. In the central route, an individual takes the relevant 
information and scrutinises this, and is conducted on a conscious level. This is relevant in the 
IBiD intervention as the aim is to involve participants in the active process of making informed 
choices about treatment. The peripheral route relies on affective associations and perceived 
credibility of the information. Persuasive communication is part of a number of BCTs and 
therefore these were used in order to target beliefs, some examples of which are provided 
here. 
Participants’ perceptions of the necessity of treatment were targeted by emphasising the 
consequences of adherence and non-adherence for them as an individual. This involved the 
use of an exercise to determine what the outcomes were of non-adherence for them in the 
past (mapped to BCT code 5.2: Salience of consequences) (Figure 5.3). This technique is used in 
psychoeducation programmes for BD (Colom & Vieta, 2006). A mood charting exercise 
provided by Bipolar UK allowed participants to track their moods and their medication taking 
behaviour thus allowing them to visualise the relationship between their mood and adherence 
(Appendix K). 
 
Figure 5.2: Your thoughts and feelings about taking medication 
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Cognitive restructuring (BCT code 13.2 Framing/ reframing) is used in CBT and aims to 
encourage participants to identify and re-evaluate their beliefs (Basco & Rush, 2005). The 
rationale being that behaviour is influenced by cognitions and mood and therefore modifying 
dysfunctional cognitions and moods will have an effect on behaviour (J. S. Beck, 1995). In IBiD, 
persuasive communication was used to frame medication-taking as a way to help participants 
to reduce the risk of problems associated with BD as opposed to changing who they are. 
To target necessity beliefs and concerns about medication, a decisional balance exercise, as 
used in CBT interventions, was included (Basco & Rush, 2005). This prompts participants to 
weigh up the reasons for adherence versus non-adherence (Figure 5.3). This maps to the BCT 
Pros and cons (BCT code 9.2) (Michie, Johnston, et al., 2013). Problem solving and decision 
making are identified as a skill required for self-management. In chronic conditions such as BD, 
people must make decisions on a day to day basis with regard to changes in mood, side-effects 
or dealing with environmental changes or life events (Lorig & Holman, 2003). This incorporates 
the principles of MI where people are more likely to make changes if the individual themselves 
identifies the potential benefits of change as they are most salient (Miller & Rollnick, 1991). 
 
Figure 5.3: Pros and cons of taking medication exercise 
 
Information was provided so participants could have sufficient knowledge on which to weigh 
up their concerns. This was framed around the BMQ concerns items (e.g. side effects, long-
term effects, fears of dependence). IBiD presents information about common side-effects to 
give participants knowledge to decide how to deal with them. Lorig and Holman (2003) 
recommend that patients with chronic conditions are given information which enables them to 
determine if symptoms are an indication of a problem which needs to be addressed and how 
urgent this need is. Participants were also advised to seek additional information and support 
from their HCP and medication information websites. The provision of knowledge about 
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treatment is a key objective of psychoeducation programmes (Colom & Vieta, 2006) and is 
identified as a prerequisite to be able to make informed decisions (Lorig & Holman, 2003). 
An additional topic in relation to medication raised by participants in the qualitative study in 
Chapter 4 was the importance of understanding the need to find treatments which are right 
for them individually. Text was included to explain the need for therapeutic experimentation 
and the importance of participants own involvement in trialling medication and doses to find 
the most effective treatment whilst minimising side-effects. This section of IBiD also highlights 
the importance of communication with HCPs and forming an effective partnership which is a 
part of self-management (Lorig & Holman, 2003) and therapeutic alliance has been identified 
as an important determinant of adherence and symptom experience (Strauss & Johnson, 2006; 
L. Thompson & McCabe, 2012). 
 
5.2.3.2 Illness perceptions & symptom monitoring 
Illness perceptions which may be associated with effectively managing BD, include perception 
of illness severity and perceived control over BD (Adams & Scott, 2000; Scott & Pope, 2002a). 
Information was included in IBiD on BD including the consequences of relapse, the chronic 
nature of the condition using persuasive communication in order to increase severity 
perceptions. In addition, information on taking control in BD was included in order to increase 
perception of personal control. 
Self-management requires ongoing symptom and behaviour monitoring and selecting and 
using coping procedures such as seeking information and help and making lifestyle changes 
(Mizock et al., 2014; S. Russell & Browne, 2005; Todd et al., 2012). Recognising the prodromes 
or early warning signs of BD episodes is the crux of self-management in BD (Lam et al., 2001; S. 
Russell & Browne, 2005). 
IBiD included a section on symptom monitoring, using a number of techniques including 
relapse prevention, decision making and problem solving (Figure 5.4). Psychoeducation 
programmes which have demonstrated effectiveness (e.g. (Colom, Vieta, Sanchez-Moreno, 
Palomino-Otiniano, et al., 2009)) recommend creating and using lists of symptoms, warning 
signs and self-management strategies which need to be put in place when these symptoms are 
identified (Colom & Vieta, 2006). The mood charting exercise allowed participants to track 
their moods and make notes on self-management used. This is a technique which has been 
used in CBT for BD (Basco & Rush, 2005). 
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Decision making and problem solving skills are followed by ‘taking action’ where patients must 
have the skills necessary to carry out the behaviours chosen to help manage mood episodes 
(Lorig & Holman, 2003). Practical actions are included and participants are advised to seek 
support from significant others and from HCPs in implementing strategies. 
In reviewing the BCT taxonomy (v1) (Michie, Johnston, et al., 2013), these strategies were 
mapped onto Problem solving (BCT code 1.2), Self-monitoring of behaviour and Self-monitoring 
of outcome(s) of behaviour (BCT codes 2.3 and 2.4). 
 
Figure 5.4: Symptom monitoring information and exercise 
 
5.2.3.3 Satisfaction with information 
Satisfaction with information has been demonstrated to be related to adherence in BD 
(Bowskill et al., 2007). In order to improve satisfaction with medication information, general 
and specific information on medications which participants were prescribed was provided. This 
comprised Patient Information Leaflets from Sussex Partnership NHS Foundation Trust 
(Appendix X) and links to the Choice and medication website (Bazire, 2013). Providing 
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information tailored to participants needs has been shown to be effective in improving 
satisfaction in chronic pain (Glattacker et al., 2012). Expert communication comprises the BCT 
Credible source (BCT code 9.1) (Michie, Johnston, et al., 2013). Providing information with a 
credible source encompasses the peripheral route of the ELM (Petty & Cacioppo, 1986). Lorig 
and Holman (Lorig & Holman, 2003) specify that finding and using resources is a key self-
management skill. However, simply signposting to resources may not be enough if people do 
not know how to use them. In the intervention delivery, it was checked that participants were 
able to access online information and a description of how to use the websites was provided. 
 
5.2.3.4 Practical barriers to adherence 
To target practical barriers to non-adherence including unintentional non-adherence an 
Implementation Intentions exercise was included (Gollwitzer, 1993). Implementation 
Intentions (IIs) are behaviour goals which are set with the intention of motivating behaviour 
and but crucially also include how and when this is to be achieved. Previous research 
demonstrates the effectiveness of IIs in a range of health areas (Gollwitzer & Sheeran, 2006) 
including mental health (Toli, Webb, & Hardy, 2015). They have also been used effectively in 
medication adherence in Epilepsy (I. Brown et al., 2009). ‘If-Then’ planning statements are 
used to operationalise the II and in IBiD participants are encouraged to create their own 
statement. ‘If’ comprises the anticipated situation (e.g. brushing teeth in the bathroom) and 
‘Then’ comprises the anticipated outcome ‘taking medication’ (Figure 5.5). IIs are included in 
the BCT Action Planning (BCT code 1.4) (Michie, Johnston, et al., 2013). 
 
Figure 5.5: IBiD Implementations Intentions exercise 
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A key self-management strategy in Psychoeducation and CBT is problem solving (Basco & Rush, 
2005; Colom & Vieta, 2006) (mapped onto BCT code 1.2), which involves defining the problem, 
generating possible solutions, implementation of solutions and evaluation of success (Lorig & 
Holman, 2003). In problem solving, patients must take an active role in generating possible 
solutions rather than just having them imposed on them. IBiD incorporates problem solving in 
addressing practical barriers to adherence by asking participants to write-down ideas which 
they feel would be useful and they would be able to carry out for remembering to take their 
medication. This technique was also used in relation to dealing with side-effects of medication. 
The BCT Prompts/cues from earlier taxonomies (Abraham & Michie, 2008) and mapped onto 
BCT code 7.1 (Michie, Johnston, et al., 2013) was used to encourage participants to introduce 
cues in their physical or social environment to prompt medication taking. This is also used as 
an exercise in (Colom & Vieta, 2006). In IBiD a range of potential solutions to the problem of 
remembering to take medication is provided including advising on use of reminders or alarms 
and dosette boxes or the location of medication storage. Participants can then select 
appropriate solutions which fit with their practical barriers and they feel they have the self-
efficacy to carry out (Figure 5.6). These strategies map onto the BCTs; Conserving mental 
resources (BCT code 11.3) and Restructuring the physical environment (BCT code 12.1). 
 
Figure 5.6: ‘Sometimes I find it difficult to take my medication’ – Practical adherence solutions 
 
5.2.3.5 Improving effective communication with HCPs 
Lorig and Holman (2003) identify that helping people to form partnerships with their health 
care providers is a key self-management skill. As identified in Chapter 1, better relationships 
with providers where there is a collaborative partnership between professional and patient 
appears to be associated with better treatment adherence (L. Thompson & McCabe, 2012; 
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Zeber et al., 2008). Effective communications and a good partnership brings together self-
management strategies in that individuals can bring their skills and knowledge to the 
consultations and can work in partnership to inform treatment decisions. This is an important 
aspect of recovery-oriented care where patients are experts in the experience of their 
condition and relationships involve shared expertise (Davidson, 2005). 
IBiD targeted the therapeutic relationship by providing advice to raise side effects, practical 
problems, feelings about medication and changes in symptoms with HCPs. The text included a 
reminder that it is important to work in collaboration with HCPs due to the nature of BD 
(Figure 5.7). These techniques map onto the BCTs Social support (unspecified), Social Support 
(practical) (BCT codes 3.1 and 3.2). The intervention included advice on how to get the most 
from consultations with HCPs. This acknowledged that it can be difficult to raise questions and 
to remember to ask them. Suggestions of possible questions and the space to write additional 
questions was provided. 
 
 
Figure 5.7: Getting the most from your consultations 
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5.2.4 Step 4: Programme plan 
The practical strategy used to implement the intervention needs to be fit for use, deliverable 
and appealing to potential participants. The materials and delivery strategy must adequately 
translate the BCTs and implementation strategies described above to ensure that the 
programme objectives can be met (Bartholomew et al., 2011). A key part of this step of IM is 
to ensure that the programme is appropriate for the population and context (Bartholomew et 
al., 2011). 
The process of selection of a written information resource supported by a face to face session 
is described below. Producing the IBiD intervention involved a number of stages (Figure 5.1). 
The stages are described with detail on what components of the intervention these 
contributed to. In section 5.3, the final IBiD intervention is described in terms of the key 
components identified for intervention development; Content, Context and Delivery vehicle 
(Horne, 2012). 
Briefly, the booklet format of the intervention was determined through discussion in the 
project management group using previous research. Written information was viewed as a 
valued way of receiving information by participants in the primary qualitative research but it 
was important to also have the opportunity to speak face to face and to be signposted to 
additional information (Chapter 4). This concurs with a review of the role of written patient 
information where it was found that tailored information was valued, however it should not be 
a substitute for interactions with HCPs (Grime et al., 2007). In a large European study it was 
determined that easily readable booklets were viewed as more helpful whereas internet and 
CD-roms were perceived as not helpful (Morselli & Elgie, 2003). Written material is a valid 
method for delivering persuasive communication messages and the exercises developed are 
consistent with those used in Psychoeducation, CBT and MI interventions (Basco & Rush, 2005; 
Colom & Vieta, 2006) (see Section 5.2.4.2 below). 
The development process was iterative in that the intervention content underwent a process 
of drafting and redrafting at each stage with ongoing communication with stakeholders and 
service-user representatives. 
 
5.2.4.1 Project Management Group (PMG) development meetings 
During PMG meetings, the intervention design and content was discussed and contributions 
from NHS Trust staff ensured that the intervention would be appropriate and implementable 
within the context of adult mental health services (Bartholomew et al., 2011). Initial ideas for 
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intervention content were provided by group members, taking into consideration the 
preliminary development work and this were then used to develop the first working draft of 
IBiD. This was consistent with methods recommended by Bartholomew and colleagues 
(Bartholomew et al., 2011) where the creativity of group members contributes towards 
designing the intervention. A key member of the PMG was a service-user representative from 
Bipolar UK who contributed to the text of the resource. Stakeholder consultation is a key 
component of intervention developments (Craig et al., 2008; NIHR; Sussex Partnership NHS 
Foundation Trust, 2012). 
 
5.2.4.2 Review of existing health information resources, intervention and therapy manuals 
and guidelines 
In developing the content of IBiD, existing resources produced by voluntary, statutory and 
professional organisations were reviewed (The British Psychological Society, 2010; Bipolar UK, 
2012; Rethink Mental Illness, 2010; Scotland, 2011). It is recommended that intervention 
planners utilise existing materials or parts of these (although these must also be pre-tested 
with potential service users) (Bartholomew et al., 2011). Existing therapeutic manuals for BD 
were consulted (Basco & Rush, 2005; Colom & Vieta, 2006) as well as more general CBT 
techniques (Centre for Clinical Interventions, 2008). The content on identifying individual signs, 
symptoms and triggers preceding episodes was developed using the techniques identified in 
these published manuals. Reviewing these manuals also served to increase the knowledge and 
skills of the researcher in delivering a face to face session with participants. 
 
5.2.4.3 Consultation with individuals with a diagnosis of BD 
Consulting with potential intervention users is crucial in ensuring that it has face validity, that 
the programme messages are clearly communicated and the delivery vehicle is credible. This is 
a key component recommended by the MRC, NIHR as well as in local NHS Research policies 
(Bartholomew et al., 2011; Craig et al., 2008; Lewin et al., 2009; NIHR; Sussex Partnership NHS 
Foundation Trust, 2012). This process in IM is referred to as formative or preproduction 
research (Bartholomew et al., 2011). Patient information needs to be reflective of actual 
patient needs, which many are not, being too centered around information which is important 
to health professionals, but not to patients themselves. When preparing patient information, 
issues are likely to be raised which were not considered initially by intervention developers 
(Grime & Pollock, 2004). 
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Once the first working draft of the complete intervention resource had been developed, a 
process of review with people with a diagnosis of bipolar was conducted. The PMG service-
user representative sought out a number of individuals with a diagnosis of BD to request their 
assistance in reviewing the resource. Five people expressed an interest and four subsequently 
agreed to provide feedback on the resource. 
The resource was emailed or posted to each individual and they were provided with a set of 
prompts to consider when reviewing the resource. Reviewers were asked for their feedback on 
the wording, design, layout, images and exercises. The feedback received from the reviewers is 
summarised in Table 5.3 and detailed in Appendix H. All reviewers felt that the resource would 
be helpful and that the exercises were relevant and useful. The reviewers’ comments were 
synthesised and through a process of discussion with PMG members the comments were 
incorporated. 
 
Table 5.3: Summary of service-user feedback on draft IBiD resource 
Content & clarity 
Additional information and clarification 
Include physical and cognitive aspects of bipolar, not just mood changes (e.g. physical early warning signs and 
changes in ability to concentrate). 
Provide examples for challenges in successfully managing bipolar. 
Clearer instructions on completing exercises (e.g. change ‘Is there anything that worries you about taking your 
medication in the long term?’ to ‘Use this space to write down any worries you may have about taking your 
medication in the long term’). 
Additional information on importance of regular blood tests when taking Lithium. 
Increase amount of information on sexual dysfunction side-effects of medication and strategies to manage this. 
Clarity 
Wording changes to improve clarity and removal of definitive statements (‘can’ and ‘usually’ as opposed to ‘is’). 
Remove the term ‘informed choice’ and change to more user-friendly language. 
Change wording of causes of BD to improve clarity on interaction of multiple causes. 
Reword information on scientific definition of addiction and reword into simpler language. 
Add suggestion to ‘write down questions for HCPs in between appointments as you think of them’. 
Additional text/ content comments 
Positive feedback on Stigma section. 
The mood chart at the end is a really great idea. 
‘Very accessible and straightforward’ 
‘Like all the headings and subheadings’ 
Visual appearance 
Layout 
‘Very well set out, layout very accessible and straightforward’ 
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No need to repeat titles on the next page of the same section (confusing). 
Include icons to indicate exercises to be completed on each section. 
Colours 
‘Lovely peaceful pale blue colouring’ 
Images 
‘No mountains’ 
‘I think photos/cartoons of people are counterproductive. People with bipolar insert own images when reading 
and those deserve to be explored. Any you insert could cause blockages and lead to a sense of frustration or of 
being controlled/ contained.’ 
‘I am not sure whether other pictures are really needed. I don't like these photos that often accompany articles 
on bipolar of close-ups of pills or of people with their head in their hands ’ 
Additional comments 
‘I wish I had had this resource when I was diagnosed! It would have saved so much loneliness and thrashing 
about in the dark until I found my way to the Bipolar UK website and online forum and got myself a 
psychotherapist.’ 
‘The exercises follow a logical and helpful order, and lead the 'service user' (horrid term) gently and in the right 
direction. I think that if it were me using it, I would come to the end wanting to move forward and feeling 
reassured.’ 
‘I think on the whole this booklet is really good and I wish I had been given something like this when I was first 
diagnosed’ 
‘Overall, I think this booklet is clearly written and easy to understand. I like fact that there's a focus on using 
real experiences of people with bipolar rather than just asking HCPs’ 
 
‘Hand writing’ icons and light blue coloured boxes to 
indicate where participants can write their responses. 
 
‘Question mark’ icons to indicate where there is something 
for participants to think about. 
 
‘Speech bubble’ icons to indicate where participants are 
reminded that they could talk to their health professional. 
 
Boxes to highlight key points on the page. 
 
Figure 5.8: Visual cues 
 
5.2.5 Step 5: Adoption & Implementation Plan 
The fifth stage of IM is planning for the adoption and implementation of the intervention 
(Bartholomew et al., 2011). This is an important part of the process when developing new 
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interventions as the adoption and implementation focuses on how the intervention would be 
tested for efficacy. 
It is crucial to design the intervention in such a way that it has the potential for adoption by 
service-providers. This includes who might adopt and implement it as well as the capacity and 
resources required. The intervention should be designed so it can be delivered by persons not 
involved in developing the intervention initially. A crucial aspect of this is in documenting the 
intervention procedure comprehensively to ensure that future replication or implementation 
was possible. The TIDieR guidelines provide a method for reporting complex interventions 
(Hoffmann et al., 2014) and a checklist of these items for the IBiD intervention can be found in 
Appendix I. 
As the intervention was tested in a feasibility study, it was necessary to consider how it was to 
be implemented at this stage. The delivery of IBiD is described in detail in Section 6.4. The plan 
for implementation in the feasibility testing phase was pragmatic to fit with the care 
procedures in place in the acute adult mental health setting in which IBiD was tested in. 
Discussions in the PMG meetings led to the decision of conducting the intervention in the 
acute setting for a number of reasons; the identified need and dissatisfaction with information 
during this phase (see Chapters 1 & 4); the availability of eligible participants and the potential 
for this to be a salient time for providing information about medication due to difficulties with 
self-management and medication adherence likely to precede inpatient admission or 
participants being newly diagnosed. It was also decided to include the Crisis Response and 
Home Treatment teams (CRHT) as they form part of acute services. 
With the aid of hospital discharge data for the preceding 12 months, an assessment of the 
potential number of eligible participants was estimated. As well as informing the recruitment 
plan for the IBiD feasibility study, this data also provides information on how many patients 
would be likely to be able to receive the intervention, aiding plans for future adoption. 
Following these discussions there was consultation with ward and team managers on 
implementation of the study. These meetings served to better understand the running of each 
ward (which differed) and how IBiD could fit in with the least inconvenience to staff and 
patients. This also relates to the evaluation of ‘community capacity’ which forms part of the 
needs assessment stage (Bartholomew et al., 2011). 
Consideration was given during the planning stage about potential future adoption within the 
setting. There are severe pressures on mental health services (BBC, 2014) and it is well 
documented that there may be little capacity for information provision or discussions with 
staff (Rose, Evans, Laker, & Wykes, 2013; Stenhouse, 2011; Walsh & Boyle, 2009). It was 
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therefore necessary that the intervention be brief and resource efficient for implementing the 
trial and to ensure potential for future adoption. 
 
5.2.6 Step 6: Evaluation Plan 
The stages of IM described above in developing the IBiD intervention all inform the plan for 
evaluating the intervention. Steps 2 and 3 in producing the programme objectives inform the 
evaluation objectives and the selection or design of outcome measures. The process 
evaluation objectives are informed in part by Step 5 (Adoption and Implementation) as these 
relate to how the intervention is delivered (Bartholomew et al., 2011). 
The evaluation model was developed in order to determine, in the first instance, the feasibility 
of conducting a full RCT of the IBiD intervention. The evaluation is described fully in Chapter 6 
and also includes a discussion of the various decisions which must be made including choice of 
study design, outcome measures and comparison groups. 
As well as quantitatively assessing the feasibility of the intervention and trial, the evaluation 
plan included a qualitative evaluation to seek in-depth feedback from participants as well as 
the study team member conducting recruitment. 
In developing the evaluation plan, the input of the PMG was crucial in order to determine 
participant eligibility criteria, recruitment strategies and facilitate access to staff and patients 
in the research sites.  
Although the primary objectives of the RCT are on the feasibility of both recruiting to and 
conducting an intervention in this setting and on how the intervention itself is received, it is 
important to ensure that the evaluation plan would be applicable to a definitive trial. An 
evaluation of an intervention should comprise both an assessment of the effect (i.e. the 
outcome or impact) and process (i.e. factors related to the implementation of the intervention 
and interpretation of the findings). 
The evaluation model follows the CONSORT Statement for reporting RCTs of non-
pharmacologic treatments (NPT) (Boutron et al., 2008). In following these guidelines, the 
evaluation of the IBiD intervention is reported transparently and comprehensively. This 
addresses inadequacies in reporting of trials and interventions identified in Chapter 3. (See 
Appendix J for a checklist detailing the CONSORT items and where these are described in this 
thesis). 
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5.3 Description of the IBiD intervention 
The intervention is a tailored written resource presented by the author to adults who have 
received a diagnosis of BD in an individual session. The resource is designed to be taken away 
by participants and follow-up contact with the author via telephone or email was available. 
The description below summarises the content and delivery of IBiD and follows 
recommendations for reporting complex interventions (TIDieR) (Hoffmann et al., 2014). 
 
5.3.1 Content of the intervention 
The final intervention for use in the feasibility RCT comprises evidence-based content on BD 
and its treatment including medication and self-management (see Appendix K for full 
intervention content). The content of the intervention is framed and structured around the 
components of the extended self-regulation model and PAPA with a focus on the NCF (Horne, 
2001, 2003b). The intervention covers the identity of BD, causes and triggers, episodic 
timeline, consequences as well as information about the need for medication and specific 
concerns related to medication for BD. The content and exercises are informed by the BCTs 
identified in Sections 5.2 above. 
The intervention also contains information which was specifically highlighted in the qualitative 
study (Chapter 4) and published research evidence (Bowskill et al., 2007; Morselli & Elgie, 
2003; Perreault et al., 2006) as being valuable for inclusion in a resource; specifically, 
information on stigma, bipolar and alcohol use, and working in partnership with professionals. 
The content of the intervention comprises of the following; 
 An introduction to the resource 
 Information about BD –framed around extended SRM 
 Stigma and mental health conditions 
 Information about specific medications 
 Information about medications –framed around e-SRM and NCF 
 Practical barriers to taking medication – framed around the PAPA 
 Self-management – monitoring prodromes 
 Getting the most out of consultations with health professionals 
 Additional resources 
 Bipolar UK Mood charting tool 
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5.3.2 Intervention tailoring 
IBiD was designed to be easily tailored to participants needs based on their baseline beliefs 
and concerns. Tailoring interventions to individuals needs has been recommended by a 
previous review in BD (L. Berk et al., 2010) as well as by the qualitative research in Chapter 4 
and other published studies in mental health (Hatonen, Suhonen, Warro, Pitkanen, & Valimaki, 
2010). 
Sections of the resource were designed to target individual perceptual barriers to acceptance 
of the illness and engagement with treatment and practical barriers in accordance with the 
PAPA approach (Horne, 2001, 2003b). The procedure for tailoring is detailed in Table 5.4. In 
summary, participants baseline responses to items on the IPQ, BMQ (specific), BMQ (practical), 
SAQ, SIMS and ISMI dictated whether or not they received the relevant sections of the 
resource, for example, if participants endorsed the BMQ item ‘I sometimes worry about 
whether there might be long-term effects of taking these medicines’, their tailored resource 
included the section which addressed this concern. 
 
Table 5.4: IBiD tailoring pages and guidelines (from baseline assessments) 
Tailored pages Theory-based tailoring Detail from baseline assessment – who 
receives the section? 
Will I always have bipolar? e-SRM - Acute beliefs Acute beliefs - IPQ item 2 <7 (0=acute 
10=chronic) 
‘There’s such a lot of stigma about giving 
yourself a label’ (2 pages) 
Internalised stigma ISMI score >2.0 for any overall score or 
subscale (2.01-4.0=mild to severe 
stigma) 
I’m worried about the side-effects from 
these medicines (3 pages) 
NCF - Side-effect 
concerns 
BMQ item C6 Strongly agree, Agree or 
Uncertain for any medication prescribed 
And/ or 
SAQ any items endorsed with 
medications as attributed cause 
I sometimes worry about whether there 
might be long-term effects of taking these 
medicines. 
NCF - LT effects 
concern 
BMQ item C2 Strongly agree, Agree or 
Uncertain for any medication prescribed 
Taking medication is an unwelcome 
reminder of my condition 
NCF - Reminder 
concerns 
BMQ items C9 Strongly agree, Agree or 
Uncertain for any medication prescribed 
I tend to hide the fact that I am taking 
these medicines from other people 
NCF - Medication 
stigma concern 
BMQ item C7 Strongly agree, Agree or 
Uncertain for any medication prescribed 
I don’t feel ill, so why should I continue to 
take my medication? 
NCF - Necessity beliefs 
e-SRM - Illness identity 
BMQ items N1, N2, N3, N4, N5, N7 
Strongly disagree, Disagree or Uncertain 
for any medication prescribed 
And/ or 
IPQ item 5 <4 (0=no symptoms, 
10=many symptoms) 
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Tailored pages Theory-based tailoring Detail from baseline assessment – who 
receives the section? 
I don’t feel like the medication is working e-SRM – treatment 
control 
Necessity beliefs 
BMQ items N1, N2, N3, N4, N5, N7 
Strongly disagree, Disagree or Uncertain 
for any medication prescribed 
And/ or 
IPQ item 4 <6 (low treatment control) 
I dislike the way these medicines make 
me feel 
NCF –feelings concern BMQ item C10, C11 Strongly agree, 
Agree or Uncertain for either item for 
any medication prescribed 
Taking these medicines affects my daily 
life 
Disruption 
Concerns/ all 
BMQ item C4 Strongly agree, Agree or 
Uncertain for any medication prescribed 
I sometimes worry that I might become 
addicted to or dependent on the 
medicines I’m taking. 
NCF - Dependence 
concern 
BMQ items C5 and C8 Strongly agree, 
Agree or Uncertain for either item for 
any medication prescribed 
Alcohol, bipolar and your medication Satisfaction with 
Information 
SIMS item 12 = ‘too little’/ ‘none 
received’ 
Sometimes I find it difficult to take my 
medication 
PAPA – Practical 
barriers 
BMQ – practical barriers & MARS 
forgetting Any barriers or forgetting 
 
5.3.3 Intervention delivery 
The detail of the procedure used in delivering IBiD is described in Chapter 6. The face to face 
delivery with the opportunity to ask questions was selected based on findings from the 
qualitative study (Chapter 4). The approach taken incorporated the principles of MI by 
promoting autonomy as decisions and goals set by the participant are more likely to be carried 
out than those imposed on them (Ryan & Deci, 2000). The delivery left scope to explore the 
most important issues for each individual. After a general introduction, the topics selected for 
discussion during the face to face session were flexible to participants’ priorities. 
 
5.4 Summary and conclusions 
This chapter described the development of the IBiD intervention using an adapted Intervention 
Mapping (IM) process (Bartholomew et al., 2011). Development of the IBiD intervention 
involved a detailed process of needs assessment, primary research, evaluation of evidence 
theory and behaviour change as well as consultation with service-users and professionals. By 
following this process, the intervention should meet an identified need, contain appropriate 
content and be in a format acceptable to patients as well as being based around techniques 
which are evidence-based for changing behaviour. However, IM has been criticised as being 
complex and time consuming and in practice, intervention development often takes place in 
conditions where there are time and financial constraints. In this programme of research, 
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steps needed to be undertaken concurrently in order to achieve the development and 
feasibility assessment within the time available. An additional criticism of IM is that it may be 
difficult to select the appropriate behavioural determinants and in this case and many studies 
do not conduct this stage adequately (Godin, Gagnon, Alary, Levy, & Otis, 2007). In the present 
research this process did present a number of challenges. Through the IM process, researchers 
specify the exact content of the intervention and how it is delivered. But it must be relevant 
for the population and context, for example techniques to enhance self-efficacy in smoking 
cessation may be very different in enhancing self-efficacy to take medication. Also what might 
work for people with a physical condition might be different for people with a BD diagnosis. 
Also within this group, people are very different with their own beliefs, hopes and fears so may 
respond to the same technique quite differently. There is limited evidence available on BCTs as 
applied specifically to the programme objectives in the context of mental health. Therefore 
knowledge from other health areas was extrapolated, consistent with recommendations 
(Michie, Johnston, et al., 2008). 
The practical application of techniques must be appropriate for the target population and the 
context in which they are being implemented. There isn’t sufficient evidence to say who, 
where and when a BCT might expected to have a positive effect. Although by conducting 
qualitative research we can gain insights into the variability of the population and context and 
find out people’s preferences and situations. How each technique is operationalised could 
potentially have a big impact on whether or not it is effective. The format of delivery had been 
called a key ‘active ingredient’ (Dombrowski, O'Carroll, & Williams, 2016). Although we may 
not have evidence as to which form of delivery is most effective in delivering a specific BCT, 
qualitative research allows us to be confident that that it will be an acceptable form for 
participants. This is an important part of the feasibility assessment of any novel intervention. 
In addition, the actual application of the technique is difficult to control and there are a lot of 
related variables, such as how the practitioner’s beliefs impact on the delivery of a technique, 
how the participant understands, perceives and responds the technique. People’s responses 
will be affected not just by the intervention but a range of intra and interpersonal and external 
factors. 
In developing the content of IBiD it was important to ensure that sufficient information was 
covered, however, the resource needed not to become too long as this would have made 
implementation too resource intensive. A balance was needed, ensuring that the focus was 
not just on medication concerns, but also on BD so as to provide context to the information on 
treatment. The issues covered were determined in part by the qualitative research (Chapter 4). 
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However, it was not possible or appropriate to include all suggestions from service-users for 
the sake of brevity and in keeping the resource focussed on the programme objectives. 
As described in the review in Chapter 3, many interventions are multi-component and 
conducted over a period of weeks or months. However, this intervention was designed with 
minimal resources available and keeping in mind the potential for future adoption. In terms of 
producing an intervention which could realistically be conducted, and not to over-burden 
patients or staff, a one session intervention was used with the resource designed as a self-
management tool which could be used by participants on their own and with their HCP. 
The intervention developed focusses on change at an individual behaviour level. However, the 
development work in Phase 1 and the evaluation of the intervention as part of the feasibility 
RCT informs more environmental, or system level factors which may also act as determinants 
for adherence and positive outcomes in BD, this will include recommendations for practice. 
The following chapter described the testing of the intervention in a feasibility RCT in line with 
the MRC recommendations for developing complex interventions (Craig et al., 2008). This 
incorporates Step 6 of Intervention mapping, ‘Planning for evaluation’, where the decisions on 
design, comparison group, selection of outcome measures is described. 
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Chapter 6 Evaluation of the Improving Information for people with 
Bipolar Disorder (IBiD) intervention: A feasibility RCT. 
 
6.1 Introduction 
This chapter presents a trial to assess the feasibility of conducting an RCT to evaluate the novel 
intervention, Improving Information for Bipolar Disorder (IBiD). This chapter describes, the 
development of the design and selection of appropriate outcome measures. This comprises 
Stage 6 of the IM procedure of ‘Planning for evaluation’ (Bartholomew et al., 2011). It then 
details the methods and procedures used in the feasibility trial. Finally the results of the 
feasibility RCT are described. This study comprises the ‘Feasibility & Piloting’ stage of the MRC 
process for the development of complex interventions (Craig et al., 2008). Section 6.3 
describes the importance of this stage during intervention development and evaluation to 
ensure that future evaluations are not beset with problems associated with the study protocol, 
materials and delivery. The evaluation description follows the CONSORT Statement for 
reporting RCTs of non-pharmacologic treatments (NPT) (Boutron et al., 2008) (see Appendix J 
for completed CONSORT checklist). 
 
6.1.1 Challenges with designing and conducting RCTs in mental health settings. 
Prior to developing the feasibility RCT protocol, it was important to consider the potential 
challenges and ethical considerations in conducting trials within a mental health setting. 
Consideration of these in a feasibility trial is a crucial part of the pre-trial phase. 
A criticism of RCTs, is that they may apply stringent inclusion criteria, such that the population 
included in the trial is not generalizable to the clinical population (Hotopf, 2002). It is 
important to ensure that trial results are applicable to real clinical situations in which an 
intervention might be taken forward (see Section 6.3 below) (J. Green, 2006). 
With a relatively diverse clinical sample, and a complex intervention, there will be significant 
individualisation needed in the content and delivery of the intervention. In alignment with the 
recovery model of mental health, any intervention must take into account individuals beliefs, 
needs and preferences and foster their own goals (Jacobson & Greenley, 2001; NICE, 2014). 
Davidson (2005) states that in mental health care there should be ‘An emphasis on individual, 
rather than collective solutions’ (pg 26). The pre-trial phase allows the exploration of the range 
of individual needs and to test the procedures and responding to them. Future protocols 
developed will then have procedures built in to respond to this complexity (J. Green, 2006). 
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As well as more practical considerations, there are a number of ethical issues specific to 
research in this setting (Graor & Knapik, 2013). There is a careful balance which must be 
maintained with recruiting potentially vulnerable groups to research. On one hand, it is 
important to ensure that people are not excluded from participating in research simply on the 
basis of having a diagnosis for a severe mental health problem. However, it is critical people 
are not put under pressure to participate and informed consent is maintained throughout. 
Challenges with staff acting as gatekeepers had been identified as a barrier to recruitment in 
mental health settings (J. Green, 2006). In the present study a number of steps were taken to 
ensure that those who were eligible to participate would be invited to do so. Ward visits and 
regular communication and discussion with staff on suitability of patients to participate took 
place. In accordance with the Mental Capacity Act (HMSO, 2005), ability to consent was 
assessed throughout. If patients were deemed unable to provide informed consent at one time 
point, this was assessed up to the point of discharge; if they became well enough, they were 
given the opportunity to consider participation. Conversely, if patients were deemed eligible 
and able to consent, but later became unwell, they were informed that their care team would 
be able to judge whether it was appropriate to continue with the study. 
To help ensure that unnecessary ‘gatekeeping’, preventing participants from being invited to 
participate did not limit recruitment, staff were shown the patient study materials and 
explained the process in order that they could see the minimal burden being placed upon 
participants and see the potential for improving information and service provision for future 
patients. In addition, minimal burden was placed on staff who were working in wards involved 
in recruitment. Ward meetings ensured that staff knew they would have to not do anything in 
addition to identifying patients who were eligible. They did not have to approach or explain 
study if they did not wish to as this was carried out by Clinical Studies Officers (CSOs.) Regular 
emails were sent to remind staff of the study inclusion criteria and study information materials 
delivered regularly and to each ward. 
The process of obtaining informed consent is described in Section 6.4.7. Ensuring informed 
consent within the mental healthcare setting presents challenges. Patients with BD may have 
difficulties with concentration and executive functioning (Quraishi & Frangou, 2002) and 
particularly at this time coming out of an acute episode. In addition, there may be a power 
balance in favour of researchers and staff, as patients are receiving healthcare within this 
service and are reliant on staff. Patients need to feel informed and empowered to make 
decisions about participating and understand they are free to withdraw. It needs to be clear 
that the research and the researchers are separate from the care they are receiving and a 
decision to participate or not will not have an impact on their care. The protocol in the 
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feasibility trial and the approach taken aimed to ensure fully informed consent. Consultation 
with service-users and seeking advice from Consultant Psychiatrists, Clinical Psychologists, 
mental health nurses and CSOs when designing the protocol all served to ensure this. 
Despite these challenges with planning and conducting research in this setting there is strong 
evidence that people participating in research in a mental health context have very positive 
experiences (Jorm, Kelly, & Morgan, 2007; Taylor et al., 2010). Positive experiences can include 
participation having a cathartic effect, result in a sense of empowerment and sense of purpose 
and lead to greater self-awareness. Only a small minority (less than 10%) experience distress in 
research participation based on a review in psychiatric research (Jorm et al., 2007). 
 
6.2 Aims & Objectives 
6.2.1 Aim 
To determine the feasibility and acceptability of an RCT of a novel, tailored intervention to 
address adherence and unmet needs in BD. 
 
6.2.2 Objectives 
This feasibility RCT was designed to explore the following objectives: 
 Number of eligible patients in the population 
 Recruitment and retention rates 
 Acceptability of recruitment, randomisation, questionnaires and the intervention. 
 Resource usage in terms of staff time and participant time in completing study 
components and intervention delivery. 
 Need for the intervention in terms of baseline illness and treatment perceptions, 
satisfaction with information and feelings of internalised stigma. 
 The potential effects of participating in the intervention and control group through 
quantitative and qualitative (Chapter 7) methods. 
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6.3 Development of the feasibility RCT 
6.3.1 Design considerations 
6.3.1.1 Pilot and feasibility trials 
Prior to conducting a large-scale definitive RCT to establish the effectiveness of a novel 
intervention it is imperative to conduct smaller scale studies to determine the feasibility of 
conducting a larger scale trial as well the acceptability of both the trial and the intervention 
(Craig et al., 2008). Problems which may beset trials such as lack of eligible participants, 
recruitment difficulties and poor retention can be anticipated and procedures to ameliorate 
these issues (Craig et al., 2008). Indeed, Clinical Trial Unit Directors identified that research 
into methods to boost recruitment in trials was of the highest priority followed by methods to 
minimise attrition (Tudur Smith, Hickey, Clarke, Blazeby, & Williamson, 2014). 
The terms pilot and feasibility study are often used interchangeably. The National Institute for 
Health Research (NIHR) state that ‘Feasibility Studies are pieces of research done before a main 
study in order to answer the question “Can this study be done?”. They are used to estimate 
important parameters that are needed to design the main study.’ (NIHR).  
However, the NIHR also state that pilot studies test whether components of a definitive trial 
can all work together (NIHR). The current study therefore does incorporate elements of both 
the definitions of feasibility and pilot studies, however the parameters investigated aim to 
address areas of uncertainty. The parameters reflect the recommendations for feasibility 
studies from NIHR and are; number of eligible patients in the population, recruitment and 
retention rates, acceptability of the trial, intervention and outcome measures to patients and 
staff. In addition the study aims to gather information on outcome data, in terms of standard 
deviations to inform a sample size calculation for a larger trial (see 6.2 above) (NIHR).. NIHR 
also advise that ‘the usual sort of power calculation is not normally undertaken. Instead the 
sample size should be adequate to estimate the critical parameters (e.g. recruitment rate) to 
the necessary degree of precision’ (NIHR). It is important in the conduct of a preliminary study 
to cautiously interpret any outcomes in terms of statistical significance due to limited sample 
size (Thabane et al., 2010). 
It is important to define criteria for success of feasibility. In this study the following criteria are 
used; 
 To estimate that it would be possible to recruit sufficient participants for a full trial 
within a reasonable period expected for conducting a definitive trial (12 months). 
 Retention rates should be comparable with published trials within this setting. 
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 Protocols should be acceptable to patients and staff with no undue burden placed 
upon them. 
 The intervention should be acceptable to patients and have the potential to have a 
positive impact on patients. 
 
6.3.1.2 Pragmatic design considerations 
To ensure that feasibility evaluation is based on the population and setting that a definitive 
trial would take place in, a number of pragmatic considerations were taken into account. 
Although a highly controlled, narrowly designed RCT has good internal validity, it can result in 
an intervention which is detached from clinical practice and the actual patient group which the 
intervention aims to target, therefore reducing its external validity (Hotopf, 2002; J. Green, 
2006). The following aspects of this study relate to pragmatic design considerations; 
 Participant selection – exclusion criteria kept to a minimum i.e. inclusion of comorbid 
physical conditions, not just newly diagnosed participants, both those who have been 
admitted for manic and depressive episodes and participants who have experienced 
psychosis. 
 Blinding and allocation concealment – It was impossible to blind participants to their 
allocated group in this study, as ethical requirements specified that participants were 
informed of the two study arms and after randomisation were informed of their 
allocation. However, measures were taken to try to ensure that members of the study 
team assessing outcomes remained blind to allocation. Minimisation by the researcher 
who was not involved in recruitment ensured that recruitment to the study remained 
independent from treatment allocation processes. Participants were requested at 
follow-up, not to disclose their treatment allocation until after the questionnaires had 
been completed. Questionnaire outcome measures also serve to reduce the possibility 
of observer bias. 
 
6.3.1.3 Selection of a Control group 
With a pragmatic trial it is important to compare a new treatment with what is currently 
practiced as it offers the potential to answer the question of whether the treatment gives 
benefit over what patients currently receive (Freedland et al., 2011; J. Green, 2006). It is 
difficult to determine whether any effect observed is due to the intervention or to other non-
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specific effects such as therapist time. However, the content and attention participants 
received are both components of the intervention and a TAU comparison is appropriate. 
 
6.3.1.4 Unit of randomisation: Individual vs Cluster RCTs 
In designing an RCT the unit of randomisation must be decided upon, whether this is at the 
level of the individual or at the level of the site or unit in which the intervention is delivered. A 
summary of these considerations in relation to the IBiD intervention is presented in Table 6.1. 
When interventions are delivered in settings such as hospital sites, consideration must be 
given as to whether there is any possibility of clustering effects i.e. will those in each cluster be 
independent of one another. When designing a trial where randomisation occurs at the level 
of clusters, a large number of clusters are required as participants within one cluster are not 
independent of one another (intra-cluster correlation) and this must be taken into account in 
the computation of statistic power (Elley, Kerse, & Chondros, 2004). A number of steps were 
taken to ensure that any cross-contamination between participants allocated to TAU was 
minimised. Specifically, the intervention resource was not provided to staff during the course 
of the study so could not be shared with other patients. It was ensured as much as possible 
that the intervention was conducted as close to the point of discharge as possible so the 
resource would not be shared between patients. 
 
6.3.1.5 Process evaluation 
In trials, consideration must be given to variables which might act to either ‘mediate’ i.e. 
change or occur during treatment and have a significant effect on the study outcome or to 
‘moderate’ i.e. exist at baseline and interacts with the intervention to have an effect on the 
outcome (Kraemer, Wilson, Fairburn, & Agras, 2002). 
Exploring process variables helps to systematically describe aspects of the intervention which 
occur during delivery of the intervention and provide a description of what constitutes 
treatment as usual which may not be otherwise systematically recorded. Identifying potential 
moderating factors provides information for future definitive trials in this setting, helping to 
either targeting the intervention or for in stratification for randomisation. Identifying potential 
mediators could lead to the development of the intervention to maximise change in particular 
variable (J. Green, 2006). The feasibility study cannot statistically investigate these factors 
influence on outcomes due to not being powered to investigate these variables. However, data 
can be obtained on the variance of potential mediators and the feasibility of collecting data on 
these. 
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Table 6.1: Advantages and Disadvantages of Parallel group and Cluster research designs for IBiD 
Design Explanation Advantages Disadvantages Possible solutions 
Parallel 
groups 
Each 
participant is 
randomly 
assigned to a 
group 
(intervention 
or TAU). 
Strong research 
design. 
Reduction of 
potential bias. 
Tends to produce 
comparable 
groups. 
Possibility of contamination 
between groups. Participants 
within wards may share the 
written resource. 
Potential of confounding 
from other variables if 
randomisation not 
conducted properly. 
Generalisability - Participants 
may not be representative of 
patient group due to 
‘volunteer effects’ and 
exclusion criteria. 
Administrative complexity. 
Intervention would be 
individually tailored, 
therefore control group 
might have accessed written 
material but would not have 
received the tailored 
element (potentially limiting 
contamination). 
 
Delivery of intervention 
close to discharge may 
minimise contamination. 
Cluster Wards or sites 
randomised 
to receive 
either 
intervention 
or TAU. 
 
Need to 
account for 
clustering in 
the design 
and analysis. 
Clusters 
would be 
based on 
Wards (n=13). 
Provides 
protection 
against 
contamination 
when 
participants are 
managed within 
the same setting 
and cannot be 
assumed to act 
independently. 
Administratively 
convenient. 
Economic 
evaluation is 
facilitated as unit 
of randomisation 
is unit of 
healthcare 
service. 
A lack of independence leads 
to a loss of power. 
To achieve the equivalent 
power of a parallel groups 
the sample size needs to be 
inflated. 
Longer fieldwork period 
needed to achieve required 
sample. 
Ethical issues of consent at 
individual level. 
Potential of individual and 
whole-cluster drop-outs. 
Sample size needs to be 
inflated by a factor 
1+ (n-1) p 
n= average cluster size 
p = an estimation of the ICC 
‘intracluster correlation 
coefficient’ i.e. the degree 
of similarity among 
responses within a cluster. 
The ICC is estimated from 
previous research. 
Adjustments needed to 
statistical tests to account 
for clustering effects. 
Multi-level modelling can 
take account of clustering 
effects from degree of 
personal interaction 
between members of 
cluster. 
 
6.3.2 Selection of outcome measures 
Selection of the outcome measures took into account a number of factors to ensure their 
reliability and validity for the study. The outcome and clinical measures selected are 
summarised in Table 6.2 and the following sections provide details of why these measures 
were selected. 
 Content validity - Must be relevant to the target population and intervention. 
 Construct validity 
 Reliability as assessed by Cronbach’s alpha. 
 Sensitive to change. 
 Minimise burden on participants. 
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6.3.2.1 Selecting an adherence measure 
The challenges and complexity associated with adherence measurement, particularly within 
psychiatry have been discussed in Chapter 1. For the present study, it was unfeasible to use 
objective measures of adherence for a number of reasons; the administration of medications 
changes at the point of discharge from hospital pharmacy supply to prescribing by patients 
GPs. Furthermore, changes in medication are likely and it would be impractical to follow these 
up. Participants may be on a range of medications and it would not be possible to objectively 
measure each of these. Administration of medications can be in tablet, liquid or depot 
injection, further complicating objective measurement. 
Self-report measures were selected for the present study in preference to clinician 
administered scales in order that the questionnaire could be completed by participants with 
minimal assistance and without the need for a mental health professional. A number of self-
report measures have been used in psychiatry (Sajatovic et al., 2010). 
The Medication Adherence Report Scale (MARS) (Horne & Weinman, 2002), a 5 item self-
report measure, was selected. This is a widely used scale (Clatworthy et al., 2009; Jónsdóttir et 
al., 2010; L. Williams, O’Connor, Grubb, & O’Carroll, 2011), only measures behaviour as 
opposed to attitudes and has been used previously in research with people with BD (Bowskill 
et al., 2007). Due to the nature of psychopharmacology for BD, participants were likely to be 
taking a number of different medications and as such it was necessary to select a brief 
measure which could be quickly completed for each medication. Sajatovic and colleagues 
(2010) recommended that adherence is assessed for each medication separately to take into 
account differing adherence to different medications. 
Other self-report scales were considered but rejected, such as the Medication Adherence 
Rating Scale, used in schizophrenia and psychosis, which includes items assessing medication 
attitudes, not solely adherence behaviour (K. Thompson et al., 2000). Participants may be 
reluctant to admit instances of non-adherence, therefore questionnaire item wording needs to 
reduce any sense of ‘judgement’ of the behaviour. The Morisky scale, consisting of four items 
with yes/ no response categories, uses the word ‘careless’ in reference to non-adherence 
which may reduce accurate self-reporting. In addition, some items contain double questions 
such as ‘If you felt worse when you took your medication, did you sometimes stop taking your 
medication?’ which may be difficult for participants to interpret (Morisky et al., 1986). 
To provide additional self-report information on adherence, a visual analogue scale (VAS) was 
included. Participants are asked to mark on a scale of 0-100%, the approximate percentage of 
medication they think they take. The VAS has been shown to be significantly correlated with 
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blood serum levels of medication in participants with schizophrenia and bipolar disorder 
(Jonsdottir et al., 2009). 
 
6.3.2.2 Selecting a medication attitude measure 
A number of scales exist to measure attitudes towards treatment. The Beliefs about Medicine 
Questionnaire (BMQ) was previously described in Chapter 2 (Horne et al., 1999). Other 
measures used in psychiatric populations including BD were rejected, for reasons including; 
mixing constructs i.e. combining items relating to both behaviour and attitudes in the Brief 
Evaluation of Medication Influences and Beliefs scale (BEMIB) (Dolder et al., 2004), measuring 
attitudes towards illness in addition to treatment in the Treatment Attitudes Questionnaire 
(Johnson & Fulford, 2008) and combining practical and perceptual barriers without separate 
subscales such as the Lithium Attitudes Questionnaire (Harvey & Peet, 1991) and Brief 
Medication Questionnaire (Svarstad, Chewning, Sleath, & Claesson, 1999). 
The BMQ has been widely used in physical health and more recently in mental health including 
BD, where it has shown utility in predicting adherence (Clatworthy et al., 2009; Horne & 
Weinman, 2002; Jonsdottir et al., 2009). The BMQ- Specific version used in this study 
comprised six ‘Necessity’ items and 11 ‘Concerns’ items. Participants completed this measure 
for all medications they were currently prescribed for BD. Participants specified the mode of 
administration of each medication (tablet, liquid or injection). Participants also completed the 
BMQ-General (described in Chapter 2). 
Practical barriers to taking medications for bipolar were assessed by participants rating a 
number of statements which were compiled from previous studies (Clatworthy et al., 2007) 
and the qualitative research presented in Chapter 4. 
 
6.3.3 Final outcome measures 
A copy of the final outcome measures formatted into the baseline and follow-up questionnaire 
booklet can be found in Appendix L. 
 
6.3.3.1 The Satisfaction with Information about Medication Scale (SIMS) 
The Satisfaction with Information about Medication Scale (SIMS) is a 17 item measure which 
has been validated with a range of health conditions (Horne, Hankins, & Jenkins, 2001). The 
items in the SIMS are derived from Association of the British Pharmaceutical Industry (ABPI) 
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recommendations for the type of information patients require to facilitate safe self-
management of medication. Participants rate each item as either ‘too much’, ‘about right’, 
‘too little’, ‘none received’, or ‘none needed’. A total satisfaction rating (0-17) is obtained by 
summing the number of positive scores (about right or none needed) with higher scores 
indicating a greater degree of satisfaction. SIMS comprises two subscales; satisfaction with 
information about the ‘action and usage of medication’ and the ‘potential problems of 
medication’. The scale has shown good internal reliability (0.81 to 0.91) and satisfactory test-
retest reliability (> 0.6) (Horne et al., 2001). SIMS has been previously used in a cross-sectional 
study investigating perceptions of information received by people with a bipolar disorder 
diagnosis (Bowskill et al., 2007). 
 
6.3.3.2 The Brief Illness Perceptions Questionnaire (Brief-IPQ) 
The Brief Illness Perceptions Questionnaire (Brief-IPQ) is a short-form of the Revised Illness 
Perceptions Questionnaire (IPQ-R) in which each dimension of illness perception is 
represented by a single item (Broadbent et al., 2006). The Brief-IPQ has been described in 
Chapter 2. The brief-IPQ as adapted for previous bipolar research was used in this study 
(Clatworthy et al., 2009; Lobban, no date). The word “illness” in the questionnaire was 
replaced by “bipolar”. In this 9-item version, five items assess cognitive illness representations 
of illness: consequences, timeline, personal control, treatment control, and identity (symptom 
experience). Two items assess emotional representations: concern about bipolar, and 
emotional effects. One item assesses how much participants agree with their diagnosis. Each 
item is rated by participants on an 11 point scale (0-10) with higher scores reflecting 
perceptions of more serious consequences, a chronic timeline, greater personal control, 
greater treatment control, many/severe symptoms, high concerns about illness and high 
negative emotional responses to illness. The B-IPQ demonstrates good reliability and construct 
validity (Broadbent et al., 2006) (Table 6.2). 
 
6.3.3.3 Illness Perceptions additional sections on Identity & Causes 
In order to provide more detailed information on participants perceptions of their illness, but 
without the use of the full IPQ-R (Moss-Morris et al., 2002), additional sections on causes and 
illness identity (acknowledging that participants may have received differing mental health 
diagnoses prior to their current diagnosis and may hold alternative explanations for their 
mental health issues). 
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Participants were presented with a list of mental health terms and asked to confirm if these 
had been used to describe their mental health problems. They were given space to also add in 
other terms which may have been used. For each term which has been used, they were asked 
to rate on a 5 point scale their level of agreement that the term described the experiences 
they have had. To gain a perspective on their current views about their mental health 
problems, there was an open-response box asking participants to write what term or label 
they felt best describes their mental health problems. 
To assess perceptions of causes, participants were asked to rate their level of agreement on a 
5 point scale (from strongly agree to strongly disagree) to 19 possible causes of bipolar. They 
were asked for their own views on possible causes rather than what health professionals, 
family or friends may have suggested. Participants were then asked to write the three most 
important causes of their mental health problems and were able to include other causes in 
addition to the pre-specified list. They were also asked to write three possible factors which in 
their view were responsible for maintaining their mental health problems. 
 
6.3.3.4 Symptoms associated with bipolar questionnaire (SAQ) 
In order to capture information on the type and severity of symptoms and side-effects 
participants were experiencing, the SAQ was included. This asks participants to endorse ‘yes’ 
or ‘no’ for whether they are currently experiencing a list of symptoms and side-effects 
associated with bipolar disorder. The list was compiled through consultations with the 
Consultant Psychiatrist in the research team as well as including items from the Glasgow 
Antipsychotic Side-effect Scale (GASS) (Waddell & Taylor, 2008). Space was also left for 
participants to add any additional symptoms they were experiencing. For items participants 
endorsed, they were asked to rate its severity on a 5 point scale from ‘Mild’ to ‘Very severe’ 
and then to select whether they thought the cause of the symptom was ‘Bipolar’, ‘Medication’, 
‘Both’, ‘Neither’ or ‘Unsure’. 
 
6.3.3.5 Internalized Stigma of Mental Illness Inventory (ISMI) 
The Internalized Stigma of Mental Illness Inventory (ISMI) is a 29 item measure with five 
subscales; Alienation, Stereotype Endorsement, Discrimination Experience, Social Withdrawal 
and Stigma Resistance. The scale has been validated in mental health outpatient populations 
(Boyd Ritsher, Otilingam, & Grajales, 2003). A review identified that this measure was 
commonly used and had the highest internal consistency of a range of measures identified, 
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with the average being 0.85 (Livingston & Boyd, 2010). The ISMI has been used within a large 
scale European survey of people with BD or depression (Brohan et al., 2011). 
The scale is scored by summing the answered items and dividing by the number of answered 
items, stigma-resistance items are reverse-coded. Higher scores indicate less internalised 
stigma and range from 1-4. Cut-offs have been defined in the literature for 4 categories 
(Lysaker, Roe, & Yanos, 2007) and 2 categories (Boyd Ritsher et al., 2003). ISMI has been 
demonstrated to have high internal consistency (r=0.90) and test-retest reliability (r=0.92) 
(Boyd Ritsher et al., 2003). 
 
6.3.3.6 Clinical measures (Beck Depression Inventory (BDI-II) & Altman Self-Rating Mania 
Scale (ASRM)) 
The Beck Depression Inventory (BDI-II) (A. Beck, Steer, Ball, & Ranieri, 1996) is a 21 item scale 
for the measurement of depression severity which can be self administered and has shown 
good internal consistency (0.92) (A. Beck et al., 1988). The BDI-II has been recommended for 
its utility in measuring depression in people with a diagnosis of BD and distinguishing between 
depressive, manic and mixed episodes (Kumar, Rissmiller, Steer, & Beck, 2006). Each item is 
scored from 0-3 and scores are summed to produce a total score ranging from 0 to 63 with 
higher scores indicating more severe depression. Cut-offs have been defined as 0 -13 - minimal 
range; 14-19 - mild depression; 20-28 -moderate depression; and 29-63 - severe depression 
(Smarr & Keefer, 2011). 
The ASRM is a 5 item scale measuring the presence and severity of manic symptoms and is 
compatible with DSM-IV criteria. ASRM is shorter than the alternatives; Young Mania Rating 
Scale (YMRS) (R. Young, Biggs, Ziegler, & Meyer, 1978), or the Clinician- Administered Rating 
Scale for Mania (CARS-M) (E. Altman, Hedeker, Janicak, Peterson, & Davis, 1994) and unlike 
these it is designed to enable self-administration, but correlates significantly with these other 
measures (E. Altman, Hedeker, Peterson, & Davis, 1997). Due to its good reliability (r = .86) and 
validity, ease of administration and imposing the least burden also in consultation with the 
Consultant Psychiatrist in the research team, this measure was selected. Each ASRM item is 
scored from 0 to 4, with total scores ranging from 0-16 with higher scores indicating higher 
probability of mania. Cut-offs have been defined as a score of 6 or higher indicating possible 
manic state (E. Altman et al., 1997). 
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Table 6.2: List of validated and adapted measures used in IBiD study 
Type Measure Items/ Scoring Cronbach’s 
alpha 
(published) 
Clinical The Beck Depression 
Inventory (BDI-II) (A. T. Beck 
et al., 1996) 
21 items 
4 point scale - 0-3 (summed) 
0–13: minimal depression 
14–19: mild depression 
20–28: moderate depression 
29–63: severe depression 
0.91 
 Altman Self-Rating Mania 
Scale (E. G. Altman et al., 
1997) 
5 items 
5 point scale - 0-4 (summed) 
0-5: no indication of mania 
6-20: possible manic state indicated 
0.79 
Treatment 
beliefs 
The Beliefs about Medicine 
Questionnaire Specific 
(BMQ Specific) (Horne et al., 
1999) adapted for BD 
17 items 
2 factor structure; Necessity, Concerns 
5 point scale, Strongly agree – Strongly 
disagree (Mean score) 
0.63-0.74a 
 The Beliefs about Medicine 
Questionnaire General 
(BMQ General) (Horne et 
al., 1999) 
8 items 
2 factor structure; Overuse, Harm 
5 point scale, Strongly agree – Strongly 
disagree (Mean score) 
0.63-0.74a 
Illness beliefs The brief Illness Perception 
Questionnaire (Broadbent 
et al., 2006) 
8 items (+1 additional for BD) 
10 point scale 
 
    
Adherence Medication Adherence 
Report Scale (MARS) (Horne 
& Weinman, 2004) 
5 items 
5 point scale - Always to never (summed) 
0.67–0.90 
Satisfaction The Satisfaction with 
Information about 
Medication Scale (SIMS) 
(Horne et al., 2001) 
17 items 
2 subscales ‘Action and Usage’, ‘Potential 
Problems’ 
Response categories – too much (0), about 
right (1), too little (0), none received (0), none 
needed (1) (summed) 
0.81 - 0.91 
Stigma Internalised Stigma of 
Mental Illness (ISMI) (Boyd 
Ritsher et al., 2003) 
29 items 
4-point scale, Strongly agree – Strongly 
disagree 
5 subscales - Alienation, Stereotype 
Endorsement, Discrimination Experience, 
Social Withdrawal, Stigma Resistance. 
Cut offs - 4-category method 
1.00-2.00: minimal to no internalized stigma 
2.01-2.50: mild internalized stigma 
2.51-3.00: moderate internalized stigma 
3.01-4.00: severe internalized stigma 
2-category  
1.00-2.50: does not report high internalized 
stigma 
2.51-4.00: reports high internalized stigma 
0.90 
a Cronbach’s alpha for psychiatric sample across specific and general subscales. 
b Cronbach’s alpha ranges across subscales. 
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6.3.3.7 Clinical and demographic data 
Information was collected on clinical factors relating to participants diagnosis and previous 
psychiatric history, this is detailed in Table 6.3. These variables were selected, as potentially 
important moderating variables and were refined through consultation with the Consultant 
Psychiatrist in the research team. The following demographic information was collected; date 
of birth, gender, ethnic origin, marital status and highest level of education. 
 
Table 6.3: List of clinical information collected at baseline 
Variable Description 
Diagnosis received Current diagnosis at recruitment 
Diagnosis before admission Previous psychiatric diagnosis (if applicable) 
Age of bipolar diagnosis Age of first bipolar disorder diagnosis 
Current hospital admission Was this admission voluntary or involuntary/detained? 
Reason for current admission Participant’s view & information from notes. 
Date of admission Date on which current admission commenced 
Anticipated date of discharge Anticipated date of discharge (if known) 
Number of previous psychiatric admissions Number of previous admissions (estimated by participant & 
checked in notes by CSO) 
Any voluntary admissions Yes/ No 
Any involuntary/ detained admissions Yes/ No 
Number of previous manic episodes Estimated number of episodes of mania 
Number of previous episodes of depression Estimated number of episodes of depression 
Any current psychotic symptoms? Yes/ No 
Family history of bipolar Yes/ No/ Unknown 
Physical health conditions Details of any co morbid health conditions 
 
6.3.3.8 Acceptability of baseline questionnaire 
In order to gather data on the acceptability of the baseline questionnaire a number of 
questions were included at the end of the questionnaire (see Appendix L). In addition, CSOs 
kept a note of any problems encountered during questionnaire completion and the researcher 
kept a record of any additional notes made by participants on their questionnaire. 
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6.4 Methods & Procedure 
Figure 6.1 represents the procedure for the IBiD feasibility study from recruitment to follow-
up. 
 
6.4.1 Setting 
The study was conducted in Adult Mental Health Services across Sussex Partnership NHS 
Foundation Trust including acute in-patient wards and Crisis Response and Home Treatment 
teams (CRHT). In total five hospital sites (including 16 wards and 5 CRHTs) were involved in the 
study. 
 
6.4.2 Ethical approvals 
Favourable NHS Research Ethics Committee approval for this study was granted in November 
2012 (REC Ref 12/LO/1615) (Appendix M). Local NHS Research and Development approval 
from Sussex Partnership NHS Foundation Trust (Ref number CSP 87823) was granted in 
November 2012 (Appendix N). A minor amendment was submitted and approved in June 2013 
in order to remove the upper age inclusion criteria for participants as the wards moved from 
having separate services for adults and older adults to being an ‘ageless’ service. A Letter of 
Access from Sussex Partnership NHS Foundation Trust allowing the author access to study sites 
and patients (Appendix O). 
 
6.4.3 Pre-recruitment site visits & staff updates 
Between May and July 2013, the research team undertook pre-recruitment visits to introduce 
the study to staff at each site, deliver study materials and arrange to commence the study. 
These visits included presentations at Governance meetings, care manager meetings, Business 
meetings and meetings arranged specifically to introduce the study. All wards and teams 
received a study pack which contained copies of the following; study protocol, staff 
information sheets, Patient Information Sheet (PIS), and posters advertising the study for 
display in staff areas (Appendix P). 
To ensure ongoing awareness and enthusiasm for the study, email updates to ward and team 
staff were sent on a monthly basis. These updates informed staff of current recruitment 
figures, targets, any changes to study team members and provided a reminder for staff about 
how to receive additional copies of study materials (Appendix Q). 
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6.4.4 Eligibility Criteria 
Patients were eligible to participate in the study if they were aged over 18 years, had a 
diagnosis of BD (as assessed during their current inpatient stay or referral to the CRHT), were 
being prescribed medication for this and were able to provide written, informed consent. 
Exclusions were limited to; patients with organic brain syndrome (including brain injury and 
degenerative disorders), active suicidal ideation as assessed by ward care team, a primary 
diagnosis of substance misuse and patients considered as presenting a risk to others. 
When conducting pre-recruitment site meetings, clinical staff advised that it would not be 
appropriate to include patients with a duel diagnosis of personality disorder and BD. 
 
6.4.5 Risk 
Initial eligibility screening with patients’ care teams ensured that those assessed as posing a 
risk to themselves or others were not approached. When ward visits were undertaken, risk 
was checked with the on-duty team and if recommended a personal alarm was provided. For 
home visits the CSO followed Sussex Partnership NHS Foundation Trust’s lone worker policy. 
The researcher informed participants Care Coordinator (CCO) of the date and time of the 
appointment and left the participants and CCO details with a colleague at UCL School of 
Pharmacy. 
 
6.4.6 Recruitment & Baseline assessments 
Potentially eligible patients were initially identified in two ways. CSOs used the electronic 
Patient Information Management System (PIMS) to identity patients at each site with a 
diagnosis of BD. Concurrently, ward staff identified patients in their care who were eligible and 
at an appropriate stage to participate. Liaison between ward staff and CSOs was maintained 
during the study to ensure that potentially eligible patients were not missed. 
Eligible patients were provided with a copy of the PIS from ward staff and informed that if they 
were interested in finding out more, a CSO would visit with them in the next couple of days. 
CSOs visited eligible patients who had expressed an interest in participating, confirmed 
understanding of the study and if appropriate took consent and conducted baseline 
assessments. These appointments took place in private locations on the wards or in 
participants’ homes or community mental health centres. Following the administration of the 
baseline assessments, CSO sent a scanned copy of the completed questionnaire to the 
researcher to enable the tailored IBiD resource to be assembled. All researchers involved in 
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recruiting to and delivery of the study completed Good Clinical Practice (GCP) training prior to 
starting recruitment. 
 
6.4.7 Informed consent 
Informed, written consent (Appendix R) obtained from participants by the CSO was taken in 
accordance with Trust procedures, the Mental Capacity Act 2005 (HMSO, 2005) and 
International Conference on Harmonisation-Good Clinical Practice (ICHGCP) (International 
Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals 
for Human Use, 1996). The PIS and the CSO when taking consent emphasised that participants 
were free to withdraw from the study at any time and that this would not affect their care. 
 
6.4.8 Sample size 
As this study formed a feasibility assessment of the RCT, a formal sample size calculation was 
not appropriate. However, a sample of 30 participants was determined to be sufficient to 
provide feasibility and acceptability data. Sample sizes recommended as necessary for 
feasibility studies range from 24 to 50 (Julious, 2005; Lancaster, Dodd, & Williamson, 2004). 
Approximate numbers of eligible participants was estimated from previous discharge data 
from the Trust (number of patients discharged from inpatient stays in 12 months with a 
diagnosis of BD =328). We estimated that 164 patients might be discharged in the fieldwork 
period of six months, however, not all may meet the eligibility criteria. Estimates of 
recruitment and retention rates in published studies were used to assess the likely rates. 
Refusal rates range between 15% and 31% and attrition between 16% and 25% (Castle et al., 
2010; Kemp, Hayward, Applewhaite, Everitt, & David, 1996; Sajatovic, Davies, et al., 2009; 
Scott et al., 2006). Recruitment of 30 participants was estimated to take six months, and by 
conducting this study we would be able to ascertain recruitment and retention to an RCT 
within this specific population. 
 
6.4.9 Randomisation 
After completion of baseline assessments, participants were randomised to the intervention 
(IG) or treatment as usual (TAU) condition independently by the researcher, under the 
guidance of a statistician. CSOs passed the identifiable participant details (name, contact 
details of both the participant and their care coordinator) to the researcher by telephone. 
These were then stored on a password protected Excel file where unique participant ID 
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numbers were linked with the personal details which was only accessible by the researcher to 
ensure confidentiality. 
The first 10 participants were randomised using a random number table (Kirkwood, 1988). 
Following this, minimisation was used in order to minimise the difference between the IG and 
TAU with regard to gender and age (D. Altman & Bland, 2005). These criteria were selected in 
consultation with the Consultant Psychiatrist. Each subsequent participant was allocated on 
the basis of minimising the imbalance between groups (Appendix S). Where both groups were 
equal during the process, simple randomisation by means of a coin toss was used to allocate 
the next participant. Minimisation is an acceptable approach where a balance is required 
between prognostic factors in small trials where other methods such as blocking and 
stratification are not appropriate (D. Altman & Bland, 2005). 
 
6.4.10 Allocation concealment 
The CSO remained blinded to participants’ allocation. They did not have access to the random 
number table or minimisation procedure so therefore could not be aware of forthcoming 
allocations when recruiting or influence randomisation. This is a critically important procedure 
to ensure that recruiters are blinded from knowledge of upcoming treatment assignments 
(Schulz & Grimes, 2002). Once participants were allocated to a treatment group, the 
researcher contacted the participants care team, either on the ward, with the CHRT or through 
the community care coordinators (CCOs) as appropriate. Participants CCOs were sent an email 
informing them of their clients’ participation (Appendix T). Both the care team and the 
participant were informed of their treatment allocation. They were asked not to feed this back 
to the CSO when they were contacted for the follow-up assessments. Incidences where 
unblinding occurred were recorded and details of these can be found in Section 6.6.3 Where 
cases did occur prior to follow-up, arrangements were made for a different CSO to conduct the 
follow-up assessments. 
 
6.4.11 Treatment as usual procedure 
Participants allocated to TAU received a letter informing them of their allocation, reminding 
them of the follow-up assessments and notifying them that they could contact the researcher 
if they required any additional information (Appendix U) for TAU notification letter. 
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6.4.12 Intervention group procedure 
The procedure for participants allocated to IG varied according to their discharge status. For 
those still admitted as inpatients, the researcher arranged with ward staff and the participant a 
convenient time to visit to conduct the intervention (arranged to fit around participant ward-
leave, mealtimes, activities and psychiatrists ward-rounds). The interventions took place in one 
of the private quiet rooms on the ward. In the cases where participants had been discharged, 
their CCO was contacted to notify them of the allocation and to seek their advice on whether 
home visits were appropriate. The researcher (LM) contacted the participant to arrange a 
convenient time to conduct the intervention either in their home or at a local community 
mental health centre. Prior to meeting the participant, the researcher compiled the tailored 
IBiD booklet to participants’ baseline questionnaires. Tailoring details for each participant can 
be found in Appendix V. Booklets also contained Patient Information Sheets for each 
medication participants were prescribed (Appendix W). 
To ensure competency to deliver the intervention, the researcher held a Masters degree in 
Health Psychology and was undergoing training for Chartered Health psychology status. They 
had undertaken training in MI, Mental health and wellbeing, Health Behaviour Change as well 
as studying Psychoeducation and CBT manuals for BD. Supervision by a Consultant Psychiatrist 
allowed ongoing support during intervention delivery. 
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Figure 6.1: IBiD procedure 
CSO completes 6-8 week follow-up assessments with participant, 
provides incentive, completes incentive receipt forms and invites 
participant to participate in qualitative interview. 
CSO contacts participant to arrange follow-up assessment. 
LM contacts participant by phone and if consent is given, conducts 
qualitative interview. 
CSO contacts CCO to determine if follow-up contact is appropriate. 
LM contacts ward or CCO depending on 
participants discharge status. 
LM contacts participant to arrange time for 
intervention delivery 
LM sends participant letter explaining TAU 
and responds to any questions by telephone 
Participant allocated to CG 
LM meets participant to deliver intervention 
LM tailors Intervention booklet to participant 
baseline responses. 
Participant allocated to IG 
LM randomises participant. 
CSO; 
telephones LM with study ID, gender, DoB, Care Coordinator (CCO) & 
patient contact details; 
sends scanned baseline questionnaires to LM by email; 
emails participant’s CCO with study information; 
If participant agrees to participate, they complete the Consent form 
(x2) with CSO. 
 
Participant completes baseline questionnaires with CSO. 
Patient is notified of the study by care team or CSO and given PIS. 
CSO visits patient and answers questions about the study. 
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6.4.13 Fidelity assessment 
It was deemed inappropriate to audio-record the intervention delivery. In consultation with 
mental health professionals and service-user representatives it was judged that participants 
may have been unwilling to disclose their thoughts, feelings and behaviour surrounding their 
condition, treatment and interactions with health care professionals if the interactions were 
recorded. Therefore steps were taken to capture information on fidelity to intervention. Each 
intervention booklet was tailored according to specific tailoring syntax using IBM SPSS 
Statistics 21 (described in Chapter 5). This ensured that all tailoring was conducted 
consistently. After each appointment, detailed field notes were made which described the 
researchers general impressions of the session, the sections covered and not covered, any 
issues discussed which are not covered by the resource and participants engagement with the 
intervention. These reflections are, however, subject to memory effects and bias on the part of 
the researcher. 
 
6.4.14 Follow-up procedure 
After 6 weeks, CCOs were contacted to ensure that it was appropriate to contact the 
participant. Appointments were made with participants at a suitable location to conduct the 
assessments, either participants’ homes or community mental health centres. Completion of 
the follow-up assessment followed the same procedure as the baseline assessments. On 
completion of the follow-up assessments participants received £20 as a thank-you for their 
participation in the study. Participants were asked if they wished to receive a copy of the 
results of the study when they became available and this information was recorded. 
 
6.4.15 Interview with Clinical Studies Officer 
After the last participants had completed follow-up assessments, a face to face interview with 
the CSO who was most involved with the IBiD study was conducted in order to gain qualitative 
data on the study process. The interview was not audio-recorded as such no verbatim quotes 
are available. Notes taken during the interview were checked by the CSO as being an accurate 
reflection of the conversation and additional points were added where necessary. The 
interview covered the following areas, but was flexible in or to allow for any additional 
pertinent issues to be raised; 
 Study set-up 
 Recruitment, challenges and positives 
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 Usefulness of study materials 
 Contacts and communication with ward staff, care coordinators and study staff. 
 Conducting baseline assessments – challenges and positives 
 Follow-up assessments, challenges and positives 
 Overall reflections on the study 
 Suggestions for improving IBiD 
 
6.5 Data processing and quantitative analysis 
Questionnaire data was organised and analysed using SPSS version 21. Descriptive statistics 
were used to determine recruitment and retention rates, to describe the demographic and 
clinical characteristics of the sample and determine the need for an intervention by examining 
baseline assessments for the whole sample. 
Although the present study focussed on feasibility outcomes, exploratory analysis was 
conducted on the outcome measures, however, with the understanding that the study is 
underpowered to detect significant effects. Paired-sample t-tests were used to examine 
changes between assessment points for the IG and TAU separately. In addition, to explore 
differences between groups at follow-up, controlling for baseline measure, ANCOVA were 
performed. In powered-trial conditions in a definitive trial, the data would need to be tested 
for the following assumptions; normality using histograms and measures of skewness and 
kutosis, multicollinearity, homogeneity of variance and homogeneity of regression slopes. As 
appropriate, non-parametric tests would be selected where available. 
 
 
6.6 Results 
The results section comprises four subsections; a description of the characteristics of the 
sample recruited; an assessment of the need for intervention from baseline measures; 
quantitative data on the feasibility and acceptability of the RCT protocol and IBiD intervention, 
qualitative data from the CSO interview; an exploratory assessment of the baseline and follow-
up assessments in order to test the data analysis protocol. 
 
189 
6.6.1 Sample characteristics 
6.6.1.1 Demographic characteristics 
Between June 2013 and January 2014, 30 participants were recruited (sample characteristics in 
Tables 6.4 & 6.5 for the 29 participants who completed baseline assessments). Participants 
mean age in the IG was 51.7 (10.93) years and 51.4 (11.81) years in the TAU, the majority were 
female and of White British ethnicity. There were no significant differences between groups in 
terms of their baseline demographic characteristics. 
 
6.6.1.2 Clinical characteristics 
Participants had been diagnosed with bipolar on average for six and a half (IG) or seven (TAU) 
years. In terms of recentness of diagnosis, only six participants were diagnosed less than a year 
previously. The only significant difference between IG and TAU was in their history of voluntary 
admissions with a higher proportion of IG participants having had voluntary admissions, χ2 (1, 
n=29) = 5.66, p=.017. With regards to measures of current affective state, both scales 
demonstrated good reliability (ASRM α=.801, BDI-II α=.926). In total, 40% of participants had 
indications of a possible manic state at baseline and 42% showed signs of a moderate to 
severe depressive state. 
Table 6.4: Sample socio-demographic characteristics 
 Total (n=29) IG (n=14) 
n (%) 
TAU (n=15) 
n (%) 
p 
Age at baseline     
Mean (sd) 52 (11.0) 51.71 (10.93) 51.40 (11.81) .941 
Median (IQR) 52 (44-61) 52 (43-59) 54 (44-64)  
Gender     
Female 20 (69.0) 10 (71.4) 10 (66.7) .782 
Ethnicity     
White British 22 (75.9) 11 (78.6) 11 (73.3) .538 
White Irish 1 (3.4) - 1 (6.7)  
White other 5 (17.2) 3 (21.4) 2 (13.3)  
Mixed ethnicity 1 (3.4) - 1 (6.7)  
Relationship status     
Single 12 (41.4) 5 (35.7) 7 (46.7) .276 
Married/ Civil partnership/Cohabiting 7 (24.1) 4 (28.6) 3 (20.0)  
Divorced/ Separated 6 (20.7) 2 (14.4 4 (26.7)  
Widowed 3 (10.3) 3 (21.4) -  
Other 1 (3.4)  1 (6.7)  
Highest level of education     
No qualifications 2 (6.9) 2 (14.3) - .124 
O levels/CSEs/GSCEs 6 (20.7) 4 (28.6) 2 (13.3)  
Vocational education 5 (17.2) 3 (21.4) 2 (13.3)  
Degree 7 (24.1) 4 (28.6) 3 (20.0)  
Higher degree 6 (20.7) 1 (7.1) 5 (33.3)  
Professional qualifications 3  (10.3) - 3 (20.0)  
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Table 6.5: Sample Clinical characteristics 
 Total (n=29) IG (n=14) 
n (%) 
TAU (n=15) 
n (%) 
p 
Age of BD diagnosis (approx)     
Mean (sd) 41.41 (13.26) 39.50 (12.16) 43.07 (14.35) .488 
Median (IPQ) 37 (31.5-51.5) 37.00 (33.5-48) 38.00 (31-56)  
Number of years since first bipolar 
diagnosis (approx) 
    
Mean (sd) 9.89 (10.79) 11.55 (12.64) 8.46 (9.11) .461 
Median (IPQ) 6.5 (2-14) 7.00 (2.5-15) 6.00 (2-13)  
Current admission     
Voluntary 13 (44.8) 6 (42.9) 7 (46.7) .837 
Involuntary/ Detained 16 (55.2) 8 (57.1) 8 (53.3)  
Current psychotic symptoms (yes) 11 (37.9) 6 (42.9) 5 (33.3) .581 
N psychiatric medications     
Mean (sd) 3 (1) 3 (1) 3 (1) .708 
Median, range 3 (2-3) 3 (2-4) 3 (2-3)  
Previous admissions     
Voluntary admissions (yes) 21 (72.4) 13 (92.9) 8 (53.3 .017* 
Involuntary/ Detained admissions 
(yes) 
23 (79.3) 12 (85.7) 11 (73.3) .411 
N previous manic episodes     
1-2 7 (24.1) 3 (21.4)) 4 (26.7) .775 
3-4 12 (41.4) 7 (50.0) 5 (33.3)  
5-6 2 (6.9) 1 (7.1) 1 (6.7)  
7+ 6 (20.7) 2 (14.3) 4 (26.7)  
Not reported 2 (6.9) 1 (7.1) 1 (6.7)  
N previous episodes depression     
0 6 (20.7) 4 (28.6) 2 (13.3) .106 
1-2 4 (13.8) 3 (21.4) 1 (6.7)  
3-4 6 (20.7) - 6 (40.0)  
5-6 5 (17.2) 2 (14.3) 3 (20.0)  
7+ 6 (20.7) 3 (21.4) 3 (20.0)  
Not reported 2 (6.9) 2 (14.3) -  
Family history of bipolar     
Yes 14 (48.3) 6 (42.9) 8 (53.3) .632 
No 12 (41.4) 7 (50.0) 5 (33.3)  
Unknown 3 (10.3) 1 (7.1) 2 (13.3)  
ASRM Scale     
Mean (sd) 5.62 (4.71) 7.14 (4.91) 4.20 (4.18) .093 
Median IQR 5 (2-9) 8.00 (4-10) 3.00 (1-6)  
No indication of mania 17 (58.6) 6 (42.9) 11 (73.3) .096 
Possible manic state indicated 12 (41.4) 8 (57.1) 4 (26.7)  
BDI-II *     
Mean (sd) 17.35 (12.62) 15.17 (10.74) 19.21 (14.15) .426 
Median (IQR) 15 (7-25) 14.50 (6.5-23) 17.00 (7-28)  
Minimal depression 13 (50.0) 6 (50.0) 7 (50.0)  
Mild depression 2 (7.7) 2 (16.7) - .379 
Moderate depression 7 (26.9) 3 (25.0) 4 (28.6)  
Severe depression 4 (15.4) 1 (8.3) 3 (21.4)  
*n=26 as unable to compute total scores due to missing items (prorated scores not recommended) 
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6.6.2 Need for the intervention – an assessment of baseline measures 
The baseline measures for the whole sample (n=29) on information dissatisfaction, treatment 
and illness perceptions and internalised stigma provide an assessment of the need for an 
intervention. 
 
6.6.2.1 Beliefs about illness 
6.6.2.1.1 Brief IPQ 
Table 6.6 presents the results from the Brief IPQ, and it can be seen that beliefs in personal 
control over BD were low (Mdn=4, IQR=3-7). BD had a severe effect on participants lives 
(Mdn=8, IQR=7-10) and strong emotional consequences (Mdn=7, IQR=5-9). 
The proportion of participants who reported higher or lower beliefs in the Brief IPQ items was 
calculated to provide an indication of how many participants might have beliefs not conducive 
to adherence. 62% reported low personal control, 62% experience higher levels of symptoms, 
69% reported higher feelings of emotional affect due to bipolar and 59% reported higher levels 
of concern. 31% were judged to have acute timeline beliefs, 31% reported low treatment 
control and 31% report lower levels of understanding. Twenty-one percent reported low 
agreement with their diagnosis. 
 
Table 6.6: Brief-IPQ descriptive statistics (n=29) 
IPQ item Mean (sd) Median 
(IQR) 
<6 
n (%) 
>5 
n (%) 
Consequences - How much does bipolar affect 
your life? 
7.53 (2.76) 8.00 (7-10) 
5 (17.2) 24 (82.8) 
Timeline - How long do you think your bipolar 
will continue? 
7.45 (3.09) 8.00 (5-10) 
9 (31.0) 20 (69.0) 
Personal control - How much control do you feel 
you have over your bipolar? 
4.53 (3.10) 4.00 (3-7) 
18 (62.1) 11 (37.9) 
Treatment control - How much do you think 
your treatment can help your bipolar? 
6.97 (2.67) 7.00 (5-9) 
9 (31.0) 20 (69.0) 
Identity - How much do you experience 
symptoms from bipolar? 
6.07 (3.32) 7.00 (4-9) 
11 (37.9) 18 (62.1) 
Concern - How concerned are you about your 
bipolar? 
6.26 (3.24) 6.00 (5-9) 
12 (41.4) 17 (58.6) 
Understanding - How well do you understand 
your bipolar? 
6.62 (3.35) 7.00 (4-10) 
9 (31.0) 20 (69.0) 
Emotional response - How much does your 
bipolar affect you emotionally? (e.g. does it 
make you angry, scared, upset?) 
6.59 (3.16) 7.00 (5-9) 
9 (31.0) 20 (69.0) 
Identity - How much do you agree with your 
diagnosis? 
7.39 (3.31) 8.00 (7-10) 
6 (21.4) 22 (78.6) 
192 
6.6.2.1.2 Illness Identity 
In terms of BD identity, almost all (93%) participants reported that the term Bipolar Disorder 
had been used to describe their mental health problems. The terms used are presented in 
Table 6.7 and the number of terms used to describe participants mental health problems 
ranged between 2 and 7, most participants had four or five terms applied (n=8 for both four 
and five terms). 
Participants generally agreed with the terms applied to their mental health problems. Only five 
out of 27 disagreed or were uncertain about whether the term Bipolar Disorder applied to 
them. Seven participants (out of 19) who had had the term Mania applied to them disagreed 
or were uncertain about this. Six (out of 16) who had had the term Psychosis applied to them 
disagreed or were uncertain about this. In terms of participants own definitions of their mental 
health problems, 19 participants stated ‘Bipolar’/ ‘Bipolar Disorder’/ ‘Manic Depression’, three 
stated ‘Depression’. Other non-diagnostic terms used included; ‘physical ailments – no mental 
health problems’, ‘Vulnerable’, ‘Extra sensory perception’ and ‘Grieving issues’ (all n=1). 
 
Table 6.7: Terms used by HCPs to describe participants mental health problems (n=29) 
Term n (%) 
Bipolar disorder  27 (93.1) 
Depression 20 (69.0) 
Anxiety 20 (69.0) 
Mania 19 (65.5) 
Psychosis 16 (55.2) 
Manic Depression 13 (44.8) 
Schizoaffective 4 (13.8) 
Other a 11 (37.9) 
a Borderline personality disorder, 'Traits' only, High, Hypomania, Mental illness, Paranoia, Religious mania, 
Schizoidpremature child, Schizophrenia - past diagnosis, Obsessive Compulsive disorder, Stress (n=2). 
 
6.6.2.1.3 Perceived cause of BD 
The most frequently endorsed prompted causes of participants BD (Table 6.8) were stress or 
worry (n=27) and family problems or worries (n=24). Participants identified the most 
important causes of bipolar for them (up to three), the most common were; Stress/ anxiety/ 
worry (n=16), Family/ relationship issues (n=9), Emotional state (n-9). The most important 
maintaining factors were Stress/ worry (n=11), Poor healthcare/ support from professionals 
(n=8), Stopping/ remembering medication (n=5) and Negative thinking/ over thinking (n=5). 
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Table 6.8: Participants agreement with causes of their BD 
 Agree 
n (%) 
Uncertain 
n (%) 
Disagree 
n (%) 
Stress or worry 27 (93.1) 2 (6.9) - 
Family problems or worries 24 (82.8) 1 (3.4) 4 (13.8) 
My emotional state e.g. feeling down, lonely, anxious 20 (69.0) 1 (3.4) 8 (27.6) 
Hereditary it runs in my family 18 (62.1) 4 (13.8) 7 (24.1) 
Overwork 18 (62.1) 2 (6.9) 9 (31.0) 
My personality 17 (58.6) 4 (13.8) 8 (27.6) 
Chemical Imbalance 16 (55.2) 10 (34.5) 3 (10.3) 
My mental attitude e.g. thinking about life negatively 12 (41.4) 3 (10.3) 14 (48.3) 
My own behaviour 11 (37.9) 5 (17.2) 13 (44.8) 
Chance or bad luck 9 (32.1) 1 (3.6) 18 (64.3) 
Pollution in the environment 8 (27.6) 2 (6.9) 19 (65.5) 
Ageing 7 (24.1) 4 (13.8) 18 (62.1) 
Alcohol 6 (21.4) 2 (7.1) 20 (71.4) 
Diet or eating habits 5 (17.2) 2 (6.9) 22 (75.9) 
Accident or injury 5 (17.2) 4 (13.8) 20 (69.0) 
Recreational drugs e.g. cannabis, cocaine, ecstasy 4 (13.8) 4 (13.8) 21 (72.4) 
Poor medical care in my past 3 (10.3) 4 (13.8) 22 (75.9) 
Smoking 2 (6.9) 3 (10.3) 24 (82.8) 
A Germ or virus 1 (3.4) 3 (10.3) 25 (86.2) 
 
Table 6.9: Medications prescribed at baseline 
 n (%) 
Atypical anti-psychotics 25 (86.2) 
Mood stabilisers 20 (69.0) 
Benzodiazepines 10 (34.5) 
Sleeping tablets 6 (20.7) 
Typical anti-psychotics 4 (13.8) 
Anti-depressants 4 (13.8) 
Other medications 2 (6.9) 
SSRI 1 (3.4) 
SNRI 1 (3.4) 
 
6.6.2.2 Medications prescribed at baseline 
Participants were prescribed, a median of three medications at baseline (IQR=2-3). The most 
commonly prescribed medications were two atypical anti-psychotics (ATAP) Quetiapine and 
Olanzapine (n=11 for both). Twenty-five participants were prescribed ATAPs and 20 were 
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prescribed mood stabilisers (most commonly Valproate, n=10) (Table 6.9). Some participants 
were prescribed more than one type in any one class of medication For example two ATAP, 
mood stabilisers or two or more Benzodiazapines. 
 
6.6.2.3 Beliefs about treatment 
6.6.2.3.1 General beliefs about medication 
The BMQ general scales demonstrated adequate reliability in this sample at baseline (Overuse 
scale α=.70, Harm scale α=.68). Participants’ general beliefs about medication at baseline 
demonstrated high levels of Overuse beliefs, 23 (79%) reported high beliefs about the overuse 
of medicines and the mean score was 3.75 (SD 0.98) out of a maximum score of 5. Levels of 
general harm beliefs about medication were lower, only seven (24%) participants reported 
high harm beliefs the mean score was 2.64 (SD 0.75) out of a maximum score of 5. 
 
6.6.2.3.2 Practical barriers to taking medication 
Almost all participants reported at least one practical obstacle to taking medication (n=27). 
Twelve participants reported experiencing four or more obstacles, the most common were; to 
get the best from their care team (52% always, often or sometimes find it difficult), and to 
remember to take their medication when their daily routine changes (48% sometimes or often 
find it difficult) (Table 6.10). 
 
6.6.2.3.3 Specific beliefs about medication prescribed for BD 
Due to the variability in medication regimens and the fact that participants were often taking 
more than one medication within a particular class, BMQ necessity and concerns scores for the 
most commonly prescribed medications are presented (Table 6.11). 
Twenty-three (79.3%) participants had low necessity beliefs about at least one medication they 
were prescribed, 19 (65.5%) had high concerns about at least one medication. The average 
number of medications with high concerns was 2 (IQR=0-3) and with low necessity was 2 
(IQR=0.5-3). 38% of participants had high concerns and the same proportion had low necessity 
beliefs about all of the medications they were prescribed. 
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Table 6.10: BMQ Practical barriers n (%) 
 Always 
n (%) 
Often 
n (%) 
Sometimes 
n (%) 
Rarely 
n (%) 
Never 
n (%) 
I find it difficult to remember to take my 
medication when my daily routine changes 
- 1 (3.7) 12 (44.4) 2 (7.4) 12 (44.4) 
I find it difficult to remember to take my 
medication when my regimen (treatment plan) 
changes 
- 1 (3.7) 6 (22.2) 8 (29.6) 12 (44.4) 
I find it difficult to keep track of when I need to 
take each medicine 
- 1 (3.6) 6 (21.4) 6 (21.4) 15 (53.6) 
I find it difficult to remember to take my 
medicines every day 
- - 3 (10.7) 7 (25.0) 18 (64.3) 
I find it difficult to cope with the costs of 
medicines 
2 (6.9) 2 (6.9) 1 (3.4) 3 (10.3) 21 (72.4) 
I find it difficult to know when to get a further 
supply when my prescription runs out 
- 2 (7.7) 5 (19.2) 3 (11.5) 16 (61.5) 
I find it difficult to travel or go on holidays 4 (14.3) 2 (7.1) 4 (14.3) 2 (7.1) 16 (57.1) 
I find it difficult to swallow my tablets 3 (10.3) 1 (3.4) 3 (10.3) 4 (13.8) 19 (62.1) 
I find it difficult to get the best from my care 
team 
3 (10.3) 4 (13.8) 8 (27.6) 5 (17.2) 9 (31.0) 
I find it difficult to get information about my 
medicines 
2 (6.9) 3 (10.3) 5 (17.2) 5 (17.2) 14 (48.3) 
 
Table 6.11: BMQ necessity and Concerns beliefs for the most commonly prescribed medications 
 
High necessity 
n (%) 
Low necessity 
n (%) 
High concerns 
n (%) 
Low concerns 
n (%) 
Total 
n 
Valproate 5 (45.45) 6 (54.55) 3 (27.27) 8 (72.73) 11 
Quetiapine 7 (63.64) 4 (36.36) 5 (45.45) 6 (54.55) 11 
Olanzapine 5 (45.45) 6 (54.55) 6 (54.55) 5 (45.45) 11 
Lithium 7 (87.50) 1 (12.50) 1 (12.50) 7 (87.50) 8 
Sleeping tablets 2 (33.33) 4 (66.67) 2 (33.33) 4 (66.67) 6 
Risperidone 5 (100.00) 0 (0.00) 1 (20.00) 4 (80.00) 5 
Lorazepam/ 
Diazepam/ Valium 
3 60.00 () 2 (40.00) 4 (80.00) 1 (20.00) 5 
 
6.6.2.4 Adherence to medication (VAS & MARS) 
The median percentage of medications taken (VAS) ranged between 90-100% (IQR=80-100) 
(See Table 6.12 for average MARS scores). The MARS data for the most commonly prescribed 
medications (prescribed to ten or more participants),showed that 60% of participants were 
classified as having high adherence (a score of 23 or more) to Benzodiazepines, 64% to 
Valproate, and 71% to Lithium. Thirteen participants had low MARS adherence scores for at 
least one medication they were prescribed. Two participants had low adherence for three 
medications. 
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Table 6.12: MARS median scores for most common medications prescribed 
 n Mdn (IQR) 
Valproate 11 24 (21-25) 
Quetiapine 11 25 (25-25) 
Olanzapine 11 25 (23-25) 
Lithium 7 24 (22-25) 
Sleeping tablets 6 25 (21-25) 
 
6.6.2.5 Symptoms and side-effects experienced 
Commonly experienced symptoms or side-effects included restlessness (n=25), difficulty 
concentrating (n=23), feeling apprehensive, fearful or anxious (n=22), dry mouth (n=21), and 
tiredness (n=21) (Table 6.13). Participants reported experiencing a median of 15 symptoms 
(IQR=10-19), and a median of 12 at a moderate to severe level (IQR=6-15). In terms of 
symptom attribution more symptoms were attributed to medication (median 8, IQR=3-12), 
than to BD (median 5, IQR=1-7). Common symptoms attributed to medication experienced at a 
moderate to severe level were dry mouth (n=10), tiredness (n=10) and sedation (n=10). 
 
Table 6.13: Symptom reporting 
 Median (IQR) 
Total number of symptoms reported 15 (10-19) 
Total number of symptoms reported (Moderate to very severe) 12 (6-15) 
Total number of symptoms attributed to BD  5 (1-7) 
Total number of symptoms attributed to medication for BD 8 (3-12) 
Total number of symptoms with unknown attribution 0 (0-1) 
 
6.6.2.6 Satisfaction with information about medication 
Both SIMS subscales demonstrated good reliability (Action and Usage α=.868, Potential 
problems of medication α=.809). Median SIMS scores were 7 (IQR=2-12) out of a possible 17 
(higher scores indicating greater degree of satisfaction). For the Action and Usage subscale the 
median was 4 (IQR=2-8) and for the Potential Problems was 3 (IQR=1-5) (Table 6.14). Overall 
59% (n=17) of participants were satisfied with less than 9 items and 72% (n=21) were satisfied 
with less than five of the Potential Problems items. 
Looking at individual SIMS items, highest levels of dissatisfaction were reported in ‘Whether 
the medicine will interfere with other medicines’ (n=23), ‘Whether the medication will affect 
your sex life’ (n=21) (Table 6.15). 
197 
Table 6.14: Mean and median SIMS scores 
 Mean (sd) Median (IQR) 
SIMS Score 7 (5) 7 (2-12) 
SIMS Action & Usage scale 4 (3) 4 (2-8) 
SIMS Potential problems of medication scale 3 (2) 3 (1-5) 
 
Table 6.15: Proportion of participants satisfied and dissatisfied with SIMS scale items 
 Dissatisfied 
n (%) 
Satisfied 
n (%) 
Whether the medicine will interfere with other medicines 23 (79.3) 6 (20.7) 
Whether the medication will affect your sex life 21 (72.4) 8 (27.6) 
How long you need to be on the medicine 20 (69.0) 9 (31.0) 
Whether the medicine will have any unwanted effects (side effects) 20 (69.0) 9 (31.0) 
How you can tell if they are working 19 (65.5) 10 (34.5) 
What are the risks of you getting side effects 19 (65.5) 10 (34.5) 
What you should do if you experience unwanted side effects 19 (65.5) 10 (34.5) 
How long they take to act 18 (62.1) 11 (37.9) 
What these medicines are for 17 (58.6) 12 (41.4) 
How they work 17 (58.6) 12 (41.4) 
What you should do if you forget to take a dose 16 (55.2) 13 (44.8) 
Whether the medication will make you feel drowsy 15 (51.7) 14 (48.3) 
If you can drink alcohol whilst taking this medicine 13 (44.8) 16 (55.2) 
What they do 12 (41.4) 17 (58.6) 
What the medicines are called 10 (34.5) 19 (65.5) 
How to use them 10 (34.5) 19 (65.5) 
How to get a further supply 9 (31.0) 20 (69.0) 
 
6.6.2.7 Internalised stigma (ISMI) 
The ISMI scale and subscales demonstrated adequate to good reliability (ISMI 29 items α=.865, 
ISMI 24 items excluding Stigma Resistance α= 929, ISMI Alienation α=.892, ISMI Stereotype 
Endorsement α=.851, ISMI Discrimination Experience α=.745, ISMI Social Withdrawal α=.829, 
ISMI Stigma Resistance α=.698). Only around one quarter of participants reported at least 
moderate internalised stigma (using the 24 item scale) (n=8). However, for the subscales, 45% 
reported moderate or severe ‘Alienation’, 48% moderate or severe ‘Discrimination Experience’ 
(Table 6.16). 
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Table 6.16: Responses to the ISMI scale – levels of internalised stigma 
 Minimal to none 
n (%) 
Mild 
n (%) 
Moderate 
n (%) 
Severe 
n (%) 
ISMI score 10 (34.5) 12 (41.4) 7 (24.1) - 
ISMI score (excluding Stigma resistance 
subscale) 
9 (31.0) 12 (41.4) 7 (24.1) 1 (3.4) 
ISMI Alienation 10 (34.5) 6 (20.7) 11 (37.9) 2 (6.9) 
ISMI Stereotype Endorsement 22 (75.9) 6 (20.7) 1 (3.4) - 
ISMI Discrimination Experience 6 (20.7) 9 (31.0) 10 (34.5) 4 (13.8) 
ISMI Social Withdrawal 12 (41.4) 8 (27.6) 9 (31.0) - 
ISMI Stigma Resistance 20 (69.0) 7 (24.1) 2 (6.9) - 
 
 
6.6.3 Feasibility of the IBiD RCT 
6.6.3.1 Recruitment 
Out of the eligible 145 patients, 44.8% (n=65) were approached. The main reasons for not 
approaching those eligible were that they were discharged before it was possible to visit the 
ward (n=55), or that they were too unwell (n=24) (Figure 6.2). Of the 65 approached, 46.2% 
agreed to participate (n=30). The main reasons why participants were not recruited after being 
initially approached were; unable to make contact once they were discharged (n=16) and not 
being interested in the study (n=10). 
 
6.6.3.2 Retention 
The overall follow-up rate at 6-8 weeks was 72% (n=21), (IG=67%, TAU=73%). The main reason 
for withdrawal was illness relapse (n=4) (Figure 6.2). One participant consented to participate, 
was allocated to the IG, subsequently was withdrawn as during completion of the baseline 
assessments (over two sessions), they suffered a relapse. 
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Allocated to IG 
n=15 
Consented & Randomised 
n=30 
Allocated to TAU 
n=15 
Relapsed during baseline 
n=1 
Received intervention 
n=15 
Withdrawn n=3 
Lacked capacity/ too 
unwell n=3 
Did not return calls n=1 
Withdrawn n=4 
Did not wish to continue, n=1 
Physically unwell =1 
Lacked capacity/ too unwell=1 
Unable to contact (delayed 
transition between services) n=1 
Completed follow-up 
n=11 
Completed follow-up 
n=10 
Approached but not consented n=35 
Unable to contact, n=16 
Relapsed, n=4 
Not interested, n=10 
Does not acknowledge Bipolar diagnosis, n=1 
Too much to take on, n=2 
‘Too old to learn anything new’, n=1 
Unable to participate due to other commitments, n=1 
Eligible 
n=145 
Approached (given PIS) 
n=65 
Eligible 
(bipolar diagnosis on PIMS) 
n=175 
Not approached n=80 
Missed on ward (discharge leave), n=55 
Advised by staff not to approach as too unwell, n=24 
Out of Area, n=1 
Excluded n=30 
Primary diagnosis Substance misuse, n=9 
Organic disorder, n=7 
Does not speak English, n=1 
Change of diagnosis- no longer Bipolar, n=5 
Over 65 (before amendment), n=2 
Dual diagnosis of Personality Disorder, n=6 
Screened (from all inpatients) 
n=900 
No bipolar diagnosis 
n=725 
Figure 6.2: Flow diagram of screening, recruitment and retention 
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6.6.3.3 Allocation concealment & Blinding 
The CSO who was recruiting participants did not have access to the minimisation criteria or the 
allocation of prior participants. Therefore they would be concealed from being able to 
determine the allocation of subsequent participants. There were four instances of unbinding 
which may have had an impact on the results, all in the IG. Participants either brought their 
booklet to the follow-up assessment or mentioned it to the CSO. Two additional participants’ 
allocation became revealed, however, they did not complete follow-up assessments due to 
illness relapse so unblinding was not an issue. 
 
6.6.3.4 Protocol deviations - Time between baseline and intervention 
It was intended that interventions would be completed within the shortest possible time frame 
after baseline assessment. In practice, a number of factors resulted in a delay for some 
participants (Table 6.17). The median number of days between baseline and intervention was 
six (range 2-20). 
Table 6.17: Reasons for delays in conducting Interventions 
 Delay (working 
days) 
Reason 
EA01 6 days Participant on day leave and we were advised to call back after ward rounds 
later in the week. 
EB09 4 weeks Seen on ward then found out was RSO after discharge so sought advice 
about appropriateness for inclusion in terms of risk and meeting in 
community. Negotiated with CCO, pt was transferred between different 
temporary accommodation so advised to contact when settled. Took time 
to book room in community setting. 
CO10 4 weeks Participant went on holiday shortly after discharge. CCO advised to contact 
once back and settled. 
WM12 8 days Pt on leave and arranged to see on ward when coming in for other 
appointment as most convenient for pt. 
HC15 9 days Pt seen at home for baseline and intervention. Appointment arranged at 
convenience of pt. 
WM25 9 days Discharged from ward just after baseline and moved area and no continuity 
with CCO. Tried to sort out CCO issue before seeing. Then arranged with pt 
to see in Community at a time they were going to be at location. Unsuitable 
for home visit. 
HC26 7 days Arranged at home at convenience of pt. 
WL27 7 days Pt on extended overnight leave. Not appropriate to visit at home. 
Appointment re-arranged to fit in with returning to ward. 
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6.6.3.5 Process – Timing and location of assessments 
The majority of baseline assessments were completed in one session (n=23), five participants 
completed them over two sessions and one over three sessions due to fatigue. All follow-up 
assessments took one session to complete. At baseline the majority of assessments took place 
on the ward (n=22), five took place in participants homes and two took place in Community 
Mental Health centres on the advice of CCOs. At follow-up, the majority of assessments took 
place in participants homes (n=17), three in Community mental health centres and one on the 
ward as this participant was still awaiting housing. 
 
6.6.3.6 Acceptability of baseline questionnaires 
The questionnaire appeared to be acceptable to participants, almost all agreed it was 
interesting to complete (93%) and helped them to reflect on bipolar (82%). However, 14% 
agreed that it was difficult to understand and 18% that it made them upset. In terms of 
questionnaire length, 78% agreed that the amount of questions was about right, however, 21% 
felt it took too long to complete (Table 6.18). 
 
Table 6.18: Opinions on completing the baseline assessments, n (%) (Shaded statements=negatively 
phrased questions) 
 Strongly 
Disagree 
n (%) 
Disagree 
n (%) 
Uncertain 
n (%) 
Agree 
n (%) 
Strongly 
Agree 
n (%) 
The questionnaire was 
interesting to complete 
1 (3.6) - 1 (3.6) 14 (50.0) 12 (42.9) 
The questionnaire helped me to 
reflect on bipolar 
2 (7.1) 3 (10.7) - 13 (46.4) 10 (35.7) 
The questionnaire made me 
upset 
9 (32.1) 11 (39.3) 3 (10.7) 3 (10.7) 2 (7.1) 
The questionnaire was difficult 
to understand 
6 (21.4) 15 (53.6) 3 (10.7) 4 (14.3) - 
The amount of questions was 
about right 
- 4 (14.8) 2 (7.4) 15 (55.6) 6 (22.2) 
The questionnaire was not 
relevant to me 
12 (42.9) 14 (50.0) 1 (3.6) - 1 (3.6) 
The questionnaire was easy to 
understand 
- 3 (10.7) 2 (7.1) 16 (57.1) 7 (25.0) 
I would recommend the 
questionnaire to others 
- - 2 (7.1) 19 (67.9) 7 (25.0) 
The questionnaire took too long 
to complete 
5 (17.9) 15 (53.6) 2 (7.1) 4 (14.3) 2 (7.1) 
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6.6.3.7 Intervention process 
Intervention sessions lasted on average for just over one hour (67 mins, range 40-90 minutes). 
Eight participants were seen on the ward, four were seen at home and two in a Community 
mental health centre. 
 
6.6.3.8 Interview with CSO – feedback on IBiD set-up, recruitment and assessments 
Results from the interview with the CSO are summarised in Table 6.19. Challenges were 
presented by the ward environment including changing staff shift patterns, ward incidents and 
covering the large geographical area. Facilitators for study delivery, recruitment and retention 
included engaging all staff through existing team meetings, identifying a key individual within 
wards, maintaining good communication with CCOs from the outset, and having the flexibility 
to conduct assessments at participants’ homes. 
 
Table 6.19: CSO feedback on IBiD 
Setting up IBiD in the study sites 
 It was sometimes challenging to ensure that the study information was communicated to all 
staff due to shift-patterns. It was difficult to ensure that information we left was distributed to 
the whole team. 
 The most effective way to communicate was by attending team meetings, this worked well 
and staff were interested in the study and knew what their role would be. 
Recruitment 
 It was often challenging to actually get onto the wards due to incidents (e.g. violence or harm) 
meaning all staff were busy dealing with this. 
 Wards are extremely busy and it was often difficult to speak with members of staff. 
 Different teams had differing levels of involvement with IBiD, some would identify eligible 
patients and introduce the CSO to facilitate recruitment. Others were happy for her to 
approach patients directly without much involvement. 
 Some wards had almost no-one with a bipolar diagnosis on the ward at the time of the study. 
Some staff reflected that this was just unlucky as at other times they would have had eligible 
patients. 
 Recruiting patients once they had been discharged was challenging. Patients expressed 
interest on the ward and then were discharged quickly with very little notice before CSO could 
meet them. At this point it was difficult to try and negotiate recruitment through crisis teams 
and CCOs. 
 Recruitment on the wards and notifying the CCO in the community was the best strategy. 
 Overall challenges with the study were covering all the sites as this took a lot of time. There 
were often wasted journeys if it was not possible to actually get on the ward at the time of 
visiting. 
Assessing eligibility 
 When assessing eligibility and ability of patients to participate in the study, ward staff assessed 
their ability to make informed consent and assessed that patients were significantly improved 
in terms of their wellness from when they were admitted. However, this did not always 
203 
correspond to whether they were well enough to complete the study assessments. When the 
CSO went to try and recruit some patients, assessed as able to consent, it was clear they 
would have struggled with the assessments. 
Communication with ward staff 
 The amount and quality of contacts with ward staff was variable depending on how much time 
they had or were interested in research. 
 Most successful recruitment was from sites where a particular member of staff such as the 
ward manager, or a consultant psychiatrist was really engaged. 
Communication with community care teams 
 Informing the CCOs that a patient under their care was participating in the study (by email or 
letter) was a good strategy and kept them informed and included. This was really appreciated 
by CCOs as it is not often done in other studies. This set up good communication and 
facilitated making follow-up contact with participants. 
The research process 
 Control group participants – when contacting for follow-up weren’t always sure of their 
treatment allocation or couldn’t remember being told what would happen next. It could be 
that they didn’t read the letters that we sent, or that in sending them c/o the CCO, they might 
have got lost in transit. 
 CSO blinding – despite the CSO asking participants not to disclose when she contacted them, 
some participants still brought their booklets to the meeting, or had them visible in the home. 
 One risk incident occurred where the CSO was not informed about one participant being on 
the Sex Offenders Register. As such this was only discovered once the participant had been 
recruited. Communication with the care coordinator ensured that risk was managed and the 
participant was met only at Community Mental Health premises. 
 Patients were frequently given leave at short notice and so were not on the wards at arranged 
times. Also they were discharged with very short notice making it challenging to meet with 
them. 
Conducting baseline assessments 
 Only a couple of participants reported to the CSO that it was too long. 
 There was sometimes not an option for participants to give a response which meant most to 
them. What they wanted to say did not fall into the options available. 
 Participants would have liked more qualitative space to give their thoughts. 
 Things which the participants felt were missing from the questionnaire were ‘lifestyle’ and 
views on other ‘treatments’ or therapies in bipolar not just medication. 
 Participants found completing the questionnaire interesting and for some it was the first time 
they had really talked about bipolar. 
Conducting follow-up assessments 
 Follow-up assessments were generally straightforward to arrange.  Often CCOs wanted to 
check with participants themselves before agreeing that the CSO could contact them. This 
seemed to work ok and the response rate was good. 
 The CSO found follow-up assessments easier to complete as participants were in their homes 
and were more stable. 
 
6.6.4 Exploratory analysis of IBiD outcome measures 
6.6.4.1 Medications prescribed 
Data was collected for each medication prescribed at baseline and follow up. A descriptive 
assessment of medications prescribed at baseline and follow-up revealed that in the TAU 
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group 3/11 and in the IG 5/10 stayed on the same medications at each time point. The 
medication changes are summarised in Table 6.20 for participants who were retained at 
follow-up. Medication changes were common at this time of discharge from acute services to 
community teams. Data was not collected on reasons for medication changes. 
 
6.6.4.2 Medication beliefs & adherence to medication 
Detailed statistical analysis of the BMQ, MARS and VAS data for individual medications is 
beyond the scope of this feasibility study as it was not powered to detect changes. In addition 
heterogeneity in medication regimens mean that there were very small numbers prescribed 
each type of medication at both assessment points, and participants were prescribed more 
than one medication in a particular class. Instead, data on medication perceptions and 
adherence at each time point is reported descriptively and summarised in Tables 6.21 and 
6.22. This demonstrates the complex nature of assessing and analysing medication perceptions 
and adherence at this time. 
 
Table 6.20: Medication changes between baseline and follow-up 
TAU participants Medication changes 
HC03 Stopped Rispeidone & Halperidol 
Started Promethazine & Palipiridone (depot) 
WM13 Stopped Diazepam 
Started Olanzapine 
MR17 Started Quetiapine 
CO18 Stopped Chlorpromazine &  Simvastatin (cholersterol) 
HM20 Stopped Mirtazapine 
HC22 Started Lamotrigine 
EB23 Started Aripiprizol 
HC28 Started Quetiapine 
Stopped Haoperidol, Zopiclone, Promethazine, Clonazepam 
IG participants Medication changes 
EB09 Stopped Olanzapine 
Started Valproate & Sertraline 
CO10 Stopped Clonazepam 
HC24 Stopped Olanzepine, Zopiclone. 
Started Paliperidone (depot) 
HC26 Started Diazepam. 
Stopped Haloperidol, Clonazepam 
WR27 Stopped Lorazepam, Zolpidem 
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Table 6.21: Intervention group treatment beliefs and adherence data (B=baseline, FU= follow-up, h=high, l=low) (MS= mood stabilisers, ATAP= Atypical antipsychotic, 
SSRI= Selective serotonin uptake inhibitors) 
Pt Medications 
(B=baseline) (FU=follow-up) 
BMQ Necessity 
(baseline-
follow-up) 
BMQ Concerns 
(baseline-
follow-up) 
MARS 
(baseline-
follow-up) 
VAS (baseline-
follow-up) 
Summary of changes 
EB09 Olanzapine B h l h 100 Retained positive MS perceptions, but decreased 
adherence. 
Discontinued ATAP. 
Started SSRIs with positive perceptions. 
 Valproate – Depakote B&FU h-h l-l h-l 100-90 
 Sertraline FU h l h 90 
Pt Med BMQ  MARS VAS  
CO10 Valproate – new B &FU h-l l-l h-l 100-90 Reduced necessity and adherence for MS. Reduced 
positive perceptions for ATAP. 
 Olanzapine B &FU h-l l-h h-h 100-90 
 Clonazepam B l l h 100 
Pt Med BMQ  MARS VAS  
WM12 Lithium B &FU h-h l-l h-h 100-100 Retained positive MS and ATAP (x2) perceptions 
and adherence. 
Retained poor benzo perceptions and adherence. 
 Quetiapine B &FU h-h l-l h-h 100-100 
 Diazepam B &FU h-l h-h l-l 35-50 
 Amisulpiride B &FU h-h l-l h-h 100-100 
 Pramipectal – (side effects) B &FU h-?? L - ?? n/a n/a 
Pt Med BMQ  MARS VAS  
HC15 Valproate new B & FU l-l l-h h-h 100-95 Reduced and retained positive perceptions of MS 
and ATAP. 
 Quetiapine –new B & FU h-l h-h h-h 100-100 
Pt Med BMQ  MARS VAS  
HC16 Olanzapine B & FU l-h l-l h-h 100-100 Increased necessity for ATAP. Retained adherence. 
Pt Med BMQ  MARS VAS  
CO21 Lithium B & FU h-h l-l h-h 100-100 Retained positive perceptions and adherence of 
MS, ATAP & antidepressant. 
 Risperidone B & FU h-h l-l h-h 100-100 
 Mirtazepine (new) B & FU h-h l-l h-h 100-100 
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Pt Medications 
(B=baseline) (FU=follow-up) 
BMQ Necessity 
(baseline-
follow-up) 
BMQ Concerns 
(baseline-
follow-up) 
MARS 
(baseline-
follow-up) 
VAS (baseline-
follow-up) 
Summary of changes 
Pt Med BMQ  MARS VAS  
HC24 Olanzepine B l h H 100 Discontinued ATAP with negative perceptions. 
Started ATAP with negative perceptions.  Zopiclone B l l H 100 
 Paliperidone FU l h h 100 
Pt Med BMQ  MARS VAS  
HC26 Epilim Chronol (valproate) B & FU l-l l-l l-h 80-100 Retained low necessity for MS. 
Retained low concerns and improved adherence 
for MS. Decreased N for ATAP, but retained low 
concerns and high adherence. 
Changed benzo. 
 Risperidone B & FU h-l l-l h-h 100-100 
 Haloperidol B L l h 100 
 Zolpidem B & FU h-h l-l L-h 80-???? 
 Clonazepam B h l l 100-100 
 Diazepam FU h l h 100 
Pt Med BMQ  MARS VAS  
WR27 Lithium B & FU h-h l-l ??-h ??-100 Retained positive MS and ATAP perceptions. 
Increased ATAP adherence.  
Retained high N and C and adherence for benzo. 
 Quetiapine B & FU h-h l-l l-h 70-70 
 Lorazepam B h h h 100 
 Zolpidem B H L h 100 
 Clonazepam B & FU h-h h-h h-h 100-100 
Pt Med BMQ  MARS VAS  
HC30 Olanzepine B & FU h-l l-l l-h 95-90 Reduced N, but increased adherence for ATAP and 
SNRI. 
Reduced C for antidepressants, but low adherence. 
 Venlafaxine B & FU h-l l-l l-h 95-90 
 Mirtazepine B & FU l-l h-l l-l 95-70 
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Table 6.22: Control group treatment beliefs and adherence data (B=baseline, FU= follow-up, h=high, l=low) (MS= mood stabilisers, ATAP= Atypical antipsychotic, SSRI= 
Selective serotonin uptake inhibitors) 
Pt Medications 
(B=baseline) (FU=follow-up) 
BMQ 
Necessity 
(baseline-
follow-up) 
BMQ Concerns 
(baseline-
follow-up) 
MARS 
(baseline-
follow-up) 
VAS (baseline-
follow-up) 
Summary of changes 
HC03 Oxycarbamazapine B &FU h-h l-l h-h 100-100 Retained positive perceptions for MS. Decreased C 
for ATAP. 
Discontinued ATAPs. 
Started depot ATAP. 
 Quetiapine B &FU h-h h-l h-h 100-100 
 Rispeidone – new B h L h 100 
 Halperidol – new B h H H 100 
 Zolpidem - new PRN B l L H 80 
 Promethazine FU l L H  
 Palipiridone (at depot clinic) FU h L h 100 
Pt Med BMQ  MARS VAS  
HC04 Lithium B &FU h-h l-l h-h 100-100 Retained positive perceptions and adherence for 
MS. 
Increased N for MS. 
 Lamotrigine – new B &FU l-h l-l h-h 90-100 
 Diazepam PRN B l h L - n/a n/a 
Pt Med BMQ  MARS VAS  
HM05 Lithium B &FU h-h l-l h-h 100-100 Retained positive perceptions and adherence for 
MS. 
Retained low N and C and high adherence for ATAP 
and antidepressant. 
 Quetiapine – new B &FU l-l l-l h-h 100-100 
 Mirtazapine B &FU l-l l-l h-h 100-100 
Pt Med BMQ  MARS VAS  
HC07 Olanzapine B &FU l-l h-h h-l 95-80 Retained negative perceptions and reduced 
adherence for ATAP. 
Pt Med BMQ  MARS VAS  
WM13 Lithium B & FU l-h h-h l-l 95-95 Increased N for MS, retained high C and low 
adherence. 
Started ATAP with negative perceptions. 
Discontinued benzo. 
 Diazepam (1 week) B h h h 95 
 Pregabalin (1 week for anxiety) B & 
FU 
h-h l-l h-h 95-95 
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Pt Medications 
(B=baseline) (FU=follow-up) 
BMQ 
Necessity 
(baseline-
follow-up) 
BMQ Concerns 
(baseline-
follow-up) 
MARS 
(baseline-
follow-up) 
VAS (baseline-
follow-up) 
Summary of changes 
 Olanzapine - cutting down dose at 
present FU 
l h H 95 
Pt Med BMQ  MARS VAS  
MR17 Risperidone B & FU h-h l-l h-l 100-70 Retains positive beliefs, but decreased adherence 
for ATAP. 
Started ATAP with low necessity and adherence. 
 Quetiapine FU l l l 50 
Pt Med  BMQ  MARS VAS  
CO18 Valproate (Depakote) new B & FU h-h h-h h-h 100-100 Retains high N, C and adherence for MS and ATAP. 
 Quetiapine B & FU h-h h-h h-h 100-100 
 Chlorpromazine B missing missing missing Missing 
Pt Med BMQ  MARS VAS  
HM20 Valproate – new B & FU l-h l-l h-h 100-99 Increased N, and maintained low N and high 
adherence for MS. 
Maintained high N and C and increased adherence 
for ATAP. 
 Quetiapine B & FU h-h h-h l-h 90-99 
 Mirtazapine – new B missing missing missing missing 
Pt Med BMQ  MARS VAS  
HC22 Valproate B & FU l-l h-h h-l 100-100 Negative beliefs and reduced adherence for MS and 
ATAP. 
Started new MS with negative perceptions. 
 Olanzepine B & FU l-l h-h h-l 100-50 
 Lamotrigine FU l h h 99 
Pt Med BMQ  MARS VAS  
EB23 Epilim Chronol (valproate) B & FU h-h l-l l-h 90-100 Positive perceptions and increased adherence for 
MS. 
SSRI retained positive perceptions, increased 
adherence. 
Discontinued high C AP. 
 Citalopram B & FU h-h l-l l-h 100-100 
 Propanylol B & FU h-h l-l h-h 100-100 
 Aripiprizol FU h h h 100 
Pt Med BMQ  MARS VAS  
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Pt Medications 
(B=baseline) (FU=follow-up) 
BMQ 
Necessity 
(baseline-
follow-up) 
BMQ Concerns 
(baseline-
follow-up) 
MARS 
(baseline-
follow-up) 
VAS (baseline-
follow-up) 
Summary of changes 
HC28 Valproate B & FU h-h l-l l-h 50-100 Positive perceptions and increased adherence for 
MS. 
ATAP maintained high N, high C and adherence. 
ATAP started high C, high N, and adherence. 
 Olanzepine B & FU h-h h-h h-h 100-100 
 Haloperidol B h h H 100 
 Zopiclone & Promethazine B h h H 100 
 Clonazepam B l h h 100 
 Quetiapine FU h h H 100 
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6.6.4.3 Changes in other outcome measures 
Paired-sample t-tests were used to compute changes in each group between assessments 
(Table 6.23). No significant differences were detected between baseline and follow-up for 
either the IG or TAU for any of the brief IPQ items. However, as a feasibility study, it was not 
powered to detect changes. For the ISMI scale, only a significant difference was detected for 
the control group with a reduction in stigma scores. Adjusted means at baseline and follow-up 
and the results of exploratory ANCOVA are also presented (Tables 6.24 and 6.25). The ANCOVA 
revealed no significant effects of the intervention relative to TAU controlling for baseline 
scores (Table 6.25). 
 
Table 6.23: Results of paired-sample t-tests for Brief-IPQ, SIMS and ISMI 
 Group Mean diff 
(sd) 
t (df) p 
Brief IPQ     
How much does your bipolar affect your life? 
(Consequences) 
IG .30 (2.31) .41(9) .691 
TAU .77(2.60) .99(10) .348 
     
How long do you think your bipolar will continue? 
(Timeline) 
IG .20(1.75) .36(9) .726 
TAU -.55(2.70) -.67(10) .518 
     
How much control do you feel you have over your 
bipolar? (Personal Control) 
IG -.80(2.66) -.95(9) .366 
TAU -.86(3.18) -.90(10) .389 
     
How much do you think your treatment can help your 
bipolar? (Treatment control) 
IG -.30(2.16) -.44(9) .671 
TAU 1.18(2.60) 1.51(10) .163 
     
How much do you experience symptoms from bipolar? 
(Identity) 
IG 1.40(5.17) .86(9) .414 
TAU -.18(4.14) -.15(10) .887 
     
How concerned are you about your bipolar? (Concern) 
IG -.90(3.07) -.93(9) .378 
TAU .68(2.76) .82(10) .432 
     
How well do you understand your bipolar? 
(Coherence) 
IG -.50(3.7) -.44(9) .668 
TAU -.09(1.87) -.16(10) .875 
     
How much does your bipolar affect you emotionally? 
(Emotion component) 
IG -1.30(2.91) -1.41(9) .191 
TAU 1.09(2.66) 1.36(10) .204 
     
How much do you agree with your diagnosis of bipolar? 
IG .77(2.11) 1.11(8) .301 
TAU 
-.73(2.24) -1.08(10) .307 
SIMS     
SIMS total score 
IG -1.80(4.29) -1.32(9) .217 
TAU -2.18(3.37) -2.14(10) .057 
     
SIMS Action & Usage scale 
IG -.30(2.87) -.33(9) .748 
TAU -.36(1.63) -.74(10) .476 
     
SIMS Potential problems of medication scale 
IG -1.50(2.42) -1.96(9) .081 
TAU -1.82(2.23) -2.71(10) .022 
ISMI     
ISMI (29 items) 
IG -.01 (.57) -.08(9) .937 
TAU .15 (.36) 1.35(10) .208 
     
ISMI (24 items – Excluding Stigma resistance subscale) 
IG .04 (.65) .21(9) .842 
TAU .21() 2.32(10) .043 
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Table 6.24: Unadjusted means for IG and TAU at baseline and follow-up 
 IG Mean (sd) TAU Mean (sd) 
 Baseline Follow-up Baseline Follow-up 
Brief IPQ     
How much does your bipolar affect your 
life?  
7.90(2.33) 7.60(1.90) 8.50(1.50) 7.72(2.10) 
How long do you think your bipolar will 
continue?  
9.40(1.35) 9.20(1.40) 7.09(2.21) 7.63(3.07) 
How much control do you feel you have 
over your bipolar? 
5.90(2.92) 6.70(1.16) 2.86(2.51) 3.72(2.90) 
How much do you think your treatment 
can help your bipolar? 
7.80(2.48) 8.10(1.52) 6.63(2.33) 5.45(2.33) 
How much do you experience symptoms 
from bipolar? 
7.20(3.32) 5.80(2.69) 6.45(3.32) 6.63(2.06) 
How concerned are you about your 
bipolar? 
5.80(3.73) 6.70(3.09) 8.23(2.22) 7.54(2.11) 
How well do you understand your 
bipolar? 
7.30(3.23) 7.80(1.98) 6.09(3.61) 6.18(2.48) 
How much does your bipolar affect you 
emotionally? 
6.20(3.76) 7.50(2.06) 8.00(2.56) 6.90(1.81) 
How much do you agree with your 
diagnosis of bipolar? 
9.33(1.00) 8.56(1.94) 7.09(2.70) 7.81(1.88) 
SIMS     
SIMS score 10.00(5.33) 11.80(3.91) 4.82(3.40) 7.00(4.05) 
SIMS Action & Usage scale 5.70(3.16) 6.00(2.74) 3.36(1.96) 3.73(1.84) 
SIMS Potential problems of medication 
scale 
4.30(2.54) 5.80(1.87) 1.45(1.57) 3.27(2.37) 
ISMI     
ISMI (29 items) 1.88(.52) 1.90(.31) 2.42(.26) 2.28(.14) 
ISMI (24 items – Excluding Stigma 
resistance subscale) 
1.94(.62) 1.90(.32) 2.50(.22) 2.29(.16) 
 
Table 6.25: ANCOVA of follow-up scores by group (adjusted for baseline score) 
 
Group 
Estimated 
Marginal 
mean 
95% CI F p ETA 
Brief IPQ       
How much does your bipolar 
affect your life? 
IG 7.417a 5.650, 9.183 .490 .544 .165 
TAU 7.858a 6.043, 9.673    
How long do you think your 
bipolar will continue? 
IG 9.083a 6.636, 11.531 .111 .795 .100 
TAU 7.475a 5.680, 9.270    
How much control do you feel 
you have over your bipolar? 
IG 6.688a 5.145, 8.230 2.152 .237 .412 
TAU 3.625a 1.960, 5.290    
How much do you think your 
treatment can help your 
bipolar? 
IG 7.806a 6.608, 9.003 2.049 .216 .308 
TAU 6.321a 5.139, 7.504    
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Group 
Estimated 
Marginal 
mean 
95% CI F p ETA 
How much do you experience 
symptoms from bipolar? 
IG 6.333a 4.466, 8.201 .250 .705 .200 
TAU 7.167a 5.324, 9.009    
How concerned are you about 
your bipolar? 
IG 6.310a 4.566, 8.053 .189 .692 .056 
TAU 7.743a 5.945, 9.540    
How well do you understand 
your bipolar? 
IG 7.690a 5.746, 9.635 3.319 .115 .341 
TAU 5.292a 3.450, 7.133    
How much does your bipolar 
affect you emotionally? 
IG 6.952a 5.450, 8.454 4.053 .099 .441 
TAU 6.733a 5.311, 8.155    
How much do you agree with 
your diagnosis of bipolar? 
IG 8.500a 7.058, 9.942 .344 .735  
TAU 7.600 6.268, 8.932    
SIMS PP IG 5.786a 4.367, 7.205 .753 .448 .197 
TAU 4.250a 2.806, 5.694    
SIMS AU IG 6.000a 4.343, 7.657 1.043 .411 .333 
TAU 4.095a 2.579, 5.612    
SIMS score IG 11.500a 9.637, 13.363 .399 .572 .116 
TAU 7.625a 5.830, 9.420    
ISMI (29 items)* IG 1.897a 1.693, 2.100    
TAU 2.272a 2.075, 2.469    
ISMI (24 items – Excluding Stigma 
resistance subscale)* 
IG 1.875a 1.747, 2.003    
TAU 2.314a 2.190, 2.438    
* Cannot compute the appropriate error term due to small mean squares. 
 
 
6.7 Discussion & Conclusions 
6.7.1 Feasibility of the RCT protocol 
6.7.1.1 Number of eligible patients in the population 
Over the course of the six month study period, 145 patients were eligible to be approached to 
participate, approximately 20 per month. Only 24 patients were not approached due to being 
too unwell as judged by ward staff. These results indicate that there is a sufficient population 
of eligible patients in this setting to undertake a definitive trial. Only a few patients (under ten 
in each case) were excluded due to having clinical diagnoses rendering them ineligible for the 
study (Organic disorder, Personality Disorder, substance misuse as a primary diagnosis). 
Informal feedback from staff on wards who had almost no eligible patients during the 
recruitment period, was that this was unlucky and they would have expected more patients 
with a BD diagnosis. 
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6.7.1.2 Recruitment and retention 
Overall the recruitment rate of those patients actually approached to participate and provided 
with the PIS was 46%. The main reason for not recruiting patients was that they were 
discharged during the time period stipulated to allow participants to consider the research 
before approaching them for consent (48 hours). The number approached also was restricted 
by the fact that they were discharged or on leave after the initial approach was made. This 
was, in part due to the rapid discharge times and compounded by the limited number of 
recruiting staff available for this small feasibility study and the large geographical area they 
were required to cover. It was sometimes difficult to get on to the wards at certain times due 
to risk situations. The pressures on space within mental health units is well documented (BBC, 
2014) and patients are discharged quickly. 
In a larger trial a number of steps could be taken to overcome these challenges; more 
recruiting staff who are based geographically closer to sites and ethics permission to contact 
eligible patients through their CCOs after discharge from hospital. 
Positive aspects of recruitment were that staff were engaged by attending team meetings. This 
provided an effective and efficient way to inform and enthuse teams about the study. 
Providing regular updates kept staff informed and establishing a key member of staff at each 
site who was interested in the research as a point of contact facilitated recruitment. This 
concurs with the results of a survey of CSOs working across mental health research in the UK. 
Having an identified member of staff to facilitate recruitment, clinician attitudes to research, 
having a senior member of the study team visit sites and providing structured updates about 
recruitment progress were key in enhancing access to participants (Borschmann, Patterson, 
Poovendran, Wilson, & Weaver, 2014). 
Retention in the study was good (72%) and comparable to other research in this area (David 
Castle et al., 2010; Kemp et al., 1996; Sajatovic, Davies, et al., 2009; Scott et al., 2006). Reasons 
for this good rate include ongoing communication between research staff and CCOs. Informal 
feedback from sites was that in other studies in this setting, CCOs are not always kept 
informed when participants are recruited on the ward. The main reason for withdrawal was 
illness relapse which is not unexpected given the variable nature of the condition and the high 
risk of relapse. This time of transition can be a difficult period for patients. Treatment decisions 
may be made quickly and there may not be time to address the social needs facing patients 
after discharge (Glick, Sharfstein, & Schwartz, 2011). Patients have reported that they struggle 
with transitions between teams following discharge and communication gaps between 
providers exist. In addition, after the structure provided during inpatient stays, patients find it 
difficult to cope with living independently (I. Jones et al., 2009). In this feasibility study, the 
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follow-up time point was 6-8 weeks post baseline. This was kept flexible to make allowances 
for the changing health status and social circumstances of participants. Retaining almost three 
quarters of participants over a period of transition between services and care teams is an 
encouraging finding in terms of the feasibility of conducting a larger trial. 
Randomisation appeared to be acceptable to participants as no-one withdrew due to their 
allocation. However, one patient, when invited for follow-up, reported having found the 
baseline assessments too tiring and difficult. However, overall feedback on the questionnaire 
was positive with participants finding it interesting and that it helped them reflect on BD. 
There were difficulties however, in comprehending the questionnaire for a minority of 
participants and one-fifth felt it took too long to complete. For a definitive trial, future work on 
reducing questionnaire burden should be explored. Qualitative feedback from participants 
including their perspectives on recruitment, the study itself and the IBiD intervention is 
covered in Chapter 7. 
In terms of completion of individual parts of the questionnaires, the procedure used, meant 
that there were very few missing responses as participants were encouraged to complete each 
item, responding ‘not applicable’ where necessary. Feedback from the CSO about difficulties 
with item completion, or additional notes made on the questionnaires were collated as part of 
this feasibility stage and can be used to inform refinement of measures as is recommended as 
part of the feasibility assessment process (NIHR). 
 
6.7.1.3 Resource usage in terms of staff time and participant time in completing study 
components, intervention delivery 
During the recruitment and follow-up period, three CSOs were working on the study. However 
all three were also involved in recruiting to other studies during this period. Baseline and 
follow-up assessments, for the most part were completed in one session and intervention 
sessions lasted on average for just over one hour. Most baseline sessions were completed on 
the ward and there was always a suitable location available to meet with participants, either in 
quiet rooms or activity rooms. Participants’ homes were also used frequently for assessments 
or intervention delivery with the level of risk being judged by CCOs. No problems were 
encountered during the study with home visits. At baseline, intervention and follow-up it was 
sometimes necessary to book rooms at Community Mental Health centres due to the 
unsuitability of participants living arrangements. No difficulties were experienced booking 
rooms for the purposes of the study. 
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6.7.1.4 Methodological quality/ protocol deviations 
As part of the feasibility study, components of RCT methodological quality were assessed 
(Higgins et al., 2011). Randomisation was conducted as per protocol, using minimisation 
criteria of age and gender and coin toss where groups were balanced (Appendix S). Allocations 
were concealed to CSOs conducting assessments and held in electronic files at UCL which 
could not be accessed by CSOs. 
Unblinding did occur on four occasions in the intervention group and therefore in a definitive 
trial, it should be emphasised more strongly to participants that they should not reveal their 
allocation to the CSO and if they have an intervention booklet, they should ensure this is not 
on display until follow-up assessments have been completed. 
In practice, the study deviated from the protocol in terms of completing interventions as soon 
as possible after baseline assessments were conducted.  
As we are unsure as to the stability of treatment perceptions, we cannot determine from this 
study if this deviation was an issue in terms of intervention delivery. However, when 
conducting the intervention sessions, no participants had had a change in prescribed 
medications since the baseline assessments. As flexibility to participants’ needs and 
circumstances is important, pragmatically allowing these deviations was essential. 
 
6.7.1.5 Intervention need 
The feasibility study allows an assessment of the need for an intervention within this particular 
population and setting. The evidence covered in Chapter 1 and Chapter 4 identified that 
patients with BD have unmet information and support needs in relation to their diagnosis and 
treatment and in addition, hold perceptions of treatment which may not be consistent with 
adhering to medication. The baseline measures in this sample demonstrate that in terms of 
illness perceptions; perceptions of personal control over BD were low and participants 
reported experiencing severe symptoms and negative consequences on their lives and 
emotions. Fewer participants reported disagreeing with the diagnosis, and many had a good 
understanding of BD. These findings offer a mixed picture of recovery-oriented care, it is 
encouraging that many had a good understanding of BD, but low levels of personal control 
may mean that they have not been supported to be involved in their treatment plans and take 
some ownership of this. These results concur with results from a UK community mental health 
sample which also found that higher consequences and more symptoms experienced 
predicted higher rates of relapse (Lobban, Solis-Trapala, et al., 2012). 
216 
Perceptions of causes corresponded to the diathesis-stress model (Salomon & Jin, 2013) with a 
predisposition or vulnerability to suffering from psychological distress, with the exposure to 
stress increasing the likelihood that problems will manifest. Common cause perceptions were; 
stress and family problems and overwork and also vulnerability from hereditariness and a 
biological chemical imbalance. This concurs with previous qualitative research (Clatworthy et 
al., 2007). Participants report of factors responsible for maintaining mental health problems 
were potentially amenable to intervention. These included; stress and worry, poor healthcare 
or support from professionals, not taking medication and negative thought patterns. 
Contextual factors like low social support and difficulties with the health service have been 
identified as barriers to recovery in BD as well as dysfunctional attitudes held by the patient, 
however significant others and HCPs are also seen as facilitators of recovery (Sanchez-Moreno 
et al., 2010). 
In terms of treatment perceptions, general beliefs about medication indicated strong 
perceptions that medications are overused. The majority of participants had negative 
treatment perceptions for at least one medication they were prescribed, eight out of ten had 
low perceived need and two-thirds had high concerns. Previous research presenting average 
BMQ data across multiple medications for a community sample of individuals with BD 
demonstrated high perceptions of medication necessity and concerns on average were not 
high (Clatworthy et al., 2009). High concerns and low necessity were associated with poorer 
adherence. The results from the feasibility trial therefore suggest that this inpatient group hold 
views inconsistent with good medication adherence for at least one of the medications they 
are prescribed. 
In terms of self-reported adherence, even in the inpatient setting where medications are 
administered by nursing staff and patients do not take responsibility for this, almost half of 
participants were classified as low adherers for at least one of their medications. 
The most common practical barriers to taking medication were getting the best from their own 
care team, consistent with other research where barriers to effective communication included 
changes to the care team and lack of communication between teams (I. Jones et al., 2009). 
Coping with the changes to daily routine and the impact this has on remembering to take 
medication was also an issue for approximately half the sample. Around one-third of 
participants at baseline found it difficult to get information about their medication. 
Participants experienced a high number of symptoms, many of which they attributed to 
medication including dry mouth, tiredness and sedation. Sedation was a reported side-effect in 
qualitative studies (Clatworthy et al., 2007; Morrison, Meehan, & Stomski, 2015). 
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Low levels of satisfaction with information about medication were observed at baseline, both 
in terms of being informed of what they do and how to use them (Action and Usage) and in 
terms of the side-effects and drug interactions (Potential problems). This concurs with a 
community survey of individuals with BD which demonstrated low levels of satisfaction using 
the same scale (Bowskill et al., 2007). It can be inferred then that being admitted as an 
inpatient does not mean that there is any better information provision in terms of medications 
which are prescribed, this is supported by data collected by the Care Quality Commission 
(2009a) and more recent qualitative research (Hatonen et al., 2010). 
In terms of feelings of internalised stigma, overall for the sample levels were low. However, 
half of participants reported stigma in terms of feelings of being different and a worse person 
(Alienation) and experiencing discriminatory treatment from others (Discrimination 
Experience) (Boyd Ritsher et al., 2003). A large European study, however, found that the 
discrimination experience was the least reported form of stigma reported (Brohan et al., 
2011). Feelings of internalised stigma have been shown to be associated with reduced 
adherence (Livingston & Boyd, 2010). 
 
6.7.2 Changes in outcome measures 
As a feasibility study, the sample was not powered to detect changes in the outcome 
measures. As such, drawing conclusions about intervention effects was not the aim of this 
study. However, exploratory analysis was conducted to test the data analysis protocol and to 
explore any changes between baseline and follow-up. 
Medication data (treatment perceptions and adherence) was complex as participants were on 
average prescribed three medications at baseline, in addition, they were often taking more 
than one of a particular class of medication, such as a combination of two ATAPs. A chart-
review study found rates of complex polypharmacy (four or more medications) was 36% 
(Weinstock et al., 2014), so many of the sample in this study were receiving a complex 
treatment regimen. 
There have been mixed results in studies which aim to target illness and treatment 
perceptions. O’Carroll and colleagues (2013) conducted a beliefs-based adherence 
intervention in anti-hypertensive medication. Mixed results were observed, with significant 
reductions in concerns and an increase in adherence, but no effect on necessity beliefs or 
illness perceptions. The authors posit that necessity beliefs were high at baseline as they were 
not new medications. In addition, this study pre-screened participants for low adherence. This 
was a small pilot study, which was not powered to detect changes. A short face to face 
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intervention for patients with chronic pain was effective in changing illness perceptions, but 
not treatment perceptions (Glattacker et al., 2012). This study, however, used a quasi-
experimental design and was underpowered to detect small changes. 
Zwikker and colleagues (2014) conducted a trial of an intervention designed to target necessity 
and concerns about medication and adherence in Rheumatoid Arthritis which was not 
successful in changing beliefs or behaviour. This study was powered to detect BMQ changes. 
They hypothesise that it could be more difficult to modify established beliefs in those with a 
long-standing diagnosis rather than helping participants form adaptive beliefs when newly 
diagnosed. 
Potential reasons for no intervention effects include, firstly, that the intervention was not 
successful in changing beliefs or adherence. The challenges in actually selecting techniques 
were due in part due to the lack of evidence of what is actually effective. Even if useful 
techniques can be identified, they may not be effective for the specific population or context 
in which they are applied. Secondly, changes in the control group could occur. There may be 
an active component of completing the assessments, prompting participants to think about 
their condition and treatment in a different way, perhaps prompting information seeking. In 
addition, asking about adherence may, in turn serve to enhance it, though the mere 
measurement effect (Sherman, 1980). However, this could only be overcome by observational 
measurement of adherence without patients’ knowledge, which poses ethical issues in 
informed consent. Other possible reasons include, baseline group differences, ceiling effects, 
limitations of the outcome measures, heterogeneity of participants (mixed new diagnosis and 
long-standing diagnosis) and high symptom burden. 
High symptom burden may be a potential problem in this study, and people with BD have 
reported that when dealing with the effects of an acute episode of illness, it is difficult to take 
on board much information (Van den Heuvel et al., 2015). 
More generally, with measurement of perceptions, Siemonsma and colleagues (2010) state 
that although the IPQ-R and BMQ do measure changes in illness and treatment perceptions, 
they may not detect changes in the specific content of the perceptions and they recommend 
that qualitative methods are used to assess these. In addition, the limitations of both 
measured outlined in Chapter 2, Section 2.4 may contribute to difficulties in establishing 
whether there are positive changes for participants. Key constructs may be missed such as the 
whether there are changes in beliefs about the efficacy of treatments, and views about 
psychological side-effects. People may have been supported to have a more recovery-oriented 
model of their BD experiences, but this may not be captured by the Brief IPQ which does take 
a more medical model. 
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6.7.3 Limitations 
There are a number of limitations to the feasibility RCT which it is important to take into 
account and also use to inform future research. The sample size was small, however, as a 
feasibility study it allowed the capture of important data to establish the acceptability of the 
study protocol and intervention. Due to limited resources (staff and time), the number of 
participants who could be engaged was restricted. 
In terms of sample bias, there were few newly diagnosed participants, with the average 
number of years since first diagnosis of BD being around nine years, as such the findings may 
not be as applicable to a sample where more individuals are newly diagnosed. The sample may 
include participants who are highly engaged and therefore not generalizable to people with a 
BD diagnosis who do not engage with formal healthcare. However, by recruiting from hospital 
it is hoped the sample is more representative of people who face challenges with managing 
their condition and therefore may be in more need of support and information. Keck and 
colleagues (1996) reported that 60% of patients admitted to hospital with acute mania had not 
taken their medication as prescribed in the previous month. 
Although participants had been stabilised and were judged to be able to consent to the 
research, they were still often being affected by mania and depression symptoms. Just over 
40% had a possible manic state indicated, and approximately the same proportion were 
indicated to be experiencing moderate to severe depressive symptoms. These experiences 
may have affected the cognitive abilities of participants, in particular in concentration and 
retaining information. A large RCT in BD found that greater severity of illness was a significant 
predictor of recruitment (Busch, He, Zelevinsky, & O'Malley, 2015). It is likely that there may 
be an increased perception of intervention need when people are struggling most with the 
symptoms of BD. The challenge in future studies would be to recruit individuals who are 
euthymic and may perceive less immediate need (although are still susceptible to future non-
adherence and relapse). 
With regards to both providing medication information and in assessing BMQ and MARS 
outcomes, these are both confounded by changes to medications between the two 
assessment times. This is a limitation of these measures as they don’t provide instructions for 
use in changing medication regimens or take account of polypharmacy and how perceptions 
and adherence to different medications taken concurrently may interact. Future studies should 
track medication use more regularly and assess reasons for discontinuation or starting new 
treatment, as this may be on clinician advice. Research should explore correlation between 
treatment beliefs and adherence to see if combined measures could be used, but this was 
beyond the scope of this study. 
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The control group in this study was treatment as usual, and therefore with this design, the 
effects of therapists contact time are not controlled for. However, this was chosen as it does 
compare the intervention to current service provision and the fact that both the content and 
attention participants’ receive are components of the intervention (Freedland et al., 2011; J. 
Green, 2006). Factorial designs where comparison groups receive different ‘active’ 
interventions could be conducted to identify the effective components of the intervention 
(Collins et al., 2007) and if the intervention is effective beyond attentional ‘Hawthorne’ effects. 
In a small sample, randomisation did not produce groups which were evenly matched at 
baseline with regard to outcome measures. Although controlling for baseline score can be 
conducted during analysis (adding baseline score as a covariate in ANCOVA), stratification 
could be used to ensure more evenly matched groups. In addition, ceiling effects were a 
possibility, where positive beliefs in at baseline had less scope for improvement. Zwikker and 
colleagues (2014) conducted an RCT of a beliefs based intervention (also using the BMQ), 
which did not find a significant effect on beliefs and adherence, and the authors propose that a 
potential reason was the lack of scope for improvement. 
The intervention follow-up assessment was only conducted at eight weeks, this limits the 
conclusions that can be drawn about both the feasibility of retaining participants beyond this 
point and about the potential changes to treatments which occur beyond this point. . 
However, participants were successfully retained during a difficult transition phase between 
care providers, from acute to community care. Other studies have followed-up participants for 
a year or more, however, these are often programmes as part of routine clinical practice so 
easier to follow-up patients (Colom, Vieta, Sanchez-Moreno, Goikolea, Popova, Bonnin et al., 
2009; Miklowitz, Simoneau, George, Richards, Kalbag, Sachs-Ericsson et al., 2000). 
During the intervention planning process, it was recommended that follow-up assessments 
were kept to a minimum to reduce participant burden. Intervention follow-up was also, in the 
end, restricted by funder restrictions on project completion timing. However, conducting 
immediate assessments of illness and treatment beliefs as well as perceptions of internalised 
stigma would have allowed for assessment of any immediate impact of the intervention. In 
addition a full RCT should follow-up participants for longer than 8 weeks as previous research 
on medication adherence indicates that lithium is only maintained continuously for around 70 
days (R. Johnson & McFarland, 1996). Although this may not generalise to continuation rates 
for other medications one study found that adherence to benzodiazepines and antipsychotics 
was lower after 1 year than to mood stabilisers (Keck et al., 1997). At this time in participants’ 
treatment journey, adherence for many medications was quite high, as at baseline participants 
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were provided with their medications as inpatients and at follow-up many were prescribed 
new medications and may start off with high adherence. 
Finally, although measures were in place to blind CSOs to participants’ treatment assignment, 
their care teams were informed of their assignment. This was necessary to arrange 
communication with participants and attending the wards to conduct the intervention. 
However, occasions occurred when staff expressed disappointment to their patients being 
assigned to TAU. This could potentially lead to them being provided with extra information on 
BD or medication, however, we have no evidence of this actually taking place. This also raises 
the issue of clinician’s understanding of clinical equipoise. As this was a trial of a novel 
intervention, there was no evidence of its superiority over care as usual. In future trials it 
would be important to ensure that clinical staff understood this. 
 
6.7.4 Conclusions & Implications 
This feasibility trial demonstrated that an RCT of a psychosocial intervention could feasibly be 
delivered in the acute mental health setting but with some important resourcing 
considerations and modifications. Important lessons were learnt in this trial, including to 
ensure efficient recruitment, sufficient staff are required to cover study sites which are 
geographically spread out and where multiple visits are required to complete the recruitment 
process. However, in a larger trial this would have substantial cost implications. 
Due to rapid discharge times, recruitment could be extended to community recruitment with 
the assistance of CCOs. Building relationships with acute community staff was a significant 
strength of this project and in future studies this is recommended and would also facilitate 
ongoing recruitment in the community. 
Baseline assessments indicate that there was a need for intervention in this group, particularly 
in being provided with information on the risk of experiencing side effects and what to do in 
the event of these occurring, and in low levels of personal control participants felt they had 
over BD. By taking a recovery-focussed approach, an intervention needs to meet information 
needs so participants can be empowered to make decisions and set goals. Their beliefs and 
fears need to be acknowledged and taken into consideration when planning treatment in a 
collaborative partnership. Helping to foster greater involvement and ownership of care would 
be anticipated to lead to better recovery-focussed outcomes which are important to an 
individual (Jacobson & Greenley, 2001; NICE, 2014). 
Medication changes during the transition period resulted in challenges in analysis and 
confounding the outcome measurement in terms of adherence, treatment perceptions and 
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satisfaction with information. Future studies should track treatment perceptions and 
adherence more frequently and record reasons for medication changes. In terms of 
intervention delivery, information should also be provided on newly prescribed medications 
after the point of discharge to address concerns. This would result in an intervention with 
greater contact as opposed to a one off, however, from the evidence on retention and 
understanding that in this patient group flexibility is key, this may result in an improved, more 
tailored intervention which better responds to a patient’s treatment journey. 
The evidence of changes to medications from the quantitative evaluation implies that access 
to information on the ward is key as patients are prescribed medications they have concerns 
about and lack information on, but also people may need more long-term support to help with 
changes to medication and adherence once discharged from hospital. However, the IBiD 
intervention was designed to be very brief to test an intervention which would have greater 
capacity for use in clinical practice. In addition, the meta-analysis in Chapter 3 revealed that 
brief interventions can be highly efficacious in improving adherence. However to achieve belief 
change, a more intensive or longer-lasting intervention may be needed. 
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Chapter 7 IBiD qualitative evaluation 
 
7.1 Rationale 
In order to capture information on the acceptability of the study procedures, materials and 
intervention, a concurrent qualitative study with participants from the IBiD feasibility RCT was 
conducted. This study is reported following the guidelines set out for reporting qualitative 
research set out in the Consolidated criteria for Reporting Qualitative research (COREQ) 
checklist (Tong, Sainsbury, & Craig, 2007), this ensures that it is transparent and complete (see 
Appendix X for completed COREQ checklist). 
 
7.1.1 Aims 
To explore the experience of participants taking part in the IBiD study to provide data on the 
feasibility of the study design and intervention. 
7.1.2 Objectives 
To explore; 
 acceptability of the study protocol, i.e. participants’ reflection on their decisions to 
enter the study, questionnaire completion and practical arrangements, 
 acceptability and use of the IBiD intervention and participants’ recommendations for 
its improvement, 
 participants’ experiences of information provision and support in mental health 
services. 
 
7.2 Methods 
Ethical permissions were granted by the local REC through the approval of a substantial 
amendment to the original application (12/LO/1615: Amendment 1) (Appendix Y). Participants 
were invited to take part in the qualitative evaluation of IBiD at the end of the follow-up 
assessment. They were provided with a PIS (Appendix Z) by the CSO and if consent was given 
(Appendix AA) they were contacted by the author (LM) to arrange a suitable time to conduct 
the interview. Both IG and TAU participants were invited to participate. It was deemed not 
appropriate to contact those who had withdrawn from the study or those who were too ill to 
complete the follow-up assessments. 
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Participants completed the interviews over the phone or in-person at hospital in one case as 
this participant was still waiting for accommodation to be arranged. Interviews were audio-
recorded with participants’ consent. 
The interviews followed a semi-structured interview guide (Appendix BB) which was preceded 
by the researcher explaining the purpose of the study and reiterating the confidential nature 
of the interviews. The interview schedule covered the following topics; 
 Initial decisions to take part in the study and reflections on participating, 
 Opinions on completing the baseline and follow-up questionnaires, 
 Views on the timing and management of the research process, 
 Views on the IBID booklet and one to one meeting (IG only), 
 Views on the communication of and assignment to TAU allocation (TAU only), 
 Views on other information received about BD and medication, 
 Recommendations for improving information or support. 
The interview schedule was used to start and facilitate discussion, but additional points which 
arose spontaneously were explored by the researcher. The process was iterative, whereby the 
interview schedule was adapted by exploring issues raised in previous interviews. 
 
7.3 Data analysis 
Interviews were transcribed verbatim from audio-recordings before being transferred to NVivo 
10. All personally identifiable information was removed, for example participants and 
healthcare professionals’ names, wards and other identifiable locations. Each transcript was 
read and re-read by the researcher to gain familiarity with the content. Thematic analysis was 
used to explore themes within the data (previously described in Chapter 4). Codes identifying 
discrete parts of the transcripts were assigned, before reviewing these codes and grouping 
these into common themes (Braun & Clarke, 2006). A process of constant comparison was 
used whereby previously coded data were re-coded with the generation of new themes and 
research questions throughout the research process (Pope et al., 2000). The themes and 
extracts were discussed with an independent researcher and refined following this process. 
 
7.4 Results 
Seven participants consented and took part in an individual semi-structured interview (IG n=4; 
TAU n=3). Reasons for non-participation were, participants were too unwell, had withdrawn 
from the study, wanted time to think about participating, but then declined. Ethics approval 
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for the qualitative evaluation was delayed resulting in not being able to invite all earlier 
participants to take part. Interviews lasted, on average for 25 minutes, (range 16 to 39 
minutes). 
 
7.4.1 Sample characteristics 
Four IG and three TAU participants were interviewed, six were female and one was male, with 
a mean age of 50 (sd 11.84) reflecting the characteristics of the whole sample participating in 
the feasibility study. In terms of clinical characteristics, the mean length of diagnosis was 4.80 
(sd 5.22) years and participants were taking a mode of three medications at follow-up (range 
1-4). Two had been admitted on a voluntary basis and five had been detained under a Section 
(Table 7.1). 
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Table 7.1: Demographic and clinical characterises of sample participating in qualitative interviews 
ID IBiD 
group 
Gender Age Marital 
status 
Education Length of 
diagnosis  
N. medications 
at follow-up 
Admission type N. previous 
admissions 
Family history 
P1 TAU M 48 Single Vocational 6 mths 2 Voluntary 0 Unsure 
P2 IG F 66 Widowed None 6 mths 3 Voluntary 4 No 
P3 TAU F 65 Single Professional 7 yrs 3 Involuntary/ Detained 2 No 
P4 IG F 36 Married Degree 2.5 yrs 1 Involuntary/ Detained 3 No 
P5 IG F 39 Single Vocational 10 yrs 4 Involuntary/ Detained 10 Yes 
P6 TAU F 44 Single Higher degree 13 yrs 3 Involuntary/ Detained 3 Yes 
P7 IG F 52 Single Degree 1 mth 3 Involuntary/ Detained 1 No 
 
 
227 
7.4.2 Thematic analysis 
The themes are structured in a way to address feasibility and acceptability of IBiD, the 
participants’ reflections on each part of the process (Figure 7.1). This is followed by wider 
mental health themes generated in the data, relating to their experiences of care received, 
information they have been provided and their reflections on their condition and views of their 
treatment (Figure 7.2). 
 
Figure 7.1: IBiD Feasibility & acceptability – Themes and subthemes 
  
The IBiD Intervention 
IBiD feasibility 
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A desire to understand themselves better 
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Decision driven by the desire to help or give 
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The assessments provided the opportunity to 
reflect on bipolar 
Gaining a better understanding/ a source of 
new information 
Questionnaire – It shouldn’t just be about 
medication 
Completing the 
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Illness had a bearing on understanding the 
study 
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bipolar, gain information and make a 
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Figure 7.2: Bipolar, treatment & the mental healthcare system - Themes and subthemes 
 
7.4.2.1 IBiD feasibility & acceptability 
7.4.2.1.1 Decision to participate 
Participants reported different factors influencing their decision to take part in IBiD: wanting to 
help or contribute to research, a hope to understand their condition better and a general 
interest in mental health. 
Decision driven by the desire to help or give back 
Participants hoped that by participating in research this would go some way to improving 
mental health care, contribute to knowledge and help to tackle public stigma around mental 
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229 
health. One participant particularly wanted to ‘give back’ in return for the NHS care he had 
received. 
P: “I think the more research and the more insight people get and the more about any type 
of mental health would be brought out to the public in general and then maybe the stigma 
will be reduced you know.” (P3: TAU, Female, 7 yrs since diagnosis) 
I: “What made you decide you wanted to take part?” 
P: “Erm, reason being because, because I’ve got mental health problems myself and I’ve 
also got members of my family with mental health problems. I’ve seen the mental health 
hospitals since back in the 80’s and anything to improve the mental health system I’m kind 
of willing to do, so that’s why I decided that it would be a good idea to take part.” (P5: IG, 
Female, 10 yrs since diagnosis) 
I: “I get the impression you like to be involved with different things, so this research fits in 
with that?” 
P: “Yes, absolutely, and the NHS have been wonderful and I’ve got to give back, 
absolutely.” (P1: TAU, Male, 6 mths since diagnosis) 
 
A desire to understand themselves better 
Participants commented that they thought it would be helpful to take part in the study and it 
was a way to get more information about their condition and understand themselves better. 
Two participants commented that it was a way to access information which had otherwise 
been lacking. 
P: “I just, well it’s a new diagnosis for me, I don’t know very much about it, it’s a way of 
getting more information.” (P7: IG, Female, 1 mth since diagnosis) 
P: “Well I was happy to try and find out anything and everything about what’s going on 
and I thought I could get some clear view, maybe helping.” 
I: “Was the study an opportunity, a way for you to explore that, the bipolar?” 
P: “Indeed yes, I was happy to do it, to see if there was anything else I could learn about 
where my heads been and is.” (P1: TAU, Male, 6 mths since diagnosis) 
 
For one participant, the invitation to take part came at a time where she was starting to reach 
an acceptance of her diagnosis and therefore it fitted into this process of acceptance, she was 
willing to discuss her diagnosis and was receptive to the study. This demonstrates the recovery 
journey which is unique to each individual. 
I: “When you were first asked to take part in the study, what made you make the decision 
to take part?” 
P: “I think because as I say I was diagnosed about 7 years ago and I’ve always resisted the 
diagnosis, this time my admission was so bad and also a beloved dog of mine got killed on 
the road and therefore I suppose I’ve more or less accepted it. [….] what I am saying is that 
I received better treatment this time and the consultants were more a two way process, 
you know..” 
I: “It seemed to be the right time for you.” 
P: “Exactly yeah” (P3: TAU, Female, 7 yrs since diagnosis) 
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7.4.2.1.2 Completing the questionnaires 
The assessments provided the opportunity to reflect on bipolar 
Participants reflected positively on actually completing the questionnaires, For many it was the 
first time they had been asked for their thoughts on their diagnosis, their experiences living 
with BD and the treatment they had been prescribed. They reported finding it helpful and 
interesting, giving them more insight into BD. The questions and their own reflections on their 
answers prompted them to consider aspects of the condition they had not previously 
considered. 
P: “Yes, the questionnaire certainly helped me yeah definitely it gave me more insight into 
bipolar” (P3: TAU, Female, 7 yrs since diagnosis) 
P: “Interested to learn about the questions. Some of the questions I had never really 
thought about before and they cropped up and I thought ‘what this?’, you know?” 
I: “It was something quite new...” 
P: “Yeah. I had not discussed my illness before, not with anyone, no.” (P2: IG, Female, 6 
mths since diagnosis) 
I: “About the questionnaires can you remember back to what you thought about the type 
of questions?” 
P: “Yeah, I thought they were quite helpful, things about taking my drugs and how I felt 
stigmatised, being seen as somebody is mentally ill. Yeah, I thought they were all quite 
interesting questions really.” (P6: TAU, Female, 13 yrs since diagnosis) 
P: “A lot of them were things were things I hadn’t thought about before, in fact when I was 
an inpatient I think, although the consultant was very good, she was about the only one 
because I asked her something about bipolar. The nurses on the wards, I have to say you 
got no, no information at all, there was very little between the nurses with the patients and 
in fact the auxiliaries were more helpful in a way than the trained staff so the actual 
research that you did, the answers and that taught me quite a bit about bipolar.” (P3: TAU, 
Female, 7 yrs since diagnosis) 
 
The questionnaire presented challenges – both in intensity and understanding 
Despite finding the questionnaires interesting and helpful to complete, participants also 
reported challenges. These related to two areas, firstly the experience of completing the 
questionnaire in terms of the intensity and understanding the meaning, and secondly the 
actual content of the questions and the relevance to them. 
Participants sometimes found it hard to articulate their experience of completing the 
questionnaire. Their difficulties focussed on the intensity or taxing experience of completing it, 
6/29 of the whole sample had to complete it over more than one session. However, two 
participants specifically commented that it was not too long (confirmed by the quantitative 
data reported in Section 6.6.3). 
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I: “Completing those questionnaires, how did you find that?” 
P: “Alright, a bit, not tiring, but a bit, wearing, a bit.” 
I: “Because they were long?” 
P: “Because of the questions themselves, you know, what they were.” 
I: “A bit tiring to think about? Was there one particular part?” 
P: “No, just bits and pieces. Not tiring really, but a bit, made you think. Had to think hard 
for the questions, and as it went on you had to think harder.” (P2: IG, Female, 6 mths since 
diagnosis) 
P: “I think you have to have it in that format to get any kind of answers from it but it can be 
a bit taxing as I say you know ‘when is this going to stop’ you know.” (P3: TAU, Female, 7 
yrs since diagnosis) 
P: “…and it was a little intense here and there, but I’m happy to bite the bullet and do it 
[...]It was ok, you know we had to break for a drink and it was a little exhaustive, but all 
right, you know. It was good, very good.” (P1: TAU, Male, 6 mths since diagnosis) 
 
Participants commented on how sometimes it was difficult to understand the questions, or 
that the wording or language used was confusing. Sometimes they connected this with how 
they were feeling at the time in terms of their ability to concentrate. But sometimes it related 
to the way the questions were phrased. 
P: “Some of the questions I didn’t really understand, because they contradicted themselves 
if you know what I mean? Some of them [were quite difficult].” (P2: IG, Female, 6 mths 
since diagnosis) 
P: “I found them quite taxing, you have to have your wits about you but that was the good 
thing, if you got a bit confused she was quite good at explaining it again.” (P3: TAU, 
Female, 7 yrs since diagnosis) 
P: “I found it, difficult isn’t the word, I found it confusing is the word.” (P5: IG, Female, 10 
yrs since diagnosis) 
P: “I don’t recall there being any major problems with it. I think some of the questions on 
both occasions were a bit strange and I wasn’t quite sure about answering them, but that 
was the questions themselves rather than the actual process. […] some that were just I 
don’t know, just the way they were phrased, just quite bizarre, so it was difficult to answer 
them.” (P4: IG, Female, 2.5 yrs since diagnosis) 
I: “The type of the questions themselves were they straightforward?” 
P: “Yeah, pretty much, yeah, some of the language you had to look at twice, yeah, like a 
political statement sometimes when you look at it.” (P1: TAU, Male, 6 mths since diagnosis) 
 
There were a couple of factors which influenced questionnaire completion. Firstly, having the 
CSO there to help through the questions was vital for some participants with being able to 
understand and get through the questionnaire. 
P: “I found them quite taxing, you have to have your wits about you but that was the good 
thing, if you got a bit confused she [the CSO] was quite good at explaining it again.” (P3: 
TAU, Female, 7 yrs since diagnosis) 
I: “Can I just check that it was having [CSO] going through it with you made the process...” 
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P: “Oh yes, a lot easier. You know where it says ‘fair’, ‘moderate’ or ‘very often’, or not etc 
etc, there’s like say 5 answers, multiple choice, maybe it’s me well lately I seem to be 
having difficulty finding words, but you kind of forget what the five answers were. She was 
very good in giving you any help you needed you know without telling you the answers or 
imposing the answers on you.” (P3: TAU, Female, 7 yrs since diagnosis) 
 
Secondly, the impact of bipolar and how participants were currently feeling influenced how 
they engaged with the questionnaire. For one participant she was feeling better at the second 
appointment and found it easier to engage with the questionnaire. For the second participant 
she was feeling sluggish because of the effects of medications she was taking and found it 
more taxing the second time around. 
I: “Can I go back, [CSO] came to see you again to complete the questionnaires a couple of 
weeks ago. Can I ask how you found filling in the questionnaires themselves?” 
P: “Because I was in a pretty well state, pretty straightforward, fine.” 
I: “This time it was a bit easier?” 
P: “It was easier. The first time round, my head was quite muffled. I found it, difficult isn’t 
the word, I found it confusing is the word. But when [CSO] came round and my head was in 
a better state and I was quite straightforward with it so I found it easy.” 
I: “It was depending on how you felt at the time,” 
P: “Well really yeah, so yeah” (P5: IG, Female, 10 yrs since diagnosis) 
I: “Can I go back to completing the questionnaires again. [CSO] came and met with you. 
How did you find completing them then?” 
P: “A little bit tricky really, now I’m out of hospital and being that I’m a little bit sluggish. 
Just a little bit, so, yeah. I’m a bit slower so everything takes a bit longer at the moment.” 
I: “Was that thinking though the questions?” 
P: “Yeah, being a bit more thinking through I think.” 
I: “How you felt about completing it depended on how you felt at the time.” 
P: “Yeah.” (P6: TAU, Female, 13 yrs since diagnosis) 
 
Questionnaire – It shouldn’t just be about medication 
Participants commented on sections of the questionnaire and their relevance to their 
situation. Specifically completing the BMQ and MARS for each medication they were taking 
was repetitive for some and gave a large focus on medications. They also sometimes felt there 
was not always the option to fully account for their own experiences. Some parts they felt 
were not relevant, or the response categories did not fit with how they wanted to respond. 
P: “Most of it was fine, the bit on medicines was a bit repetitive I thought. Going through 
every single medication and answering the same set of questions I found a little bit 
laborious. Yeah.” 
I: “Did you feel you had a different opinion about the different medications?” 
P: “Erm, no, I felt that the questionnaire itself was very much the medical model and there 
wasn’t really room for anything else. […]” 
I: “[Summarising] Competing the questionnaires themselves, it didn’t incorporate all your 
experiences and it was a little bit tedious to fill out?” 
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P: “Yes, (laughs) because my answers were more or less the same for all the medications. I 
mean, there were slight variations, but nothing.” (P7: IG, Female, 1 mth since diagnosis) 
I: “Were there any questions which were not relevant?” 
P: “I can’t remember. I think a lot of them didn’t refer to me really. The way I felt.” (P2: IG, 
Female, 6 mths since diagnosis) 
I: “About the questionnaire were there things you felt weren’t relevant to you?” 
P: “Erm, yeah, but it’s difficult because of my background [nursing]. I think they were 
relevant to anybody who has been an inpatient and suffered from bipolar yeah. I mean 
some of the questions, maybe about medication ‘do you forget to take it’, do you do this 
that or the other, some of them were a wee bit, my responses might have been based on 
myself and my career if you like. Other people wouldn’t have found the same kind of 
thoughts about it.” (P3: TAU, Female, 7 yrs since diagnosis) 
P: “I didn’t think it was too long, just that some of them were awkward to answer, just 
sometimes end up giving, not incorrect answers, but answers to fill out, rather than ones 
that didn’t apply.” 
I: “There wasn’t an option there that applied to you?” 
P: “Yeah.” (P4: IG, Female, 2.5 yrs since diagnosis) 
 
7.4.2.1.3 Research process & reflections 
A person-centered research approach 
Participants were given an information sheet before having time to consider whether or not 
they wished to participate. This process was straightforward and everyone interviewed 
reported that they had the information and time necessary to make the decision. Participants 
also commented positively on the approach of researchers and the way the study was 
conducted. No problems with the practical arrangements of the study were raised, with 
participants commenting on how it was straightforward to arrange the appointments and find 
appropriate locations for each stage of the process. 
I: “Did you think you had enough time to decide?” 
P: “Yes, I think so. This is in the beginning, yes I did really, I was quite keen to do it. It was 
all explained. It was explained all right.” (P2: IG, Female, 6 mths since diagnosis) 
I: “Then [CSO] contacted you to do the follow-ups can I ask about arranging that process?” 
P: “And very considerate, and making appointments that were convenient to me and very 
considerate and polite and respecting you in your own home.” (P3: TAU, Female, 7 yrs since 
diagnosis) 
I: “And it was ok in terms of arranging coming to meet you?” 
P: “Yes, I think it feels nice that it is in my home, that you’re making an effort you know and 
it doesn’t feel so clinical so that’s nice.” (P7: IG, Female, 1 mth since diagnosis) 
 
Timing of participation needs to take account of individual needs 
Discussions arose about the timing of the research in terms of being invited whilst participants 
were in hospital and also the appropriateness of completing the study stages whilst in hospital 
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or once discharged and how this related to how participants were feeling. The timing of being 
approached whilst in hospital was felt to be appropriate by participants but they did reflect 
how there would have been an inappropriate time for them, or that other people may not 
have been able to cope with or understand the research in hospital. 
I: “The timing of the study for you in hospital, is it an ok time to approach people to take 
part in research?” 
P: “I think so, I think if you leave it until they are discharged a certain amount of them 
won’t be bothered because you get out and its all passed by you are on medication and you 
are involved then in your life and some might not want to be reminded having been an 
inpatient.” (P3: TAU, Female, 7 yrs since diagnosis) 
P: “I think you’ve got to be a bit, careful who you select, you know that some people would 
be, depends on their stage of recovery.” (P3: TAU, Female, 7 yrs since diagnosis) 
 
Some commented that their time in hospital was a positive time to participate in research and 
they did not have other things going on for them at the time and it gave them focus or 
purpose. For one participant, it was convenient as she was then in a position where she was 
able to make enquires about her treatment whilst still on the ward. 
I: “In terms of the timing of the study, was it ok being approached when you were in 
hospital?” 
P: “Yes. Break the tedium (laughs) it’s very boring on the ward.” (P7: IG, Female, 1 mth 
since diagnosis) 
I: “The timing of it, you were approached when you were in hospital.” 
P: “I mean it was ideal in a way, I was going to say ‘sitting audience’ I don’t really know 
what I mean by that, I was available. If it had been any earlier... I mean I was on the road 
to recovery at that point which is good, but if it had been any earlier I probably wouldn’t 
have been in the right space to be able to make the decision about whether to get involved 
in the study or not, well not a very informed decision anyway.” (P4: IG, Female, 2.5 yrs since 
diagnosis) 
P: “I think it was really good in hospital, I felt like it gave me a purpose” (P6: TAU, Female, 
13 yrs since diagnosis) 
I: “In terms of the timing for me coming down to provide the information, was that ok in 
hospital or better when you were discharged.” 
P: “No it was fine actually I think it was a good time as it led to me making enquiries about 
medication and things which I might not have done otherwise. I think it was probably good 
that it was whilst I was in hospital.” (P4: IG, Female, 2.5 yrs since diagnosis) 
 
For one participant she felt that being asked to participate whilst in hospital was fine, but 
actually completing the questionnaires and intervention was better conducted once she was at 
home. 
I: “The timing of the study, you were asked whilst you were in hospital, is that an ok time?” 
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P: “I’m talking for me personally that’s absolutely fine. I imagine there would be patients in 
there that wouldn’t but for me personally it wouldn’t have mattered whether I was in 
hospital or not.” 
[…] 
P: “For me personally, I don’t know I saw a few other people doing the first part on the 
ward. Other people might be able to concentrate, but not me personally. My head was all 
over the place, I could not concentrate and that was only asking me a few questions.” (P5: 
IG, Female, 10yrs since diagnosis) 
 
Another participant initially felt unable to participate when first approached, but then as she 
felt better she was interested in taking part, and in the end waited until she was discharged 
which suited her better. 
P: “I think she probably did approach me and I said not at the moment or something. And 
then she came back. Because I was very unwell. So I wasn’t getting involved in anything at 
all for a long time. I was in there for 10 weeks.” 
I: “There would have been a time where it wasn’t appropriate.” 
P: “Yeah, but I felt able to say, I didn’t feel pressurised.” (P7: IG, Female, 1 mth since 
diagnosis) 
 
Illness had a bearing on understanding the study 
Most participants felt that the process was well explained and they knew what each step of 
the process was, however the exact details about what they were told were hard to recall at 
the time of interview. 
I: “Then the next stage, was me phoning you and bringing down the information pack. Did 
you understand about, how you may or may not receive the information pack?” 
P: “Erm , yes I think [CSO] explained that 50% of people would and 50% wouldn’t and she 
didn’t know who that would be.” 
I: “But you were still happy to take part in the study regardless of whether you were going 
to receive or not.” 
P:” Yes, but I guess I was hoping I would get the information (laughs). Which I did. It would 
be slightly frustrating I think to know that there’s an information pack out there and not 
get it.” (P7: IG, Female, 1 mth since diagnosis) 
I: “Can I take you back to the study when [CSO] left after doing those first questionnaires, 
what were you told about what would happen next?” 
P: “Yeah I was told, I can’t remember exactly. I was told everything yes definitely.” 
I: “That was communicated ok?” 
P: “Yes definitely from the start what the set up was.” (P3: TAU, Female, 7 yrs since 
diagnosis) 
 
Participants did comment on how it was difficult to remember and absorb the details of what 
the study would involve at the time of recruitment due to how they felt. However, they felt the 
ongoing parts of the study were communicated appropriately and they felt informed. 
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I: “Can you tell me a bit about what you understood about the study and what it would 
involve?” 
P: “Not much actually to be honest, just literally, where I was in hospital at the time I 
wasn’t at my wellest, yeah, obviously one of the nurses, was like ‘its just answering 
questions basically about the mental health system’. I didn’t remember much at all apart 
from answering questions.” 
I: “Maybe it could have been explained better?” 
P: “It could have been yeah, it could have been explained better definitely.” (P5: IG, Female, 
10yrs since diagnosis) 
I: “Did you have a clear idea about what would be involved?” 
P: “Erm, I don’t know at the time I was probably a bit elated really, because I was in 
hospital.” 
I: “Then after [CSO] left, did she explain the next stage of the study?” 
P: “Erm, she must have done, but I can’t quite remember.” (P6: TAU, Female, 13 yrs since 
diagnosis) 
 
Reflecting on the research as an opportunity to reflect on bipolar, gain information and 
make a contribution 
Participants reflected on what they had gained from the experience of participating in IBiD. 
This included, IG participants reflecting on having obtained new information about bipolar. 
TAU participants also got something out of having the opportunity to speak about their 
condition and having people listen to them. Having the opportunity to speak about BD was 
new to some participants (both IG and TAU), having never spoken to anyone about it before. In 
addition, as mentioned previously, being given a sense of purpose whilst on the hospital ward 
was felt to be valuable. 
P: “I’m glad I did as I have got some information from it all.” (P2: IG, Female, 6 mths since 
diagnosis) 
I: “How you felt about the study and being involved overall?” 
P: “Erm, I was pleased about the study and I found the information quite useful” (P4: IG, 
Female, 2.5 yrs since diagnosis) 
P: “I thought it felt quite relaxed and not pressurised into doing it and quite interested to do 
it for my own self. I kind of welcome, the more information the better.” (P7: IG, Female, 1 
mth since diagnosis) 
P: “I thought it was really good idea, yeah, really good idea that I was involved, it was like 
taking part in something, like you say that was outside of the hospital and was quite nice 
seeing somebody, (not) a staff member and would like time to talk through something, 
things that are relevant to people with bipolar really.” (P6: TAU, Female, 13 yrs since 
diagnosis) 
 
Both IG and TAU participants reflected that it was worthwhile participating in the research as it 
contributes to knowledge and potentially to improvements in mental healthcare in the future, 
reflecting their feedback on why they wanted to participate in the research originally. 
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P: “I felt very pleased to be in it and I think it’s wonderful that you are doing this kind of 
thing, really do.” (P3: TAU, Female, 7 yrs since diagnosis) 
P: “I felt pleased really. There’s not, I’ve never known about anyone who’s wanting to 
change the system. I’ve never spoke to anyone who’s wanted to change the system, I’ve 
never been part of anything like that so I was interested really.” (P5: IG, Female, 10 yrs 
since diagnosis) 
 
7.4.2.1.4 The IBiD Intervention 
Gaining a better understanding/ A source of new information 
Participants commented on what they had got out of receiving the IBiD resource, this included 
gaining a better understanding of BD. They also commented on how it addressed concerns 
they had and the information was reassuring. This reflects the feedback provided during the 
consultation phase during the development of the resource (Section 5.2.4.3) where the 
service-users said that they would have found it very useful when they were diagnosed and 
reflected how it would have reassured them. 
P: “Well I understand more about the illness and why it starts really. If that’s possible. The 
reason for it.” (P2: IG, Female, 6 mths since diagnosis) 
P: “I remember it [the booklet] being useful and reassuring at the time and I’ve still got it.” 
(P4: IG, Female, 2.5 yrs since diagnosis) 
 
New information to participants contained in the booklet varied for each individual and 
included the information on medication, side-effects, BD and its symptoms and causes or 
triggers. The quotes from people with a bipolar diagnosis, the mood charts and information 
about specific medications and side-effects were mentioned as being particularly useful or 
reassuring. This also reflects the feedback provided during the development of the resource 
(Section 5.2.4.3) where the service-users particularly liked the mood charts and the inclusion 
of experiences of real people with a BD diagnosis. 
P: “It was quite interesting to read about bipolar generally and all sorts of material I had 
never had access to before.” (P4: IG, Female, 2.5 yrs since diagnosis) 
I: “Can I ask about coming to that understanding, what you have learnt fits in with your 
experiences and that information has come from the information we went through and the 
book?” 
P: “Yeah, I think, because I’d never thought of myself as bipolar because I’ve never had 
great periods of elation, I have more of the depression so I’ve always thought I was 
depressed and well and not depressed and well and elated and well. I didn’t see that so I 
could identify with some of the mania, not all of it.” (P7: IG, Female, 1 mth since diagnosis) 
I: “Was that new to you the information about the medication?” 
P: “It was really because no one ever discussed medication with me.” (P2: IG, Female, 6 
mths since diagnosis) 
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P: “It had everything that I needed to know. I’m not getting kind of like, terrible side effects 
off any of the medications, so it’s not like I need to say. But it did answer a few of the 
symptoms that I’ve been getting. Yeah.” (P5: IG, Female, 10yrs since diagnosis) 
P: “And I was intrigued to find that it is genetic or hereditary and looking back through my 
family, I’m not sure I could think of anyone who would fit the bill.” (P7: IG, Female, 1 mth 
since diagnosis) 
P: “I remember that there were some sections where people, sort of anecdotes from people 
saying their experiences which is always quite reassuring when you hear that other people 
are experiencing similar things.” 
I: “You particularly liked the section with other peoples experiences, it was the most useful?” 
P: “Yeah, or kind of, not useful, but reassuring” (P4: IG, Female, 2.5 yrs since diagnosis) 
P: “The mood chart was very useful and what was particularly helpful, the mood charts, and 
the bits where you gave me, the medication and all the side effects of the medications.” 
I: “The leaflets?” 
P: “That was really helpful. Those were the two particular bits.” (P5: IG, Female, 10yrs since 
diagnosis) 
P: “That was another thing that was handy on your bipolar booklet.” 
I: “The information about other resources?” 
P: “Yeah that’s right yeah, to sort of find out information about the [charity], so I’m sure if I 
did need more information, I’m sure the [charity] would provide me with that.” (P5: IG, 
Female, 10yrs since diagnosis) 
I: “[…] there was some information at the back about identifying early warning signs and 
triggers which I think we spoke about briefly.” 
P: “I think that’s very helpful. I think each individual probably knows or has thought about 
what the triggers are. Yeah, I guess that would be a useful thing to actually write down in 
the booklet, reminders for yourself.” (P7: IG, Female, 1 mth since diagnosis) 
P: “There’s also, the stigma is covered isn’t it within the booklet. I think that’s really 
important” (P7: IG, Female, 1 mth since diagnosis) 
A couple of participants commented on content of the resource which was a repetition of 
information they were already aware of, this related to medications and practical barriers 
(information on unintentional non-adherence). Leading on from this one of these participants 
felt that it would have been useful to include more information on lifestyle and an alternative 
health approach to managing BD and also issues related to employment and mental health. 
P: “There were bits which for me personally which I thought didn’t find useful, like how to 
take your medication and remembering to take the medication.” (P5: IG, Female, 10yrs 
since diagnosis) 
P: “I suppose I had already had a lot of the information about medication, that was a 
repetition of what I already knew.” (P7: IG, Female, 1 mth since diagnosis) 
P: “I think, more about a kind of holistic package would be much more welcome, what you 
can do for yourself apart from pop pills.” (P7: IG, Female, 1 mth since diagnosis) 
P: “Erm, might be useful to know about mental health and work actually, that’s another 
question in my mind. How much do you disclose if you are going for a job for example, 
what are your rights, that side of it would be really useful to know.” (P7: IG, Female, 1 mth 
since diagnosis) 
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IBiD prompting actions 
Participants commented on actions that they had taken as a result of receiving IBiD. One 
participant was prompted to find out about different medications available to her which led to 
changing to a monthly injection which she felt was a better alternative for her. Two 
participants used the mood charting exercises and found this useful to visualise their moods. 
The information on charity organisations/ other resources was planned to be or had been used 
by two participants, with one also sharing this with a peer support worker.  
P: “I was prompted by it to go and find out about the different medications out there and 
yeah, just some enquiries with the pharmacist.” 
I: “Did you get the opportunity to talk to the pharmacist in hospital about your 
medications?” 
P: “Yeah, I discussed the medication I was prescribed at the time and the options for when I 
was going to be leaving hospital.” 
[…] 
I: “Has that helped, the information [booklet] help with managing to take it and any doubts 
or worries?” 
P: “A little bit, I’ve still got concerns about taking it at all, but it’s led me to a new 
medication which I wasn’t aware of before which is the, I’m currently taking a monthly 
injection. Rather than tablets so that wasn’t something I was aware of at all that I 
discussed with the pharmacists and looked at the pros and cons of taking that instead.” 
I: “You found something that could be a better alternative for you?” 
P: “Yes.2 (P4: IG, Female, 2.5 yrs since diagnosis) 
P: “I do now with that mood chart, I used that. Before that bipolar research study I’d write 
a daily diary of my moods anyway, but sometimes I can’t explain my moods, that chart kind 
of and the colours have kind of helped me see where my head is. Writing down wise, the 
mood chart was really, really helpful.” 
I: “It was useful to visualise your moods?” 
P: “Yeah that’s right to visualise my moods as have someone else, put my moods on paper 
was really, really handy.” 
I: “Did you share that with anyone?” 
P: “Yeah, the only people I’ve seen since you have been the transition team and I told the 
transition team about it.” (P5: IG, Female, 10yrs since diagnosis) 
P: “I’m thinking, something that I will definitely will do, is joining the [charity] which is in 
[town]. I’ve never actually been to a meeting. That was another thing that was handy on 
your bipolar booklet.” 
I: “The information about other resources?” 
P: “Yeah that’s right yeah, to sort of find out information about the [charity], so I’m sure if I 
did need more information, I’m sure the [charity] would provide me with that.” (P5: IG, 
Female, 10yrs since diagnosis) 
P: “And also there’s a guy here who comes in, he was a patient, and he works here now and 
he takes people for walks and things like that and does board games and that sort of thing 
and he is bipolar and he was looking for somewhere where he could go near where he lived 
and I got the information from the booklet of Bipolar and everything.” 
I: “The charities?” 
P: “The charities and the three books I wrote out for him and he found it very interesting as 
he had not seen them before so that was something really. Pass it on.” (P2: IG, Female, 6 
mths since diagnosis) 
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Flexibility in how the resource is used 
Participants used the resource in a way which suited them, they described how they used the 
booklet as a resource to return to or as something which they used once. 
P: “I read through the folder, that was quite interesting and I shall probably go back to it 
and read it again, because I don’t always take in everything all at once. I’ll have to go back 
and read over.” 
I: “There was a lot of information to read, and you have had a look afterwards. You like to 
dip in and out?” 
P: “Yeah.” (P2: IG, Female, 6 mths since diagnosis) 
P: “Yes, I did look at it and then I left it for a bit and then I read a bit more, kind of went to 
the bits that appealed to me most.” (P7: IG, Female, 1 mth since diagnosis) 
I: “Did you use it since that day?” 
P: “I read through the whole thing and no, I haven’t looked back at it since then, but I did 
find it quite interesting and informative at the time.” (P4: IG, Female, 2.5 yrs since 
diagnosis) 
One participant reflected that she found it useful to go through the information during the 
session as there was a large amount of information. For another, she found it useful to go 
through the information in her own time. 
P: “For me it was useful to have the guided session to start with to be honest as far as I can 
tell I would have been a bit daunted by the amount of information.” […] “I found the pack 
really useful, but I don’t know, as I say it was really useful initially to have someone else to 
go through some of it beforehand rather than just being left to read it on my own.” (P4: IG, 
Female, 2.5 yrs since diagnosis) 
P: “I remember you came round and I had that cold. I found it useful more after you left as I 
was able to spend a bit of time going through the book myself you know. So yeah, at the 
point you came round I really wasn’t feeling particularly well. But I did find it useful as I was 
able to go through it myself.” (P5: IG, Female, 10yrs since diagnosis) 
Only one participant interviewed completed the exercises themselves, this was not the way 
the resource appeared to be used by others. 
I: “There were spaces to write your own responses in there, did you get to use that?” 
P: “Yeah a couple of times I did, not all the time, a couple of times I was filling those out 
yeah.” (P4: IG, Female, 2.5 yrs since diagnosis) 
I: “There were spaces to write your own notes...” 
P: “I didn’t fill any of them in I must admit. But I will do because I shall go back and read it 
over and over and then make my comments. When it’s more in my mind, because there 
was so much going on recently and I only found out yesterday lunchtime that I had got a 
flat.” (P2: IG, Female, 6 mths since diagnosis) 
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7.4.2.2 Bipolar, treatment & the mental healthcare system 
Alongside discussions about the study, participants frequently reflected on their experience 
with their diagnosis, treatment and the mental healthcare system. These important insights 
provide context around their IBiD participation and recommendations more generally for how 
better to support people with a bipolar diagnosis. 
 
7.4.2.2.1 Struggles with medication 
Necessity beliefs were high, but there was uncertainty about future need 
Participants expressed an acceptance of the necessity of medication for them to get well and 
therefore be able to be discharged from hospital. However, doubt or uncertainty was reported 
in the ongoing need for medication. They judged the success of medication on how they were 
feeling, but also then expressed doubt for its need when symptoms were not present. 
One participant described how she felt her medication was working well for her at the 
moment. She appeared to have found a balance with a medication which was keeping her 
moods stable and she was feeling well. 
P: “Overall I am very happy, because I feel well, I don’t feel manic, even slightly manic, I 
don’t feel depressed I feel quite level. I don’t either feel like I’ve been numbed to the world. 
I feel quite in touch as well, so I imagine I am experiencing the world the way most people 
experience the world if they haven’t got bipolar. So the proof is in the pudding isn’t it so for 
me that’s my gauge, and if I stop feeling like that then I will go to my GP.” (P7: IG, Female, 
1 mth since diagnosis) 
However, she later reported finding it confusing that she still needed an ‘antipsychotic’ as she 
was not experiencing psychotic symptoms. In a way, the names of the medications did not 
correspond to what she felt she needed at the time and did not have a common-sense fit with 
her symptoms. She questioned the ongoing need for medication in the long term. 
P: “And Olanzapine is an anti-psychotic and I’m not psychotic so is it appropriate now? 
Now it was while I was in hospital, but I’m not. So she’s reduced the dose of that down to 5 
mg with a view to getting off it completely which would be good.” (P7: IG, Female, 1 mth 
since diagnosis) 
P: “Do you get to a point where you don’t need to take it anymore, that I don’t get. It would 
be quite useful to know, interesting to know.” (P7: IG, Female, 1 mth since diagnosis) 
Participants commented about the uncertainties around how medicines work and how 
medication-related decisions are taken in mental health, they acknowledged that it was not an 
exact science, however, it may not have been presented as such by healthcare professionals. 
This also ties in with the quote above and the final quote below around confusion about 
medication types and changes needed. 
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P: “The other thing I don’t understand is, are you on this medication for life. Surely if it’s a 
chemical imbalance you put these drugs into your body, I mean do they disappear, I don’t 
understand. Do you get to a point where you don’t need to take it anymore, that I don’t 
get. It would be quite useful to know, interesting to know.” 
I: “It’s quite a mystery?” 
P: “My take on psychiatric medication is that it is an experiment every time because 
everyone is unique and they go with their gut feeling everyone and then they tweak it. And 
if it doesn’t suit you they take you off it and try a different one. There’s no exact science to 
it, but it’s presented as an exact science.” (P7: IG, Female, 1 mth since diagnosis) 
P: “I mean I’ll take, you see, with bipolar or with a lot of mental health illnesses there is no 
thing, you can’t take a blood test and therefore the medication is hit and miss, sometimes 
you are afraid to not take it but you don’t know if it’s doing you good or whether you just 
feel a bit better. I think that is the difficulty with mental health with regard in contrast with 
physical.” (P3: TAU, Female, 7 yrs since diagnosis) 
I: ”In terms of changing medication, have you changed since you left hospital?” 
P: “Yes I mean when I saw this consultant he has changed a lot and I don’t know where I 
am at the moment, the Chemist has made a few mistakes saying its ready and it’s not. 
Some of the medications that I was on is being got rid of, kind of like a sliding scale to 
complete it and then the other medication is to come in, it’s could be a bit confusing 
really.” 
I: “Knowing what you have to take now...” 
P: “Yes exactly and when one finishes and the other takes over, the other one is going to be 
increased, and I think that is a bit difficult.” (P3: TAU, Female, 7 yrs since diagnosis) 
 
Ambivalence and a desire to be medication-free 
Despite appearing to accept the diagnosis and the need for medication participants still 
expressed concerns about taking medication generally and a desire to not be taking it, there 
was an ambivalence with understanding the need for medication, but a wish to be medication 
free. One participant commented that after the intervention she still had concerns about 
medication, these did not go away, but she was able to find a medication where the 
advantages for her outweighed the disadvantages. 
P: “There was a GP on it [TV programme] who controlled it with diet, so I wish I could do 
that because I don’t like medication, I mean anybody I think if you can cut down on 
medication its good. There are things that are vital that you have to take. (P3: TAU, 
Female, 7 yrs since diagnosis)” 
I: “Has that helped, the information [IBiD booklet] help with managing to take it and any 
doubts or worries?” 
P: “A little bit, I’ve still got concerns about taking it at all, but it’s led me to a new 
medication which I wasn’t aware of before which is the, I’m currently taking a monthly 
injection” (P4: IG, Female, 2.5 yrs since diagnosis) 
P: “For me, well I don’t like to be on medication, I was very anti-medication prior to having 
very severe clinical depression and I don’t think it is the single determinant of recovery, but 
it’s played out in the hospital as if that’s the only thing to get you better really. That you 
must take your medication and that’s the bottom line and although its voluntary if you are 
not sectioned, there is a very strong pressure to take the medication and you know, you are 
considered an idiot if you don’t take it (laughs).” (P7: IG, Female, 1 mth since diagnosis) 
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Participants experienced side-effects, but the degree to which these bothered them varied, 
and it also varied as whether they took action to address the side-effects. 
P: “I’m not getting kind of like, terrible side effects off any of the medications, so it’s not 
like I need to say [report them to their care team].” (P5: IG, Female, 10 yrs since diagnosis) 
P: “Yeah, unfortunately I’ve come, my medication has come, he’s introduced a new 
medication that I used to be on and, erm, a new one that was introduced in hospital and its 
kind of slowed me down quite a lot. So I feel like I’m going down a bit at the moment, so 
I’m a bit sluggish, a bit opposite to what I was in hospital really.” (P6: TAU, Female, 13 yrs 
since diagnosis) 
P: “I’ve been to my doctor and said I’ve been putting on loads of weight, I think that’s the 
Olanazapine and I’ve said I want to look at something else and she suggested reducing.” 
(P7: IG, Female, 1 mth since diagnosis) 
 
7.4.2.2.2 Experience of bipolar and reflections on diagnosis 
A determination to stay well this time & taking action 
Participants reflected on how their illness had improved, there appeared to be a determination 
after their most recent admission, not to return to hospital. Participants described new 
opportunities and activities they have engaged with since being discharged from hospital this 
time, these all feed into their determination to stay well. The recovery model highlights the 
importance of setting personal goals and how the definition of what recovery means to a 
person is unique. 
P: “Yes, it’s all been full on, moved to this fantastic place with fantastic staff. I’m 
determined not to go back [to the ward]. I saw people come and go and I thought, no I 
can’t live like that.” (P1: TAU, Male, 6 mths since diagnosis) 
P: “Well, I’ve just starting a new group called a recovery education group and that’s coming 
up and I think with my primary worker there were are going to be talking about episodes of 
bipolar, so that is something new.” (P6: TAU, Female, 13 yrs since diagnosis) 
I: “Things have been going well since you left [hospital]?” 
P: “Yes, absolutely, I go back a couple of times a week for my art class and chat, the book 
lady, there’s a lot going on.” 
I: “They are still keeping in touch..” 
P: “Yeah.” (P1: TAU, Male, 6 mths since diagnosis) 
P: “I’ve done, outside of hospital, with my care coordinator, I did a WRAP [wellness 
recovery action plan], you know where you look at all your triggers, and you make an 
action plan of what should happen, what help you need, who can step in.” (P7: IG, Female, 
1 mth since diagnosis) 
P: “Eventually I would like to do voluntary work in the mental health system, because it is a 
bit shoddy, its just the way the mental health system is.” (P5: IG, Female, 10 yrs since 
diagnosis) 
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Participants discussed and reflected on their diagnosis, in particular that this was a time when 
they had come to terms with and accepted it. This was prompted by their experiences 
surrounding their most recent admission. 
P: “I just sort of accept it every day and get on with it. I didn’t sort of dive into it and 
analyse it and think shall I do this, shall I do that. I just take each day as it comes and hope 
for the best [laughs].” (P2: IG, Female, 6 mths since diagnosis) 
P: “I think because as I say I was diagnosed about 7 years ago and I’ve always resisted the 
diagnosis, this time my admission was so bad and also a beloved dog of mine got killed on 
the road and therefore I suppose I’ve more or less accepted it and also the, when I was an 
inpatient the Psychiatrist I had whose name was [name], was quite good, so it was easier 
to accept it you know and the consequences of me being ill were so, well nearly horrific, 
and I never want it to happen again. “(P3: TAU, Female, 7 yrs since diagnosis) 
P: “I’ve just been diagnosed with bipolar, I think I’ve had it since I was a teenager, actually 
it’s, I might not like a label, but it’s good to know cos now I know what I am dealing with 
and I feel more optimistic about the future because I’ve got different medication and 
hopefully I won’t have these great lows where I go into hospital’. So for me it feels a very 
positive thing to have the diagnosis, or the correct diagnosis.” (P7: IG, Female, 1 mth since 
diagnosis) 
P: “I guess I have been manic and I think back to me and it does describe me I suppose and 
then a big part of it is acceptance. I’ve had to accept being in hospital in the first place.” 
(P1: TAU, Male, 6 mths since diagnosis) 
 
The impact of the bipolar diagnosis for those newly diagnosed– confusion or explanation 
Two participants interviewed were newly diagnosed having had a previous diagnosis 
respectively of schizophrenia and severe depression. For one, she felt no different to how she 
had felt before and so having a different label did not make sense for her. For the other, 
having the bipolar diagnosis helped to explain her experiences both to herself and her family 
and had a positive impact in terms of her relationship with her family. 
P: “I don’t feel any different to how I felt when I was schizophrenic. I don’t feel any different 
now I am bipolar. They are telling me I am bipolar, which was a bit confusing at first.” (P2: 
IG, Female, 6 mths since diagnosis) 
I: “Can I ask, was that since the diagnosis of bipolar, had things changed?” 
P: “I think my family suspected it before it was diagnosed, and they saw me when I was 
well and the hospital didn’t so for them it was confirmation or validation and so I think it 
has been quite positive in that respect.” (P7: IG, Female, 1 mth since diagnosis) 
I: “Your family are trying to make sense of the new diagnosis.” 
P: “It probably makes them more compassionate, because some of my behaviour’s been a 
bit off the wall. Now they’ve got an understanding of why that might have happened.” (P7: 
IG, Female, 1 mth since diagnosis) 
I: “So in that way the diagnosis itself has been of some help.” 
P: “Yeah. You know it’s that kind of ‘ah-ha! oh God, that’s why that happened, that’s why I 
haven’t managed to keep down a job or have a successful relationship, or whatever’, 
because I’ve had these periods of severe episodes, which I wasn’t hospitalised for but 
maybe I should have been (laughs). So it kind of makes sense of a lot of my journey, if you 
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like, so for me that is quite empowering, rather than disempowering.” (P7: IG, Female, 1 
mth since diagnosis) 
She also reflected on the consequences of her illness in terms of her employment history, she 
now understood why she had been unable to work at particular periods which she had 
attributed to stress, but now understands this was periods of severe depression. 
P: “My mental health is why I am self-employed. I kept becoming unwell and losing jobs 
and I felt like being self-employed was the answer as I could work when I was well and take 
time out when I wasn’t but not really understanding that it was anything more than stress. 
I thought it was just stress.” (P7: IG, Female, 1 mth since diagnosis) 
 
Previous experiences shape personal model of illness 
Learning from the IBiD intervention about the different ways that mania can be characterised 
was a revelation to one participant. Her personal model of bipolar, was that highs were always 
periods of elation with consequences such as spending large amounts of money. She did not 
characterise the times when she was working constantly and being very confident as signs of 
mania, but just as a return to normality. For the second participant, she had a model of bipolar 
based on her mother who has the diagnosis so she was able to relate her experiences to those 
of her mothers and the diagnosis made more sense for her. 
P: “I’d never thought of myself as bipolar because I’ve never had great periods of elation, I 
have more of the depression so I’ve always thought I was depressed and well and not 
depressed and well and elated and well. I didn’t see that so I could identify with some of 
the mania, not all of it, I don’t think I have it in the extreme form. And I think that’s why it’s 
been so difficult to diagnose. Because I’ve just thought of it as ‘oh I’m back on top of it, I 
can get things done’. But actually I was like overdoing things and taking on far too much. I 
would have described it more as over confident and no confidence whatsoever. Fluctuating 
between those two places and they are self-sabotaging because I would start a project in 
the confident place and then become unwell as think what the hell am I doing, I can’t do 
this!” 
I: “Some of those classic signs of mania, actually there are a wide range of symptoms of 
highs.” 
P: “Well I’ve been asked before, do I go out and spend lots of money, well no I don’t 
because I don’t have it. Perhaps if I had it I would, but that’s never been an issue for me.” 
I: “Being able to identify some of the other experiences you had been having..” 
P: “Yeah and just being over busy and filling every second and talking far too quickly and 
getting excited and passionate about things. But I didn’t ever see that as anything anybody 
else wouldn’t do. It just felt like a return to being not depressed.” (P7: IG, Female, 1 mth 
since diagnosis) 
P: “Right, well the first time I was diagnosed was probably when I was 19, it was with 
depression and elation. They didn’t really say ‘you’ve got bipolar’. I don’t know really if it 
was that clear, that that was definitely what I had. And my mum has manic depression, or 
bipolar as well. So I had a little bit of an idea of what happens when you do and when you 
go high or a bit low, because I’d seen her going into hospital.” 
I: “In your experience, it didn’t come completely out of the blue?” 
P: “No.” (P6: TAU, Female, 13 yrs since diagnosis) 
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7.4.2.2.3 Unmet information & support needs 
‘On the ward’ is a key time of unmet information need 
The ward was seen as a key time to provide information and support. Information is not 
routinely provided in participants experience and this could leave them feeling unsupported 
and uninformed when they were discharged. These unmet needs included information about 
medication but also about BD itself. Even those who reported receiving information reported 
that it was insufficient, or that they would have liked the opportunity to discuss the 
information with a health professional. 
I: “Can I ask about the information you received about medication?” 
P: “I don’t think it was that brilliant to be honest.” 
I: “Did you get given anything?” 
P: “No flyers, leaflets that were inside the tabs really.” 
I: “Just the standard information?” 
P: “Yeah.” (P6: TAU, Female, 13 yrs since diagnosis) 
I: “You hadn’t got much on the wards.” 
P: “No, no, I never have done when I’ve been on the wards, unless, unless I’m in a well 
enough state to ask. But yes, I’ve never had any information about medications on the 
wards.” 
I: “It’s not routinely provided?” 
P: “Yes, (not) for me personally.” (P5: IG, Female, 10 yrs since diagnosis) 
P: “I’m sorry, you don’t really receive much information in hospital, certainly I hadn’t until 
that point.” (IG, Female, 2.5 yrs since diagnosis) 
P: “Yeah I mean that’s one of the things that is lacking as an inpatient [information about 
medication], let’s leave that aside [during discussion about IBiD].” (P3: TAU, Female, 7 yrs 
since diagnosis) 
I: “Were you given new medication this time in hospital?” 
P: “Yes, I was.” 
I: “In terms of getting information about those new medications?” 
P: “Dr [name] actually gave me a sheet with the medication listed and possible side effects 
etc etc, but nobody actually went through it with me.” (P3: TAU, Female, 7 yrs since 
diagnosis) 
I: “Would it have been useful to have information when you are on the wards? 
P: “Erm, yeah actually it would. Because the only information I got was about the 
medication and a two-page thing about bipolar disorder and the different types.” (P7: IG, 
Female, 1 mth since diagnosis) 
I: “Did you ever get information about your medications from the hospital?” 
P: “The stuff written down on bits of paper, on sodium whatever, but overall there was like 
blank bit missing with the whole subject [the subject of bipolar itself].” (P1: TAU, Male, 6 
mths since diagnosis) 
 
Following on from these areas where information was felt to be lacking, participants 
recommended that more information should be provided on bipolar, medication including 
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side-effects and different doses, disclosure of mental health diagnosis in the workplace. It was 
also recommended that more psychological support should be provided on the ward. 
P: “Probably just a little bit more information about bipolar, I think there were some 
leaflets on the ward, could be better I think.” (P6: TAU, Female, 13 yrs since diagnosis) 
P: “No one seems to know what this thing is, what this monster.” 
I: “You were given information about medication, but not about what bipolar is or what it 
means..?” 
P: “Pretty much yeah, it’s the new manic depression, I suppose that’s enough to know. I 
don’t know.” (P1: TAU, Male, 6 mths since diagnosis) 
P: “But if I was applying to go back into the labour market and I was filling out an 
application form, what do I disclose, that’s still a question for me.” (P7: IG, Female, 1 mth 
since diagnosis) 
P: “I don’t know, for example what the alternatives are to Mirtazepine, that would be quite 
useful for me to know, to make an informed choice. And what the side effects of each of 
those are. And also short term effects compared to potential long term effects.” 
I: “Side effects that you might expect when first taking medication versus if you are on 
medication for some time. That’s not been 100% clear?” 
P: “No, I don’t feel that has been clear, and it was all very new and I trusted the doctor and 
they’ve put me on this and I don’t know what the alternatives are and I also don’t 
understand about the dosage and you know, how they decide what dosage you are going 
to be on.” (P7: IG, Female, 1 mth since diagnosis) 
P: “Yeah, I always thought it would be good to have some sort of information or therapy 
during the time when you are on the wards really. Or some sort of counselling. Because you 
are sort of left and then you get out into the community you just kind of left a little bit 
without... […]” 
I: “It might be time on the wards that would be a good opportunity to provide some 
support?” 
P: “Yeah.” (P6: TAU, Female, 13 yrs since diagnosis) 
P: “I mean when it’s supposed to be a psychiatric ward and yet you don’t have any 
psychological support when you are actually in there. It is a shame and the only time, well 
it depends on the nurse, is when you are getting your medication. You’ve any chance to ask 
anything. I don’t know what they are doing with these computers, it would be much better 
if they were interacting with the patient.” (P3: TAU, Female, 7 yrs since diagnosis) 
 
Participants’ recommendations on when information should be provided demonstrate that it is 
important to receive information when on the ward, to have someone take the time to explain 
bipolar, symptoms and treatments as illustrated by the following narrative. 
I: “If you were going to recommend what would have been useful in terms of information 
or anything you still feel you could receive more information on about bipolar or 
medication?” 
P: “I think it would help in the ward when you are admitted, unless you are a long term 
bipolar patient, I mean I was never ill until 7 years ago. If someone would, trained staff, or 
somebody would sit you down and even after the acute stage when you come in and 
explain exactly what has happened, why it has happened, I mean to a degree, they may not 
know but the contributing factors and have a chat and explain exactly what bipolar is I 
think that would definitely be. I think also to say to people ‘well what help can we gave to 
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you?’. You know, we are here for you to talk to etc. I think staffing issues but it would be 
great if they had the time or the inclination to do that. Because I think you are totally 
ignorant as to what exactly it is. Unless you have had it for years and years.” 
I: “That’s crucial to get that information.” 
P: “When you have come out of that acute stage, you are with it, well as with it as you can 
be. It would be very, it doesn’t have to be the whole thing in one session but if that was 
continued until both parties were happy with it, it would be great. Because otherwise you 
are going in, you are given the knockout pills and then you get better than then you come 
home.” (P3: TAU, Female, 7 yrs since diagnosis) 
 
However, one participant felt that information should be provided once you are at home and 
able to concentrate better. 
I: “Being provided with information when you are in hospital. When is the best time?” 
P: “I think it is best back at home. Better able to concentrate really.[…] For me personally, 
when you are on a one to one, in your own space where it’s a bit quieter.” 
I: “It’s important to be in your own space.” 
P: “Yeah, yeah.” (P5: IG, Female, 10 yrs since diagnosis) 
 
Waiting until discharge might be more practical in terms of when to provide information as 
participants were aware of how quickly discharge occurs after you show signs of illness 
improvement. 
P: “GPs might be a point where that information could be given as well, because discharge 
is very quick as you know, as soon as you show the slightest signs of recovery you are out! 
Because they haven’t got the beds so care is handed back to the GP.” (P7: IG, Female, 1 
mth since diagnosis) 
 
Illness impact on help seeking 
A couple of participants acknowledged that the nature of their illness itself has an impact on if 
and how they might seek information or support for bipolar. 
P: “Trouble is that sometimes depending on what way it goes and you get ill you are 
reluctant to seek help and I think for me personally if you become aware of it, because you 
are not always aware of it. But after this particular incident I have kind of identified the 
triggers and seek help as quick as you can.” (P3: TAU, Female, 7 yrs since diagnosis) 
P: “[…] one thing with me is that I find it really difficult to speak, to communicate when I 
am unwell. When I am in the depths of severe depression or anxiety state and can barely 
get my words out.” (P7: IG, Female, 1 mth since diagnosis) 
 
Useful information sources 
Information sources which people have used or feel confident in knowing they could provide 
the information needed included participants Community Psychiatric Nurse (CPN), Psychiatrist 
and books. 
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P: “I would turn to my support worker.” (P5: IG, Female, 10 yrs since diagnosis) 
P: “Yeah, my CPNs have downloaded information and printed it out and given it to me 
before.” (P6: TAU, Female, 13 yrs since diagnosis) 
P: “Well, I usually ask my psychiatrist, I feel like, he could tell me that really.” 
I: “So if you had any concerns you could discuss it with your psychiatrist?” 
P: “Yeah, I can discuss it with him or I can discuss it with the social worker that I see.” (P6: 
TAU, Female, 13 yrs since diagnosis) 
P: “I’m just going to read that book [Bipolar survival guide] and then there was another 
one with quite similar title that people have recommended, I think it might be 
recommended in your information booklet. I might get that as well.” (P7: IG, Female, 1 mth 
since diagnosis) 
 
7.4.2.2.4 Healthcare experiences and recommendations 
Anxiety about access to care and support 
Participants described the care they had been receiving since being discharged from hospital. 
Although they were able to describe the support they were currently receiving, when they 
reflected on this, there was a sense of anxiety about getting access to the support they might 
need. One participant felt there was a pressure to be discharged quickly which she was not 
ready for. 
P: “I think the difficulty arises then of getting an appointment. My appointment with him is 
for 3-4 months later and it was at half nine and I’m not good at getting up early. It was said 
to me if I didn’t take that appointment it would be a long time before I could get one again. 
I think the system is if it is an urgent appointment it can be got. That’s the best way in 
terms of doing it. I think the CPN, if mine is off, there is a duty CPN.” (P3: TAU, Female, 7 yrs 
since diagnosis) 
P: “Yes and probably to a degree trying to get it [support] , and against that, it sounds a 
contradiction, when I mean, they are restricted budget wise and time wise, like the CPN is. 
But I think the level of support would be great if you could get more of it, it’s not their fault, 
it’s the system if you want to call it that.” (P3: TAU, Female, 7 yrs since diagnosis) 
P: “I mean, I feel like my doctor, there is a sort of slight, lack of clarity about who is 
prescribing the medication and when it gets formally handed back to your GP if you like. I 
felt a slight hesitance with my GP as to whether she might be stepping on the Psychiatrists 
toes if she changes the medication. So that’s a slightly grey area really.” (P7: IG, Female, 1 
mth since diagnosis) 
I: “And then once you were well, you were discharged.” 
P: “Yeah, exactly (laughs) as soon as you show any signs of recovery you are out the door. I 
had to insist that they didn’t discharge me for a week and they said ‘oh we are going to 
discharge you’ and I said ‘that’s ridiculous, I haven’t even been home’, so I refused to be 
discharged, and made them wait a week until I was ok at home before I was formally 
discharged.” (P7: IG, Female, 1 mth since diagnosis) 
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Reflections on previous and current care 
Participants described a range of difficulties they had experienced with care received both 
previously and in relation to their most recent admission. For one participant she described a 
number of difficulties experienced, including prescribed inappropriate medication, staff not 
having the time to focus on her care and a lack of support. 
P: “And, for example, last time as an outpatient, Dr [name] was one of the psychiatrists, 
overprescribed lithium for me and I ended up in a coma in the general hospital, so I’ve had 
bad and good.” (P3: TAU, Female, 7 yrs since diagnosis) 
P: “There was an office, you had to knock on the door and wait, you had people going by all 
the time so you were lucky even if you got to the door to, it should have been in private, but 
you had to ask in an open corridor and I was in for quite a long time and I heard a patient 
say to one of the auxiliaries, ‘oh can I have a chat with you later?’. And I thought ‘oh my 
goodness you can do that!’ I hadn’t realised you could do that.. “ 
I: “You weren’t told.” 
P: “No, and apart from the odd trained staff it was more medication time or something, 
you might have a question. But I really did, any information, on bipolar or that was very 
scant it was even worse than 7 years ago.” (P3: TAU, Female, 7 yrs since diagnosis) 
P: “I mean when it’s supposed to be a psychiatric ward and yet you don’t have any 
psychological support when you are actually in there.” (P3: TAU, Female, 7 yrs since 
diagnosis) 
 
Two participants described the status of the Consultant Psychiatrist on the wards and how 
they were detached from the actual patients and their time spent understanding the individual 
patient was limited. 
P: “But I do feel that it runs from the Psychiatrists down and the Consultant Psychiatrist is 
God and these poor front line staff who know you better than anyone, although they keep 
copious notes, does the Psychiatrist actually read them, they don’t have time!” (P7: IG, 
Female, 1 mth since diagnosis) 
P: “I don’t know if you are aware of the ward rounds. It’s it was built up to such a thing as if 
God was coming round, and in that process when you are actually in with the consultant, 
they don’t have the time to go into a lot of what is wrong.” (P3: TAU, Female, 7 yrs since 
diagnosis) 
 
Despite some poor experiences, participants commented positively on their involvement in 
their own care now, compared to previous experiences, for one the experience after 
discharge, and for the other the experience in hospital. 
I: “You mentioned you being involved in the decisions, has this got better?” 
P: “On Friday the psychiatrist I saw, it was a lot better than what it had been 7 years ago, 
there was more give and take, definitely, more explanations given.” (P3: TAU, Female, 7 yrs 
since diagnosis) 
I: “How does that feel? Does it feel you are an active part?” 
P: “Yes it did actually to be fair to the hospital, they’re looking for feedback all the time, 
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how you are doing, and they do change it. What do they call them, the rounds they have 
every week. They do ask for lots of feedback and they do make adjustments.” (P7: IG, 
Female, 1 mth since diagnosis) 
 
However, one participant reflected on how medication is seen as the one way to stay well and 
so although you may be involved in care and treatment is voluntary, you are still under 
pressure to take medication. 
P: “it’s played out in the hospital as if that’s the only thing to get you better really. That you 
must take your medication and that’s the bottom line and although its voluntary if you are 
not sectioned, there is a very strong pressure to take the medication and you know, you are 
considered an idiot if you don’t take it (laughs).” (P7: IG, Female, 1 mth since diagnosis) 
 
 
7.5 Discussion 
7.5.1 Overview of findings 
The findings from this qualitative evaluation identified themes related to research 
participation, both in acceptability of the IBiD intervention and RCT protocol and in wider 
aspects of mental health, namely understanding illness and treatments and reflections on 
mental health care. There are a number of themes which link and corroborate the findings 
from Chapter 4 from participants who were recruited from a community-based treatment 
population as opposed to those in acute treatment in the IBiD study. 
Unmet information and support needs were a key theme in this evaluation, motivating 
participation in the study. These relate to finding out more for themselves but helping others 
in the future to have better access to information. In terms of timing of provision, the inpatient 
time was a challenging but equally important time to be allowed to participate in research and 
receive information. Participants identified benefits to taking part in the study, having the 
opportunity to talk and being prompted by the intervention to take actions and to better 
understand the experiences they have as part of their illness. 
Wider issues raised in the interviews were that participants found it hard to accept the need 
for long-term medication. They reflected on challenges with the inpatient environment in 
getting information they needed and being involved in decisions. The findings indicate that 
care is not always provided in accordance to recovery-focussed care. Factors which support 
recovery include developing good relationships with care providers, being listened to and 
having their beliefs respected and having the opportunity for personal growth (Jacob, 2015). It 
was clear that people felt that their beliefs were not always acknowledged during their care. 
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The research gave them the opportunity to speak and have their views valued. In order that 
people have the full opportunity to be involved and empowered to participate in their care, 
they need their information needs to be met (NICE, 2014) and this was not always the case for 
these participants. The intervention helped to meet this unmet need. 
 
7.5.2 Research participation 
Participants’ decisions to take part were based on both a desire to improve services and give 
back for care received and also desire to get more information about their diagnosis and 
treatment. This emphasises the unmet information needs of people with BD in the acute 
mental health setting, reflecting the findings from the community-based research in Chapter 4. 
People do not appear to have the opportunity to learn about and explore their diagnosis, 
which is not consistent with recovery-focussed care. 
In terms of decisions to take part in research, these findings concur with previous studies in 
mental health. Zullino and colleagues (2003), found that three-quarters of patients in an acute 
mental health setting would hypothetically be willing to participate in a study which would 
involve follow-up after discharge, their desire to participate was led by a desire to progress 
science and help other patients. These desires have also been reported in real trials as 
opposed to hypothetical participation studies (Woodall, Howard, & Morgan, 2011). The 
present evaluation included participants who had both declined and agreed to take part in the 
trial. The finding in the study by Woodall and colleagues that the research gave them a sense 
of purpose and something to get up for agrees with the findings in the IBiD evaluation 
(Woodall et al., 2011). Given the potential positives of and the enthusiasm for research 
participation it is important that people have the opportunity to take part in trials. However, a 
survey by the NIHR Clinical Research Network found that only 21% of people surveyed would 
feel confident in asking about asking their clinician about research opportunities. As a 
response to this, the ‘OK to ask’ campaign encouraged patients and carers to ask about 
research opportunities (NIHR, 2015). Initiatives like this should mean that the enthusiasm for 
research participation is translated into greater numbers of people being involved. 
We found that recruitment in hospitals was an acceptable time for patients, but flexibility must 
be allowed for completion of baseline and interventions both in their location and timing. This 
concurs with findings from Zullino and colleagues (2003) described above about hypothetical 
participation in a study which would involve follow-up after discharge. In the present study, 
this time appeared to be appropriate for participants who reported that it was a time of 
information need, relevant due to their recent admission, they had the time to take part in the 
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research and were potentially able to explore treatment options for after discharge. However, 
recruitment in this setting needs to be carefully judged as potential participants may still be 
too ill, or they may be more comfortable participating in their own home environment and 
some may like the detachment from the hospital/ healthcare system. This reflects findings in 
Chapter 4 that having an acute episode should not preclude the option to receive information 
about what is going on for them and what treatments they are taking, however this needs to 
be carefully judged. Due to the speed that discharge can occur once participants’ illness 
improves, although recruitment is practical in the ward, after discharge may be better to 
provide information as there is more time to do this. Short hospital stays are increasingly 
common with the aim of inpatient treatment being crisis management and ensuring patient 
safety (BBC, 2014; Glick et al., 2011). Woodall and colleagues qualitative research around 
participation in a psychosis trial also revealed that timing of approach is important and may act 
as a barrier to participation if it is inappropriate (Woodall et al., 2011). 
 
7.5.3 Positives of taking part – both in IG & TAU 
The actual research process appeared to confer some self-reported benefits for participants, 
which was not anticipated. Participants found the process of completing the questionnaires 
interesting and it helped them to reflect on BD and this was the case in both groups. This 
concurs with other research where completing the questionnaires normalised mental health 
issues for participants (R. Byrne & Morrison, 2014). The questionnaires covered topics they 
had not been asked about before and revealed potential symptoms and side-effects which 
they had not been told about. Despite some having a long standing diagnosis, participants 
report not having received information on their condition. This could have significant 
implications for people, for example not being able to recognise early signs of illness episodes 
and not having information on potential medication side-effects, and what to do in the 
eventuality that they experience them. This concurs with previous research identifying unmet 
information needs in the mental health setting (Bowskill et al., 2007; Care Quality Commission, 
2009a, 2011a; Morselli & Elgie, 2003). 
Benefits from research participation alone have been reported in a number of studies in 
mental health. A qualitative study alongside an early intervention in psychosis trial reported 
that participants found having the opportunity to open up and for some it was the only 
opportunity they had to actually speak about their experiences and concerns (R. Byrne & 
Morrison, 2014). Woodall and colleagues (Woodall et al., 2011) found that some participants 
reported that speaking to a researcher was beneficial and different to discussing problems 
with a clinician. The researcher may be seen to be more interested in the participants’ beliefs 
254 
and experiences and see value in them. Clinicians may be viewed as interpreting their 
experiences in the medical model of illness. Perhaps participants felt there may be 
consequences for their own care in disclosing beliefs and behaviours not consistent with the 
clinician expectations. 
The helpful and potentially therapeutic effects of completing the questionnaires themselves 
should be explored as it could provide a quick, efficient way to raise important issues for 
patients in clinical practice which could be shared with care teams. This was also noted in 
qualitative research by Pollack and Aponte (2001) who found that interviews served to raise 
new issues for patients to consider and allowed then to speak openly about them. The authors 
also point out that this method would be useful for raising issues which would be of value for 
discussion with their care team. 
 
7.5.4 Challenges with understanding - completing the questionnaire & the research process 
Feedback from participants revealed important insights into how the study was communicated 
and the acceptability of the questionnaire. Some participants reported that the questionnaire 
at times could be confusing or the language used was not clear. Participants did not always 
feel there was a space for them to write exactly how they felt in the questionnaire and 
questions at the baseline were not always appropriate to the inpatient setting. Cognitive 
interviewing or think-aloud studies could be used to identify the specific problems with 
understanding and where participants would want to add additional views or response items, 
and to ensure that they are fully valid in a mental health context (van Oort et al., 2011). 
Participants’ ability to concentrate and engage with the research was affected by their mood 
state and side-effects affecting their cognition. The flexibility of completing the questionnaire 
over two sessions allowed participants who would have been unable to concentrate for long 
periods the opportunity to take part. In addition, having support from the CSO was seen as 
vital for some, they reported finding completing the BMQ and MARS repetitive for each of 
their medications so the assistance helped them get through it. Research has shown cognitive 
deficits including verbal memory, attention and executive function can occur during 
symptomatic periods of illness (Quraishi & Frangou, 2002). This concurs with an evaluation of a 
psychoeducation programme where participants reported that their mood affected their 
ability to engage with the course by affecting their concentration, enthusiasm and ability to 
focus (Poole, Simpson, & Smith, 2015). 
In future studies it would be important to ensure that the process of the research was 
effectively communicated to participants. TAU participants who, as they received fewer 
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contacts, were not always sure of the process and when their next contact with the research 
team would be. Although being assessed as having the ability to consent at each time point by 
their care team, this does not preclude the chance that their memory for specific details may 
lapse and need to be refreshed. 
 
7.5.5 Acceptability of the study – practical arrangements 
Practically the study was acceptable to participants, for example, arranging appointments and 
suitable locations to meet. Overall, there was positive feedback on the process of taking part. 
Participants commented positively on the approach of researchers including the flexibility and 
respectful attitudes, this appears to be a key part in maintaining participants’ engagement. The 
research team are viewed positively where they maintain empathy, informality and 
professional understanding around the personal and potentially difficult disclosures involved in 
mental health research (R. Byrne & Morrison, 2014). Lessons can be learned from this as to 
what is valued by patients in mental healthcare. Recovery-focussed care which values patients’ 
perspectives and is flexible to acknowledge and respond to their fears, needs and goals would 
clearly be viewed positively by patients (Jacob, 2014). 
 
7.5.6 The IBiD intervention 
The intervention was commented on positively in the qualitative interviews and participants 
were able to benefit from it depending on their needs and priorities (information, reassurance, 
prompting into finding out more, tracking moods etc.) and used it in different ways. Having 
written information was a good way to receive information and having the flexibility to speak 
about it, reflect in their own time or raise issues with their care team confirm that this delivery 
method was acceptable. The ward environment is a time of information need, but people are 
often not given information at this time. In Chapter 4, participants described how they did not 
receive information when they needed it. 
Self-reported actions taken after the intervention were; investigating different medication 
options, finding out more about BD and monitoring mood. Participants also reported feeling 
reassured by the information about symptoms and side effects. One participant felt that the 
information about the different ways that mania can be characterised was extremely useful 
and helped her to identify her own personal prodromes of mania. These outcomes reflect 
those reported in a qualitative evaluation of a group psychoeducation programme in the UK, 
where participants reported that mood diaries were useful and the content of the programme 
helped participants to better understand the symptoms of BD and provided information on 
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medication which they felt was lacking from their care (Poole et al., 2015). A pilot study of a 
web-based intervention in BD found self-reported impacts on insight into illness, health 
behaviour, personal routines and positive attitudes towards medication (Poole, Simpson, & 
Smith, 2012). 
The self-completion exercises had only been used by one participant interviewed, another 
remarking that she planned to go back and look at them. It could be that an additional 
appointment in person or over the telephone with the researcher might prompt use of these 
exercises. The mood charting exercise was commented on positively, with a couple of 
participants finding this useful for visualising their moods. 
 
7.5.7 Broader aspects of mental health raised in the interviews 
The interviews raised additional issues which participants wished to discuss about their views 
and experiences about the diagnosis and treatment and the care they have received. 
For some participants there was still some confusion and difficulties with accepting the long-
term need for medication, for example the need for an ‘anti-psychotic’ when not actively 
psychotic. This reflects the challenges reported in Chapter 4 by participants in agreeing with 
the need for medication when they were not acutely ill. This adds weight to the premise of the 
extended model of self-regulation (Horne & Weinman, 2002), whereby the identity of the 
medication did not have a common-sense fit with symptoms. There was a lack of 
understanding that this medication was prescribed to help prevent mood episodes as opposed 
to just treating periods of psychotic symptoms. Participants’ narratives also supported the idea 
of personal models of their illness, part of the CSM (Leventhal, Brissette, & Leventhal, 2003). 
One participant described how her model of mental illness was formed by witnessing her 
family history of illness, others’ models were influenced prior diagnoses of schizophrenia and 
severe depression. 
Ambivalence was clear in the narratives of participants. The messages in the IBiD intervention 
may not have fully addressed medication concerns for individuals. There appeared to be a 
strong desire in two of the individuals interviewed in the qualitative evaluation to be 
medication free in the long-term although understanding the need for it to get well during and 
after a hospital admission. Participants in an adherence therapy for psychosis study also 
acknowledged benefits of medication in stabilising them and therefore having a positive effect 
on their lives. However, they still felt that there was an over-emphasis on medication and 
participants still had concerns about taking it (E. Brown, Gray, Jones, & Whitfield, 2013). These 
beliefs are important personal views of medication and clinicians need to acknowledge and 
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work with them rather than against them. Indeed, one participant still had concerns about 
medication but had been prompted to find out about a medication which, for her, had on 
balance, more advantages than disadvantages. This provides support for the recovery model 
and the importance of being actively involved in treatment decisions as recommended by NICE 
guidelines for BD (NICE, 2014). Participants in Chapter 4 also described the need for trialling 
different medication to find the right treatment, but report that this process was not always 
well communicated or straightforward. 
Participants’ narratives included their experiences with mental health services and provide a 
narrative on the extent to which the recovery-model is implemented in current care and 
therefore a number of implications for service provision. Participants expressed their 
difficulties with the transition period between services and how any medication changes were 
decided upon and arranged. This difficulty between changing from the care of mental health 
services to primary care was reported in a qualitative study by Gale and colleagues (2012). In 
addition, Jones and colleagues (2009) found that people found transitions confusing, they 
disliked the difficulties presented in building relationships with providers due to changes and 
found that communication gaps meant that personal or care changes were not always 
communicated. Participants in the IBiD evaluation had mixed reports of moving medication 
prescribing from psychiatrists to GPs. Challenges faced were when GPs did not get the 
information that medication or dose changes were needed, or GPs were reluctant to interfere. 
Participants commented about their uncertainties around how medication-related decisions 
are taken in mental health. They felt that HCPs had not fully informed them of the 
uncertainties around medication decisions and the need for trialling different options, this also 
reflects the reports of participants interviewed in Chapter 4 who reported feeling like an 
experiment and that medications were just tried out without a real strategy. Participants in 
this evaluation also expressed anxiety about ongoing access to care and where and how to get 
the support they might need. This demonstrates clearly that there is a long way to go in 
ensuring everyone receives recovery-focussed care. A key aspect of care in line with the 
recovery model is empowering people to be active and informed partners in their treatment 
(Davidson, 2005). If patients feel like an experiment, it is clear that they have not had an active 
role in decisions. 
We found some support for the inpatient setting being an appropriate time to start to provide 
information. There were unmet information needs, as for some they were newly diagnosed 
and needed information about BD and new medications were prescribed. Even when 
information had been provided, participants reflected that they would have appreciated the 
opportunity to discuss it. Time with their Consultant Psychiatrist was particularly limited, with 
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participants describing the ward rounds and the hierarchy of clinicians. This hierarchy was also 
described by Happell and colleagues (2004) that in inpatient settings the psychiatrists were not 
approachable even by the nurses. Sweeney and colleagues (2014) also report on how the 
inpatient time is difficult for developing therapeutic relationships, in part due to the loss of 
liberty. 
Satisfaction with ‘care information’ as an inpatient has been shown to be associated with 
participation in treatment after discharge from hospital (Bowersox, Bohnert, Ganoczy, & 
Pfeiffer, 2013). Care information included involving patients in decisions about their care. The 
authors hypothesise providing more information and opportunities for involvement in care 
decisions during an inpatient stay may reduce the risk of nonadherence to subsequent 
outpatient appointments’ (pg 561). 
Previous research has revealed individuals felt some medication information was deliberately 
withheld by doctors, for example side-effects. When not informed, they were then not 
prepared when side-effects occurred, did not know how to manage them and this resulted in 
patients making dose changes without informing their clinicians. If participants felt better 
informed, they were more inclined to ask questions, voice concerns and thus felt more 
involved in their treatment (Happell et al., 2004). Patients interviewed by Duxbury and 
colleagues (2010) also reported information they were provided with about medication tended 
to mostly be about the therapeutic effects and not the possible side-effects. 
A review of inpatient care found that patients accepted the need for medication as part of 
their treatment, but had not been provided with education about medication or side-effects 
and there was a lack of involvement in treatment planning. Discharge planning involvement 
was another common theme of research included in the review. Patients wished to be 
involved in planning, informed about arrangements and needed better continuity of care 
between inpatient and outpatient providers. Early discharge was a factor in difficulties 
experienced after discharge (Hopkins, Loeb, & Fick, 2009). 
Patients’ need for information is likely to extend beyond the inpatient setting. This may be due 
to changes to medication after discharge, moving from treatment to stabilise someone after 
an acute episode of illness, changing to prophylactic treatment. In line with the recovery 
model, patient’s own perceptions of treatment, their priorities and goals may change and 
along with this, information provision and support should continue after discharge. As 
mentioned, more work is required to determine if concerns about medication can be 
assuaged, or whether actually finding the medication with least concerns and providing 
accurate information about side-effects may be more effective. 
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7.5.8 Limitations 
This qualitative evaluation provides important insights on the RCT protocol and intervention, 
however, the findings must be interpreted in light of some limitations. 
The qualitative study was limited by only including seven participants, due to delays in 
processing the ethics submission it was not possible to return to participants who had 
participated early on in the study. The results from these participants may then not fully 
generalise to those recruited at the outset of the study. We cannot be sure more themes 
would not have emerged, had we interviewed more participants. However, the reflections and 
feedback provided from each participant provide valuable lessons for assessing the feasibility 
and acceptability of the study. 
The results are also only from participants who were retained at follow-up. However, the 
reasons for withdrawal were frequently due to illness relapse (Chapter 6), therefore it was not 
appropriate to contact those who had withdrawn to invite them to participate in the 
qualitative interviews.  
Participants often found it difficult to recall specifics about the questionnaires or the 
interventions to provide more detailed feedback. Byrne and colleagues (2014) reported 
participants in their qualitative evaluation of an early intervention trial also found it hard to 
recall details of the study, however, they could describe aspects which were helpful to them. 
This recall difficulty could be addressed by providing participants with copies of the materials 
during the interview to prompt their memory. 
The interviews took place up to a couple of months after participants had been recruited to 
the study, therefore are subject not only to recall effects, but also to participants reflecting 
back on the process. Participants’ reflections on decisions, for example, may not accurately 
represent how they felt at the time, but may be affected by subsequent experiences. 
Finally, participants may have been unwilling to give negative feedback on the study due to the 
researcher conducting the intervention sessions also interviewing the participants. Participants 
were encouraged to provide frank and honest feedback as this was a feasibility study with the 
aim of making improvements. However, they may have been unwilling to do so. 
 
7.5.9 Conclusions 
The qualitative evaluation indicated the IBiD RCT was acceptable to patients. There was a clear 
need for information, with participants expressing that the decision to participate was led, in 
part, by the desire for information about BD and treatment. Some had a recent diagnosis and 
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they needed information, and others felt that they had the time to explore medication 
options. It was acceptable to participants to approach them whilst in hospital, but only once 
their mood had stabilised and to allow for flexibility in how the different stages of the research 
are conducted, in timing and location. 
Valuable aspects of research participation were reported by both those receiving IBiD and 
those assigned to TAU. The research provided both an opportunity for reflection about the 
diagnosis and their experiences and to speak about these with the research team. In addition, 
even the questionnaire provided insights into symptoms and side-effects, helping to explain 
some of the experiences they had been having. This potentially therapeutic effect of assisted 
questionnaire completion could have implications for clinical care, opening up communication 
between patient and clinician which could have an influence on treatment decisions. 
The questionnaires used in this study could potentially be modified through cognitive 
interviewing or think-aloud studies. This evaluation revealed participants could be confused by 
the response categories and felt it did not always incorporate the full range of their views and 
experiences. This would ensure outcome assessment for future studies evaluating an 
intervention of this kind would have higher levels of validity to BD. The importance of allowing 
flexibility in questionnaire completion and in having the CSO to help with both motivation and 
concentration was clear. 
The IBiD resource itself was used flexibly according to participant need and priorities, they 
reported using the information on medication and symptoms of BD, mood monitoring exercise 
and sources of additional help. One participant found it useful to have the facilitated session 
and one preferred to read it through on her own. The resource prompted one participant to 
change to a medication which better fitted with her needs and preferences. In the future the 
intervention could benefit from having additional follow-up sessions and assistance in working 
through the exercises as there was not time to cover these in the single session. 
By including participants in both groups in the qualitative evaluation the potential therapeutic 
effects of research participation and how the randomisation process was accepted can be 
assessed. Both groups reflected positively on the process of the study, particularly in how 
arrangements were made which were sensitive to participants needs and the assessments and 
intervention contacts were conducted respectfully. Maintaining these positive relationships 
may have been the key factor in maintaining participants’ engagement with the study. This has 
implications also for engagement with treatment. Care providers developing and maintaining 
good relationships with patients could help to facilitate engagement with treatment including 
adherence. 
261 
As well as providing important feedback on the feasibility RCT, participants’ reflections provide 
insight into the application of models of illness and adherence in mental health as well as 
reflections on the care process itself. It is clear that the transition period between acute 
services and community-teams can be associated with not only medication changes, but 
potential confusion with the care pathway. It may be that this time may not be the most 
appropriate for an intervention which aims to target perceptions about prescribed 
medications, but perhaps this could be incorporated at a later follow-up once maintenance 
medication is initiated. 
For some, medication is still associated with symptom perception and personal models of 
illness are influenced by prior experiences and social factors. The common-sense model of 
illness and extended self-regulation model is supported. There was strong medication 
ambivalence for participants. Although there was a need for it in hospital, this appeared to 
taper off once symptoms improved and there was a strong desire to be medication-free. The 
IBiD intervention is not sufficient to challenge medication perceptions over this short time 
frame at this particular time point. Instead, helping people to find a treatment which fits better 
with their beliefs and practical needs, but which is still efficacious may be a more realistic goal. 
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Chapter 8 Treatment perceptions and Shared Decision Making in bipolar 
disorder: A cross-sectional study 
 
8.1 Introduction 
Service-user involvement in planning care and making decisions about treatment, referred to 
as Shared Decision Making (SDM) is increasingly important in mental health care policy under a 
more recovery-focussed care model (Coulter, Edwards, Elwyn, & Thomson, 2011; Jacob, 2015). 
This reflects a move away from paternalistic care where decisions are made by clinicians based 
on their perception of what is best for the patient (Farrelly et al., 2015). 
Before describing SDM in mental health and the factors associated with patient experiences 
and preferences it is important to consider how it has been defined and operationalised. SDM 
is a process where patients receive evidence-based information about treatment options 
including areas of uncertainty as well as a process of counselling to reach a decision and the 
recording of patients’ preferences (Coulter et al., 2011). Charles et al (1999) identify four 
features of SDM: both the clinician and patient are involved in the process, sharing of 
information is bi-directional, both parties can express treatment preferences and the decision 
is based on an agreement between the two. A challenge is presented by the fact that various 
measures exist to assess SDM preferences and experiences and they have often been 
developed for particular healthcare contexts. It has been recommended that modifications are 
often needed to ensure they are context and language appropriate (Fischer, 2006). Scholl and 
colleagues (2011) conducted a review of SDM instruments. Most are self-report of the 
patients’ perspectives on the decision making process. But other aspects included role 
preferences, evaluating the decision outcomes or patients’ reflections on the process. The 
psychometric properties of existing scales is generally good in terms of reliability, but validity 
has often not been fully investigated (Scholl et al., 2011). Barr and Elwyn (2015) found two 
main threats to validity in SDM measures, specifically that patients may not be aware of what 
and where the decision making points are and the measures don’t take account of the number 
of decisions involved in consultations. 
Returning to SDM in mental healthcare, the momentum is shifting towards the view that 
information provided to patients in psychiatric care should enhance choice and reflect their 
values (Deegan & Drake, 2006; Hope, 2002). This acknowledges that patients themselves have 
valuable expertise on their condition, how they respond to treatment and their hopes and 
wishes for outcomes. Mental health patients’ generally prefer to be informed and involved in 
their care and treatment (Bilderbeck et al., 2014; de las Cuevas et al., 2012; Hill & Laugharne, 
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2006; Sajatovic et al., 2005). A recent online study conducted in Germany including people 
with a BD diagnosis found that 65% preferred an SDM role (Liebherz et al., 2015). There are, 
however, a range of preferences expressed. Eliacin and colleagues (2015) report preferences 
from full engagement in decision making to no input at all. 
As described in Chapter 1, Section 1.2.5, where patient preference and involvement is used, 
outcomes are improved (adherence and clinical) and patients are more satisfied with 
treatment (Lindhiem et al., 2014; Wilder et al., 2010). In a qualitative study, patients viewed 
SDM as an important part of recovery (Eliacin et al., 2015). Medication changes driven by 
patient choice have been found to be associated with better treatment engagement, 
adherence and in medication attitudes (Sajatovic et al., 2014). The authors posit that these 
improvements were related to feeling more actively involved in treatment. Conversely, 
patients have reported that they change medication dosages in response to side-effects 
without consultation with health professional as they found it difficult to communicate with 
them (Happell et al., 2004). 
Despite the policy shift towards SDM, UK surveys reveal that in practice, patients are not 
always involved to the extent they wish to be (Care Quality Commission, 2009a, 2011a, 2013). 
Analysis of psychiatric consultations showed a minimal attempt to involve patients in decisions 
(Goss et al., 2008). Liebherz and colleagues (2015) found that 55% of people with BD reported 
that, in their most recent consultation, decisions were shared. However, half reported finding 
it difficult to make decisions around taking a different treatment or changing dose. Patients 
have also reported that a lack of knowledge and worry about making an incorrect decision was 
a barrier to involvement in decisions (Eliacin et al., 2015). This highlights that information on 
medication choices is a key unmet need, concurring with previous work (Bowskill et al., 2007; 
Morselli & Elgie, 2003). Unmet needs appear to affect patients’ perceived control over their 
medication management, with a lack of knowledge about how long they would have to take 
medication for affecting perceptions of their control (Happell et al., 2004). 
In a UK study on anti-psychotic prescribing, around 40% of patients with a diagnosis of 
schizophrenia felt they had not been given enough information about their medication. 
However, half of these said they did not want more information as they trusted their doctors’ 
decisions. This still means that these patients may then not be familiar with potential side-
effects or how to take the treatment (Paton & Esop, 2005). 
Recent research explored barriers to implementing SDM in a UK mental health setting (Farrelly 
et al., 2015). Implementation of SDM was affected by the power differential between patients 
and psychiatrists. Clinicians had concerns that patients may not choose what they saw as the 
most suitable options or that they might choose treatments which were not available. Patients 
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described feeling disempowered and having little influence on their own care and feeling 
unsure about trusting their own decisions (Farrelly et al., 2015). This concurs with findings 
reported in Chapter 7, where participants were acutely aware of the Consultant Psychiatrists 
status and reported difficulties in communicating with them. They also reported that there 
was rarely time to speak to other care staff on the ward. This emphasises the importance of 
patients being fully informed about options and feeling that they can discuss their care openly. 
A qualitative study with UK psychiatrists indicated that they desired a concordant relationship 
characterised by shared decision making, making choices that reflect the patient’s wishes, 
negotiated agreements and a sense of partnership, with patients. They reported sometimes 
withholding information about adverse effects of medication as it was perceived that this may 
discourage acceptance of treatment (Seale, Chaplin, Lelliott, & Quirk, 2006). This reflects 
findings from the current programme of research where patients reported that they were not 
fully informed about how treatment decisions are made and the different alternative 
medications available (Chapter 4 & Chapter 7). As Charles and colleagues point out, for SDM to 
occur both clinician and the patient must perceive that there are choices available (Charles et 
al., 1999). 
The barriers to SDM reported by mental health nurses reflect the barriers reported by 
psychiatrists. In addition, mental health nurses also identified that a lack of resources inhibited 
involving patients more in their care planning. Lack of time, staffing levels and greater 
priorities on the ward meant that patient involvement did not take precedence (Anthony & 
Crawford, 2000). The qualitative evaluation of the IBiD intervention (Chapter 7) also found that 
there was little opportunity for participants to ask questions about their diagnosis or the 
medication they were prescribed which is a key aspect of SDM. Satisfaction with care as an 
inpatient has been shown to be associated with participation in treatment after discharge from 
hospital (Bowersox et al., 2013). However, in this study respondents with higher satisfaction 
may be overrepresented in those responding to the survey at discharge and satisfaction with 
inpatient care may be subject to recall bias influenced by experiences after discharge. It is, 
however, possible that having a negative experience in hospital may result in disengagement 
once discharged. Despite this, other factors may mitigate against this such as having a strong 
belief in the necessity of treatment to avoid readmission. Nurses have also reported that some 
patients were not motivated to be involved in care planning and see it as the professionals’ 
role. The authors highlight that traditional expectations of the ‘patient role’ could come across 
as a lack of motivation to be involved in their care, however, this does not necessarily indicate 
a lack of desire or interest (Anthony & Crawford, 2000). Indeed, patients have reported fearing 
that trying to be involved in decision making crosses the boundary of normal patient and 
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clinician roles and that any disagreements could result in a difficult ongoing relationship 
(Eliacin et al., 2015). The results of the qualitative study in Chapter 4 also highlighted some 
patients do still experience the ‘traditional’ relationship where they follow instructions without 
having input. However, participants did discuss how the better way to manage their illness was 
collaboratively with both parties offering their expertise. This is encouraging that participants 
are in agreement that a recovery model which, as Davidson (2005) states includes patients as 
the experts in their own experience. 
Concurring with the perspectives from nurses and psychiatrists, mental health service users 
reported that being included in the decision making process depended in part on their ability 
to articulate themselves or how much their provider perceived they could understand (Gale et 
al., 2012). Participants have also reported having a mental health diagnosis affected the 
perceived credibility of their input to health professionals, they felt their views and input was 
dismissed as being symptomatic of their illness (Happell et al., 2004). Patients have also 
reported struggling to be perceived as competent and having an equal role in their own care, 
in direct contravention of the recovery model (Dahlqvist-Jönsson, Schön, Rosenberg, Sandlund, 
& Svedberg, 2015). In mental health, treatment choices may sometimes be limited, however, 
patients’ fears and values must be acknowledged and respected. Psychiatrists may assume 
patients are not able to deal with information and choice so they may not be asked to 
participate in decision making (Samele, Lawton-Smith, Warner, & Mariathasan, 2007).  
There is little evidence on factors associated with SDM preferences. A qualitative US study 
identified the relationship with the clinician was a factor in patients involvement in decisions, 
particularly the level of trust they felt. Involvement and preferences for SDM fluctuate 
according to condition stage and previous experiences (Eliacin et al., 2015; Sajatovic et al., 
2005). The patient having adequate knowledge and a sense of empowerment were two main 
facilitators of SDM in a large review across health conditions (Joseph-Williams, Elwyn, & 
Edwards, 2014). The combination is key, as knowledge is not useful without a sense of being 
able to or having the opportunity to voice opinion. 
A cross-sectional survey involving people with serious mental illness on involvement in 
decisions found that older age was associated with stronger preferences for involvement in 
decisions. However, in terms of previous experiences, older adults were more likely to have 
been in a passive role (O'Neal et al., 2008). This study had a number of limitations, firstly a 
small sample size (n=65), secondly a quarter of the older adults were recruited from a 
residential facility so do not represent a community-living population and finally there were 
few participants from the upper and lower ends of the age spectrum. Hill and colleagues 
(2006) found that younger age and being employed were associated with a greater desire to 
266 
be involved in decision making in patients from a much larger mixed psychiatric sample 
(n=160). 
Despite barriers to SDM, resources exist to empower patients in decisions over their 
treatment, in order that care has a recovery-focus (Jacob, 2015). Advance statements are 
written statements which allow an individual to set out their preferences for future care such 
as where and how they wish to be cared for and how practical arrangements will be made 
such as childcare in the event of the person losing the capacity to make decisions (Rethink 
Mental Illness, 2013). Advanced Directives are a type of advance statement and are 
documents which are drawn up in accordance with the Mental Capacity Act (HMSO, 2005) 
which gives individuals a legal right to refuse certain medical treatments in the future. The 
content of user-created advance directives has been shown to be feasible, useful and 
consistent with clinical standards (Srebnik et al., 2005). Completing an advance directive can 
lead to greater therapeutic alliance and patients report receiving mental health services 
consistent with their wishes (Swanson et al., 2006). Wilder and colleagues (Wilder et al., 2010) 
found that patients whose advance directives contained requests for particular medications 
were more likely to be prescribed these treatments at 1 year follow-up and if they were 
prescribed any of their requested medications they had higher overall adherence. However, 
the authors also point out that in their sample completing an advance directive doesn’t 
guarantee that it will be adhered to. Joint Crisis Plans (JCPs) are statements which are 
negotiated by patient and provider together covering treatment preferences in the event of a 
psychiatric emergency. The content of crisis plans show that requests are reasonable and 
consistent with current treatment guidelines (Farrelly et al., 2014). However an RCT indicated 
that JCPs may not be implemented consistently and did not always fully incorporate patient 
preferences (Thornicroft et al., 2013). Wellness Recovery Action Planning (WRAP) was 
developed in the US and is a tool to plan strategies to maintain wellness including 
identification of triggers and warning signs of relapse and action plans to deal with these 
including crisis planning (Copeland, 1997). It involves self-management, education, healthy 
lifestyle promotion and peer support. WRAP training has been associated with improvements 
in self-management and detecting early warning signs of illness (Cook et al., 2010) as well as 
feelings of hope (Fukui, 2011). An RCT demonstrated significant improvements in both 
symptoms, recovery scores as well as personal confidence and goal orientation (Cook et al, 
2012). The WRAP approach may promote volitional motivation for changing behaviour, as it is 
highly individualised, incorporating the values and goals of each person. In turn, these goals 
may be more likely to be enacted and maintained, with the support of a peer network. 
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The literature above and findings from the primary research in this thesis demonstrates a 
number of barriers inhibiting patient involvement in mental health care and treatment 
decisions; some of these appear more relevant to mental health, for example paternalism and 
the power differential between clinician and patient, potential lack of insight or competence to 
understand information and make decisions during illness phases and a lack of access to 
accurate and comprehensible information about a patient’s condition and treatment options. 
There appears to be a lack of evidence as to the psychological factors associated with SDM 
preferences and experience. It is hypothesised that factors such as illness and treatment 
perceptions and satisfaction with information received might contribute to this. A better 
understanding these factors might be utilised in developing ways to improve involvement, 
concordance with medication and informed decision making. 
During the course of the IBiD feasibility trial (Chapters 6-7) broader contextual factors around 
bipolar and medication emerged from both the qualitative study and from field-notes during 
intervention delivery. These related to how people feel about and engage with their treatment 
including a lack of opportunity to find out information about medication, or discuss this with 
their healthcare professional. This did not allow people to fully understand and manage their 
treatment when discharged from hospital. It appeared that for some participants the 
motivation to take treatment was extrinsic, i.e. to keep their clinician happy, because they 
were detained under a section, to avoid compulsory treatment or to stay out of hospital once 
discharged. 
However, autonomous regulation where an individual is acting out of volition due to the 
personal importance of the behaviour and their level of perceived autonomy has been found 
to be associated with increased adherence (G. Williams, Rodin, Ryan, Grolnick, & Deci, 1998). It 
follows patients involved in SDM might have increased autonomous regulation and may be 
more inclined to be adherent to medication as it has personal importance to them. The 
authors posit that supporting patients’ autonomy might help improve adherence and meet 
their needs (G. Williams et al., 1998). A meta-analysis revealed across a range of areas, choice 
has a positive effect on intrinsic motivation (Patall, Cooper, & Robinson, 2008). 
The factors influencing whether a person wishes to be involved in their treatment decisions is 
not well understood. Fischer (2006) identifies in a commentary around SDM in mental health 
that there is a paucity of knowledge about the ‘extent, variability, and correlates of shared 
decision-making in mental healthcare, especially in care for individuals with severe mental 
illness (SMI)’ (pg 108). Specifically the links between SDM and treatment perceptions are not 
understood. This study was conducted in order to address these outstanding questions. 
Specifically to explore whether greater involvement in care and planning (shared decision 
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making) is associated with more positive treatment perceptions and is SDM associated with 
adherence. It is hoped that by exploring these links, it may be possible to begin to extend 
existing models of treatment perceptions, cognitions and adherence within mental health to 
include potentially important aspects of SDM. 
 
8.1.1 Aims & Objectives 
8.1.1.1 Aim 
To describe SDM experiences in BD and explore whether a stronger desire for SDM is 
associated with more positive illness and treatment perceptions and adherence to medication. 
8.1.1.2 Objectives 
To investigate; 
 experiences with and the extent of SDM in people with BD in a community population, 
 the relationship between psychological factors experience and preferences for SDM, 
to explore whether more positive perceptions are associated with stronger 
preferences for SDM, specifically 
o treatment perceptions 
o perceptions of illness 
o satisfaction with information about medication 
 the relationship between SDM preferences and experience and adherence to 
medication to explore if SDM is associated with higher adherence. 
 
8.2 Methods 
8.2.1 Design 
This study comprised a cross-sectional survey, using validated questionnaires, conducted 
online using Qualtrics software. Ethical approval for the study was granted by UCL Research 
Ethics Committee (Reference 6811/001). 
 
8.2.2 Inclusion criteria 
Participants were eligible for the study if they self-reported a diagnosis of bipolar disorder and 
reported being currently prescribed medication for this, were over 18 years of age and living in 
the UK. 
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8.2.3 Recruitment 
Recruitment was conducted via online advertisements, through twitter, Facebook groups and 
established links with charity organisations (Bipolar UK and the Scottish Association for Mental 
Health). (See Appendix CC for advertisements/ tweets). 
 
8.2.4 Procedure 
Individuals interested in the survey were directed, via a Qualtrics survey link, to a Participant 
Information Sheet contacting information about the study and contact details for the research 
team if they had any questions (Appendix DD). If they wished to proceed, they were directed 
to an online consent form, and once completed, were directed to the survey. They were 
assured of their right to withdraw and confidentiality. The survey took approximately 15-20 
minutes to complete. 
 
8.2.5 Measures 
8.2.5.1 Treatment and illness perceptions, adherence and satisfaction 
The questionnaire comprised the measures summarised in Table 8.1. For consistency with 
previous surveys (Bowskill et al., 2007; Clatworthy et al., 2009) and with the feasibility RCT 
data (Chapters 6-7), treatment and illness perceptions, adherence and satisfaction with 
information about medication were measured using the Beliefs about Medicine Questionnaire 
Specific & General (BMQ) (Horne & Weinman, 1999), the Brief Illness Perception 
Questionnaire (Broadbent et al., 2006), the Medication Adherence Report Scale (MARS) (Horne 
& Weinman, 2004), adherence Visual Analogue Scale (VAS) and the Satisfaction with 
Information about Medicines Scale (SIMS) (Horne et al., 2001) (Described in detail in Chapter 6 
Section 3). 
 
8.2.5.2 Shared decision making and treatment empowerment 
As described in Section 8.1, SDM has been operationalised in different ways. To measure 
preferences for SDM in this study, two scales were selected for conciseness and reliability, the 
Treatment Empowerment Scale (TES) (10 items) (D. Webb, Horne, & Pinching, 2001) and the 
Autonomy Preference Index (API) (Ende, Kazis, Ash, & Moskowitz, 1989). 
The TES is a concise, 10 item scale designed to assess control over the choice and use of 
medications incorporating communication, treatment choice, decision-making and 
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satisfaction. It uses a 5 point scale (5=very often, 4=often, 3=sometimes, 2=rarely and 1=never) 
and items are summed to produce a total score with higher values indicating a greater degree 
of treatment empowerment. This measure has been used with HIV patients (D. Webb et al., 
2001) and has demonstrated acceptable reliability (Cronbach’s alpha 0.85). 
The API (Ende et al., 1989) consists of two scales; decision making preference (6 items) and 
information seeking preference (8 items). Clinical vignettes used in the original scale were not 
included. The scale is scored on a five point Likert scale (Strongly agree to Strongly disagree) 
and each scale is summed (reversing items as necessary). The API demonstrated good internal 
consistency in psychiatric samples (Cronbach’s alpha 0.79) (Hamann et al., 2007; Hill & 
Laugharne, 2006). 
To measure SDM experience for each medication participants were prescribed they were 
asked to indicate their perceived level of involvement in starting the medication and in 
continuing with the medication on a scale of 1 (not involved at all in the decision) to 5 
(completely involved in the decision). In addition, participants were asked if they had ever 
completed advance requests or directives or joint crisis plans and to describe their experience 
with this. 
 
8.2.5.3 Demographic and clinical data 
Two validated clinical measures were included to assess levels of depression and mania. The 
Patient Health Questionnaire - Nine Item (PHQ-9) (Kroenke, Spitzer, & Williams, 2001) and the 
Altman Self-Rating Mania Scale (E. G. Altman et al., 1997). Demographic and clinical data was 
collected at the end of the survey, this comprised; age, gender, ethnic origin, marital status 
and highest level of education, age of bipolar diagnosis, history of inpatient admissions, and 
timing of most recent admission. 
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Table 8.1: List of validated and adapted measures used in IBiD study 
Type Measure Items/ Scoring Cronbach’s 
alpha 
(published) 
Treatment 
beliefs 
The Beliefs about Medicine 
Questionnaire Specific 
(BMQ Specific) (Horne et al., 
1999) adapted for BD 
17 items 
2 factor structure; Necessity, Concerns 
5 point scale, Strongly agree – Strongly 
disagree (Mean score) 
0.63-0.74a 
 The Beliefs about Medicine 
Questionnaire General 
(BMQ General) (Horne et al., 
1999) 
8 items 
2 factor structure; Overuse, Harm 
5 point scale, Strongly agree – Strongly 
disagree (Mean score) 
0.63-0.74a 
Illness 
beliefs 
The brief Illness Perception 
Questionnaire (Broadbent 
et al., 2006) 
8 items (+1 additional for BD) 
10 point scale 
 
Adherence Medication Adherence 
Report Scale (MARS) (Horne 
& Weinman, 2004) 
5 items 
5 point scale - Always to never (summed) 
0.67–0.90 
Satisfaction The Satisfaction with 
Information about 
Medication Scale (SIMS) 
(Horne et al., 2001) 
17 items 
2 subscales ‘Action and Usage’, ‘Potential 
Problems’ 
Response categories – too much (0), about 
right (1), too little (0), none received (0), 
none needed (1) (summed) 
0.81 - 0.91 
SDM Treatment Empowerment 
Scale (TES) (D. G. Webb et 
al., 2001) 
10 items 
5 point scale - Very often to never 
(summed) 
0.85 
 The Autonomy preference 
scale 
14 items 
2 subscales ‘Decision making preference’ 
and ‘Information seeking preference’ 
5 point scale, Strongly agree – Strongly 
disagree (summed) 
0.82 
Clinical Patient Health 
Questionnaire (PHQ) 
(Kroenke et al., 2001) 
9 items 
Not at all (0), Several days (1), More than 
half the days (2), Nearly every day (3) 
(Summed) 
0-4 None, 5-9 Mild, 10-14 Moderate, 
15-19 Moderately Severe, 20-27 Severe 
0.89 
 Altman Self-Rating Mania 
Scale (E. G. Altman et al., 
1997) 
5 items 
5 point scale - 0-4 (summed) 
0-5: no indication of mania 
6-20: possible manic state indicated 
0.79 
a Cronbach’s alpha for psychiatric sample across specific and general subscales. 
b Cronbach’s alpha ranges across subscales. 
 
8.2.6 Data analysis 
Data was analysed using SPSS Statistics 22, all scales were scored according to published 
guidelines. MARS data was dichotomised into low (≤ 21) and high (>21) adherence for 
consistency with published studies (Bowskill et al., 2007; Clatworthy et al., 2009). 
Medications were grouped into classes; mood stabilisers, atypical anti-psychotics (ATAPs), 
typical anti-psychotics, antidepressants, benzodiazepines and sleeping tablets. When more 
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than one medication was prescribed within a class of medication, an average of BMQ, MARS 
and VAS scores was calculated for that participant. Analysis was subsequently run for the most 
common classes of medication, mood stabilisers, atypical anti-psychotics and antidepressants 
due to small numbers of participants prescribed the other medication classes. 
Descriptive statistics were used to describe the samples scores for each scale and reliability 
statistics were conducted (Cronbach’s alpha). Scale distributions were assessed for normality 
in order to run parametric analysis. MARS and VAS data were not normally distributed, 
therefore for continuous outcomes, non-parametric tests were selected. Spearman’s Rho were 
performed to investigate the relationship between SDM experience and preferences and 
demographic, clinical, illness and treatment perceptions and adherence. 
 
8.3 Results 
8.3.1 Response rate, sample demographic & clinical characteristics 
Ninety-four individuals accessed the survey and reached the participant information sheet. 
Fifty-seven (61%) participants proceeded to complete the information on their prescribed 
medications (valid psychiatric medications). Demographic and clinical data was completed by 
51 participants (Tables 8.2 and 8.3). The mean age of the sample was 44 (SD 14.42) years, 65% 
of the sample were female, the majority were of White British ethnicity (82%), there was a mix 
of relationship status and educational levels. This is a similar demographic profile to the 
community sample in Chapter 4, and broadly similar to the participants recruited to the 
feasibility RCT with the exception of that sample being on average slightly older. 
The mean age of receiving a BD diagnosis was 32 (SD=9.79) years, and participants were 
prescribed a median of 2 (IQR 2-3) medications for BD. 17% of participants had been an 
inpatient within the last 12 months. Eighty percent of participants described their mental 
health problems as ‘Bipolar Disorder’, others characterised it as manic depression, 
schizoaffective disorder or depression. In terms of current episodic state, the ASRM scores 
indicated on average low mania scores, but 43% had scores indicating a possible manic state. 
Average PHQ-9 scores indicated that the sample generally had moderate levels of depression, 
however, there was a spread of the number of people in different depression status categories 
(none through to severe) (Table 8.3). 
Medications prescribed are described in Table 8.4, mood stabilisers were the most commonly 
prescribed class of medication (81%), followed by atypical anti-psychotics (58%). Over one-
third of the sample (39%) were prescribed anti-depressants. All medications were taken by 
tablet except two participants who took their typical anti-psychotic by injection.   
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Table 8.2: Sample socio-demographic characteristics 
 Total (n) 
Age at baseline  
Mean (sd) 43.67 (14.42) 
Median (IQR) 41 (32-53) 
Gender  
Female 64.7 (33) 
Ethnicity  
White British 82.0 (41) 
White Irish 2.0 (1) 
White other 10.0(5) 
Indian 2.0 (1) 
Chinese 4.0 (2) 
Relationship status  
Single 31.4 (16) 
Married/ Civil partnership/Cohabiting 47.1 (24) 
Divorced/ Separated 13.7 (7) 
Other 3.9 (2) 
Highest level of education  
O levels/CSEs/GSCEs 13.7 (7) 
A levels / AS levels 7.8 (4) 
Vocational education 3.9 (2) 
Degree 35.3 (18) 
Higher degree 21.6 (11) 
Professional qualifications 17.6 (9) 
 
Table 8.3: Sample clinical characteristics 
 Total % (n) 
Term best describing own mental health issues 
Bipolar Disorder 
Manic depression 
Schizoaffective Disorder 
Depression 
 
80.4 (41) 
11.8 (6) 
5.9 (3) 
2.0 (1) 
Age of BD diagnosis (approx)  
Mean (sd) 32.31 (9.79) 
Median (IPQ) 30 (24-39.75) 
N psychiatric medications  
Mean (sd) 2.23 (0.95) 
Median, range 2 (2-3) 
Previous admissions  
Voluntary admissions (yes) 53.1 (26) 
Involuntary/ Detained admissions (yes) 41.3 (19) 
Timing of most recent admission 
4-12 months ago 
More than 12 months ago 
 
17.2 (5) 
82.8 (24) 
ASRM Scale (Cronbach’s alpha = 0.78)  
Mean (sd) 4.75 (3.92) 
Median IQR 4 (1-8) 
No indication of mania 56.9 (29) 
Possible manic state indicated 43.1 (22) 
PHQ-9(Cronbach’s alpha = 0.93)  
Mean (sd) 10.10 (8.21) 
Median (IQR) 7 (3-17) 
None 37.3 (19) 
Mild 19.6 (10) 
Moderate 9.8 (5) 
Moderately severe 11.8 (6) 
Severe 21.6 (11) 
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Table 8.4: Medications prescribed (base n=57) 
 Percentage a (n) 
Mood stabilisers 80.7 (46) 
Lithium 31.6 (18) 
Lamotrigine 31.6 (18) 
Valproate 24.6 (14) 
Carbamazepine 5.3 (3) 
Atypical anti-psychotics 57.9 (33) 
Quetiapine 22.8 (13) 
Aripiprazole 15.8 (9) 
Olanzapine 8.8 (5) 
Risperidone 7.0 (4) 
Amisulpride 1.8 (1) 
Lurasidone 1.8 (1) 
Typical anti-psychotics 7.0 (4) 
Flupentixol 3.5 (2) 
Chlorpromazine 1.8 (1) 
Zuclopenthixol 1.8 (1) 
Antidepressants 38.6 (22) 
Venlafaxine 15.8 (9) 
Citalopram 8.8 (5) 
Duloxetine 3.5 (2) 
Mirtazapine 3.5 (2) 
Escitalopram 1.8 (1) 
Fluoxetine 1.8 (1) 
Sertraline 1.8 (1) 
Phenelzine 1.8 (1) 
Agomelatine 1.8 (1) 
Bupropion 1.8 (1) 
Trazodone 1.8 (1) 
Benzodiazepines 10.5 (6) 
Diazepam 5.3 (3) 
Clonazepam 5.3 (3) 
Sleeping tablets 7.0 (4) 
Zolpidem 3.5 (2) 
Promethazine 1.8 (1) 
Zopiclone 1.8 (1) 
Other psychiatric medications 3.5 (2) 
Propanolol (beta blocker) 1.8 (1) 
Pregabalin (anticonvulsant) 1.8 (1) 
a Participants may take more than one medication in each class accounting for where total number for class is less 
than the total of each medication within that class. 
 
8.3.2 Experience of and preferences for SDM – Descriptive statistics 
In general, participants appear to be involved in decisions to start and continue treatments, 
Table 8.5 shows that for most classes of medication there was high average levels of 
involvement in both starting and continuing medications, with the exception of 
benzodiazepines. However, a significant minority have had no involvement i.e. a quarter of 
those prescribed mood stabilisers (Table 8.5). 
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Descriptive statistics for each SDM scale are summarised in Table 8.6. The cronbach’s alpha for 
TES was acceptable, however, for the API Information seeking scale, the item ‘As you become 
more unwell you should be told more and more about your illness’ reduced the overall scale 
alpha slightly from 0.69 to 0.65, and this item was removed from the scale as it was deemed to 
be less appropriate for mental illness which can result in cognitive difficulties in worsening of 
illness episode. Treatment empowerment was high in the sample as was information seeking, 
reflecting a strong preference for receiving information about BD and its treatment. 
Preferences for decision making tended towards the desire for personal over physician control. 
Eight (15%) participants had completed advance requests or directives about their mental 
health care, 7 (14%) had completed joint crisis plans, overall 14 (26%) participants had 
completed one or the other. Participants provided details about this experience, these are 
summarised in Table 8.7. Positive and negative experiences of completing plans were 
reported, with some participants finding it a simple process that they completed with help and 
support from their care providers. They found it reassuring to have the knowledge that this 
was in place even though they had not had reason to use it. However some commented on 
experiences or fear of plans not being honoured and others did not feel that they were fully 
involved in the process of completing the plans. 
 
Table 8.5: Involvement in starting and continuing prescribed medications 
 Starting medication Continuing medication 
Medication (n) Mdn (IQR)a Little or no 
involvement % (n)b 
Mdn (IQR)a No involvement 
at all % (n) 
Mood stabilisers (43) 4 (2-4) 25.7 (10) 5 (3-5) 21.4 (9) 
Atypical anti-psychotics (27) 4 (2-5) 29.1 (7) 5 (3-5) 11.1 (3) 
Antidepressants (21) 4 (3-5) 15.0 (3) 4.5 (3-5) 5.6 (1) 
Benzodiazepines (2) 2.5 (1-) 50.0 (1) 3.5 (2-) 50.0 (1) 
Typical anti-psychotics (4) 3 (1-) 50.0 (2) 5 (2-5) 25 (1) 
Sleeping tablets (2) 5 (4-) - 5 (5-5) - 
a 5 point scale, 1=no involvement, 5=completely involved 
b Participants selecting 1 or 2 
 
Table 8.6: Descriptive and reliability statistics for validated scales 
 Mean (sd) Min-max Cronbach’s 
alpha 
Treatment Empowerment Scale (TES) a 35.15 (9.70) 10-50 .93 
API Decision making b 16.04 (3.76) 6-30 .63 
API Information seeking (7 items) c 31.86 (2.43) 7-35 .69 
a TES – higher scores indicating greater degree of empowerment 
b API Decision making – higher scores indicate a greater desire for physician involvement 
c API Information seeking - higher scores indicating a greater desire for information. 
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Table 8.7: Participants experience of advanced directives and JCPs 
Theme Example text 
Description of plan The joint crisis plan was written with a GP trainee to complete a government 
document-it says contact GP and ask them to contact crisis equivalent team, 
which is adequate as I live with my husband. 
Daughters have power of attorney for both health and property. This is only 
to be used if I am incapable of making my own decisions and hasn't been 
used yet. 
Process of completing 
plan (positive) 
Hi process was very simple, I did this with my care coordinator a long time 
ago but I no longer have any contact with them. 
The doctor asked if I would be ok with him [friend] making a medical 
decision for me if I was unable to do so due to mental health issues. I told the 
doctor that if my mental health deteriorated to that point, I had instructed 
my friend to drag me to the doctor - kicking and screaming if necessary - and 
to do whatever was necessary to get me back on track.  As my condition is 
bipolar II, and very well managed with medication, I don't foresee this ever 
being an issue, but it's good to have a plan, and I was glad my doctor 
thought to bring it up 
My JCP was completed after I had passed the low point of my 
crisis/breakdown so thankfully never had to fully put the plan into action.  I 
think it is a good idea though, knowing you have a backup plan if it all goes 
pear shaped again. 
Work based for disability adjustments not CMHT. Straightforward 
Process of completing 
plan (negative) 
When I moved to [location] two years ago, I was told I would only get care if 
in crisis so I was not able to establish an advance directive. They have 
recently engaged with me and I have started this process but progress is 
slow as their mental health resources are stretched. 
Lack of involvement I made an advance request to use Thioridazine next time (in the days it was 
available.  They ignored the request making my hospital stay longer than it 
needed to be. 
I was very ill when the JCP was written up. So a psychiatric nurse at the 
hospital where I was being assessed wrote it up. They did explain everything 
to me, but I don't feel I was very involved in the plan. 
Plan not adhered to/ 
worry about lack of 
adherence 
It seemed to be a useful process at the time but when I needed it to be used 
no one was aware that it existed or able to find it. 
Useful to write advance request but feel it would never be honoured. 
 
8.3.3 Treatment perceptions & adherence - Descriptive statistics 
Adherence to medications was generally high (Table 8.8). However around one quarter of 
those prescribed mood stabilisers, atypical anti-psychotics and antidepressants were 
categorised as having low adherence. Around half of participants had high concerns about 
their medication and between half and three-quarters of participants had low necessity 
beliefs, this was true for each medication class (Table 8.9). 
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8.3.4 General medication beliefs, satisfaction with information about medication and illness 
perceptions – Descriptive statistics 
Descriptive statistics for each scale are summarised in Table 8.10. Cronbach alphas for the 
BMQ-General and SIMS scales were acceptable. Overall there were high beliefs about the 
overuse of medications, but lower than midpoint average beliefs about the general harm of 
medication. There were low levels of satisfaction with information about medications 
particularly in receiving sufficient information on the potential problems of medication (this 
includes the risks of side-effects and what to do in the event of these occurring). In comparison 
to the sample recruited to the feasibility RCT, this sample had higher levels of satisfaction with 
information, however, this was still not at an acceptable level, demonstrating that in both 
settings, people have unmet information needs. 
In terms of illness perceptions, on average participants held beliefs consistent with severe 
illness consequences, a chronic timeline, high levels of concerns and emotional responses but 
a clear understanding of illness and strong agreement with the diagnosis. Perceptions of 
treatment and personal control as well as symptom experience were around the scale 
midpoint. With the exception of the two control items, the other illness perceptions were 
consistent with those found in the group of participants recruited to the feasibility RCT. This 
community sample had higher levels of personal control and lower levels of treatment control. 
Perhaps this may be due to experiences of managing BD themselves and potentially using 
other ways, besides medication to stay well, whereas in the inpatient sample their feeling of 
personal control may have been reduced by the fact that they had experienced an acute illness 
episode, and treatment control may be higher as they felt this had been an effective way to 
improve their symptoms. 
 
Table 8.8: Medication adherence data (MARS & VAS)a 
Medication (n) MARS VAS 
 Mdn (IQR) Low adherence % (n) Mdn (IQR) 
Mood stabilisers (43) 24.00 (21-25) 25.6 (11) 99.00 (81-100) 
Atypical anti-psychotics (27) 24.00 (21-25) 25.9 (7) 98.50 (91.25-100) 
Antidepressants (21) 23.00 (21-24) 23.8 (5) 92.50 (61.75-100) 
Benzodiazepines (2) 24.00 (23-25) - 100.00 (100-100) 
Typical anti-psychotics (4) 24.00 (11-24.75) 25 (1) 100.00 (99-100) 
Sleeping tablets (2) 23.00 (21-25) 50 (1) 54.00 (8-100) 
a MARS and VAS data were not normally distributed, therefore Mdn and IQR are presented 
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Table 8.9: BMQ Specific necessity and Concerns scales 
 BMQ Concernsa BMQ Necessity b 
Medication (n) Mean (sd) High concerns % (n) Mean (sd) Low necessity % (n) 
Mood stabilisers (43) 3.00 (0.71) 45.2 (19) 2.82 (1.08) 67.40 (29) 
Atypical anti-psychotics (27) 2.97 (0.87) 48.1 (13) 2.75 (1.14) 58.60 (17) 
Antidepressants (21) 2.95 (0.71) 55.0 (11) 2.74 (0.84) 77.80 (14) 
Benzodiazepines (2) 2.58 (1.24) 50.0 (1) 3.50 (0.71) 50.0 (1) 
Typical anti-psychotics (4) 2.75 (0.64) 50.0 (2) 3.46 (1.02) 25.00 (1) 
Sleeping tablets (2) 2.45 (0.99) 33.30 (1) 2.83 (0.60) 66.70 (2) 
a Scores range from 1-5 with higher scores indicating higher levels of concerns 
b Scores range from 1-5 with lower scores indicating greater doubt about the necessity of medication 
 
Table 8.10: Descriptive and reliability statistics for validated scales 
 Mean (sd) Median (IQR) Min-max Cronbach’s 
alpha 
BMQ General Overuse a 3.29 (1.02)  1-5 .84 
BMQ General Harm a 2.29 (0.88)  1-5 .86 
SIMS scale b 10.39 (4.84)  0-17 .89 
SIMS Action and Usage 6.31 (2.66)  0-9 .83 
SIMS Potential problems 4.08 (2.70)  0-8 .83 
Brief IPQ c   0-10 for all n/a 
Consequences - How much does 
bipolar affect your life? 
7.06 (2.60) 8.00 (6-10)   
Timeline - How long do you think 
your bipolar will continue? 
9.24 (1.77) 10 (9-10)   
Personal control - How much 
control do you feel you have over 
your bipolar? 
5.02 (2.40) 5 (3-7)   
Treatment control - How much do 
you think your treatment can help 
your bipolar? 
6.39 (2.15) 6 (5-8)   
Identity - How much do you 
experience symptoms from bipolar? 
5.96 (2.10) 6 (4-8)   
Concern - How concerned are you 
about your bipolar? 
7.16 (2.69) 8.00 (6-10)   
Understanding - How well do you 
understand your bipolar? 
7.84 (1.99) 8.00 (6-10)   
Emotional response - How much 
does your bipolar affect you 
emotionally? (e.g. does it make you 
angry, scared, upset?) 
7.39 (2.60) 8 (6-10)   
Identity - How much do you agree 
with your diagnosis? 
8.33 (2.21) 9 (8-10)   
a BMQ General – higher scores indicate greater perceptions of overuse and harm 
b SIMS – higher scores indicate greater degree of satisfaction 
c Brief IPQ – higher scores indicate; greater severity, chronic timeline, greater personal and treatment control, 
experience of symptoms, greater concern, better understanding, greater emotional impact and greater level of 
agreement. 
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8.3.5 Associations between SDM and other measures 
Spearman’s rank order correlations were run to explore relationships between variables. As 
expected, a significant positive correlation was present between MARS and VAS scores for 
mood stabilisers (rs = .53, p<.001), ATAPs (rs =.50 , p=.015) and antidepressants (rs =.54, 
p=.031). There were no age or gender differences for any of the SDM variables. 
 
8.3.5.1 Involvement in the decision to start and continue prescribed medications 
There was a significant positive correlation between involvement in the decision to start and 
to continue medication for mood stabilisers (rs =.43, p=.007). Involvement in the decision to 
start mood stabilisers was significantly correlated with overall SIMS (rs =.42, p=.011), and both 
subscales (Action and usage rs =.36, p=.034) (Potential problems rs =.42, p=.010). Involvement 
in the decision to continue mood stabilisers was significantly correlated with overall SIMS (rs 
=.33, p=.037), and the Action and usage subscale (rs =.35, p=.028) as well as with agreement 
with the BD diagnosis (rs =.45, p=.003). Involvement in the decision to start ATAPs was 
significantly correlated with overall SIMS (rs =.49, p=.019), and the Potential problems 
subscale (rs =.50, p=.016). Involvement in the decision to start antidepressants was 
significantly correlated with overall SIMS (rs =.46, p=.046), and the Action and usage subscale 
(rs =.57, p=.010). It was also significantly positively correlated with personal control (rs =.47, 
p=.042), and negatively correlated with symptom experience (rs =-.54, p=.018), concern about 
BD (rs =-.52, p=.022) and agreement with diagnosis (rs =-.47, p=.042). Involvement in the 
decision to continue ATAPs was significantly correlated with three Brief IPQ items, personal 
control (rs = .40, p=.044), treatment control (rs = .61, p=.001) and agreement with diagnosis (rs 
= .45, p=.022). 
For ATAPs, there was a significant negative correlation between VAS adherence and 
involvement in the decision to continue treatment (rs =.44, p=.035), but not to start treatment 
and also not between involvement and MARS adherence. For antidepressants there was a 
positive correlation between VAS adherence and involvement in the decision to continue 
antidepressants (rs = .60, p=.031). There was no association between involvement and 
adherence for mood stabilisers. There was also no association between involvement and 
necessity and concerns beliefs for mood stabilisers, ATAPs, or antidepressants. There was a 
negative correlation between BMQ General Harm score and involvement in the decision to 
continue antidepressants (rs = -.52, p=.033). 
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8.3.5.2 Treatment Empowerment 
For the TES, there were positive correlations with satisfaction (rs = .62, p<.001), and for the 
two subscales, Action and Usage (rs = .56, p<.001), and Potential problems (rs = .56, p<.001). 
There was also a positive correlation between TES and two Brief IPQ items, treatment control 
(rs = .39, p=.004), and agreement with diagnosis (rs = .36, p=.009). 
No association was found between TES score and adherence to mood stabilisers, ATAPs or 
antidepressants or to necessity or concerns beliefs. There was also no association between 
TES and either Information seeking or decision making preferences. 
 
8.3.5.3 Autonomy Preference – decision making and information seeking 
For mood stabilisers, positive correlations were found between MARS score and API 
information seeking (rs =.36, p=.025). There was no association for either ATAPs or 
antidepressants. 
For ATAPs, a negative correlation was found between BMQ necessity beliefs and API Decision 
making (rs = -.44, p=.020), and a positive correlation with API information seeking preferences 
(rs = .47, p=.012). 
There were significant negative correlations between information seeking preferences and 
overall satisfaction (rs = -.28, p=.049) and for the Potential Problems subscale of the SIMS (rs = 
-.29, p=.043). There was a positive correlation between information seeking preferences and 
two Brief IPQ items, impact of bipolar (rs = .29, p=.037), and understanding of bipolar (rs = .37, 
p=.007). 
 
8.3.5.4 Other associations 
Additional post-hoc analysis was conducted to explore relationships between the treatment 
and illness perceptions and adherence. For mood stabilisers, positive correlations were found 
between BMQ General Harm score and length of time on mood stabilisers (rs = 41, p=.015). 
There was a negative correlation between BMQ General Overuse beliefs and VAS adherence 
(rs = -.64, p=.010), and for BMQ General Harm score and VAS (rs = -.65, p=.009) and MARS 
score (rs = -.74, p<.001). There were no significant differences between those who had created 
an advance directive or JCP for any of the SDM variables. 
T-tests explored differences between adherence groups (high or low) and illness and 
treatment perceptions, satisfaction and SDM preferences and experience. For mood 
stabilisers, there was a significant difference in the number of prescribed medications, with 
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low adherers (M=1.91, SD=0.54) being prescribed significantly fewer medications than high 
adherers (M=2.59, SD=0.945); t(31)=-2.94 , p= .006. For ATAPs, there was a significant 
difference between groups and BMQ General harm scores with low adherers (M=2.83, 
SD=0.89) having significantly higher perceptions of medication harm than high adherers (M= 
2.00, SD=0.81); t(24)=, p= .033. For antidepressants, there was a significant difference 
between groups for the API information seeking scale with low adherers having a greater 
desire for information (M=29.40, SD=2.19) than high adherers (M=32.53, SD=1.92): t(18)=-
3.06, p=.007. In addition, the level of understanding of bipolar (from the Brief IPQ) was 
significantly lower in low adherers (M=5.60, SD=2.61) than high adherers (M=8.27, SD=1.58); 
t(18)=-2.78, p=.012. No significant differences were observed between adherence group and 
BMQ concerns or necessity for mood stabilisers, ATAPs or antidepressants. 
 
8.3.6 Participants’ additional comments 
At the end of the survey, participants were given the opportunity to provide additional 
comments on the topics covered (Table 8.11). Participants raised issues relating to mixed 
feelings about medication, the lack of support and information, problems with medication and 
experiences with adherence and non-adherence. The ambivalent feelings about medication 
reflect those reported by participants in Chapter 4 and Chapter 7, having strong concerns 
about their medications but taking it as it is the tool to help them to function. Participants’ 
experiences of non-adherence confirmed the necessity of medication. The findings on lack of 
information and support and experiences with side-effects also reflect those findings from the 
smaller samples in the qualitative studies in Chapters 4 and 7. 
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Table 8.11: Participant additional information provided 
Theme Example text 
Mixed feelings 
about medication 
I feel like taking Lamictal [Lamotrigine] has taken away some of my creativity, 
and I don't feel as smart as I used to. I don't have a great memory anymore, and I 
feel like Lamictal is the reason I haven't done as well in my academic and 
professional life as I should have. That said, I don't know if I'd be able to function 
without it. 
I was recently strongly advised to resume Lamotrigine after a relapse and was 
told I could not work until I had complied with the doctor's instructions. I was 
quite upset as I felt that my choice/freedom had been restricted but at the same 
time I am now gad to be back on the medication as I am feeling much better 
and able to function ok. 
I think lithium has helped me the most. I just miss my energy and creativity. 
Lack of support 
and information 
A major issue is GPs not informing patients about side effects. The NHS does not 
help with the consequences, e.g. side effects and withdrawal syndrome, of 
psychotropic medications they have prescribed. 
I also feel psychiatrists don't care about awful side effects so long as your mood 
is under control. When I was prescribed olanzapine my weight shot up, I went 
from being clinically underweight to overweight in a year. More attention needs 
to be paid to the person as a whole so they understand when a side effect is 
having a really bad effect on your life. 
Problems with 
medication 
Going through repeated med changes. Lamotrigine isn't fully tackling my 
symptoms but all the antipsychotics I've tried cause horrendous side effects at 
lowest dose. 
The thing about having been on medication so long is that I don't know who I 
am without it. I couldn't tell you if I'm an introvert or an extrovert, because my 
behaviour was first ruled by my illness, and then by my medications. 
Adherence to 
treatment 
All I know is that the time I tried to come off my medications did not go well, and 
I have no desire to try again 
I've recently quit all my meds for bipolar because they had made me gain 
weight.  I am discovering I do need the meds for my mental health, and plan to 
restart them this week. 
In 2013 I had my Depixol [Flupentixol] reduced by half which transformed me 
from a zombie into a fully functioning individual and therefore made me 
medicine compliant. 
Your questions tackled the heart of the issues, I have no wish to take any 
medication but I'm too afraid to stop as when I do, within 10 days I'm not 
sleeping, over thinking and very anxious.   if I could ascertain how long this 
would go on for I would be prepared to continue.. 
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8.4 Discussion 
This study aimed to describe SDM experiences and preferences in BD as well as explore 
whether psychological factors of illness and treatment perceptions and satisfaction with 
information are associated with SDM. In addition, to explore whether SDM was associated 
with higher adherence to medication. In terms of experience of SDM, the majority of 
participants were involved in the decisions about starting and continuing the medications they 
were currently prescribed. There was also a high degree of treatment empowerment in this 
sample with individuals feeling that they have control over the choice and use of medications. 
However, a significant minority felt they had no involvement and only one quarter had 
completed statements or plans to specify future care or treatment in the event of crisis or lack 
of capacity. There was a significant correlation between being involved in starting and 
continuing mood stabiliser. This indicates that if SDM can be instigated at the start of 
treatment, it may then be extended to ongoing involvement. In terms of preferences 
(measured using the API scale), scores on the Decision Making subscale indicate that there is a 
general preference for more personal and less physician involvement in making decisions 
about their care. In terms of information seeking there was a strong preference for being 
informed about their care and treatment.  
With regard to associations between the SDM measures and psychological factors, higher 
levels of satisfaction with information about medication was associated with increased 
involvement in decisions about individual medications and with treatment empowerment, i.e. 
overall experience in being involved in treatment.  
In terms of the relationship between adherence, treatment beliefs and both involvement in 
specific medication decisions and overall treatment empowerment, there were no consistent 
associations. For antidepressants there was a significant association for the VAS adherence 
measure and involvement in the decision to continue this medication. There was a significant 
positive association between adherence to mood stabilisers and a greater preference for being 
informed about treatment. Stronger belief in the necessity of treatment of ATAPs was 
significantly related to both a stronger preference for personal involvement in decision making 
and for being informed about illness and treatment. Lower preferences for information about 
illness and treatment were associated with higher levels of satisfaction with information about 
medication. Higher satisfaction levels can reflect a lack of desire for information as individuals 
may perceive that they do not need any, and this is part of the SIMS measure, this may 
account for this result. 
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It is encouraging to note the high level of treatment empowerment, as the perceived power 
differential between patient and clinician had been reported as a significant barrier to patients 
having an influence on their own care in the UK (Farrelly et al., 2015). The power differential 
which was reported qualitatively by participants in the IBiD evaluation (Chapter 7) in the acute 
setting, is perhaps less of an issue in community mental health care. Empowerment has been 
shown to be a facilitator of SDM in a large review across health conditions (Joseph-Williams et 
al., 2014) so the high empowerment seen in this population in encouraging, patients 
undergoing mental health treatment are likely to be involved in their care decisions. 
The finding that a higher degree of satisfaction with information about medication was 
associated with increased involvement in decisions and with treatment empowerment concurs 
with the results of a review in psychiatric care. This found that a lack of information about 
treatments and choices was a barrier to involvement in care planning (Bee, Price, Baker, & 
Lovell, 2015). Another barrier which has been reported is worry about making an incorrect 
decision (Eliacin et al., 2015). Therefore, being provided with appropriate information about 
medications, may enhance potential for involvement, or indeed those who are more 
empowered to be involved may also be more likely to seek out information about treatments. 
The lack of associations found between SDM measures and adherence and treatment 
perceptions is surprising, as other studies have indicated that there may be an association as 
medication driven by patient choice was associated with improved attitudes and adherence 
(Sajatovic et al., 2014) and between levels of autonomy and adherence (G. C. Williams et al., 
1998). However the study by Sajatovic and colleagues (2014) had a small sample size (n=29) 
and an uncontrolled design therefore switching medication at all, whether informed by patient 
choice could have improved adherence. A meta-analysis of 32 studies in mental health found 
that those receiving preferred treatment or who were involved in SDM had higher treatment 
satisfaction (Lindhiem et al., 2014). The present study hypothesised involvement in decisions 
would be associated with more positive treatment perceptions, however this was not found. 
The limitations discussed below may account for this and there may be other factors, not 
included in this study which account for differences in treatment perceptions. 
The investigation of illness perceptions and SDM, has to our knowledge, not been reported to 
date in BD. It was found that increased involvement in decisions was associated with greater 
perceptions of personal and treatment control over BD. Being involved may enhance self-
efficacy to manage BD through having positive experiences of involvement, thus improving 
people’s perceptions of how they can affect their own outcomes or receiving affirmation from 
HCPs on how their input in their own care is important. Or perhaps, having a more positive 
view of how BD can be controlled by medication may lead to feeling empowered to get 
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involved. However, associations do not imply causation and the direction of causation may be 
the other way around. Being involved in decisions could potentially lead to greater views about 
the effectiveness of treatment as participants may be taking a treatment which works better 
for them as they were involved. Involvement and treatment empowerment was also 
associated with greater levels of agreement with the diagnosis, again this ties in with 
effectively self-managing the condition which has shown to be associated with insight and 
acceptance of the diagnosis (Gonzalez-Pinto et al., 2010; Látalová, 2011). A qualitative study 
with patients with depression also showed that insight into severity of depression affected 
engagement in decision making (D. Simon, Loh, Wills, & Härter, 2007). 
The findings from this study relating to whether people wish to be involved in decisions, i.e. 
their SDM preferences, indicated a general preference for more personal and less physician 
involvement and strong preferences for being informed about care and treatment. This 
concurs with previous research in mental health where patients report that they wish to be 
involved in their care (Bilderbeck et al., 2014; de las Cuevas et al., 2012; Hill & Laugharne, 
2006; Sajatovic et al., 2005). Woltmann and Whitley (2010) elaborate on what shared decision 
making means to patients from the results of a small qualitative study with people with severe 
mental illness. Participants descriptions of what they meant by ‘shared’ was that they wish to 
have an autonomous role in the first instance only to defer to clinician judgement if necessary. 
This does differ from the definitions of SDM where the whole process is collaborative in that 
information is shared and discussed and the decision is reached together. 
We did not find an association between SDM and whether participants had actually created a 
treatment or care plan, although the numbers actually having done this was small. As relatively 
few make these formal, written decisions, it appears that more informal SDM is occurring as 
many reported they are involved in the decisions. Previous research in a trial of completing 
advanced directives has shown that being helped to complete these was associated with 
greater likelihood of receiving desired treatment than those given no assistance in completing 
a directive (Swanson et al., 2006; Wilder et al., 2010). However, participants’ feedback, 
although only from a small number, indicated experience and fears that plans would not be 
enacted, concurring with an RCT showing that implementation of JCPs was not consistent 
(Thornicroft et al., 2013). Further work is needed to establish whether plans were followed 
and the outcomes of this in terms of adherence and perceptions of treatment. 
We found no age or gender differences for any of the SDM measurements, this ties in with the 
mixed evidence in this area, demographic differences do not seem to be consistently 
associated with SDM. However these studies include different populations recruited from 
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different settings and so are not directly comparable (Hill & Laugharne, 2006; O'Neal et al., 
2008). 
Although not the primary hypothesis of this study, analysis revealed no associations between 
adherence and either necessity beliefs or concerns about medication for any of the classes of 
medication prescribed. However, beliefs about the general harm of medication were 
associated with poorer adherence for antidepressants and mood stabilisers, and a belief that 
medications are overused and poorer adherence for mood stabilisers only. 
 
8.4.1 Limitations 
This cross-sectional study is limited by the small sample size, this was compounded by the 
need to analyse different classes of medication separately. It was important to acknowledge 
the differences between medications and not create composite measures which mask 
differences. Different results were observed for different classes of medication participants 
were prescribed, this emphasises the importance of measuring behaviours and beliefs 
separately instead of, as other studies have done, asking participants to generalise across their 
medications. However, by doing this, the power for this analysis is reduced. However, a major 
limitation is that the aspects of SDM measured using scales may actually be different for 
different classes of medication. It may be possible that participants prefer to be involved in 
decisions about some classes of medication they have more experience and / or more 
information about and might wish for a more paternalistic approach for new treatments. This 
would need to be investigated with further research. 
The study only achieved a small sample and it was found that recruitment through social 
media was challenging. It was not possible to recruit through some channels which initially had 
been proposed as potential sources of participants. With more resources, linking with 
community mental health teams would enhance recruitment. However, a strength of this 
research is that the recruitment strategy aimed to recruit participants who do not necessarily 
engage with specialist mental health services, just with primary care to give a more 
representative sample of people with BD. By using social media to recruit participants, we 
cannot be sure that there are only UK respondents, however, UK based social media users and 
groups were contacted to minimise the chance of responders from outside the UK. 
The cross-sectional design only allows us to investigate the relationship between factors, and 
not direction of causation. Further longitudinal research would be needed to investigate how 
SDM might actually alter perceptions and behaviours. In addition, it would be possible, with a 
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larger sample to analyse whether SDM preferences change over time and are affected by 
illness stage for example. 
This study explored the different measures of SDM as well as multiple possible related 
variables. Corrections for multiple testing were not performed as the analysis was exploratory 
in nature and the study was not powered to do so. 
Participants’ diagnosis was unconfirmed by diagnostic interview, although as all participants 
reported psychotropic medications, this goes some way to verifying that they had received a 
diagnosis. One participant was excluded from the analysis as their medications were reported 
as ‘drug a’, ‘drug b’. 
There may be a number of factors not explored in this study which may contribute to 
experience of SDM and medication adherence, for example therapeutic alliance as there is 
evidence for this from qualitative research (Eliacin et al., 2015). 
This study only focussed on decisions around medication, however we acknowledge that 
mental healthcare includes a number of other decisions which are made in an individual’s care. 
For example, referral for psychological treatment, hospital admission and discharge and 
provision of acute or primary care as an outpatient. Therefore it doesn’t cover the full 
spectrum of decision making which might occur for individuals. 
 
8.4.2 Conclusions 
People with a BD diagnosis in this sample appear to generally be involved in their treatment 
decisions and express a preference for this. This is reassuring given concerns in mental health, 
issues of a history of containment and compulsory treatment may present a significant barrier 
to involvement (Bee et al., 2015). However, the fact that there were participants who were not 
involved demonstrates that there is clearly work still to be done to achieve the aims to make 
sure that all psychiatric patients have the opportunity to be involved in their care (Coulter et 
al., 2011). This concurs with national surveys of community and acute patients which show 
that not all are involved in their care (Care Quality Commission, 2009a, 2011a, 2013). 
This study goes some way to addressing the paucity of knowledge about the ‘extent, 
variability, and correlates of shared decision-making in mental healthcare, especially in care for 
individuals with severe mental illness’ which was previously identified (pg 108) (Fischer, 2006). 
Our study was the first to investigate illness perceptions and SDM and found the importance of 
personal and treatment control beliefs as well as agreement with the diagnosis in involvement 
in treatment decisions. 
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The importance of having sufficient and appropriate information about treatment and BD itself 
was emphasised in this research with a preference for receiving information being expressed 
and the association between satisfaction with information and involvement in treatment 
decisions. Having accurate and sufficient information as well as feelings of empowerment are 
important aspects involved in SDM. 
Although we did not find consistent associations between adherence and treatment beliefs 
and SDM experience, we did find some evidence for adherence being associated with a 
preference for being informed and greater perceived necessity of treatment being associated 
with stronger preference for personal involvement in decision making and for being informed 
about illness and treatment. It is unclear from this study why SDM preferences as opposed to 
actual experience demonstrated these associations. 
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Chapter 9 General Discussion 
9.1 Overview 
The final chapter of the thesis provides an overall discussion of the key findings, summarising 
how the results addressed the research aims and places the findings in the context of 
published research. It discusses the main limitations, theoretical and clinical implications and 
areas for future research. 
This thesis sought to: 
 Understand patients’ perceptions of the challenges in dealing with a diagnosis of BD and 
engaging in self-management. 
 Uncover the unmet information and support needs of people with BD. 
 Investigate how current understanding of the determinants of health behaviour and 
behaviour change theory can be applied to adherence and self-management. 
 Determine the effectiveness of existing interventions to address adherence in BD. 
Following this the thesis sought to: 
 Develop a novel intervention to target adherence to medication through proximal 
determinants of perceptions, understanding, satisfaction with information and 
internalised stigma by using the step-wise method of Intervention mapping (IM) 
involving behaviour change theory and service-user consultation. 
 Test the feasibility and acceptability of conducting an RCT of the intervention in an acute 
adult mental health setting. 
 Investigate the extent to which patients with BD wish to be involved in treatment 
decisions, the extent to which they are involved, the association of these two factors 
with their illness and treatment perceptions and their adherence to medication. 
 Investigate the level of involvement in treatment decisions, preferences for this and 
association with illness and treatment perceptions and adherence in a population of 
people with BD. 
 
9.2 Summary of research 
In Chapter 1 the unique challenges presented by BD for many individuals, HCPs and service 
planners were identified. Staying well with BD can be dependent on; acknowledging and 
understanding the condition, holding beliefs consistent with adherence, receiving and 
understanding information on medication, effective relationships with HCPs and effective self-
management such as monitoring mood and behaviour for early warning signs of relapse. It can 
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be affected by personal factors such as people’s hopes, fears and how they view their 
experiences as well as contextual factors, the environment around them and the care they 
receive. Potential barriers to staying well and factors associated with medication adherence 
are clear. From these, potentially modifiable determinants of adherence were identified. The 
next stage was to select appropriate techniques to modify these determinants to improve 
outcomes for people with BD and devise a trial to evaluate the effects of an intervention. 
Chapter 2 discussed how current theory and research in health psychology and behavioural 
medicine contributes towards understanding how people with BD view their condition and 
how this can contribute to improving outcomes. Self-regulation theories, specifically the CSM 
(Leventhal et al., 1984) and e-SRM (Horne, 2003b), which address patients’ common sense 
understanding of their condition and treatment are of value, as they allow us to understand 
how people see their condition, their treatment, and how this affects their selection and 
appraisal of coping strategies. 
Chapter 3 formed a key stage in the process of developing an evidence-based intervention. By 
conducting a systematic review, we can see if there are current effective interventions which 
could be utilised, and by conducting moderation analysis we can see what may be promising 
content to improve adherence as well as ways of targeting and delivering an intervention. This 
was the first systematic review of adherence-focussed interventions in BD which used meta-
analysis to quantify the magnitude of effect. The review of 30 years of interventions 
demonstrated that they are generally effective in improving adherence relative to control 
groups and the effects appear to be durable. 
A key part of the MRC framework and IM process for the development of a novel intervention 
is conducting primary research to inform the intervention. It is particularly important to draw 
from the population and if possible, context where an intervention would be implemented. 
Chapter 4 comprised primary qualitative research which supports and elaborates on findings 
from CQC reports of the extent of unmet information and support needs in mental health care 
(Care Quality Commission, 2009a, 2013). The research identified crucial, specific insights into 
people’s own perceptions of their condition, their medication and information they have 
received and would wish to receive. The qualitative research provided detailed and specific 
service-user perspectives on which to develop the intervention, specifically to inform the 
content, delivery vehicle and context (Horne, 2012). 
The findings from the literature review, meta-analysis and primary qualitative research 
contributed to the development of a novel intervention described in Chapter 5 using IM. The 
Improving Information for People with Bipolar disorder (IBiD) intervention comprised a 
tailored, written booklet framed around the NCF and PAPA. The booklet, Bipolar Disorder: A 
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question of balance, was developed in consultation with individuals with a diagnosis of BD and 
a carer. The intervention aimed to improve adherence through the proximal measures of 
illness and treatment beliefs and satisfaction with information. BCTs were selected based on 
research evidence into potentially effective techniques to modify beliefs and behaviour. These 
included comparisons of pros and cons of taking medication, providing information from 
credible sources, promoting social support and problem solving. 
Once developed, IBiD was tested in a feasibility RCT within an acute adult mental health 
setting (Chapter 6-7). In terms of recruitment and retention, it was determined that there 
would be a sufficient population of eligible patients in this setting for a large trial. The study 
identified key aspects of good practice in recruitment in this setting, namely engaging staff 
well in advance of the study and maintaining communication throughout. Retention rates 
were good and again this can be attributed to the relationships built at recruitment stage and 
good ongoing communication between research staff, care-coordinators and participants. 
It was clear from the IBiD feasibility trial that more development work is required for a brief 
psychosocial intervention to address adherence and illness and treatment perceptions and 
meet other information and support needs which would help people to recovery and manage 
their condition. Particularly in dealing with some of the issues particularly pertinent to mental 
health treatment, namely, lack of involvement in treatment decisions, power differentials 
between clinician and patient and ongoing need for support in the context of fluctuating illness 
state and associated changing treatment. To this end a cross-sectional study of Shared 
Decision Making (SDM) was conducted (Chapter 8) to explore how both experiences and 
preferences around treatment decisions relate to illness and treatment perceptions and 
adherence. Participants had experience in being involved in decisions about their care and 
treatment and a preference for being involved. They reported feeling a high degree of control 
over their choice and use of medications. Overall the results of this study emphasised the 
importance of both receiving accurate and sufficient information about treatment and feeling 
empowered to be involved in care. However, there is still some way to go to ensure that all 
individuals with BD have the resources and capability to be involved. 
 
9.3 Strengths and contribution of this research 
9.3.1 Patients’ perceptions of BD, engaging in self-management and their information and 
support needs. 
This programme of research aimed to better understand patients’ experiences in being 
diagnosed with BD, and how they have found managing their condition. Alongside this it 
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sought to understand the information and support needs they had in relation to both the 
diagnosis and treatment. 
A review of published literature revealed that elements of self-management in BD included, 
receiving and understanding information on the condition and medication, building effective 
relationships with HCPs and using tools such as monitoring mood and behaviour for early 
warning signs of relapse (Chapter 1). In addition to this review, the primary qualitative 
research (Chapter 4) identified crucial, specific insights into people’s own perceptions of their 
condition, their medication and information they have received and would wish to receive. 
This was a vital step in developing a novel intervention and forms a key part of the MRC 
framework and IM process. Illness could be a burden to participants, in dealing with 
symptoms, challenges to sense of self and wider stigma. However, we heard how participants 
came to an understanding of BD and medication which allowed them to recover their sense of 
self and live well with the condition. This provides support for the recovery model, in that 
despite the fact that they may still experience symptoms, they were able to achieve recovery 
in the sense of living a life which fulfilled their goals and wishes. 
With regard to the effect of the diagnosis and treatment on individuals’ sense of self, taking 
medication was seen as either a return to the true sense of self or taking this away. By 
investigating both perceptions of peoples’ perceptions of mood modifying medications, and 
how these impact on their feelings about themselves, this study adds greater insight into the 
area. It was illuminating to discover that for people with ostensibly the same diagnosis, their 
experiences and reactions to the diagnosis and treatment varied considerably and also how 
much it could change through their lives. Stevenson and Knudsen (2008) also found that the 
fact that medication has been prescribed meant that individuals were able to understand that 
the problems they were experiencing were more than sadness and were depression. For some 
people, taking medication can represent acceptance of the diagnosis so there was ambivalence 
with a feeling that they should be able to come to a solution that is not reliant on medications, 
but that this was in many cases the only way to live a normal life. Chang and colleagues (2015) 
investigated the links between attitudes to medication and social factors in people prescribed 
mood stabilisers. More favourable medication beliefs were associated with higher levels of 
social support and a belief that others (family and clinicians) can influence their health. 
However, those taking part in IBiD often did not have support, were isolated and depended on 
care coordinators as opposed to family and friends.  
Despite the fact that individuals expressed that medication is helpful, some expressed a desire 
to be medication free, to reach a stage where they could manage mood episodes with lifestyle 
changes. This area has not received a great deal of research attention. We do know from 
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adherence rates a high proportion of patients will stop taking their prophylactic medication 
(Arvilommi et al., 2014; Cavanagh, Smyth, & Goodwin, 2004). Research conducted by 
Cappleman and colleagues (2015) adds to the knowledge of reasons which people might not 
wish to take medication (adding to insight, necessity beliefs and concerns about medications). 
Individuals carried out their own cost-benefit analysis in deciding whether to stop. Costs 
included side-effects and how these affected them as individuals, for example their ability to 
work. Those experiencing episodes whilst taking medication had reduction in perceived 
effectiveness. They searched for alternatives to medication, managing lifestyle, exercise, trying 
to change how they think about things in trying to keep mood stable. But experienced 
difficulties in recognising these changes and having an incentive to bring mood down. We also 
observed this in this programme of research. Participants in the IBiD qualitative evaluation 
(Chapter 7) wished to find other ways to manage their BD. This was perhaps why the mood 
monitoring exercise included in the IBiD intervention was viewed positively as it may have 
served as a way for participants to feel more informed and empowered, in alignment with the 
recovery model. It was clear throughout the development of IBiD, that instead of simply 
developing an intervention just focussing on adherence to medication, it needed to address 
their wider needs and acknowledge that people want ways to stay well and help them set and 
meet personal goals. 
Cappleman and colleagues (2015) found people conducted cost-benefit analysis to evaluate 
the outcomes of their self-management strategies, in the same way that medication is 
evaluated. This fits with self-regulation theory of choosing coping behaviours which fit with the 
symptoms and schema of illness. If they judged medication had not been effective an 
alternative strategy was selected and tried. In IBiD, this technique was used in the form of an 
exercise and during discussions, participants were able to identify these costs and benefits for 
themselves. A participant in the qualitative evaluation reported finding a new medication 
which she felt had more benefits and therefore was happier to take it. This was an extremely 
encouraging finding and an example of the recovery model in action. She was empowered to 
seek out information and make an informed decision. It is vital that patients are told about 
medication alternatives, not just alternatives to medication and that their fears are 
acknowledged and addressed. The cross sectional study identified a strong desire to be 
informed about different types of treatments and to be given accurate information about side-
effects. A decision to stop taking medication may for a patient represent the outcome of their 
own cost benefit analysis and this must be acknowledged. This idea supports the movement 
towards SDM. The cross-sectional research showed that people generally have been involved 
in decisions about their treatments. Previous research indicated that treatments involving 
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shared decisions are more likely to be adhered to and effective (Sajatovic et al., 2014; Wilder 
et al., 2010). However, the small cross-sectional study was not able to corroborate these 
findings. 
The empirical research identified stigma as a significant issue for some people with BD. In the 
qualitative study, the stigma of mental illness made it difficult to accept the diagnosis and be 
labelled as mentally ill. They felt they were treated differently because of their condition. In 
the feasibility RCT, although rates of overall internalised stigma were not high, half of 
participants reported feelings of being different and a worse person (Alienation) and 
experiencing discrimination (Discrimination Experience). Participants in the qualitative study 
also reported concerns about disclosure, particularly in the workplace. In a similar vein, 
findings from Healthwatch England found that people with a mental health condition were 
treated differently from others by health professionals because of their diagnosis (Healthwatch 
England, 2015). In particular, as with participants in the qualitative study in Chapter 4, people 
felt that physical health problems were overlooked as professionals took physical symptom 
reporting as a part of the mental health condition. This is a significant issue as people with a 
mental health diagnosis have an increased risk of physical illnesses (Hert et al., 2011). Stigma 
has been shown to be associated with reduced help seeking for mental health problems 
(Clement et al., 2015). At present stigma is included only in one item of the BMQ ‘I tend to 
hide the fact that I am taking this medicine from other people’ and it is not covered in the brief 
IPQ. The addition of stigma, particularly experience of discrimination would be important to 
investigate and potentially adding explicitly to treatment and illness models to increase their 
relevance for mental health. 
The dissatisfaction of information about side-effects found in this programme of research in 
both the qualitative and quantitative studies within community and the acute setting is 
reflected in the published literature. Indeed, patient reports are corroborated by professionals 
who report concerns about giving too much information about side effects so information was 
withheld, they did not always inform patients that medication was needed in the long-term as 
they had a fear of putting people off (E. Brown & Gray, 2015). Clinicians own views about 
medication and adherence are likely to be an important consideration for future interventions 
to help patients adhere and to promote informed decisions. Mental health staff have reported 
regarding side-effects as an inevitable consequence which must be accepted or ignored, and 
some community mental health staff appear to also lack knowledge of medications (Morrison, 
Meehan, & Stomski, 2015). 
In acute wards in the UK, patients have reported accepting the need for medication 
administration, but were troubled by side-effects and reported that these were not routinely 
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monitored (Duxbury et al., 2010). This finding was also reported by participants in this 
programme of research. Patients wanted more information and some of their anxieties were 
associated with a limited understanding of their treatment. However the nature of medication 
administration on the wards means that this may not be an appropriate time for information 
exchange due to time pressures and a lack of opportunity for confidential discussions (Duxbury 
et al., 2010). On the ward, there is a key need for information provision to ensure informed 
consent and facilitate a good therapeutic relationship, but the time and place for this requires 
consideration. In addition, this programme of research found that on the wards, patients 
wished to spend more time with staff and engage in therapeutic activities. A review of how 
inpatient mental healthcare provision meets the needs of users (Hopkins et al., 2009) found 
that they expect to form relationships with staff, but administration responsibilities mean 
there is little contact time. It has been found that there is decreasing amounts of time on 
wards for social interaction or activities and nurses time spent with patients has decreased and 
little of this time is actually spent in therapeutic intervention (Sharac et al., 2010). We know 
that the length of inpatient psychiatric stays has decreased and the focus is on ensuring safety 
and stabilising patients after a mental health crisis (Glick et al., 2011). Participants in the 
current research also identified that discharge was sometimes too quick and they didn’t feel all 
their needs were met. It may indeed be difficult to rationalise the needs of patients with the 
practicalities of the inpatient setting. Interventions need to have flexibility in how they are 
delivered. The IBiD intervention comprised a resource which could be used in the inpatient 
setting and also following discharge. Comparing the findings from this programme of research 
and current mental health policy in the UK, gives clear indication that there is a considerable 
way to go to meeting targets. The 2011 mental health strategy sets out that more people with 
mental health problems will recover, have greater ability to manage their own lives and have a 
positive experience of care and support (HM G, 2011). It also states that people should have 
access to interventions which give people choice and control over their lives. Participants in 
this programme of research often reported experiences of care, particularly in the inpatient 
setting which were not positive. However, the fact that many in the cross-sectional study had 
been involved in treatment decisions and felt high levels of personal control implies that the 
government targets could be met with effective, understanding care and adequate resources. 
 
9.3.2 The application of frameworks for understanding health behaviour and behaviour 
change theory to adherence and self-management in BD 
This programme of research identified and applied appropriate models and frameworks which 
aim to explain health behaviours and also drew on the behaviour change evidence and apply 
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this to adherence and self-management in BD. The CSM (Leventhal et al., 1984) and e-SRM 
(Horne, 2003b) incorporate patients’ common sense understanding of their condition and 
treatment. The programme of research conducted aimed to better understanding how people 
see their condition and treatment so add to the applicability of the models to BD. The models 
cover the relationship between people’s beliefs to their selection and appraisal of coping 
strategies, one of which is adherence to medication. The findings from the research in this 
thesis support the dynamic nature of the models as illness and treatment perceptions may 
change, particularly in an episodic condition such as BD. It was clear during the research that 
there are aspects of mental health conditions which mean that some further development of 
the models are needed to ensure they apply adequately to these conditions. These 
implications and future research directions are addressed in Section 9.5, but include a more 
detailed emotion component (not solely anxiety, fear etc.), perceived discrimination, 
relationships with care providers and involvement in and preferences for decision making. 
Linked in with developing the frameworks to increase applicability to mental health, is the 
corresponding need to ensure that the measures used to operationalise the frameworks 
contain all the relevant constructs. This was explored in Chapter 2, section 2.4 and the findings 
from this programme of research provide insights into how measures of illness and treatment 
perceptions might be adapted. These include taking into account that individuals may view 
medication as one of the factors which help them to stay well or manage BD and the wording 
of the BMQ should acknowledge this. For the influence of side-effects on an individual’s 
beliefs, the side-effects item needs to acknowledge that people experience both physical 
effects and effects on how they feel. With regards to illness perceptions, as mentioned above, 
the measurement of the emotional impact of the condition in the brief IPQ should be 
expanded and not just include negative emotions. The measure does not take a recovery-
model approach as people may understand that the diagnosis may be chronic but they also 
forsee that they may recover and live a fulfilling life so the single item does not provide any 
understanding of how people view their ongoing life with BD. As discussed below in 1.4.1, 
findings from the IBiD qualitative evaluation and cross-sectional study indicate that further 
development is required to improve the applicability of the measures for people with BD> 
Returning to the support for self-regulatory models, findings from this programme of research 
support the concept that adjustment and agreement with the diagnosis may be a facilitating 
factors in better engagement with treatment, being involved in decisions and accepting 
medication. A large European study found that improvements in insight and improvements in 
therapeutic relationship were associated with improvements in adherence and clinical 
outcomes. Relationships between these variables may be bidirectional (Novick et al., 2015). 
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Interventions targeted particularly at those with low levels of insight might be worthwhile to 
improve adherence. 
 
9.3.3 The effectiveness of existing interventions to improve adherence in BD 
Through a systematic review and meta-analysis, the effectiveness of existing interventions for 
adherence in BD was explored. This is a key part of developing any evidence-based 
intervention as key moderating variables of effectiveness can be identified. The systematic 
review was reported in accordance with PRISMA guidelines (Liberati et al., 2009), ensuring that 
the review was transparent and replicable. 
The review identified that interventions are generally effective in improving adherence relative 
to control groups and the effects appear to persist. Moderation analysis revealed that even 
brief interventions were effective and the effects were robust when sensitivity analysis was 
conducted to include only high quality studies. However, many interventions were 
inadequately reported, both in terms of what the intervention comprised and how it was 
delivered. Reporting of trial design and procedure was also frequently inadequate, meaning 
that the risk of bias was impossible to judge accurately. It was not possible, from the published 
evidence to specifically identify what would work for a particular patient group, in a particular 
context. However, within the context of the development of a novel intervention for this 
programme of research, the review demonstrated that a brief intervention would have the 
potential to improve adherence. CBT and psychoeducation techniques should be selected due 
to the findings indicating that these would be valuable components of an effective 
intervention where adherence was the primary target. It wasn’t possible to identify a specific 
intervention which was brief, well described in sufficient detail to be implemented and 
appropriate for the needs for this particular group of patients. In order to ensure that an 
intervention would be appropriate for and acceptable to the target population, additional 
development work was conducted to design a novel intervention. 
 
9.3.4 The development and feasibility assessment of a novel intervention to target adherence 
to medication in BD 
A novel intervention (IBiD) was developed which aimed to target adherence through the 
proximal determinants of perceptions, understanding, satisfaction with information and 
internalised stigma. IBiD was tested in a feasibility RCT to establish the viability and 
acceptability of the intervention in an acute adult mental health setting. Development of the 
IBiD intervention was conducted using MRC guidelines (Craig et al., 2008) and the IM process 
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(Bartholomew et al., 2011) to ensure methodological rigour and that the interventions were 
based on, not only up to date research evidence on behavioural determinants and behaviour 
change theory, but also were relevant and applicable to the actual target population. 
Published guidelines were used to report the feasibility RCT, the CONSORT Statement for 
reporting RCTs of non-pharmacologic treatments (NPT) (Boutron et al., 2008) and the TIDieR 
guidelines to guide reporting of the intervention description (Hoffmann et al., 2014). This 
ensured that the study was reported transparently, it would be replicable and the descriptions 
are comprehensive. 
Patient information must reflect actual patient need, which current written information may 
not (Grime & Pollock, 2004). A strength of the current intervention was that it was written 
using insights gained through the primary research with patients (Chapter 4) as well as the 
content and wording being developed in consultation with service-users. The qualitative 
research provided detailed and specific service-user perspectives on which to develop the 
intervention, specifically to inform the content, delivery vehicle and context (Horne, 2012). 
Namely, that medication can help regain self-identify, was a means to living well and that 
patients valued being given written information and having the opportunity to discuss this. The 
content needs to cover information on illness and treatment, in particular, side-effects, but 
also acknowledge people’s varied beliefs, experiences and needs. The appropriate time to 
provide this was found to be both at the acute stage of illness and when not experiencing an 
episode. The IBiD intervention has a number of features which add strength to its design. The 
intervention uses personal pronouns which have been shown to be related to greater 
satisfaction with explanation about medication side-effects than non-personal language (Berry, 
Michas, & Bersellini, 2003). BCTs were selected based on research evidence into potentially 
effective techniques to modify beliefs and behaviour. These included comparisons of pros and 
cons of taking medication, providing information from credible sources, promoting social 
support and problem solving. 
In keeping with the aims of a feasibility study, the IBiD intervention study provided valuable 
data on available participants in an acute setting, recruitment, retention & acceptability. In 
terms of recruitment and retention, it was determined that there would be a sufficient 
population of eligible patients in this setting for a large trial. However, by extending the 
recruitment to patients after discharge a greater number of eligible patients who were initially 
approached on the ward and expressed interest in taking part but were discharged rapidly 
would be able to be followed up once in community treatment. This would potentially increase 
the recruitment rate. 
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The protocol provides an example of good practice in conducting research in this area and the 
study set-up, recruitment and retention strategies concur with recommendations for 
successful conduct of studies in mental health (Borschmann et al., 2014). In particular, 
engaging healthcare providers at the beginning, ensuring the study is relevant for the setting 
and maintaining respect and ongoing communication are vital. Borschmann and colleagues 
(2014) also conclude that robust feasibility studies are crucial to the success of studies. The 
feasibility RCT research process ensured that there was a strong focus on ethical 
considerations of conducting research in the mental health setting. It was vital to ensure that 
there was appropriate access for people with mental health difficulties to participate in 
research (Graor & Knapik, 2013; Lakeman, McAndrew, MacGabhann, & Warne, 2013). 
Gatekeeping can be an issue in recruiting to studies in this area (Borschmann et al., 2014). A 
severe mental illness diagnosis shouldn’t be a reason for not being able to participate in 
research and many patients wish to take part. Potentially the focus on protecting vulnerable 
participants can have the unintended effect of removing their autonomy which is unethical in 
itself. However, it is crucial to be aware that participants may be experiencing difficulties with 
cognitive and executive functioning (Quraishi & Frangou, 2002). The study protocol for the RCT 
was also flexible to the illness fluctuations and practical needs around the discharge period 
such as getting housing issues arranged. 
Retention rates were good and again this can be attributed to the relationships built at 
recruitment stage and good ongoing communication between research staff, care-
coordinators and participants. This study provides important learning for recruitment in this 
complex time of transition between inpatient and community mental healthcare. 
Randomisation was found to be acceptable to participants and they reported finding it 
interesting to take part in the study itself and complete the assessments. However it was 
important to remain flexible to the needs of individual participants, illness fluctuations and 
symptoms and side-effects associated with BD and medication throughout the whole study 
and intervention process. 
There was clearly a need for an intervention demonstrated by baseline illness and treatment 
perceptions, feelings of stigma and lack of satisfaction with information. The intervention was 
well received and self-reported actions included mood-charting and investigating different 
medication options. The IBiD feasibility trial provided benefits from participation in the study. 
In particular having the opportunity to open up about BD and to complete the questionnaires 
was reported by participants as helping them with their own insight into their condition. This 
supports published studies and reviews in mental health which has also shown benefits of 
research participation (Biddle et al., 2013; R. Byrne & Morrison, 2014; Jorm et al., 2007; Pollack 
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& Aponte, 2001). Lakeman and colleagues (2013) discuss a number of potential benefits for 
research participants, including the knowledge that their participation may help people in the 
future, potentially by altering how individuals viewed themselves as a valuable contributor 
rather than a service-user. Often vulnerable people may see themselves as powerless and 
research participation can give them a voice (Holloway & Freshwater, 2007). Participants may 
benefit by telling their story as it helps to frame and find meaning in their experiences 
(Lakeman et al., 2013). 
The complexities of medication regimens and the changes to treatment during the transition 
period presented challenges in how to measure outcomes for the trial and challenges for 
intervention delivery in how to take account of these changes. Future studies should conduct 
more regular assessments and track reasons for medication changes. Additional aspects of 
perceptions and behaviour around medication should be incorporated into questionnaires and 
some aspects are not appropriate for inpatient care. Questionnaires need to take account of 
the fact that some barriers may not be present in the inpatient setting, such as forgetting 
medication, and there may be other factors affecting adherence such as taking medication to 
satisfy clinicians and to be discharged. Current measures do not include these aspects. Future 
studies should also include a measure of motivations to take treatment as this also provides a 
useful discussion point for any adherence intervention and was not measured in this study. 
It was clear from the IBiD feasibility trial that more development work is required for a brief 
psychosocial intervention to address adherence and illness and treatment perceptions. 
Particularly in dealing with some of the issues particularly pertinent to mental health 
treatment, namely, lack of involvement in treatment decisions, power differentials between 
clinician and patient and ongoing need for support in the context of fluctuating illness state 
and associated changing treatment. 
 
9.3.5 Patients’ experiences and preferences for involvement in treatment decisions in BD 
The final aims of this programme of research were to explore peoples’ involvement in 
decisions about treatment. Specifically, how much people with BD have been involved, their 
preferences and how these relate to both illness and treatment perceptions as well as 
adherence to medication. The cross-sectional study of Shared Decision Making (SDM) explored 
these aims (Chapter 8) and was among the first to quantitatively explore SDM in a UK sample 
of individuals with BD. It contributes to addressing the paucity of knowledge in this area 
(Fischer, 2006). 
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Overall participants expressed both having experience in being involved in decisions about 
their care and treatment and a preference for being involved. Participants expressed feeling a 
high degree of control over their choice and use of medications. Being involved in starting a 
mood stabiliser was associated with involvement in continuing to take it, demonstrating that if 
SDM can be instigated at the start of treatment, it extends to ongoing involvement. This 
provides reassurance that there appears to be a move towards SDM in mental health with 
many people feeling empowered to be involved and make decisions about their care. 
However, there is still some way to go as a minority who wish to be involved are not and few 
have the opportunity to make advanced plans about their treatment. 
To date, illness and treatment perceptions and their association with SDM in BD had not been 
investigated. This study highlighted three key factors related to how involved people were in 
their treatment decisions, firstly perceptions of personal control over BD, secondly perceptions 
of how effective treatment is in controlling BD and finally agreement with the diagnosis. 
Greater satisfaction with the information they have received about medication was related to 
more involvement and preference for SDM. By identifying and implementing BCTs which 
enhance perceptions of control and also by providing sufficient and appropriate information 
about treatment, there is evidence that this may enhance SDM. 
In terms of outcomes, no consistent association between SDM experience and adherence was 
found. Larger studies, powered to detect changes in adherence in the same medications are 
needed to investigate this further. Overall the results of this study emphasise the importance 
of both receiving accurate and sufficient information about treatment and feeling empowered 
to be involved in care. However, there is still some way to go to ensure that all individuals with 
BD have the resources and capability to be involved. 
Dissatisfaction with a number of areas of current mental health care, information provision 
and support was uncovered through this thesis. Since this programme of research was 
conducted, the most recent CQC community mental health report continues to identify some 
dissatisfaction with involvement in care, although the Trust involved in this programme of 
research performed to an equivalent level to other NHS Foundation Trusts. Not all patients felt 
involved in their care and treatment decisions or given medications information (Care Quality 
Commission, 2014). In addition, generally Trusts performed poorly in supporting people in 
areas such as finance, housing and signposting to other services (Questions changed between 
2010-2013 surveys and 2014 so results are not able to be directly compared). The cross-
sectional research in this thesis found that generally people feel empowered to be involved in 
their treatment and there was a preference for personal involvement and receiving 
information. However, in practice, few had made advanced requests about their care and 
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there were low levels of satisfaction with information about medications particularly on the 
potential problems like side-effects of medication. This concurs with the CQC surveys 
indicating that unmet needs are still very much an issue in mental healthcare. Further research 
is needed to investigate how both SDM preferences, and specific information needs might 
differ across illness fluctuations and over the care journey from pre-diagnosis to the longer 
term. Psychiatrists often cannot predict patients’ preferences for SDM (Hamann et al., 2010). It 
is therefore important that as well as encouraging involvement right from the start of 
treatment, clinicians check with patients regularly about their experience and preferences 
towards their treatment. SDM training of five sessions demonstrated encouraging results in a 
pilot study where an increase in preferences for participation and desire for greater 
responsibility. However, a decrease in trust in clinicians and increased scepticism toward 
psychiatric treatment was also observed (Hamann et al., 2011). It is key that any SDM 
intervention is combined also with psychoeducation on illness and treatment and also that 
clinicians are also aware of the importance of SDM and how to effectively communicate 
around treatment decisions. 
A qualitative investigation with mental health service-users in the UK identified both positive 
and negative experiences of mental healthcare, consistent with the studies in this thesis. It was 
highly individual whether people felt they had been involved in their care. There was strong 
dissatisfaction between the continuity of care between services, and also inconsistency 
regarding messages about medication (Gale et al., 2012). This concurs with our findings that 
after discharge there was a lack of clarity as to what care was provided, who it was provided by 
and who was responsible for medication prescription. Previous research identified that 
changes in care providers were a concern for patients who also felt that there was a lack of 
ongoing support for preventing mental health crisis, and care was focussed on crisis periods, 
during periods of stability, they felt ‘invisible’ (I. R. Jones et al., 2009). 
A recent inquiry by Healthwatch England (2005) regarding support after hospital discharge 
raised a number of issues which reflect the findings from this thesis. One issue was a lack of 
coordination between services meaning that individuals were unsure who was to provide their 
care. Also, people are often discharged without the knowledge, skills and support to manage 
BD. However, in the Healthwatch enquiry as with the qualitative findings in Chapter 4 and the 
IBiD evaluation (Chapter 7), positive stories of good relationships with care providers were 
reported. We know good therapeutic relationships are associated with better adherence and 
outcomes (M. Byrne & Deane, 2011; Zeber et al., 2008). Healthwatch England (2005) also 
found that people did not feel involved in hospital discharge planning and did not feel that 
their concerns were acknowledged. 
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9.4 Limitations 
This programme of research extends knowledge in the field of BD and informs the future 
development of interventions to improve adherence and self-management in BD. However, 
the research programme is subject to a number of limitations. These limitations relate to the 
following areas; 
 Introduction of potential bias and threats to validity in the research 
 Limitations of the scope and scale of the studies 
 
9.4.1 Bias, validity and generalisability 
Research studies are often subject to a number of threats to validity. Bias can be introduced by 
different systematic, unintended errors such as selection and information bias which threaten 
internal validity, namely, whether results are true or as a result of how the study was 
conducted. In addition, external validity or generalizability refers to the extent to which results 
apply in other settings or populations (Kukull & Ganguli, 2012). This section describes how 
these limitations apply to the research in this thesis. 
 
9.4.1.1 Selection bias 
Within the systematic review the specific limitations of both the studies included and in the 
review methodology are detailed in Chapter 3. Potential bias may have been introduced by the 
selection of data for computation of effect sizes. Included studies were not homogeneous, 
therefore decisions were made by the researchers on how to best select the most comparable 
data. The outcome measures subject to lowest risk of bias (starting with serum medication 
levels) were chosen in preference to minimise bias introduced by self-report. Potential 
selection bias may have also been caused by the inclusion of published data only, however, no 
evidence of publication bias was observed in the meta-analysis. Moderation analysis may be 
affected by bias, in that the necessary data was not provided in published papers in order to 
include some studies in each analysis. In addition, the issues in participant retention in many of 
the studies introduce bias. 
Selection bias may have impacted on the findings from the qualitative and empirical studies in 
this thesis. The qualitative study in Chapter 4 did not include those who had disengaged with 
formal care. However, the objective was to include those who are prescribed medication and 
as such, recruiting from those engaged with psychiatrists was appropriate. The IBiD feasibility 
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study may be subject to selection bias as staff advised on participants who it was felt not 
appropriate to approach. This was for risk purposes to ensure that only participants well 
enough to provide consent were approached. Those who were eligible but we were unable to 
contact or were not interested in participating may differ from those recruited. However, the 
data is not available on which to make an assessment of this. 
Random sequence generation aims to mitigate against selection bias. The Cochrane 
Collaboration’s tool for assessing risk of bias in randomised trials allows an assessment of the 
risk of bias in the feasibility RCT (Higgins et al., 2011). The random sequence generation to 
allocate participants (described in Chapter 6, section 6.4) used minimisation, which is an 
acceptable approach where a balance is required between prognostic factors in small trials 
where other methods such as blocking and stratification are not appropriate (D. Altman & 
Bland, 2005). Minimisation ensured that groups were balanced on age and gender and the 
method was judged to have low risk of bias. Although this is a small, feasibility study and 
ensuring balanced groups was not necessary, it was noted that groups were not equivalent on 
key outcome measures at baseline. A baseline imbalance is an additional potential source of 
bias for a definitive trial, and either this should be included as a minimisation criteria or 
controlled for in the analysis if an imbalance is present.  
Selection bias may also be present in the cross-sectional study (Chapter 8). Participants were 
self-selected based on their willingness to complete measures relating to treatment and illness 
perceptions. The findings may not represent those who have a neutral view of treatment. In 
addition, in this study, the diagnosis of BD was not verified by clinical interview, however, 
participants all reported being prescribed medication consistent with the management of BD 
which provides validity to their self-report. 
 
9.4.1.2 External validity 
In the systematic review, a threat to external validity was that studies mostly included 
community samples where patients were euthymic. The applicability to an acute population 
may be limited, however, the dearth of research in this population meant that it was not 
possible to select according to this. Further studies in this area will help address this, as long as 
they are well described and high quality and future reviews could account for illness stage in 
the moderation analysis. 
Limitations in the generalizability of the qualitative research in Chapter 4 have already been 
described. The small sample were all of white British ethic origin, however, there was a 
mixture of genders, ages and length of BD diagnosis. Results generalise to the target 
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population for the intervention, this may be sufficient for the purpose for which the study was 
conducted. Indeed, generalizability is not always a target of qualitative research. It is more 
important to achieve sample adequacy to address the research questions (O’Reilly & Parker, 
2013). It is recommended that primary research for intervention development is conducted 
with the intended population (Craig et al., 2008). In terms of wider generalisation to other 
populations the results may not be as applicable. It is possible, for different ethnic groups, 
there may be key differences in illness and treatment perceptions, such as the cause of the 
illness, personal control and the necessity of medication. Further qualitative research and 
additional service-user testing with more diverse groups would add insight here. 
In terms of the external validity of the IBiD feasibility RCT, the small sample was majority 
female and aged on average 52 years. This compares with UK hospital admissions for affective 
disorders, with more females than males admitted in 2013/2014 and a mean age of 50 years 
(HSCIC, 2015). Participants had an average length of diagnosis of nine years with the majority 
having had previous hospital admissions and multiple episodes of mania and depression. 
Results may not generalise to newly diagnosed patients. However, within this population, the 
total number of patients who were eligible is small. 
 
9.4.1.3 Ascertainment bias 
Results of a trial may be influenced by knowledge of participants’ treatment allocation, this is 
referred to as ascertainment bias (Jadad & Enkin, 2007). Inadequate allocation concealment 
may result in exaggerated intervention effect sizes (Pildal et al., 2007). Allocation concealment 
was ensured by conducting the allocation separately from the CSOs involved in recruitment. 
They did not have knowledge or access to either the minimisation criteria, or previous 
allocations. Allocation concealment was judged to have low risk of bias. 
In terms of blinding, participants could not be blinded to the intervention as the comparison 
was TAU and we were upfront to participants about the two groups and their allocation. 
Blinding of personnel delivering the intervention was not possible, nor was blinding the care 
team of participants for pragmatic reasons, however, blinding of personnel conducting 
assessments was attempted. This was, in the most part, successful with six instances of 
unblinding and only four in those followed-up, which could therefore have impacted on the 
results. It is recognised that blinding of personnel and participants may be difficult or 
impossible in the delivery of psychosocial interventions and in these cases, blinding of 
outcome assessment reduces potential bias (Davidson et al., 2003). 
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Assessments based on non-blinded assessors results in a more beneficial intervention effect 
compared to blinded assessors (Hróbjartsson et al., 2013). Outcome assessments were 
conducted by blinded assessors and used validated tools. However, as outcomes were self-
report data, they cannot be regarded as blinded. There is therefore the potential for high risk 
of bias in the outcome assessments. 
 
9.4.1.4 Measurement bias 
There is the potential for self-presentation bias in the use of self-report measures. Participants 
may be fearful of admitting non-adherence in the hospital setting for fear of being held under 
section or subject to community treatment order. However the fact that the research team 
were separate from the care team and participants were reassured of confidentiality to reduce 
the potential of self-presentation bias. The wording of questionnaires also normalises and 
gives permission to report negative attitudes to treatment and instances of non-adherence. In 
the cross-sectional study, responses were anonymous in order to attempt to reduce the risk of 
self-presentation bias. 
Incomplete outcome data refers to either missed data from attrition or non-completion of 
questionnaire items and exclusions by investigators (Borenstein et al., 2011). The 
questionnaires were completed without missing data, potentially due to the CSOs going 
through the questionnaires with participants encouraging them to complete items and the 
questionnaire contained space for participants to indicate they were ‘unsure’ or the question 
was ‘not applicable’. In terms of attrition, follow-up data was not available for seven 
participants, however attrition numbers were comparable in the two groups. 
The outcome measures selected may have issues around validity of the results. There is the 
potential that the questionnaires may not have face validity. The IBiD evaluation and SDM 
study used validated questionnaires. However, it would be of value to conduct research to find 
out what outcomes are of value to patients. A review of existing outcome measures in mental 
health revealed that service-users felt that there was too much emphasis on the negative, that 
what was considered a ‘good’ outcome according to the scales, didn’t always reflect what 
participants felt was a positive outcome for them (Crawford et al., 2011). 
Indeed, participants in the IBiD qualitative evaluation and feedback from the cross-sectional 
study highlighted that there was not always a response category which they felt best fitted 
with their views and they wished to have more opportunity to add their own words. By 
conducting additional development work on both the validated measures and including 
outcomes pertinent to patients, the assessments would have greater validity. A fine balance is 
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needed between measures which are comprehensive enough to capture patients’ experiences, 
but brief enough not to cause fatigue and exacerbate any problems with concentration and 
comprehension which people might be experiencing as a result of a BD episode or side-effects.  
Regarding the BMQ specifically, there may be value in adding additional components or 
revising existing items in order to generate a BD specific version, this would acknowledge the 
differences and complexity of medication in this area as well as specific perceptions in mental 
health, for example the threats to sense of self reported in the qualitative study in chapter 4. 
The BMQ also doesn’t include a measurement of perceived efficacy of treatment and a 
separate efficacy subscale may be warranted (Horne, 2003b). 
Both the IBiD feasibility study and the cross-sectional study presented the challenge of the 
complex and changing medication regimens in BD. The medication outcome measures were 
confounded by changes between timepoints. Other studies have dealt with the issue of 
multiple medications by selecting one medication to measure, or asked patient to give their 
global feedback. For example, Levin and colleagues (Levin, Sams, Tatsuoka, Cassidy, & 
Sajatovic, 2015) computed an average self-report score when multiple medications were 
taken, but using electronic adherence monitoring for the medication taken most frequently. 
This removes the nuances of treatment beliefs and adherence whereby an individual patient 
may have different views on their mood stabilisers compared to their benzodiazepines for 
example. We found that differences were observed in adherence and perceptions between 
different medications in the cross-sectional study and therefore asking about individual 
treatments is important to capture this variability. This observed variation may be a result of 
the small sample, further studies are needed to investigate whether there are real variations 
between adherence and treatment perceptions within individuals. 
Data from the qualitative studies and IBiD evaluation indicate that other behaviours, aside 
from adhering to medication are important in maintaining wellness and preventing relapse, for 
example sleep management and monitoring prodromes. A new measure of self-management 
could be developed and used to assess changes in using self-management techniques. 
Research has identified techniques which patients find useful (S. Jones, Deville, Mayes, & 
Lobban, 2011; Suto et al., 2010; Todd et al., 2012). In fact this may represent a useful patient 
reported outcome measure to capture, not recovery from illness, but having the skills and 
empowerment to manage the condition well. Early work on the development of the Mental 
Health Self-Management Questionnaire (MHSQ) may provide a promising tool to measure this 
and should be integrated into future work on adherence and self-management (Coulombe et 
al., 2015). This scale incorporates active involvement in accessing information and treatment 
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decisions, monitoring for signs of illness and engaging in healthy lifestyle activities in addition 
to taking medication and engaging with mental healthcare. 
 
9.4.1.5 Selective outcome reporting 
Selective outcome reporting occurs where only a selection of the original outcomes are 
included in publication. It might be the case that after analysis, non-significant results are not 
reported. In the IBiD feasibility trial, the aims were, not to determine, statistically the 
intervention effectiveness and the trial was not powered to do so. As is demonstrated by the 
inclusion of the study questionnaire as Appendix L it can be seen that all original outcomes are 
presented in this thesis. The study therefore has a low risk of bias with regard to selective 
outcome reporting. 
 
9.4.2 Scope and scale of the research 
The research programme here forms the necessary preliminary work prior to a definitive trial. 
As such it is limited in its scope and scale. We did not have the capacity to quantitatively draw 
conclusions on the efficacy of the intervention. Exploratory analysis did not reveal any 
indications of superiority of the intervention over the control group, and the potential reasons 
for this were outlined in Chapter 6, section 6.7.2. The scope to assess outcomes was limited by 
the measures used. The fact that this was a feasibility trial does allow us to gather data on 
potential what other factors might be important to collect and which might provide data on 
potential confounders. It was clear that the follow-up assessments need to incorporate the 
collection of more information on medication changes between the time points including 
reasons for the changes. 
The feasibility study could be viewed as being limited in that the comparison group was TAU, 
rather than an existing intervention or attention-matched control. However, as this was the 
trial of a novel intervention with no evidence of superiority over usual care (clinical equipoise) 
it was a valid comparison group. As discussed in Chapter 6, Section 6.3.1, it was also necessary 
for pragmatic reasons and provides a valid comparison as it compares to current service 
provision. Definitive trials of a psychosocial intervention might investigate comparing an 
intervention against both TAU or an attention matched control, as well as possibly comparing 
the self-management written resource on its own and with support from a therapist. The 
follow-up period in this study was limited to 6-8 weeks, so we are unable to draw conclusions 
about the feasibility of retention over a longer period. In addition, we were unable to assess 
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the immediate effects by conducting an assessment immediately post-intervention due to HCP 
concerns about participant burden. 
The scope of the IBiD intervention itself was also limited. Partly by the desire to keep it brief to 
enhance the potential use in clinical practice and also by the lack of available evidence on 
effective BCTs and how exactly to implement them, both within this context and for this 
patient group. The use of BCTs in intervention development has been challenged for the fact 
that in order to be successful, certain conditions are necessary, including that the selection of 
techniques should carefully match the behavioural determinants and that the determinants do 
in fact predict the behaviour (Kok et al., 2015). There is good evidence within this programme 
of research that the second condition was met. However, the lack of evidence to draw upon 
for matching specific methods to implement techniques means that the intervention 
development drew on the best available evidence from mental health and adherence research 
in physical health and the qualitative research from people with BD. As such, it is possible that 
these techniques may not work in practice to affect behaviour or with this particular group. 
Modelling work where intervention messages are tested in an experimental setting would be a 
useful avenue for further developing the intervention content. 
The cross-sectional study was also limited by its scope and scale. A cross-sectional design does 
not allow for analysis to determine causation, as such the conclusions drawn only infer the 
association. However, from these associations, hypotheses can be made which could further 
be tested using a longitudinal design. For example, are illness perceptions of treatment and 
personal control a cause of SDM preferences and experience, or do perceptions change as a 
result of experiences with care. The cross-sectional study was also limited by the small sample 
size. Larger samples would allow for determining the predictive value of other variables on 
SDM or for more detailed analysis of different medication classes. However, recruitment to 
research in mental health clinical populations is challenging and a strength of this research is 
that recruitment was not restricted to people who are engaged with mental healthcare and 
recruited through their clinicians and may not have previously been given a voice to participate 
in research. 
 
9.5 Theoretical implications & future research directions 
Overall the findings from this thesis support the components of self-regulation models of 
illness and treatment (Horne, 2003b; Leventhal et al., 1984). Beliefs about illness and 
treatment appear to be related to adherence and engage in self-management (Chapter 4 and 
Chapter 7). There is support for the parallel processesing of emotions and cognitions, the 
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emotional impact of the diagnosis, taking medication and the life experiences people had had 
due to BD was a strong theme for paricipants narratives. The impact of emotional aspects 
should be investigated further in terms of the relationship with treatment engagement. The 
utility of illness perceptions in relating to how people are involved in care adds support to the 
utility of the CSM in mental health and in being associated with outcomes. 
However, conducting this research has provided the opportunity to add insight into how BD 
research could inform future development of these models. Future research in this area should 
incorporate measuring other moderators of behaviour (Sniehotta, 2009; T. Webb & Sheeran, 
2006). These could include volitional control as people may not actually have the control over 
performing the behaviour and habitual control, which may be particularly important in 
adherence due to the behaviour being repeated within the same context (T. Webb & Sheeran, 
2006). Additional factors which would be useful to add into current models of adherence for 
further testing are stigma, in particular, perceived discrimination, therapeutic alliance, 
involvement in and preferences for decision making and perceived coercion or enforced 
treatment. The wider determinants of adherence should also be incorporated, including these 
social and interpersonal factors.  
Longitudinal research is needed to determine the stability of illness and treatment beliefs as 
well as decision making preferences during both episodes of mania, depression and euthymia 
and also from first diagnosis to later in the illness journey. In addition, this would help to 
determine the relationship between perceptions, behaviour and clinical outcomes. 
A further issue, specific to BD is that individuals may not perceive some components of their 
illness as a problem (during periods of mania), therefore these may not be included in their 
perceptions of symptoms or challenges with BD. Illness perceptions during periods of 
hypomania may be rated with less severity. The findings from Chapter 4 which showed the 
differences between how people distinguish between themselves and their illness compound 
the difficulties with measurement of illness perceptions in mental health, this is backed up by 
research in schizophrenia (Kinderman, Setzu, Lobban, & Salmon, 2006). The component of 
identity in the CSM (Leventhal et al., 1984) warrants further exporation. Given this future 
research, along with service-user led development, outcome measures which have greater 
validity for use in BD could be developed. 
This research highlighted and emphasised the importance of comprehensive and accurate 
reporting of studies and interventions. The implication from this research is that high quality 
frameworks for describing studies and interventions exist and should be utilised. By using the 
TIDieR framework in assessing studies for systematic review, this process extends the original 
aim of this guidance. The outcomes of this assessment demonstrate that researchers need to 
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be clearer about their interventions, in particular, the materials used, who delivered the 
intervention and their training, the healthcare context of delivery, dosage and whether the 
intervention was modified or delivered differently than intended. 
With regards to intervention delivery, further research is warranted to better understand how 
to best target and deliver an intervention. Whether baseline assessments should be used to 
target interventions towards those most at risk of adherence should be investigated. However, 
longitudinal work on the stability of these variables, as mentioned above may mean that 
vulnerability to non-adherence and relapse may be difficult to predict based on baseline 
scores. Additional work is needed to determine the effectiveness of the intervention in a fully-
powered study and whether it should be delivered in multiple stages or with follow-ups to 
address additional concerns and information needs as they arise. 
 
9.6 Clinical and policy implications 
The unmet information and support needs for people with BD was confirmed by all studies in 
this thesis. Participants were not routinely provided with information on their condition, and 
frequently also on the treatments they were prescribed and the potential problems associated 
with taking treatment. The impact of this was that it was difficult for people to accept and 
move forward with managing their condition. An important point also raised was that people 
were not given sufficient information about side-effects or what could be done to alleviate 
these or change to alternative medications. This ties in with research with HCPs in the UK, 
where professionals working with people with schizophrenia reported withholding information 
on side-effects for fear of providing too much information and fear of putting people off (E. 
Brown & Gray, 2015). Illness should not be a factor which precludes information provision and 
therefore in line with SDM principles, an open, honest discussion should take place around 
medication where the side-effects and any uncertainties around effectiveness are included. 
Clinicians should be trained in having these conversations. 
Personal control perceptions within BD are an area in which intervention is warranted, 
concurring with previous research in illness perceptions in mental health (Baines & Wittkowski, 
2013). The IBiD intervention did not explicitly target this and it is worthwhile investigating 
specific techniques which could target personal control and self-efficacy. 
This programme of research indicates that the use of questionnaires in themselves may be 
useful clinical intervention. They give patients the opportunity to consider symptoms and side-
effects they may not have been told about. It is, however, imperative that they have the 
opportunity to complete these with a staff member so that issues can be raised. The 
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questionnaire could provide a way for them to raise issues which they may not feel 
empowered to do so otherwise. 
There are challenges with introducing clinical interventions within the mental health setting 
with pressures on mental health services (BBC, 2014) and there may be little capacity for 
information provision or discussions with staff (Rose et al., 2013; Stenhouse, 2011; Walsh & 
Boyle, 2009). In addition, increasing patient choice and responsibility will change the way that 
services are delivered. However, this programme of research indicates that there may be ways 
to integrate information provision and prompting discussion between patient and HCPs in 
order to empower patients within existing clinical encounters. 
 
9.7 Summary conclusions & recommendations  
This programme of research adds to the field of understanding, both of how it is to live with a 
diagnosis of BD and how we can start to assist people to better understanding and more 
effective management of the condition. Specifically this research has extended the evidence in 
a number of key areas outlined below. 
The challenges faced to living well by many people with BD are more complex than simply 
managing medication. There is a complex interplay between acceptance of the diagnosis, 
perceptions of treatment and ongoing management. These processes are also variable within 
and between individuals. The evidence from this thesis adds further support to the extended-
SRM, NCF and PAPA and in particular investigates these theories and frameworks within the 
context of long term mental health problems as opposed to physical illnesses. This further 
extends the applicability of these models to different health areas. 
It is recommended that further research, particularly longitudinal studies are conducted into 
applying illness and treatment perception models in mental health. This should include 
additional factors which this thesis has shown may impact on adherence and illness outcomes 
including stigma, the emotional aspect of receiving and living with a mental health diagnosis 
and its impact on self-identity, interpersonal factors such as therapeutic alliance and family 
relationships, shared decision making and the impact of enforced treatment and coercion. This 
will give a clearer picture of the determinants of adherence and outcomes in BD. 
Effective adherence interventions exist for people in BD and brief interventions can have 
durable effects. Focusing on knowledge, beliefs and attitudes can be an effective strategy to 
improve adherence. However, studies are generally poorly described, therefore the potential 
to replicate successful interventions accurately is limited. It is recommended that fully 
powered, adherence trials are conducted using theory-based behaviour change techniques 
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and these are described using published guidelines to ensure that findings can be replicated 
and interventions built upon and accurately targeted to appropriate populations. 
The feasibility RCT allowed assessment of illness and treatment perceptions in an under-
researched population. For patients in the setting of acute mental health services, personal 
control over illness was low and they felt negative consequences from their condition, both on 
their lives and emotions. They experienced many moderate or severe symptoms and side-
effects. Most participants held treatment inconsistent with good adherence (low necessity/ 
high concerns) for at least one of the medications they are prescribed. There were low levels 
of satisfaction with information about medication. It is recommended that the IBiD 
intervention provides a starting point to address these needs but should be adapted and 
tested as described above. Opportunities for people with BD to find out information and 
explore their diagnosis and treatment are severely limited. There may be some merit in the 
intervention in terms of prompting information seeking, mood monitoring and providing 
reassurance. Completing questionnaires about BD and treatment may be associated with a 
therapeutic benefit. 
The findings from the feasibility study should be used in developing protocols for research in 
mental health acute settings. It was demonstrated that with sufficient staffing resources, it is 
feasible to recruit and retain patients with BD to an RCT during the transition between acute 
inpatient and community adult mental health services. Good practice in conducting research in 
this area was identified and this should be adhered to in future studies: building relationships 
with teams, reducing burden on HCP staff, maintaining contacts with staff and patients. 
Many people in both acute and community services are still facing significant unmet 
information and support needs. However, providing honest and sufficient information on BD 
and its treatment as well as empowering patients to make decisions and seek information is of 
vital importance for effective mental healthcare. This thesis has provided important insights 
into the challenges faced by many people living with BD and how to begin to address some of 
these challenges through better understanding of what the areas of unmet need are and also 
how to meet these needs. 
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 PRISMA checklist 
Section/topic  # Checklist item  
Reported 
in 
Chapter, 
section # 
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or 
both.  
Chapter 
3,  
ABSTRACT   
Structured 
summary  
2 Provide a structured summary including, as applicable: 
background; objectives; data sources; study eligibility criteria, 
participants, and interventions; study appraisal and synthesis 
methods; results; limitations; conclusions and implications of 
key findings; systematic review registration number.  
n/a 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is 
already known.  
3.1 
Objectives  4 Provide an explicit statement of questions being addressed 
with reference to participants, interventions, comparisons, 
outcomes, and study design (PICOS).  
3.2 
METHODS   
Protocol and 
registration  
5 Indicate if a review protocol exists, if and where it can be 
accessed (e.g., Web address), and, if available, provide 
registration information including registration number.  
n/a 
Eligibility 
criteria  
6 Specify study characteristics (e.g., PICOS, length of follow-up) 
and report characteristics (e.g., years considered, language, 
publication status) used as criteria for eligibility, giving 
rationale.  
3.3.1 
Information 
sources  
7 Describe all information sources (e.g., databases with dates of 
coverage, contact with study authors to identify additional 
studies) in the search and date last searched.  
3.3.2 
Search  8 Present full electronic search strategy for at least one 
database, including any limits used, such that it could be 
repeated.  
3.3.2, 
Box 3.1 
Study selection  9 State the process for selecting studies (i.e., screening, 
eligibility, included in systematic review, and, if applicable, 
included in the meta-analysis).  
3.3.3.1 
Data collection 
process  
10 Describe method of data extraction from reports (e.g., piloted 
forms, independently, in duplicate) and any processes for 
obtaining and confirming data from investigators.  
3.3.3.2 
Data items  11 List and define all variables for which data were sought (e.g., 
PICOS, funding sources) and any assumptions and 
simplifications made.  
3.3.3.2 
Risk of bias in 
individual 
studies  
12 Describe methods used for assessing risk of bias of individual 
studies (including specification of whether this was done at the 
study or outcome level), and how this information is to be used 
in any data synthesis.  
3.3.3.2 
Summary 
measures  
13 State the principal summary measures (e.g., risk ratio, 
difference in means).  
3.3.3.2 
Synthesis of 
results  
14 Describe the methods of handling data and combining results 
of studies, if done, including measures of consistency (e.g., I2) 
for each meta-analysis.  
3.4 
Risk of bias 
across studies  
15 Specify any assessment of risk of bias that may affect the 
cumulative evidence (e.g., publication bias, selective reporting 
within studies).  
3.3.3.2 & 
3.4 
Additional 
analyses  
16 Describe methods of additional analyses (e.g., sensitivity or 
subgroup analyses, meta-regression), if done, indicating which 
3.4 
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Section/topic  # Checklist item  
Reported 
in 
Chapter, 
section # 
were pre-specified.  
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and 
included in the review, with reasons for exclusions at each 
stage, ideally with a flow diagram.  
3.3.3.1 & 
Figure 
3.1 
Study 
characteristics  
18 For each study, present characteristics for which data were 
extracted (e.g., study size, PICOS, follow-up period) and 
provide the citations.  
Tables 
3.8 & 3.9 
Risk of bias 
within studies  
19 Present data on risk of bias of each study and, if available, any 
outcome level assessment (see item 12).  
Figure 
3.3 
Results of 
individual 
studies  
20 For all outcomes considered (benefits or harms), present, for 
each study: (a) simple summary data for each intervention 
group (b) effect estimates and confidence intervals, ideally with 
a forest plot.  
Figure 
3.4 
Synthesis of 
results  
21 Present the main results of the review. If meta-analyses are 
done, include for each, confidence intervals and measures of 
consistency 
3.6.1 & 
Table 3.4 
Risk of bias 
across studies  
22 Present results of any assessment of risk of bias across 
studies (see Item 15).  
3.5.5.1.6 
Additional 
analysis  
23 Give results of additional analyses, if done (e.g., sensitivity or 
subgroup analyses, meta-regression [see Item 16]).  
3.6.2, 
3.6.3, 
3.6.4 
DISCUSSION   
Summary of 
evidence  
24 Summarize the main findings including the strength of 
evidence for each main outcome; consider their relevance to 
key groups (e.g., healthcare providers, users, and policy 
makers).  
3.7.1 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of 
bias), and at review-level (e.g., incomplete retrieval of identified 
research, reporting bias).  
3.7.2 & 
3.7.3 
Conclusions  26 Provide a general interpretation of the results in the context of 
other evidence, and implications for future research.  
3.7.4 & 
3.7.5 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and 
other support (e.g., supply of data); role of funders for the 
systematic review.  
n/a 
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 Data extraction template 
Review of the effectiveness and methodological quality of interventions designed to improve 
medication adherence in bipolar disorder. 
 
Source 
Study ID  
Citation  
 
Participants 
Total number 
randomised Total   Intervention   Control  
 
Intervention 
Number of intervention groups  Number of control groups  
Content/ 
elements 
Description of 
intervention/s 
What was the 
content of the 
intervention? 
Psychoeducation (all elements)  CBT/ CBT type   
Education     Psychotherapy   
Social/ family therapy   Device/ packaging  
Other _____________________________________________________________ 
 _____________________________________________________________ 
 _____________________________________________________________ 
Intervention 
focus 
(tick one option) 
Adherence is primary focus    
Multi-focus intervention     
Unclear – insufficient information to judge   
Provider 
Intervention 
delivered by.. 
(tick all that 
apply) 
 
Psychologist     Psychiatrist  
Nurse (mental health)    Trainee/ student  
Other health professional  ______________________________________ 
Social worker   
Other ____________________________________________________________ 
Not specified  
Format 
Method(s) of 
intervention 
administration 
(tick all that 
apply) 
Face-to-face (individual)   Face-to-face (group)  
Online     Telephone   
Device/ Packaging  
Other ____________________________________________________________ 
Not specified  
Setting 
(intervention 
delivery) 
 
 
 
 
 
Hospital outpatient psychology/ psychiatry department  
Specialist affective disorder/ bipolar clinic/ unit   
University psychology/ psychiatry dept (not specialist BD)  
Other  ______________________________________________________ 
  ______________________________________________________ 
  ______________________________________________________ 
Actual delivery location unclear  
 348 
Recipient 
Intervention 
delivered to 
 
Patient      Practitioner  
Family/ partner and Patient  Family/ partner (only)   
Other ____________________________________________________________ 
Intensity Number of different 
patient contacts (or range 
and average) 
 
Total contact time 
involved (or range and 
average) 
 
Duration Time period of 
intervention contact 
Months/ years 
 
Spacing of intervention 
contact e.g. Weekly/ 
Biweekly/ monthly 
 
Tailoring 
 
 
 
 
 
 
 
http://www.marijndebruin.eu/sites/default/files/Coding%20Manual%20&%20Taxonomy.pdf 
 Yes No Unclear 
1. Individualization    
2.a) Macro-tailoring (group level)    
b) Attention-tailoring (individual level)    
c) Micro-tailoring (individual level)    
3. Participation    
 
Intervention 
retention 
% completing 
parts of 
intervention 
 
Control group 
 
 
 
 
 
 
 
 
 
Code actual TAU described.... 
1. General care – outpatient psych or GP appointments/ medication management usual – no 
specific education or psychological support mentioned. 
2. Intensive support – structured specialist support, i.e more than general psychiatric 
appointments 
TAU care (tick one) General care  Intensive support   
Code all additional components in addition to above care for Control group 
Sessions (attention matched)  
Education   Psychoeducation   
Compliance feedback  GP training   
Other  ________________________________________________ 
Fidelity 
Intervention 
delivered as 
intended? How 
was this 
monitored and 
measured? 
Formal assessment   Informal assessment  
No reported assessment  
Details ________________________________________________________ 
 ________________________________________________________ 
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TIDieR – Intervention description assessment 
Use primary citation & papers referenced by the authors, available protocols and manuals, online supplementary material, and websites. 
 Adequately 
described 
Inadequately 
described 
Not reported Not applicable 
to intervention 
Description 
1. Brief name      
2. Why (rationale, theory or goal)      
3. What (materials used)      
4. What (procedures used)      
5. Who provided      
6. How (mode of delivery)      
7. Where (location)      
8. When and how much      
9. Tailoring      
10. Modifications      
11. How well (planned)      
12. How well (actual)      
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Adherence Outcomes – every measure listed as a separate outcome 
Primary outcome  Adherence   Other   Not specified  
 Description of measure (inc. units of 
measurement – Include medications analysed 
Time points 
assessed 
Sample size analysed Result 
Self-report 
 
    
Physician report 
 
    
Informant report 
 
    
Biological (lithium/ 
serum level) 
    
Pill counts/ 
prescription refill 
    
Chart review 
 
    
Composite measure 
 
    
Other 
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Methodological quality - Risk of bias – See Cochrane guidelines for instructions on assessing risk of 
bias 
 Risk of bias  
 Low High Unclear Description 
Random sequence 
generation 
   
 
 
 
Allocation 
concealment 
   
 
 
 
Blinding of 
participants 
   
 
 
 
Blinding of 
personnel 
   
 
 
 
Please specify risk for all outcome measures used. 
Blinding of 
adherence 
outcome 
assessment 
   
 
 
 
 
Incomplete 
adherence 
outcome data 
   
 
 
 
Selective 
adherence 
reporting 
   
 
 
 
     
Blinding of 
adherence 
outcome 
assessment 
   
 
 
 
 
Incomplete 
adherence 
outcome data 
   
 
 
 
Selective 
adherence 
reporting 
   
 
 
 
     
Other bias    
 
 
 
 
Other Comments 
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 COREQ Checklist for Chapter 4 
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  Phase 1 research- Semi-structured interview 
schedule 
A study examining patients’ satisfaction with information about medicines prescribed for bipolar disorder 
Qualitative research – Interview schedule 
Introduction 
Many thanks for agreeing to participate in this study. 
First we will ask you to fill in a questionnaire about how you have been feeling recently. 
This will be followed by a second questionnaire that will help us explore your information needs and any concerns 
you may have about your prescribed medication. 
Finally, we will ask you to tell us a bit more about your answers to the questionnaires and we will also show you 
examples of existing information about medicines for bipolar disorder and ask you to tell us what you think of 
these. 
Reiterate confidentiality & No right or wrong answers, interested in your personal views. 
Part 1: Clinical assessments  
We will now ask you to complete a questionnaire (Beck Depression Inventory) about how you have been feeling 
recently. 
Could you also tell us what medicines you have been prescribed? 
Part 2: Questionnaire Completion (Beliefs about Medicines Questionnaire (BMQ), Satisfaction with Information 
about Medicines Scale (SIMS) and Sources of Information Questionnaire (SIQ)) 
We would like you to complete another questionnaire that explores people’s beliefs about their medicines for 
bipolar disorder and also their satisfaction with the information they have received about these medicines. 
We will score your questionnaire as soon as you complete it and we will ask you to talk a bit more about your 
answers.  
Part 3: Interview & evaluation of existing information 
Section 1: Identified concerns about the prescribed medication  
First, we would like to explore your answers to the questionnaires in a bit more detail. 
Prompts:  
What concerns, if any, do you have about your medicines? 
How do you feel about the long-term use of your medication? 
To what extent do the medicines affect how you feel? Does medication affect your ability to work, your 
relationships or your social life? 
What concerns, if any, do you have about side effects? 
Section 2: Satisfaction with information received about the prescribed medication  
Prompts: 
What do you think about the information you received regarding the potentially beneficial effects of your 
prescribed medication? 
What do you think about the information you received regarding the potential side effects of your 
prescribed medication? 
Section 3: Sources of Information 
We would like to explore in a bit more detail your answers to the Sources of Information Questionnaire (SIQ).  
Most trusted sources Would you mind telling us a bit more about the sources you say you trust the most? 
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Prompts: Why is this? 
Least trusted sources Would you mind telling us a bit more about the sources you have say you trust the least? 
Prompts: 
Why is this? 
Ease of getting information? 
Timing when information was received? 
Section 4: Evaluation of existing information about medicines for bipolar disorder  
We are really interested to hear your views on existing information about medicines prescribed for bipolar 
disorder. 
These have been written by the Sussex Partnership NHS Foundation Trust and a charity. 
(NB: interviewers to present information leaflets during the interview) 
There are no right or wrong answers; we are interested in your personal views.  
(NB: Interviewer to go through questions/prompts for each information leaflet separately) 
Familiarity with information  
Have you seen written information about medicines prescribed for bipolar disorder before? 
Have you seen these NHS leaflets and/or this booklet before? 
Evaluation of information  
What do you think about the information presented in this booklet/leaflet? 
Usefulness of information 
Prompt: 
Do you find this information useful? 
Does this leaflet/booklet address any concerns you may have about your medication? 
(NB: Interviewer to ask this if specific concerns were reported in the questionnaire) 
Adequacy of information 
Prompt: 
Is there anything that you would like to know about your prescribed medication that is not included here? If 
yes, what? 
Is there any information you have been given about your medicines that you wish you hadn’t? 
Comprehension / Clarity 
Prompt: Is the information presented in a clear way? Is it understandable? 
Presentation / design 
Prompt:  
What do you think about the size of the letters and the illustrations included in this booklet/leaflet? 
Do you find the information in this booklet/leaflet is presented attractively?  
Preferred format/medium of information 
So, to summarize what is your preferred format of information? 
What is the best way of getting information? 
Have you obtained information in any different way that you might wish to share with us? 
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  Confirmation of ethical approval for Phase 1 
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 Participant Information pack 
 
 
 
 
Dear  
 
A study examining patients’ satisfaction with information about medicines 
prescribed for bipolar disorder 
 
I am writing to inform you about a research study that is being carried out by 
researchers at the Centre for Behavioural Medicine, School of Pharmacy, University of 
London. 
 
The purpose of the research is to find out what people think about the information they 
receive in relation to their prescribed medication for bipolar disorder. The findings of 
this study will aim to improve the information about prescribed medications that 
patients receive in the future. 
 
Please read the enclosed information sheet to find out more about the study.  If you 
would like to participate in the study, please contact Dr Marcia Kapari at the Centre for 
Behavioural Medicine.   
 
If you decide that you do not want to participate in the study, the care that you receive 
will not be affected in any way. 
 
If you would like any further information about the study, please telephone Dr Marcia 
Kapari on 020 7874 1287. 
 
Yours sincerely, 
 
Dr ……………………… 
Consultant Psychiatrist 
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A study examining patients’ satisfaction with information about medicines prescribed for bipolar 
disorder 
Participant Information Sheet 
 
You are being invited to take part in a research study. Before you decide whether or not to take part it is 
important for you to understand why the research is being done and what it will involve. Please take time 
to read the following information carefully.  You may wish to discuss it with others. If there is anything that 
is not clear or if you would like more information, please contact Dr Marcia Kapari on 020 7874 1287. 
 
What is the purpose of the study? 
The purpose of this study is to find out what people think about the information they receive in relation to 
their prescribed medication for bipolar disorder.  
 
Why have I been chosen?  
You have been chosen because you have been prescribed medication for bipolar disorder from a mental 
health professional within the Sussex Partnership NHS Foundation Trust.  It is hoped that forty people will 
decide to take part in this study. 
 
Do I have to take part? 
It is up to you to decide whether or not to take part.  If you do decide to take part you will be given this 
information sheet to keep and be asked to sign a consent form.  If you decide to take part you are still free 
to withdraw at any time and without giving a reason.  A decision not to take part, or a decision to withdraw 
at any time, will not affect the standard of care that you receive.   
 
What will happen to me if I take part? 
If you decide to take part, please contact Dr Marcia Kapari, a researcher at the Centre for Behavioural 
Medicine, School of Pharmacy, to arrange a one-off appointment which will take place at the Mill View 
Hospital in Hove. Two researchers will be present at the appointment, which is expected to last one and a 
half hours. The appointment will have four parts: 
1. You will be asked to answer some questions about how you have been feeling recently. 
2. You will be invited to complete a short “writing task” in response to how you felt about first taking 
your medication for bipolar disorder.  
3. We will ask you to fill in a questionnaire which explores peoples’ beliefs about their medicines for 
bipolar disorder and also their satisfaction with the information they have received about these 
medicines.  
4. We will ask you to talk a bit more about your answers to the questionnaire. We will show you 
examples of existing information about these medicines and ask you to tell us what you think of 
these. 
 
Will I be paid for my participation? 
You will not be paid for participating to the study but your travel expenses to and from the Sussex 
Education Centre, Hove, will be reimbursed. We will also offer you refreshments during the interview. 
 
What are the possible benefits of taking part? 
You may not benefit personally from taking part.  However, we hope that findings from this study will help 
to address patients’ information needs about prescribed medications for bipolar disorder and improve their 
overall quality of care in the future. 
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Will my taking part in this study be kept confidential? 
Everything that you say during the interview or write during the writing task and on the questionnaire will 
be kept strictly confidential and will not be fed back to those caring for you, unless the researchers feel that 
the health and safety of you or others is at severe risk.  In this unlikely event, you will be informed that your 
care coordinator will be contacted. 
All information you provide (e.g. during the audio-recording of the interview, the written task and the 
questionnaire) will be stored securely. Any sections of the interview that is typed out will not include your 
name (a participant number will be used instead) so it will not be possible for people to match any 
information to you personally. 
 
What will happen to the results of the research study? 
If the results of this study are published, your identity will not be revealed.  If you wish to obtain a copy of 
the published results, please tell one of the researchers and they will happily supply you with one. 
 
Who is organising and funding this study?  
This study is being organised by researchers at the Centre for Behavioural Medicine, Department of 
Practice and Policy, School of Pharmacy, University of London and is being funded by the National 
Institute for Health Research, Patient Benefit Programme.  
 
Who has reviewed the study? 
The study has been reviewed by the Brighton East Research Ethics Committee (Ref 09/H1107/110). 
 
What should I do now? 
If you would like to participate in this study, please contact Dr Marcia Kapari (her details are listed below) 
in the next two weeks to arrange a date to meet with her.  
 
Contact for the study: Dr Marcia Kapari, Research Fellow 
Centre for Behavioural Medicine, Department of Practice and Policy, The School of Pharmacy, University 
of London, BMA House, Mezzanine Floor, Tavistock Square, London WC1H 9JP 
Phone: 020 7874 1287 Email: marcia.kapari@pharmacy.ac.uk  
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 Consent form 
 
Patients’ satisfaction with information about medicines prescribed for bipolar 
disorder. 
 
CONSENT FORM 
Contact Researcher: Dr Marcia Kapari 
 
 
1. I confirm that I have read and understand the participant information 
sheet dated … for the above study and have had the opportunity to 
contact Dr Marcia Kapari to ask questions. 
 
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical 
care or legal rights being affected. 
 
 
3. I understand that the interview will be audio-taped and that sections 
of it (with my name removed) may be used in published articles and 
conference presentations. 
 
4. I agree to take part in the above study. 
 
 
5. I understand that the research data collected during this study may be looked at 
by other individuals from the research team, sponsor, from regulatory authorities 
or from the NHS Trust, where it is relevant to my taking part in this research. I give 
permission for these individuals to have access to my data. 
 
……………………..  ……  ………….  
Name of participant   Date   Signature    
……………………… ……  …………. 
Name of researcher  Date  Signature 
 
 
Please initial box 
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 Feedback from service-users on IBiD content and design 
Bipolar: A question of balance - Intervention content feedback 
Page  Feedback 
How we hope this 
booklet can help you 
SO Suggested change: 'Throughout this booklet we have LEFT space' not we have made space. 
Final box - replace 'We hope you find the information useful' with 'Turn to page XXX for a list of other resources you might find useful' - I think the current sentence isn't really saying 
anything 
LM This booklet aims to help to answer your questions about bipolar and its treatment. 
We have drawn on the real experiences of people with bipolar and from research looking at what helps people need to get the best from their treatment. 
Our We are a team includes of people with bipolar, researchers in health communication researchers, NHS psychiatrists, and pharmacists and representatives from Bipolar UK. 
This Our project is funded by the the NHS through the National Institute for Health Research (NIHR), the research division of the NHS. 
Everyone’s experience of bipolar is differentunique. 
Throughout the booklet we have made space for you to make notes to help you to manage your treatment and work with your health professionals. 
We do are not expectting this booklet to be the only information you will ever need. We have included a list of other resources you might find helpful at the end. 
We hope that it will answers some of the main questions you have and points the way to wherehow you can get any extra if help you need to. 
Understanding bipolar 
(2 pages) 
JT Need to acknowledge physical and cognitive aspects of bipolar  - not just mood changes. 
Physical early warning signs (e.g. the 'someone just tipped cold water over me, I'm shivering!' symptom). 
Brain fluctuating in its ability to think and function. 
AMB Mention rapid cycling bipolar. Highs and lows don't necessarily last for weeks or months. 
‘Bipolar is part of who I am and I embrace it. I would not even call it an "illness". I think perhaps you could mention this’ (Think this is covered in ‘making sense of the diagnosis’) 
Many creative people in the past had bipolar, e.g. Tchaikovsky, Beethoven etc. 
Make people see bipolar in a positive way. 
SO p3. Suggest rewording this: Bipolar does not fit with the common idea of a disease as something which you get and then it goes away when you find the right treatment (like a chest 
infection or headache). This sentence suggests that people aren't familiar with chronic conditions that can be managed, such as diabetes, but I think they are. Could reword to 
something simple like: Bipolar is not a condition that goes away when you find the right treatment (like a chest infection or a headache). 
p4. Need to be careful here that statements aren't definitive ie. need to say People with bipolar CAN experience intense highs. Depression IS USUALLY a big part of bipolar.  
Don't know why 'out of control' is in inverted commas - suggest removing them.  
Suggest rewording the Q&A to: A: Bipolar is treated as an illness because it can cause moods to go out of control, often leading to distress and suffering. It can be effectively treated, 
though, to restore balance and stability over time. 
LM WAs human beings we all experience a variety of emotions and moods. SHowever, some people experience larger swings in their mood with extreme from highs andto lows. 
For some people, tEhese xtreme mood swings don’t necessarily have a big impact on someone’sn their life,. especially if  most of the time, they Some manage to keephow things stay 
more or less under controlin balance. For others people, mood swings can make life very difficult, causing , it can cause huge problems for them and those around them. 
Extreme mMood swings may be labelled as bipolar disorder when they affect a person’s ability to live a normal life. 
ISo in some ways, bipolar is simply a label that is applied when mood swings stop someone being able to interfere with a person’s ability to function in their every day day to day life or 
interfere with their relationships with other peoples. 
The aim of treatment is not to cure the condition. Bipolar does not fit with the common idea of a disease as something which you get and then it goes away when you find the right 
treatment (like a chest infection or a headache). 
The aim of treatment is to help people the person to restore and then maintain balance in their moods so that the highs and lows have less impact on their lives. 
People with bipolar can experience intense high energy moodss. In everyday life. At the time, this can make them outgoing, energetic. They can often feel and they are often very 
creative, or be seen as the “life and soul of the party”. 
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However these intense high energy moods can become At other times these highs can tip into something which is much more of a problem, especially if the mood goes on for too 
long.. 
The person may find their high energy mood makes their behaviour difficult or even impossible to control  and this causes y may experience times when things go too far and highs 
become “out of control”, their behaviour then causes problems forto themselves and for their families. 
For example, sSomeone people might spend money recklessly, be extremely irritable or get involved in sexual behaviour that is out of character. 
Depression is a big part of bipolar. Periods of high energy Highs can be followed by crushing periods of low energys and often feelings of despair. Sometimes pPeople often feel that 
their mood and energy plummets for no particular reason. This low can also happen after a period of fairly even mood. 
You might recognise some of the signs of depression as sadness, thinking negatively and a difficulty concentrating. 
People with bipolar often find their periods of low mood or energy also mean they lose interest in doing things they might usually enjoy and notice more include other signs such as a 
lack of energy, loss of interest in activities and physical aches and pains. 
Q: If it is just an extension of normal moods, why is bipolar treated as an illness? 
A: A person’s moodsIt can geto out of control and cause distress and suffering. Treatment aims over time, to help a person’s moods become more , but it can also be 
effectively treated, restoring 
Mood mapping SO p5. In the para explaining the second chart, delete the word ALSO: These periods can [ALSO] have a negative impact on a person's life. 
In the box below the charts, can we relate/link the text to the second chart? Also, these three points could be annotated into three separate points rather than lumped together as one 
sentence - would read clearer.  
In box mentioning tools to create own mood chart, is it possible to add a page number so it's more useful? 
Is there a cause of 
bipolar? (2 pages) 
AMB "biological changes in the brain" and a "chemical imbalance" -  these ideas have only ever been theories, should not really be presented as facts, only ideas. 
2nd page - "Episodes of bipolar" don't really exist, only episodes of euphoria or mania, and episodes of depression. Bipolar itself is not episodic but usually a lifelong condition. 
SO p6-7. I'm not quite sure what this sentence means: This is one of the mysteries of science that our minds are linked to our biological and physical nature. Usually the complex interplay 
between our minds and body reacts to maintain a balance. 
Saying that scientists haven't yet agreed on the cause of bipolar suggests that one day they might agree on the cause. My understanding is that they currently do agree that there isn't 
a single cause and isn't ever likely to be! So I think this needs to be reworded. Suggesting that scientists don't agree isn't helpful. 
LM Science cannot explain how This is one of the mysteries of science that our minds are link ed to our biological and physical nature. However there is a Usually the complex 
interactionplay between our minds and body and they inter react to give moods, emotions and thoughtss to maintain a balance. Naturally there are many ways in which these 
interactions  balance themselves. 
Bipolar can run in tends to run through families, may it can be passed on from parent to child. But it does not mean that everyone who has a parent with bipolar will go on to develop it 
or that it will definitely be passed on to children, it just means that there is an increased chance of this happening. 
Research has also shown that people who experience more stressful life experiences seem to be more at risk of the development of bipolar. 
The cause of someone’s bipolar may be different from those things that trigger What may have caused the development of bipolar, and what might trigger a recurrence of symptoms 
or relapse.may be different, For example, this means that even though a stressful relationship, problems or change in job might trigger a depressive or manic episode, but it does not 
mean that this is the these are not causes of the disorder. 
A long journey to 
diagnosis 
Making sense of the 
diagnosis: Does taking 
medication mean I have 
to accept I am ill? (2 
pages) 
AMB Mentioning that it is not easy to diagnose, and sometimes GPs or consultant psychiatrists can get it wrong. 
SO p8. Final sentence: Should this read 'why they have been experiencing so many CHALLENGING symptoms' rather than so many changing symptoms? 
p9. In time, most people with bipolar learn to understand and accept etc etc. Is this true? Suggest change to: In time, MANY people with bipolar etc etc 
Need a full-stop after final sentence. 
LM This can mean that some people have mixed feelings about the condition. For example, their relief at finding out what the problem is, mixed with resentment at having had to wait so 
long for a diagnosis or resenting being given athe idea  of having a mental health diagnosis. 
Some people are upset by the diagnosis of Getting a diagnosis of bipolar can be very upsetting for many people. Apart from the symptoms of the condition, Iit can feel as thoughlike an 
important part of a person’s character, things about themselves which seem tocan make make them them attractive to other people, are now seen as part of a medical condition 
requiring treatment. 
TheyPeople may find it confusing that parts of their personality (such as being extremely creative and joyous) are being described as part of an illness. 
Successful treatment of bipolar does not change your personality but aims to reduce the problems associated with the more extreme mood swings. 
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For other some people, receiving a diagnosis can come as a relief as it helps them understand why they have been experiencing so many changing symptoms. 
Will I always have 
bipolar? 
SO p10. Change 'were' to: It is much better to see it as a process WHERE people become 'ill'  
Can we add page number to final box - ie. on page XX 
LM As bipolar disorder is a tendency that someone has to experience extreme mood swings, rather than an illness with a known cure, the susceptibility may never fully goes away, even if 
you don’t experience the symptoms anymore. 
‘There’s such a lot of 
stigma about giving 
yourself a label’ 
AMB Liked the section which points out how people are not so negative about sufferers of mental health problems as you might think. 
LM Many people with bipolar feel stigmatised. Bbecause of their diagnosis. they may be This can mean feeling discriminated against in work, personal life orand when using healthcare. 
Experiencing feelings of stigma can make people feel less hopeful about their recovery. 
Taking control SO p12. Add page number and full-stop after final sentence. 
LM Many things can make it difficult for people to be able to successfully manage bipolar. It might be useful to try and think of some things which make it difficult for you to manage your 
condition. This might be something to do with your work, or someone who you have to be in contact with, such as a relative who is not happy with your diagnosis. You can use these 
next time you see your health professional to try and work out strategies to deal with them together. 
Medications prescribed 
for bipolar 
AMB Should read "in bipolar, there is scientific evidence which shows that pathways in the brain which regulate mood ARE not functioning in the normal way". 
SO Suggesting rewording first sentence of Q&A answer to: In PEOPLE WITH bipolar, there is scientific evidence which shows that pathways in the brain which regulate mood DO NOT 
FUNCTION in the usual way.   
Making an Informed 
choice about 
medications prescribed 
for bipolar 
SO Suggest rewording first sentence to: It is important to be able to access the information you need about the DIFFERENT medications available SO YOU CAN make an informed choice.  
I think it's a bit confusing that the heading refers to 'mood stabilisers and antipsychotics' and then the text goes on to talk about 'This type of medication' as if they're one and the 
same... Need to clarify. 
LM It is important to be able to find access the information you need about differentthe range of medications so as to be able to choose which medication might help you the most, whilst 
causing the fewest side effects available to make sure you are able to make an informed choice. 
Making decisions about medications is not easy. Getting all the information you need and weighing up the pros and cons of differenta treatments can helps. 
Medication sheets LM Essential to have blood tests to check lithium levels, kidney function and thyroid function every six months 
Important long term side effect of lithium – getting up in the night to pass urine, this may mean your kidneys are affected by the lithium, making it difficult to concentrate urine 
overnight, so your bladder fills up and you need to get up to pass urine. It is important to discuss this symptom with your doctor. 
Your thoughts and 
feelings about taking 
medication (3 pages) 
SO p17. Taking medication appropriately in the long term can be difficult, no matter what condition or illness you are taking IT for.  
Many people at one time or another have periods [of time DELETE] when either they take their treatment in a different way than it was prescribed, miss a dose or have a break from 
taking IT ALTOGETHER. 
p19. Repetition - the second half of point 3 and all of point 4 are saying the same thing.  
Suggest rephrasing point three to: It means relapses are likely to last a shorter time. 
I’m worried about the 
side-effects from these 
medicines (3 pages) 
AMB The most important information people need to know about medication is what side-effects there are. 
GPs very often do not know about even well-known side-effects. 
People can be having side-effects which they do no attribute to the drug because it is not listed. 
SO p20. Throughout - sometimes side effects, sometimes side-effects? Needs to be consistent with or without hyphen. 
p21. Suggest rewording sentence: Now, think about what might HELP to manage these side-effects. 
p22. The box about sexual dysfunction is so short and unhelpful compared to the other boxes, it almost seems like an after-thought/dismissive. Is there any way to edit down the other 
boxes a bit to make room to expand this/add some advice? 
LM  Take regular exercise 
Finding it hard to have an orgasm or having . nNo desire for sex. Discuss with your doctor. 
I sometimes worry 
about whether there 
might be long-term 
AMB Some drugs are really difficult to come off. 
Withdrawal symptoms can mimic the symptoms of the problem they are designed to treat. 
People should always have the option to try going med-free if they want to. 
I don't think advocating permanent drug therapy is such a good idea. () 
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effects of taking these 
medicines. 
SO p23. Reword this sentence to: Is there anything that worries you about taking your medication in the long term? to USE THIS SPACE TO WRITE DOWN ANY WORRIES YOU MAY HAVE 
about taking your medication in the long term  
Reword this sentence to: Lithium can increase the risk OF HAVING an underactive thyroid. Some medications, SUCH AS XXXX, increase the likelihood etc etc  
Suggest deleting this sentence: [Having this information means you can be more informed about possible long-term effects.] because it's repeating the sentence above the link  
Will the person reading the booklet know how the research team referred to in this sentence is? If you don’t have access to the internet, one of the research team can the information 
printed off for you.  
LM TWorries about the possible risk of possible long-term effects of any medication need to be balanced alongside the positive aspects of effective treatment and the risks of a relapse. 
With medications for bipolar there are some increased risks of long-term effects. It doesn’t mean they will definitely happen after taking medication in the long term, just that there is 
an increased risk of it happening. 
Lithium can affect theincrease the risk of underactive kidneys and thyroid gland. Regular blood tests ensure that problems are recognised and  treated early. Some medications 
increase the likelihood of weight gain which can increase the risk of diabetes. 
Taking medication is an 
unwelcome reminder of 
my condition 
SO George's quote doesn't read well.... 
I tend to hide the fact 
that I am taking these 
medicines from other 
people 
SO I don't like the idea of advising people to challenge negative opinions about them taking medication. I think it makes more sense to talk about responding / ignoring / dealing with but 
NOT challenging. Suggesting that they challenge someone seems unhelpful and unnecessarily inflammatory. 
LM It is a personal issue about who you decide to tell about your condition and treatment. You do not have to tell your employer that you have bipolar disorder, only that you have a long 
term health condition. Your employer can then refer to Occupational Health who can ensure that you have appropriate adjustments to your work to reduce the likelihood of further 
episodes, for example, keeping a regular shift pattern so you get regular sleep.  
Some people find it helps to explain to people the biological/ chemical reasons for psychiatric medication. 
I don’t feel ill, so why 
should I continue to 
take my medication? 
SO Suggest deleting second sentence in title box as follows: [Taking medication when I feel well doesn’t make sense to me] 
I don’t feel like the 
medication is working 
SO Suggest rewording to: Some people will remain free of symptoms WHILST taking mood stabilisers; [for] others [they] may experience episodes of depression or mania during [this] 
treatment, but for most these will be fewer and less severe.   
Medication changes: 
Why does the 
medication I am given 
keep changing? 
SO Delete first two words of title [Medication changes:] Why does the medication I am given keep changing?  
Suggest rewording to: For your health professional, it is difficult to know in advance which treatments will help you [personally], SO [this is why] you may need to try different 
medications, doses or combinations. Adjustments and changes are very common. 
I sometimes worry that I 
might become addicted 
to or dependent on the 
medicines I’m taking. 
SO I don't think the explanation about whether drugs prescribed for mental health conditions are addictive or not is very clear - needs rewording so it's more reassuring. eg. In scientific 
terms, drugs which are actually addictive  
cause tolerance, produce artificial reward or euphoria and cause cravings for the drug. What does 'cause tolerance' mean? What does 'produce artificial reward' mean? 
Alcohol, bipolar and 
your medication 
AMB Good idea to advise people to steer clear of alcohol altogether. 
Mention that marijuana and other street drugs are known to make bipolar worse. 
LM The problem with this is that even legal substances like alcohol can worsen psychiatric symptoms such as depression and anxiety. 
It is ’s really important to talk to your health professional about any worries you have about alcohol or any other drugs and bipolar. 
‘Sometimes I find it 
difficult to take my 
medication’ (3 pages) 
AMB Suggestion to remove Implementations intention exercise as can be seen as patronising as ‘makes it sound as though you think bipolar folk need help to do this, which they don't’. 
Could just say "take your meds with your morning cup of tea" or something. 
SO p36. It might be a good idea to stick a little 'eg' in the box with the example to make it clear that it's an example... 
What should I do if I am 
having any problems 
SO Is this the right heading for this page? This isn't really about having problems, but more about being prepared/having support lined up for when you need it... Suggest changing title to 
something like: Organising your support network for when you need it 
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and who should I 
contact in an 
emergency? 
LM You can write this information in the space below. 
Include a space for medication 
Monitoring your 
symptoms and looking 
after yourself (2 pages) 
JT Mention some people have physical early warning signs (e.g. the 'someone just tipped cold water over me, I'm shivering!'). 
Symptom - Brain fluctuating in its ability to think and function, and therefore need to map my daily activities to current capability. 
AMB Advice about what to do if you are "high" or "low" is not really practical. If you are "high" it is simply not physically possible to get more sleep, and when you are "low" you cannot stop 
yourself sleeping too much. These are symptoms and not behaviour.  It's like telling someone not to experience pain when they have a heart attack. 
SO p38. Suggest rewording to: Some things which may be useful for you to consider if you think  YOU'RE IN THE EARLY STAGES OF a relapse. 
Getting the most from 
your consultations (2 
pages) 
SO p40. Suggest rewording to: MENTION TO your health professional any concerns you may have about your medicines and any side effects you may be experiencing. 
Suggest rewording to: It CAN BE difficult to remember to or feel like we can ask all the questions we want to ASK.  
Think we need to add a sentence above the three bits of advice here / could also annotate or number then? - something like: You might find it helpful to: 1. Ask your doctor to clarify 
etc; 2. Talk about your concerns. 3. Do not worry etc 
p41. Suggest rewording second question to: FOR how long will I have to take this medication? 
LM It is really important to make sure you always keep your health professional informed about how you are feeling and what effect how your medication has on how you feel is working 
for you. 
It is difficult to remember to or feel like we can ask all the questions we want to. Between appointments, write down the questions you want to ask as  you think of them. 
Completing your own 
mood chart (4 pages) 
AMB The mood chart at the end is a really great idea. 
SO p43. Suggest rewording to: You can then use this when you meet with your health professionals to discuss how things have been going, SO you have [a] more reliable information to 
help you both decide on the best course of action.  
Suggest adding: USING THE CHART PROVIDED ON THE NEXT PAGE, each day etc 
 
Wording & Text 
Very accessible and straightforward. Like all the headings and subheadings. (JT) 
In the title boxes, I think it makes sense for all the 'I' statements to be in quotations marks - ie. add to headings on pages 10, 20, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32 and 37. 
I think there are too many boxes throughout prompting people to turn the page to find out more (ie. on page 6 'Find out more about bipolar causes and triggers over the page') - I think they are unnecessary and get in the 
way. I prefer the idea of encouraging the reader to concentrate on the page they're on rather than to think ahead. (SO) 
Like the font. (JT) 
Layout 
Very well set out, layout very accessible and straightforward. (JT) 
I think the blue title boxes work really well - the headings are simple and bold. What I find confusing though is that on some pages the titles are big and bold while on others the titles are smaller (ie. p17 & 18). I realise 
that you're differentiating between the first and second page of the same subject, but I don't think it's obvious that it's a continuation - it simply looks like a new subject heading (just with a smaller font size). On some of 
the second pages of the same topic you haven't used a heading at all, you've just continued with text (ie. p6 & 7). I think this works much better, plus it gives you more space / a cleaner, less cluttered feel. 
Colours/ Images 
Lovely peaceful pale blue colouring with birds - just what people need to focus their eyes on when trying to shut out so much 'noise' from within and without! I'd stick to pale blue. Maybe small and gentle waves coming 
onto a beach with pretty pebbles. No mountains. (JT) 
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I like the graphics of the bird in flight and the blue background. (AMB) 
I think photos/cartoons of people are counterproductive. People with bipolar insert own images when reading and those deserve to be explored. Any you insert could cause blockages and lead to a sense of frustration or 
of being controlled/ contained. (JT) 
I am not sure whether other pictures are really needed. I don't like these photos that often accompany articles on bipolar of close-ups of pills or of people with their head in their hands. (AMB) 
Mental imagery in bipolar people is incredibly strong, which is actually one reason why suicidal ideation often leads to carrying out an attempt, because the whole process is more or less instantaneously visualised. (JT) 
Next to some of the exercise boxes there's a blue 'EXERCISE' circle (with or without a little pen!) to flag up the fact that there's a space to write in, yet this is missing on many of the pages. I think it works really well to help 
the reader clearly see which bits they're meant to fill in. Is it possible to add it throughout? (SO) 
Suggested additions 
Advance statement proforma (or link to PDF of one online). (JT) 
Debt and mental health evidence form. (JT) 
Comorbidity. It's well-known that as soon as people focus on mental health, physical health conditions/symptoms get ignored. So a warning somewhere to keep checking breasts, testicles etc. (JT) 
'engaging in meaningful social activity', good nutrition, fresh air - things people can do to be more well. (JT) 
Mention in the text all the ways to combat bipolar, either with or without drug therapy. For example, CBT, mindfulness meditation, mind mapping, regular exercise, and owning a pet. (AMB) 
Something brief on the kind of stupid things others might say to you when they find out/you tell them, and some quick, appropriate answers. 
E.g. 'Oh well everyone gets down sometimes - that's normal' 
Answer: 'Sorry but this is of a different order. Would you like to know more or shall we change the subject?’ 
Appropriate ways of dealing with environmental difficulties and social injustice; staying at home, rehearsing things to say and do in a crisis, joining online campaigns rather than being confrontational. (JT) 
Other 
‘I wish I had had this resource when I was diagnosed! It would have saved so much loneliness and thrashing about in the dark until I found my way to the Bipolar UK website and online forum and got myself a 
psychotherapist.’ (JT) ‘I love the idea that you work through it with a professional.’ (JT) 
‘The exercises follow a logical and helpful order, and lead the 'service user' (horrid term) gently and in the right direction. I think that if it were me using it, I would come to the end wanting to move forward and feeling 
reassured.’ (JT) 
‘I think on the whole this booklet is really good and I wish I had been given something like this when I was first diagnosed’ (AMB) ‘On the whole I think it is great and full of really good advice’ (AMB) 
Overall, I think this booklet is clearly written and easy to understand. I like fact that there's a focus on using real experiences of people with bipolar rather than just asking hcps to give a more detached/expert view - 
there's a personal, 'inclusive' feel right from the intro. (SO) 
I would think that the exercises are very useful. (SO) 
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 TIDieR checklist for IBiD 
Checklist*: Information to include when describing an intervention and the location of the 
information 
Item 
number 
Item  Where located ** 
 Primary paper 
(page or appendix 
number) 
Other † (details) 
 
BRIEF NAME 
  
1. Provide the name or a phrase that describes the intervention. 5.1 ______________ 
 WHY   
2. Describe any rationale, theory, or goal of the elements essential to the intervention. Chapter 2 & 5 _____________ 
 WHAT   
3. Materials: Describe any physical or informational materials used in the intervention, including those provided to participants or used in 
intervention delivery or in training of intervention providers. Provide information on where the materials can be accessed (e.g. online 
appendix, URL). 
5.3 & Appendix J 
 
_____________ 
4. Procedures: Describe each of the procedures, activities, and/or processes used in the intervention, including any enabling or support 
activities. 
5.3 _____________ 
 WHO PROVIDED   
5. For each category of intervention provider (e.g. psychologist, nursing assistant), describe their expertise, background and any specific 
training given. 
6.4.12 _____________ 
 HOW   
6. Describe the modes of delivery (e.g. face-to-face or by some other mechanism, such as internet or telephone) of the intervention and 
whether it was provided individually or in a group. 
5.3 & 6.4.12 _____________ 
 WHERE   
7. Describe the type(s) of location(s) where the intervention occurred, including any necessary infrastructure or relevant features. 6.4.1 _____________ 
 
WHEN and HOW MUCH 
  
8. Describe the number of times the intervention was delivered and over what period of time including the number of sessions, their schedule, 
and their duration, intensity or dose. 
6.4.12 _____________ 
 TAILORING   
9. If the intervention was planned to be personalised, titrated or adapted, then describe what, why, when, and how. 5.3.2, 6.4.12 & 
Appendix J 
_____________ 
 MODIFICATIONS   
10.ǂ If the intervention was modified during the course of the study, describe the changes (what, why, when, and how). n/a _____________ 
 HOW WELL   
11. Planned: If intervention adherence or fidelity was assessed, describe how and by whom, and if any strategies were used to maintain or 
improve fidelity, describe them. 
6.4.13 _____________ 
12.ǂ 
 
Actual: If intervention adherence or fidelity was assessed, describe the extent to which the intervention was delivered as planned. 6.6.3.8 _____________ 
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 CONSORT checklist for IBiD study 
CONSORT 2010 checklist of information to include when reporting a randomised trial* 
 
Section/Topic 
Item 
No Checklist item 
Reported in 
section no. 
Title and abstract 
 1a Identification as a randomised trial in the title 6.1 
1b Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts) n/a 
Introduction 
Background and 
objectives 
2a Scientific background and explanation of rationale Chapters 2 & 5 
2b Specific objectives or hypotheses 6.2 
Methods 
Trial design 3a Description of trial design (such as parallel, factorial) including allocation ratio 6.3, 6.4.9 
3b Important changes to methods after trial commencement (such as eligibility criteria), with reasons 6.4.2 
Participants 4a Eligibility criteria for participants 6.4.4 
4b Settings and locations where the data were collected 6.4.1 
Interventions 5 The interventions for each group with sufficient details to allow replication, including how and when they were actually administered 6.4.11 & 6.4.12 
Outcomes 6a Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed 6.3.3 
6b Any changes to trial outcomes after the trial commenced, with reasons n/a 
Sample size 7a How sample size was determined 6.4.8 
7b When applicable, explanation of any interim analyses and stopping guidelines n/a 
Randomisation:    
 Sequence 
generation 
8a Method used to generate the random allocation sequence 6.4.9 
8b Type of randomisation; details of any restriction (such as blocking and block size) 6.4.9 
 Allocation 
concealment 
mechanism 
9 Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps 
taken to conceal the sequence until interventions were assigned 
6.4.9 
 Implementation 10 Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions 6.4.9 
Blinding 11a If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) 
and how 
6.4.10 
11b If relevant, description of the similarity of interventions n/a 
Statistical methods 12a Statistical methods used to compare groups for primary and secondary outcomes 6.5 
12b Methods for additional analyses, such as subgroup analyses and adjusted analyses n/a 
Results 
Participant flow (a 
diagram is strongly 
recommended) 
13a For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the 
primary outcome 
6.6.3 
13b For each group, losses and exclusions after randomisation, together with reasons 6.6.3.2 
Recruitment 14a Dates defining the periods of recruitment and follow-up 6.4 
14b Why the trial ended or was stopped n/a 
Baseline data 15 A table showing baseline demographic and clinical characteristics for each group 6.6 
Numbers analysed 16 For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned 
groups 
6.6 
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Outcomes and 
estimation 
17a For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% 
confidence interval) 
6.6 
17b For binary outcomes, presentation of both absolute and relative effect sizes is recommended n/a 
Ancillary analyses 18 Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from 
exploratory 
6.6 
Harms 19 All important harms or unintended effects in each group (for specific guidance see CONSORT for harms) n/a 
Discussion 
Limitations 20 Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses 6.7.3 
Generalisability 21 Generalisability (external validity, applicability) of the trial findings 6.7.3 
Interpretation 22 Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence 6.7 
Other information 
 
Registration 23 Registration number and name of trial registry n/a 
Protocol 24 Where the full trial protocol can be accessed, if available n/a 
Funding 25 Sources of funding and other support (such as supply of drugs), role of funders n/a 
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 IBiD Questionnaire booklet 
 
 
 
 
This questionnaire is the first part of the study looking at different ways of providing information to 
people who have received a diagnosis of bipolar disorder. 
The questions in this booklet will ask; how you have been feeling lately, how you feel about taking 
medication, your opinions about your diagnosis and how satisfied you are with any information you 
might have received, it will also ask about your experience of living with a mental health diagnosis. 
 
The survey should around 35 minutes to complete. 
 Please answer the questions as completely and honestly as possible.  
 Answer each of the questions in turn. 
 Please don’t feel that you have to spend a long time over each question. Often the first answer 
that comes to you is the best. 
 Please answer every question. 
 Most of the questions can be answered by ticking the box. 
 
Use of your responses 
 Your responses will be seen only by the research team. 
 Your responses will not be seen by any of your healthcare team 
 Reports or publications based on information provided will be based on everyone’s responses 
brought together. Individual responses will not be identifiable. 
 
 
Improving Information for people with a diagnosis of bipolar 
Participant Baseline Questionnaire booklet 
What this questionnaire is about 
How to fill out the questionnaire 
This questionnaire is completely confidential 
If there is anything that is not clear, please ask the researcher who will be able to help 
you completing this questionnaire. 
 384 
 
 
- We would like to ask you about the medicines you are prescribed for bipolar. 
- We know that you may be taking several different medicines for bipolar and that you may have different views 
about each one. 
- We would therefore like to ask you about your medicines separately. 
- Please look at the list of medicines below and draw a circle around any that are being prescribed for you at the 
moment. 
 
Medicines 
1. Lithium (Priadel, Camcolit) 
2. Valproate (Valproic Acid, Depakote, Epilim Chrono) 
3. Carbamazepine (Tegretol) 
4. Lamotrigine (Lamictal) 
5. Quetiapine (Seroquel) 
6. Olanzapine (Zyprexa) 
7. Risperidone (Risperdal) 
8. Haloperidol, Chlorpromazine, Stelazine 
9. Modecate, Depixol, Haldol, Piportil, Clopixol 
10. SSRI antidepressants (Fluoxetine (Prozac), Citalopram (Cipramil), Sertraline (Lustral), 
Paroxetine (Seroxat), Escitalopram (Lexapro, Cipralex)  
11. Venlafaxine (Effexor) Duloxetine 
12. Tricyclic antidepressants (Dothiepine, Dosulepin, Prothiadine, Amitriptyline, Clomipramine, 
Anafranil) 
13. Mirtazapine (Zispin) 
14. Lorazepam, Diazepam, Valium 
15. Sleeping tablets (Temazepam, Zopiclone, Zolpidem, Nitrazepam, Oxazepam, Promethazine) 
16. Other (please specify) 
 
 
 
MEDICINES PRESCRIBED FOR YOUR BIPOLAR 
 
To tell us how you feel about each of the bipolar medicines prescribed for you, please would 
you fill out a separate copy of the next two pages of the questionnaire for each medicine? 
We are sorry to ask you the same questions about each medicine but we are interested in your 
views about each one. 
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Please choose one of the medicines that you are prescribed and you circled on the table on the previous 
page. Write its name in this box. 
 
How do you take this medicine? (please tick) Tablet 
 Injection  
We would like to ask you about your personal views about this medicine. 
In the table are statements that other people have made about their medicines. 
Please show how much you agree or disagree with them by ticking one box for each statement. 
There are no right or wrong answers. We are interested in your personal views 
 
 
Views about this medicine 
Strongly 
Agree 
Agree Uncertain Disagree 
Strongly 
Disagree 
N1 My health, at present, depends on this medicine      
C1 Having to take this medicine worries me      
N2 My life would be impossible without this medicine      
C2 I sometimes worry about long-term effects of this medicine      
N3 Without this medicine I would be very ill      
C3 This medicine is a mystery to me      
N4 My health in the future will depend on this medicine      
C4 This medicine disrupts my life      
C5 
I sometimes worry about becoming too dependent on this 
medicine 
     
N5 This medicine protects me from becoming worse      
C6 This medicine gives me unpleasant side effects      
C7 
I tend to hide the fact that I am I am taking this medicine from 
other people 
     
C8 I sometimes worry about becoming addicted to this medicine      
C9 
Having to use this medicine is an unpleasant reminder of my 
condition 
     
C10 This medicine makes me feel ‘flat’      
C11 I dislike the way this medicine makes me feel      
N7 I need to take this medicine to prevent going into hospital      
 
 
 
 
Your views about medicines  
PRESCRIBED FOR YOUR BIPOLAR 
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Many people find a way of using their medicines which suits them. This may differ from the instructions 
on the label or from what their doctor has said.  
We would like to ask you a few questions about how you use this medicine. 
 
Here are some ways in which people have said that they use their medicines. 
For each of the statements, please tick the box which best applies to you. 
 
 
 
 
Your way of using this medicine: Always Often Sometimes Rarely Never 
M1 I forget to take them      
M2 I alter the dose       
M3 I stop taking them for a while      
M4 I decide to miss out a dose      
M5 I take less than instructed       
 
 
Approximately what percentage of this medication do you think you take? Please make a cross on the 
line to show this. (For example, if you think you take about half of your medication, put a cross at 50%) 
 
None 
0% 
 
10% 
 
20% 
 
30% 
 
40% 
Half 
50% 
 
60% 
 
70% 
 
80% 
 
90% 
All 
100% 
 
 
 
 
 
 
 
 
 
 
 
 
 
Using your medicines for bipolar 
If you are prescribed any other medicines for bipolar disorder, please 
continue on the extra pages. 
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These are statements that other people have made about medicines in general. 
Please show how much you agree or disagree with them by ticking the appropriate box. 
There are no right or wrong answers; we are just interested in your views. 
 
Your views about medicines in general 
Strongly 
Agree 
Agree Uncertain Disagree 
Strongly 
Disagree 
BG1 Doctors use too many medicines      
BG2 
People who take medicines should stop their treatment for a 
while every now and again 
     
BG3 Most medicines are addictive      
BG4 Natural remedies are safer than medicines      
BG5 Medicines do more harm than good      
BG6 All medicines are poisons      
BG7 Doctors place too much trust on medicines      
BG8 
If doctors had more time with patients they would prescribe 
fewer medicines 
     
 
 
 
These are statements that other people have made about the obstacles that prevent them from taking 
their medication as it was prescribed by their doctors. 
For each of the statements, please tick the box which best applies to you. 
 
 I find it difficult to: Always Often Sometimes Rarely Never 
P1 
Remember to take my medication when my 
daily routine changes 
     
P2 
Remember to take my medication when my 
regimen (treatment plan) changes 
     
P3 
Keep track of when I need to take each 
medicine 
     
P4 Remember to take my medicines every day      
P5 Cope with the costs of medicines      
P6 
Know when to get a further supply when my 
prescription runs out 
     
P7 Travel or go on holidays      
P8 Swallow my tablets      
P9 Get the best from my care team      
P10 Get information about my medicines      
 
 
We would like to ask you about the information you have received about your medications prescribed for bipolar 
disorder. 
Your views about medicines in general 
Using your medicines for bipolar 
Information about Medicines 
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Please rate the information you have received about each of the following aspects of medication. There are also 
options to tell us if you did not receive or did not need the information. 
There are no right or wrong answers. We are interested in your personal views. 
 Have you received enough information about... 
Amount of Information Received 
Too 
much 
About 
right 
Too 
little 
None 
received 
None 
needed 
S1 What the medicines are called      
S2 What these medicines are for      
S3 What they do 
     
S4 How they work 
     
S5 How long they take to act 
     
S6 How you can tell if they are working      
S7 How to use them      
S8 How long you need to be on the medicine      
S9 
Whether the medicine will have any unwanted effects 
(side effects) 
     
S10 What are the risks of you getting side effects  
     
S11 
What you should do if you experience unwanted side 
effects 
     
S12 If you can drink alcohol whilst taking this medicine 
     
S13 
Whether the medicine will interfere with other 
medicines 
     
S14 Whether the medication will make you feel drowsy 
     
S15 Whether the medication will affect your sex life 
     
S16 What you should do if you forget to take a dose 
     
S17 How to get a further supply      
 
 
 
 
Please tick any of the following terms that 
have been used to describe your mental 
health problems, and add any other terms 
that may have been used. 
 
 For each term, please indicate the extent to 
which you would agree that this label 
describes the experiences you have had. 
 
Your views about your mental health 
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Label/ term 
Tick if been used to 
describe your 
mental health 
problem 
 
Strongly 
Agree 
Agree Uncertain Disagree 
Strongly 
Disagree 
I1 Bipolar Disorder        
I2 Manic Depression        
I3 Mania        
I4 Psychosis        
I5 Depression        
I6 Schizoaffective        
I7 Anxiety 
       
I8 Other 
_____________________  
 
     
I9 Other 
_____________________  
 
     
I10 Other 
_____________________  
 
     
 
Please write in the box below, the term or label that you feel best describes your mental health 
problems. 
 
 
 
 
 
We are interested in what you consider may have been the initial causes of your mental health 
problems. As people are very different, there is no correct answer for this question. We are most 
interested in your own views rather than what others including doctors or family may have suggested to 
you. 
Please tell how much you agree or disagree that the items below were causes of your bipolar disorder 
by ticking the appropriate box. 
 
Possible causes 
Strongly 
Agree 
Agree Uncertain Disagree 
Strongly 
Disagree 
C1 Stress or worry      
C2 Hereditary - it runs in my family      
C3 A Germ or virus      
C4 Diet or eating habits      
C5 Chance or bad luck      
C6 Poor medical care in my past      
C7 Pollution in the environment      
C8 My own behaviour      
C9 My mental attitude e.g. thinking about life 
negatively 
     
C10 Family problems or worries      
C11 Overwork      
Your views about the causes of your bipolar 
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Possible causes 
Strongly 
Agree 
Agree Uncertain Disagree 
Strongly 
Disagree 
C12 My emotional state e.g. feeling down, lonely, 
anxious 
     
C13 Ageing      
C14 Alcohol      
C15 Smoking      
C16 Accident or injury      
C17 My personality      
C18 Chemical Imbalance      
C19 Recreational drugs (e.g. cannabis, cocaine, 
ecstasy) 
     
 
 
In the spaces below, please write down what you think are three most important causes for the start of 
your mental health problems. You may use any of the items from the box on the last page, or you may 
have additional ideas of your own. 
 
Possible causes 
C20 
 
C21 
 
C22 
 
We are also interested in what factors you think may be MAINTAINING your mental health problems i.e. 
preventing you from getting better. 
In the spaces below, please write down what you think are possible factors that are maintaining your 
mental health problems. 
 
 
Possible Maintaining factors 
C23  
 
C24  
 
C25  
 
 
Your views about the causes of your bipolar 
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We would like to ask you about your personal views about bipolar disorder. 
Please answer the following questions by circling the number which best describes your views about how you feel 
at the moment. 
1. How much does your bipolar affect your life? 
No affect 
at all 
 Severely affects 
my life 
0 1 2 3 4 5 6 7 8 9 10 
 
2. How long do you think your bipolar will continue? 
A very short 
time 
 
Forever 
0 1 2 3 4 5 6 7 8 9 10 
 
3. How much control do you feel you have over your bipolar? 
Absolutely 
no control 
 
Total control 
0 1 2 3 4 5 6 7 8 9 10 
 
4. How much do you think your treatment can help your bipolar? 
Not at all 
 Extremely 
helpful 
0 1 2 3 4 5 6 7 8 9 10 
 
5. How much do you experience symptoms from bipolar? 
No symptoms at all  Many severe 
symptoms 
0 1 2 3 4 5 6 7 8 9 10 
 
6. How concerned are you about your bipolar? 
Not at all 
concerned 
 Extremely 
concerned 
0 1 2 3 4 5 6 7 8 9 10 
 
7. How well do you understand your bipolar? 
Don’t 
understand at 
all 
 Understand 
very clearly 
0 1 2 3 4 5 6 7 8 9 10 
 
8. How much does your bipolar affect you emotionally? (e.g. does it make you angry, scared, upset?) 
Not at all 
affected 
emotionally 
 Extremely 
affected 
emotionally 
0 1 2 3 4 5 6 7 8 9 10 
 
9. How much do you agree with your diagnosis of bipolar? 
Don’t agree 
at all 
 Totally agree 
0 1 2 3 4 5 6 7 8 9 10 
Your views about your mental health problems 
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Listed below are a number of experiences that you may or may not have had since your mental health problems began. 
Please indicate by ticking Yes or No whether or not you have had each of these experiences. 
Next, please rate the severity of any symptoms you are currently experiencing by circling the appropriate number on the scale, where 1 indicates very mild and 5 indicates very severe. 
 
 
 
Are you currently 
experiencing this 
symptom 
 
If yes, please circle the symptom’s severity 
Tick box to indicate what you think caused the 
symptom 
 
 Yes No  Very mild Mild Moderate Severe 
Very 
severe 
 Bipolar Medication Both Neither Unsure 
SS1 Tremor/ shaky    1 2 3 4 5       
SS2 Weight gain     1 2 3 4 5       
SS3 Restlessness    1 2 3 4 5       
SS4 Constipation    1 2 3 4 5       
SS5 Dry mouth    1 2 3 4 5       
SS6 Tiredness    1 2 3 4 5       
SS7 Dizziness    1 2 3 4 5       
SS8 Sexual problems    1 2 3 4 5       
SS9 Sedation    1 2 3 4 5       
SS10 Nausea    1 2 3 4 5       
SS11 Stiffness    1 2 3 4 5       
 
 
Are you currently 
experiencing this 
symptom 
 
If yes, please circle the symptom’s severity 
Tick box to indicate what you think caused the 
symptom 
 
 Yes No  Very mild Mild Moderate Severe 
Very 
severe 
 Bipolar Medication Both Neither Unsure 
Symptoms and side effects you have experienced 
  
 
SS12 Sore eyes    1 2 3 4 5       
SS13 Headaches    1 2 3 4 5       
SS14 Upset stomach    1 2 3 4 5       
SS15 Sleep difficulties    1 2 3 4 5       
SS16 Loss of strength    1 2 3 4 5       
SS17 Speech Problems    1 2 3 4 5       
SS18 Slowed thinking    1 2 3 4 5       
SS19 Hearing voices    1 2 3 4 5       
SS20 Depressed mood 
(feelings of sadness, 
hopeless, worthless) 
   
1 2 3 4 5 
      
SS21 Mood swings    1 2 3 4 5       
SS22 Feeling apprehensive, 
fearful or anxious 
   
1 2 3 4 5 
      
SS23 Difficulty concentrating    1 2 3 4 5       
SS24 Involuntary muscle 
movements 
   1 2 3 4 5       
SS25 Loss of interest in 
hobbies or work 
   
1 2 3 4 5 
      
If you have experienced any other symptoms recently, please write them in the spaces below. 
 
 
Are you currently 
experiencing this 
symptom 
 
If yes, please circle the symptom’s severity 
Tick box to indicate what you think caused the 
symptom 
 
 Yes No  Very mild Mild Moderate Severe 
Very 
severe 
 Bipolar Medication Both Neither Unsure 
SS26  
 
 
   
1 2 3 4 5 
      
 
  
 
 
We are going to use the term ‘mental illness’ in this question, but please think of it as whatever you feel 
is the best term for it. 
For each statement, please tick whether you strongly disagree, disagree, agree or strongly agree. 
  
Strongly 
Agree 
Agree Disagree 
Strongly 
Disagree 
IS1 I feel out of place in the world because I have a mental 
illness. 
    
IS2 Mentally ill people tend to be violent.     
IS3 People discriminate against me because I have a mental 
illness. 
    
IS4 I avoid getting close to people who don’t have a mental 
illness to avoid rejection. 
    
IS5 I am embarrassed or ashamed that I have a mental illness.     
IS6 Mentally ill people shouldn’t get married.     
IS7 People with mental illness make important contributions 
to society. 
    
IS8 I feel inferior to others who don’t have a mental illness.     
IS9 I don’t socialize as much as I used to because my mental 
illness might make me look or behave “weird.” 
    
IS10 People with mental illness cannot live a good, rewarding 
life. 
    
IS11 I don’t talk about myself much because I don’t want to 
burden others with my mental illness. 
    
IS12 Negative stereotypes about mental illness keep me 
isolated from the “normal” world. 
    
IS13 Being around people who don’t have a mental illness 
makes me feel out of place or inadequate. 
    
IS14 I feel comfortable being seen in public with an obviously 
mentally ill person. 
    
IS15 People often patronize me, or treat me like a child, just 
because I have a mental illness. 
    
IS16 I am disappointed in myself for having a mental illness.     
IS17 Having a mental illness has spoiled my life.     
IS18 People can tell that I have a mental illness by the way I 
look. 
    
IS19 Because I have a mental illness, I need others to make 
most decisions for me. 
    
Stigma of mental illness 
  
  
Strongly 
Agree 
Agree Disagree 
Strongly 
Disagree 
IS20 I stay away from social situations in order to protect my 
family or friends from embarrassment. 
    
IS21 People without mental illness could not possibly 
understand me. 
    
IS22 People ignore me or take me less seriously just because I 
have a mental illness. 
    
IS23 I can’t contribute anything to society because I have a 
mental illness. 
    
IS24 Living with mental illness has made me a tough survivor.     
IS25 Nobody would be interested in getting close to me 
because I have a mental illness. 
    
IS26 In general, I am able to live my life the way I want to.     
IS27 I can have a good, fulfilling life, despite my mental illness.     
IS28 Others think that I can’t achieve much in life because I 
have a mental illness. 
    
IS29 Stereotypes about the mentally ill apply to me.     
 
 
  
 
 
Choose the one statement in each group that best describes the way you have been feeling for the past week. 
Please note that on this page the word; "occasionally" means once or twice; “often” means several times or more; 
"frequently" means most of the time. 
Circle the number next to the statement you picked. 
 
 
0 I do not feel happier or more cheerful than usual. 
1 I occasionally feel happier or more cheerful than usual. 
2 I often feel happier or more cheerful than usual. 
3 I feel happier or more cheerful than usual most of the time. 
4 I feel happier or more cheerful than usual all of the time. 
 
0 I do not feel more self-confident than usual. 
1 I occasionally feel more self-confident than usual. 
2 I often feel more self-confident than usual. 
3 I feel more self-confident than usual most of the time. 
4 I feel extremely self-confident all of the time. 
 
0 I do not need less sleep than usual. 
1 I occasionally need less sleep than usual. 
2 I often need less sleep than usual. 
3 I frequently need less sleep than usual. 
4 I can go all day or night without any sleep and still not feel tired. 
 
0 I do not talk more than usual. 
1 I occasionally talk more than usual. 
2 I often talk more than usual. 
3 I frequently talk more than usual. 
4 I talk constantly and cannot be interrupted. 
 
0 I have not been more active (either socially, sexually, at work, home or school) than usual. 
1 I have occasionally been more active than usual. 
2 I have often been more active than usual. 
3 I have frequently been more active than usual. 
4 I am constantly active or on the go all the time. 
Questions about how you feel 
 397 
 
Diagnosis received 
 
 
Diagnosis before admission (if 
different) 
 
 
Age of bipolar disorder diagnosis  
Current hospital admission 
Voluntary   
Involuntary/ Detained  
Other (details below)  
_______________________________________________ 
Reason for current admission 
 
 
Date of admission  
Approximate date of discharge  
Number of previous psychiatric 
hospital admissions 
 
Any Voluntary admissions? Yes   No  
Any Involuntary/ Detained 
admissions? 
Yes   No  
Number of previous manic episodes  
Number of previous episodes of 
depression 
 
Any current psychotic symptoms?  Yes   No  
Family history of bipolar Yes  No  Unknown  
Physical health conditions  
 
Date of Birth  
Gender Male   Female   
Ethnic Origin 
White British    Black Caribbean  
White Irish    Black British   
White Other    Black African   
     Black Other   
Indian    
Pakistani     Mixed ethnicity  
Bangladeshi   
Chinese    
Asian Other   
Marital Status 
Single    Married/ Civil partnership/Cohabiting/  
Divorced/ Separated  Widowed  
Other(please state) _____________________________________________ 
Highest level of 
Education 
No qualifications   
O levels/CSEs/GSCEs   
Vocational education NVQ/GNVQ/ HNC/ HND  
A levels/AS levels   
Degree     
Higher degree    
Professional qualifications (e.g. nursing, accountancy)  
 
Clinical Information 
Demographic information 
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Thanks-you for completing this questionnaire. 
We are interested to find out your opinions of the questionnaire and how you found completing it. 
For each statement, please tick whether you strongly disagree, disagree, agree or strongly agree. 
 
  
Strongly 
Agree 
Agree Uncertain Disagree 
Strongly 
Disagree 
Q1 The questionnaire was interesting to complete      
Q2 
The questionnaire helped me to reflect on 
bipolar 
     
Q3 The questionnaire made me upset      
Q4 The questionnaire was difficult to understand      
Q5 The amount of questions was about right      
Q6 The questionnaire was not relevant to me      
Q7 The questionnaire was easy to understand      
Q8 
I would recommend the questionnaire to 
others 
     
Q9 The questionnaire took too long to complete      
 
Please use the space below to tell us anything else about completing the questionnaire 
 
 
 
  
Your views of this Questionnaire 
 
Thank-you for taking the time to complete this questionnaire. Your response is 
greatly appreciated. 
All the responses you have given are completely confidential and will not be 
seen by anyone involved in your care. 
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We would like to ask you some questions about your experiences and your care since you 
completed the first questionnaire in this study. 
 
Please tell us how many appointments or visits with the following health professionals you have had 
since you completed the first questionnaire in this study. 
Please tell us if these were planned (for example, appointments or meetings which were routine as 
part of your usual care), or if they were unplanned (for example, for unexpected or emergency 
situations). If you have not had any, please write 0 in the spaces provided. 
 
  Number of planned 
appointments/ visits 
Number of unplanned 
appointments/ visits 
 Your GP for mental health problems   
 Community Mental Health Team   
 Crisis Resolution and Home Treatment Team 
(CRHT) 
  
 Your Psychiatrist   
 A Pharmacist   
 Any other health professionals (please tell us who 
in the boxes below) 
  
    
 
Please tell us if you have had any contact with mental health support groups or charities since you 
completed the first questionnaire in this study. 
Yes    No  
If yes, please tell us about this in the space below ... 
 
 
 
 
To what extent have the following things had a positive or negative effect on your mental health 
problems. Please tell us by ticking the appropriate box. 
  Made my 
mental 
health a lot 
worse 
Made my 
mental health 
a bit worse 
No effect on 
my mental 
health 
Made my 
mental 
health a bit 
better 
Made my 
mental 
health a lot 
better 
 Physical health problems      
 Family/ people around 
you 
     
 Finance/ money issues      
 Housing/ where I live      
Please use the space below to tell us about anything else you think might have had an effect on your 
mental health since you completed the first questionnaire in this study. 
 
 
 
 
 
 
About your recent care 
Thank-you for taking the time to complete this questionnaire and for your involvement in the study. 
Your responses are greatly appreciated. 
All the responses you have given are completely confidential and will not be seen by anyone involved 
in your care. 
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 IBiD study pack for staff 
Improving Information for people with Bipolar Disorder: 
a randomised controlled trial 
Study Protocol 
 
Chief Investigator Professor Rob Horne 
Sponsor  Sussex Partnership NHS Foundation Trust 
Funders  NIHR RfPB 
 
1.0 Introduction & Background 
Bipolar disorder is a serious, long-term mood disorder affecting approximately one person in every 
hundred (Fajutrao et al., 2009). It is characterised by episodes of mania and depression, which can 
severely impair the quality of life of those affected and the people around them (Goldberg et al., 1995). 
Recent estimates of the annual cost of managing bipolar disorder to the UK healthcare system at £342 
million, with hospitalisations accounting for 60% of this (Young et al, 2011). 
Medication is recommended as a key part of the treatment of manic and depressive phases as well as 
prophylaxis preventing recurrence (National Institute for Health and Clinical Excellence, 2006). 
Adherence to maintenance treatment medication is associated with, reduced relapse rates (Hong et al., 
2011), fewer hospital admissions (Scott & Pope, 2002), a reduced risk of suicide and attempted suicide 
(Baldessarini et al., 2006), and significantly lower healthcare costs (Hong, et al., 2011). However, many 
patient do not adhere to medication prescribed for bipolar disorder; a review by Lingam and Scott 
(2002) estimated a non-adherence rate of 41% to long-term prophylactic medication (Lingam & Scott, 
2002). 
Research has found that many people prescribed medication for bipolar disorder are concerned about 
their medicines and do not feel they have been given enough information about them. In order to 
decide to take medication, an individual must first perceive that they have a condition, and this 
condition warrants treatment. Studies in physical illnesses have shown that negative perceptions of 
treatment are linked to perceptions of illness and the degree of ‘fit’ between patients belief about the 
problem (illness) and preferred solution (the treatment) (Horne & Weinman, 2002). Individuals 
formulate a commonsense understanding of their condition and the subsequent treatment they have 
been prescribed. A commonsense model in which an individual has a recognition of their condition, a 
perceived need for medication, and their concerns about the prescribed treatment have been 
acknowledged would be likely to lead to engagement in positive self-management strategies, including 
adherence to medication (Horne, 2003). 
Non-adherence to medication for bipolar disorder has been shown to be associated with people’s 
beliefs about their illness and treatment, in particular their doubts about the need for treatment and 
concerns about adverse effects (Clatworthy et al., 2009; Clatworthy et al., 2007). A person’s individual 
beliefs and concerns will be associated with the information they may choose to seek and their 
unanswered questions surrounding their diagnosis and treatment. 
In terms of information, knowledge about bipolar and its treatment has been associated with adherence 
(Berk et al., 2010). Yet dissatisfaction with information about medicines among service users is 
commonplace (Bowskill et al., 2007) (Morselli & Elgie, 2003) (National Schizophrenia Fellowship, 2000). 
In the 2011 Care Quality Commission survey of users of community mental health services, Sussex 
Partnership NHS Trust showed scope for improvement in terms of provision of information about 
medicines and patients’ opinions of having their views taken into account during medication decisions. 
In addition, there was scope for improvement with regard to whether patients felt they had enough 
time to discuss their condition and treatment (Care Quality Commission, 2011). Findings for the 
inpatient setting have also indicated patient dissatisfaction in receiving explanations about medication 
and being involved in their own care and treatment (Care Quality Commission, 2009). 
To inform the development of the current study, a qualitative study was carried out with adults 
currently prescribed medication for bipolar disorder. Themes which emerged from the analysis 
concurred with findings from previous research, with regard to necessity beliefs and concerns held by 
patients. Insights from the qualitative study, in particular; the importance of internalized stigma; 
necessity and concern beliefs; unmet information needs and the importance of individual needs, will be 
used to inform this intervention (Unpublished data). 
There is a clear need to improve information provision regarding bipolar disorder and medicines 
prescribed for its treatment in the Trust. There is a need individuals' information requirements to be 
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elicited and addressed, in order to facilitate informed choice and adherence to treatment (Bowskill, et 
al., 2007). However, rather than healthcare professionals providing generic information, it is important 
that patients are allowed to discover and understand information which is relevant to them and helps to 
build accurate, common sense models of their illness. 
In addition to the above research and qualitative work carried out by our research group, informing the 
development of the current pilot intervention, an exploration of the literature on improving adherence 
in mental health has contributed to the development phase. In terms of improving medication 
adherence, a review by Sajatovic and colleagues (2004) concluded that for bipolar disorder, effective 
therapies occur in the context of long-term management of illness that incorporates a good 
understanding of medications and their risks and benefits as well as education about illness awareness 
and self-management. The majority of effective therapies feature an interactional component between 
patients and their care providers or therapists (Sajatovic et al., 2004). We have as a result incorporated 
these findings in the design of our intervention. A review by Berk and colleagues concluded that ‘a 
person centred approach that considers risk factors for non-adherence and barriers to other health 
behaviours may assist with the development of more targeted briefer interventions’ (Berk, et al., 2010). 
In addition to the recommendations from reviews of mental health interventions, the most recent 
Cochrane review of adherence interventions for chronic health problems acknowledged the lack of 
evidence for effective adherence interventions and recommended that ‘High priority should be given to 
fundamental and applied research concerning innovations to assist patients to follow medication 
prescriptions for long-term medical disorders’ (Haynes et al., 2008). 
The evidence related to non-adherence in bipolar disorder clearly indicates that interventions are 
needed to facilitate informed choice and support optimal adherence to appropriately prescribed 
treatment. 
The intervention will take a novel approach informed by theories of self-regulation of illness and 
commonsense representations of illness and treatment. The content of the intervention will be tailored 
to meet individual need. This will be achieved by identifying, for each individual, the salient perceptual 
factors (e.g. beliefs about illness and treatment) and practical factors (e.g. capacity and resources) 
influencing the motivation and ability to engage with treatment and use it to best effect. 
 
1.1 Development of the present study – Using the MRC Framework for the development of 
complex interventions 
This programme of research has been funded by a grant from the National Institute for Health Research 
(NIHR) and applies the approach recommended by the Medical Research Council (MRC) framework for 
the development of complex interventions (Craig et al., 2008). The qualitative research was preceded by 
a preclinical/ theoretical phase which explored existing evidence and identified the theoretical 
framework, the extended self-regulation model (Horne, 2003). This phase will pilot the intervention to 
allow for a larger, more definitive trial. 
This broader research programme comprises the following sub-studies: 
Phase 1 (09/H1107/110): Identifying the components of the intervention 
 A qualitative study identified unmet information needs and evaluated existing information 
from a service-user perspective (completed). Results confirmed previously identified beliefs 
and concerns of patients with bipolar disorder. Identified information needs included; 
information about diagnosis, side effects of treatments and a desire to be informed about and 
contribute to their care plan (unpublished data). 
Phase 2: Pilot Randomised Controlled Trial. 
 Development, implementation and pilot study of the intervention as an RCT. 
 
1.2 Intervention Aim 
 To facilitate informed choice and support optimal adherence to appropriately prescribed 
treatment through the delivery of an information resource with tailored individual support 
which addresses participants’ personal information needs and concerns about treatment. 
 
1.3 Intervention Development 
1.3.1 Content 
The intervention is informed by theories of self-regulation of illness and commonsense representations 
of illness and treatment. As stated in section 1.0 above, research has shown that adherence behaviour is 
associated with people’s beliefs about their illness, their beliefs about the necessity of treatment and 
concerns about adverse effects of treatment. 
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The perceptions and practicalities approach (PAPA) (Horne, 2001) provides a framework to guide the 
development of the intervention itself as it operationalises both intentional and non-intentional non-
adherence. 
For each individual, the content of the written material used to guide the session will be tailored to 
meet individual need. This will be achieved by identifying, for each individual, the salient perceptual 
factors (e.g. beliefs about illness and treatment) and practical factors (e.g. capacity and resources) 
influencing the motivation and ability to engage with treatment and use it to best effect. This is 
described in section 4.2 below. 
Written material will be prepared to address beliefs and perceptual and practical barriers related to 
engagement with treatment: 
 Beliefs about illness, operationalised by the Illness Perception Questionnaire constructs; 
identity, cause, timeline, consequences, personal control, treatment control, illness coherence, 
and emotional representation. 
 Perceptions of medication, operationalised by the sub-scales of the Beliefs about Medication 
Questionnaire, i.e. perceived need and concerns about medication. 
 Practical factors to address non-intentional non-adherence, e.g. capacity and resources. 
Only those relevant to participants’ individual responses will be included in their tailored intervention.  
 
1.3.2 Delivery vehicle 
The intervention will consist of tailored written material delivered in a face-to-face session with the 
researcher. In addition, as this material will be provided for participants to take away, they will be able 
to refer back to this and seek additional support from the researcher in the follow-up telephone contact. 
This method was suggested during the Phase 1 qualitative work with service users. 
1.3.3 Context 
The intervention will be delivered in the in-patient setting when participants are close to discharge. 
Phase 1 qualitative work and the care Quality Commission survey identified that this is a time where 
patients may not receive information they require about their diagnosis and treatment. By delivering 
the intervention close to discharge this will minimise the impact of, for example, cognitive difficulties 
during a manic or depressive episode. 
1.3.4 Content development – consultation with service users 
The draft content and delivery mechanism will be discussed with service-users in a consultation 
exercise. Refinements will be made following this consultation before the final intervention is 
developed.  
 
2.0 Research Aims 
2.1 Principle research aim 
 To determine the effect of a theory-based intervention on participants perceptions of bipolar 
disorder and its treatment. 
 
2.2 Secondary research aims 
 To determine the effect of the intervention on the secondary outcome measures; satisfaction 
with information about medication prescribed for bipolar disorder, adherence to treatment, 
and self-stigmatisation. 
 To determine the effect size of the intervention versus treatment as usual (TAU) to inform the 
power calculation for a definitive RCT. 
 To conduct a process evaluation to gather information on the acceptability and feasibility of the 
intervention in terms of recruitment and retention. 
 
3.0 Methods 
3.1 Design 
A pilot RCT will allocate patients to receive either the intervention plus treatment as usual (I + TAU) or to 
the control group (TAU) and investigate changes to the identified outcome measures. 
3.2 Participants 
Participants (aged over 18) with a diagnosis of bipolar disorder will be recruited from inpatient 
Psychiatric services across Sussex Partnership NHS Foundation Trust. It is estimated that a potential pool 
of approximately 320 patients will be eligible over a period of 12 months (based on previous 12 months 
discharge data). 
3.2.1 Inclusion Criteria 
 Receiving care as an inpatient within Sussex Partnership NHS Foundation Trust 
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 Received a diagnosis of bipolar disorder 
 Currently prescribed medication for bipolar disorder 
 Ability to give written informed consent 
 Aged over 18 years 
 
3.2.2 Exclusion Criteria 
 Organic brain syndrome 
 Active suicide ideation 
 Primary diagnosis of substance misuse 
 
3.3 Recruitment 
Participants will be recruited from inpatient wards across 12 wards within Sussex Partnership NHS 
Foundation Trust. Identification of patients meeting the inclusion criteria will be carried out by their 
direct care team on the wards. These staff will identify whether potential participants are able to 
provide consent and are at a stage in their care where it is appropriate for them to take part. 
Staff will be provided with Information sheets, a copy of the Protocol and Patient Information Sheets. 
This will provide them with inclusion and exclusion criteria and the procedure for identification and 
recruitment of participants. Eligible patients will be provided with a Participant Information Sheet (PIS). 
Participants will be informed that it is their decision whether or not to participate and agreeing or 
declining will not affect their care in any way. For further information participants will be able to contact 
the Clinical Studies Officer or Researcher. 
Recruitment will be carried out by the Clinical Studies Officer (CSO) who will arrange to meet with 
eligible patients before taking them through the content of the PIS to ensure informed consent is able to 
given for those wishing to participate. At this point an appointment will be made for them to give 
consent and complete the baseline assessments. 
3.3.1 Consent 
Fully informed consent will be ensured by the direct care team identifying that informed consent can be 
provided, and by the CSO explaining the information in the PIS and confirming understanding with 
participants. The CSO has GCP and Informed Consent Training as well as previous experience of 
consenting in other Mental Health research studies. 
3.3.2 Site information 
12 wards will be included for participant recruitment across 6 units. 
 Woodlands Centre, East Sussex (Woodlands) 
 Department of Psychiatry, General Hospital, Eastbourne (Amberley, Bodiam) 
 Centurion Mental Health Centre, Chichester (Orion) 
 Langley Green Hospital, Crawley (Jade, Coral, Opal) 
 Meadowfield Hospital, Worthing (Maple, Rowan) 
 Mill View Hospital, Hove (Meridian, Regency, Caburn) 
 
3.4 Randomisation 
Participants will be randomly allocated to the intervention or treatment as usual (TAU) condition. 
Randomisation will be carried out independently by Kings College London Clinical Trials Unit using an 
online randomisation system. The Researcher will coordinate this and receive email confirmations of 
allocation. 
3.4.1 Treatment allocation & Allocation concealment 
Following participants providing consent, this information will be passed to the Researcher. Patients will 
be allocated to either the intervention or control group. Participants assigned to the control group will 
be notified of their allocation by letter. The CSO will remain blinded to participants allocation to ensure 
allocation concealment. The Attrition rate at this point will be recorded for inclusion in the assessment 
of feasibility for a larger trial. 
 
3.5 Sample & sample size 
Participants (aged over 18) with a diagnosis of bipolar disorder will be recruited consecutively from in-
patient Psychiatric services across Sussex Partnership NHS Foundation Trust. The number of participants 
the study is estimated to be able to recruit during the fieldwork period allowed for the study (12 
months) has been estimated from previous 12 month discharge diagnosis data. 
In a 12 month period 328 patients were discharged with a diagnosis indicating bipolar disorder from 12 
eligible wards (adult in-patient mental health services, excluding intensive care). A sample of 30 
participants was determined to be sufficient to provide feasibility and acceptability data.  
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3.6 Outcome measures 
Validated questionnaires and modified measures will be used to investigate time and treatment effects 
following the delivery of the intervention in the primary and secondary outcome measures; beliefs 
(illness and treatment), adherence, satisfaction with information and self-stigmatisation. These 
measures will be taken at baseline, and repeated 6-8 weeks post-intervention delivery. Demographic, 
diagnosis and treatment related information will also be recorded including mental health service-
utilisation. Clinical measures will be administered in order to control for current state in analysis. 
3.6.1 Piloting questionnaires 
The questionnaires will be presented to a small group of service users to obtain their feedback on the 
wording and format of the questionnaires. Following this process the questionnaire booklet will be 
refined, minor adaptations to wording will be made and the format will be finalised. 
Table 1: List of measures to be used 
Clinical The Beck Depression Inventory (BDI) 
 Altman Self-Rating Mania Scale 
Treatment beliefs The Beliefs about Medicine Questionnaire (BMQ) 
The BMQ consists of two scales assessing patients’ beliefs about the necessity of prescribed 
medication for controlling their disease and their concerns about potential adverse 
consequences of taking it. 
Illness beliefs The Illness Perception Questionnaire (IPQ Bipolar adaptation) 
The IPQ assesses the cognitive and emotional representations of illness. This has been adapted 
for use with patients with Bipolar Disorder. 
Adherence Medication Adherence Report Scale (MARS) 
Satisfaction The Satisfaction with Information about Medication Scale (SIMS) 
Stigma Internalised Stigma of Mental Illness (ISMI) 
 
4.0 Procedure 
4.1 Baseline assessment 
Prior to randomisation and delivery of the intervention, participants will be asked to complete baseline 
assessments, through an interview with the CSO. These baseline assessments will consist of the 
measures outlined above in section 3.6. The interviews will take place at the inpatient setting at a time 
convenient to the participant. Baseline data will also be collected on participants’ demographic 
information, diagnosis and treatment data. 
4.2 Intervention delivery 
Participants responses to the baseline BMQ and IPQ-BD measures will be used to tailor written 
information to address the specific concerns about bipolar disorder and its treatment. For each 
individual, the salient perceptual factors (e.g. beliefs about illness and treatment) and practical factors 
(e.g. capacity and resources) influencing the motivation and ability to engage with treatment and use it 
to best effect will be identified. 
Participants will then have a one-to-one appointment with the Researcher to work together through the 
intervention material, address concerns raised at this stage and advise on self-help aspects of the 
resource. The information gathered from scoring the BMQ and IPQ measures collected at baseline will 
also provide a starting point for discussion about these issues. Participants will also receive existing 
material produced by Sussex Partnership NHS Foundation Trust on specific medications which they have 
been prescribed. These sessions will take place in a private location in the inpatient setting. The 
Researcher will contact each participant by telephone on one occasion to follow-up on any additional 
concerns. 
4.3 Control group 
Those participants allocated to the control group will be notified of their allocation by letter and will be 
able to have any questions answered by the unblinded Researcher. They will continue to have treatment 
as usual with their healthcare professionals. They will be asked to complete the same follow-up 
measures as participants in the intervention group. 
4.4 Follow-up 
The baseline assessment measures will be repeated in order to assess any changes 6 weeks post-
intervention, or 6-8 weeks post discharge for the control group participants. In addition, data will be 
collected on possible confounders such as participants’ contacts with mental health professionals and 
prescribers at any point between baseline and follow-up, and changes to their medication regimen. 
These interviews will be carried out by the Clinical Studies Officer in a location convenient for the 
participant, either at home, at the hospital or in a community mental health setting. If necessary, this 
can also be carried out by telephone. Participants will be requested not to disclose their treatment 
allocation to the CSO. 
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4.4.1 Qualitative follow-up 
At the follow-up appointment with the CSO, all participants will be invited to take part in a semi-
structured interview with the Researcher to assess the feasibility and acceptability of the study. This 
interview will take place over the telephone and will be audio-taped with the participants permission. 
4.5 Incentives 
Participants will receive an incentive of £20 for their participation in the study. An incentive is offered in 
order to maximise the retention rate at follow-up. Participants will be reimbursed for any travel 
expenses incurred and will be offered refreshments during their appointments and interviews. 
 
5.0 Data analysis 
The validated questionnaire measures will be scored as per published guidelines. BMQ data will be 
analysed using and intention to treat protocol with a repeated measure design with two groups and two 
time points. Interaction effects will be explored. This will be repeated for the secondary outcome 
measures. The pattern of missing data will be examined and appropriate methods to account for this 
will be applied. 
Qualitative data from the follow-up interviews will be subject to Thematic analysis in order to elicit 
themes and provide recommendations for a definitive RCT. 
 
6.0 Anticipated outputs of the study 
The expected outcomes of the study will be the development of an intervention designed to improve 
satisfaction with information about medications for bipolar disorder and address service-users concerns 
about their condition and treatment. If the intervention is successful, we anticipate that by increasing 
satisfaction with information, this will enhance informed and collaborative decision making. By 
encouraging individuals to address personal concerns, the intervention will aid with personalised care 
planning. 
 
6.1 Dissemination plan 
 Conference presentations. 
 Publication in peer-review journal. 
 Publication through service-user magazine (Pendulum, the Bipolar UK journal) 
 
7.0 Core research team 
Professor Rob Horne (Chief Investigator, Academic Lead, UCL School of Pharmacy) 
Dr Richard Bowskill (Clinical Lead, Sussex Partnership NHS Foundation Trust) 
Dr Mark Hayward (Director of R&D, Sussex Partnership NHS Foundation Trust) 
Lindsay MacDonald (Researcher/ PhD student, UCL School of Pharmacy) 
Sally Skipper (Clinical Studies Officer, Sussex Partnership NHS Foundation Trust) 
Mr Michel Syrett (Service User Representative, Bipolar UK) 
Additional Clinical Studies Officers (Kelly Humphreys & Philippa Case, Sussex Partnership NHS 
Foundation Trust) 
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Improving Information for people with Bipolar Disorder 
(IBiD) 
Participant Information Sheet 
 
Invitation 
We would like to invite you to take part in our research study. Before you decide whether or not to take 
part it is important for you to understand why the research is being done and what it will involve. Please 
take time to read the following information carefully. You may wish to discuss it with others. A member 
of our team will go through the information with you and answer any questions you may have. 
 
What is the purpose of the study? 
Often people with a diagnosis of bipolar disorder do not have access to the information they need and 
this can make understanding their diagnosis and treatment they have been prescribed more difficult. It 
is important however, rather than healthcare professionals providing generic information, patients are 
allowed to discover and understand information which is relevant to them. 
This study aims to find out whether providing information which is tailored or personalised to people’s 
individual needs is more helpful than the information that is currently available within Adult mental 
health services. This type of study is called a ‘randomised controlled trial’. 
 
What is a randomised controlled trial? 
A randomised controlled trial (RCT) is the best type of research to test new approach when we don’t 
know which option is best. To find out we need to compare different approaches. We put people into 
groups and give each group a different approach. The results are compared to see if one is better. To try 
to make sure the groups are the same to start with, each patient is put into a group at random (by 
chance). 
 
Why have I been chosen? 
You have been chosen because you are receiving care from health professionals in Sussex Partnership 
NHS Foundation Trust and have been prescribed medication for bipolar disorder. In total approximately 
90 people will participate in the study. Half of these will be offered the additional information and half 
will continue with their usual care. 
Your care team have agreed that it would be ok/ appropriate for you to take part in this study if you 
wanted to. The research team will keep in touch with your care team throughout the study to make sure 
that everything is still ok. 
Do I have to take part? 
It is up to you to decide whether or not to take part. If you do decide to take part you will be given this 
information sheet to keep and be asked to sign a consent form.  If you decide to take part you are still 
free to change your mind at any time and without giving a reason. A decision not to take part, or a 
decision to withdraw at any time, will not affect the care that you receive. 
 
What will happen to me if I take part? 
If you are interested in taking part after reading this Information Sheet please let your care team know 
and they will pass your contact details on to a member of the research team. They will make direct 
contact with you and arrange a meeting within the next couple of days.  
When you meet, the researcher will go through this Information Sheet with you, make sure you 
understand everything about the research and answer any questions you might have about the 
research. If you wish to participate you will be asked by an experienced research nurse to sign an 
Informed Consent form. You may still choose not to take part in the research at this stage, without 
giving a reason and with no detriment to you. You can also ask for more time to consider whether or not 
to take part.  
If you proceed with the study we will ask you to complete a questionnaire. The questionnaire will 
include five sections. These will ask; how you have been feeling lately, how you feel about taking 
medication, your opinions about your diagnosis and how satisfied you are with any information you 
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might have received, it will also ask about your experience of living with a mental health issue. This will 
take between 40 – 60 minutes and will take place in a private place in the hospital. 
After this meeting someone independent to the study and without knowing your name or details will 
allocate you at random to either the group where the information you receive will be tailored 
specifically for you or to continue with your usual care. Half of the people in the study will be allocated 
to a therapy group and the other half will not be allocated to a therapy group.  
If you are allocated to receive the new approach, you will be invited to meet with the Researcher on a 
one-to-one basis to informally talk about your thoughts and opinions about your diagnosis and 
medications. You will be provided with written information tailored for you and you will also have the 
opportunity to discuss this with the Researcher after the meeting via telephone or email. This 
appointment will last between one hour and one and a half hours and will also take place in a private 
place at (insert hospital). If you are allocated to this group, you will also continue to receive standard 
care from your care team. 
If you are allocated to the usual care group, you will continue to receive the standard care and 
information from your care team. You will receive a letter letting you know that you have been allocated 
to the usual care group. Participating in the study will not interfere with your usual care.  
Everyone in both groups will be asked to complete a second questionnaire about 2 months after their 
previous appointment with the researcher. This should take no longer than about 30 minutes and will 
take place in a location convenient for your, for example in your home or where your care team work. 
You will receive £20 to compensate for your time in taking part in the study. 
 
Will my taking part in this study be kept confidential? 
Yes. All the information you give during the study will be confidential and only the research team will 
have access to your responses. All information you provide will be stored securely. The questionnaires 
you complete will not have your name on them, (a number will be used instead) so it will not be possible 
for people to match any information to you personally. The study complies with data protection laws. 
No NHS staff involved in your care will be able to see your individual responses. In the unlikely event 
that the researchers feel that the health and safety of you or others is at severe risk, you will be 
informed that your care coordinator will be contacted. 
 
What are the possible benefits of taking part? 
This study is testing a new approach, for this reason we do not know whether or not it will be effective. 
By taking part in the study you will help us learn if this approach is helpful and this will in the future help 
mental health services to provide information for people using these services.  
You may find that receiving information and having the opportunity to talk about your medication and 
diagnosis is helpful and rewarding for you. 
 
What are the possible disadvantages of taking part? 
It is unlikely that there are any risks or disadvantages of taking part.  
If you are allocated to receive the new approach, taking part in the study will involve talking to a 
researcher about the diagnosis you received and symptoms and side-effects you may have experienced. 
For some it may be difficult to consider these feelings and experiences. You do not have to discuss 
anything that you find difficult to talk about. If difficult issues come up during the interview you are free 
to stop the session at any point to take a break, reschedule or finish the session, or withdraw from the 
study, again with no detriment to yourself or the service you receive. In discussion with you the researcher 
can make arrangements for you to receive support from an appropriate person. Either you or the 
Researcher, with your permission, can seek support from members of your care team in the event that 
you might need this. 
 
What will happen to the results of the research study? 
The results of the study will be written up for publication in a journal. No-one will be identified in any 
part of the write-up or article. If you would like to obtain a copy of the published results of the study, 
please tell one of the researchers and they will happily supply you with one when they become 
available. 
 
 
Who is organising and funding this study? 
This study is being led by Professor Rob Horne, Professor of Behavioural Medicine at UCL School of 
Pharmacy in collaboration with Sussex Partnership NHS Foundation Trust. The research is being funded 
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by the Research for Patient Benefit Programme, National Institute for Health Research. The study is part 
of a PhD being undertaken by Miss Lindsay MacDonald. Funding is available for the duration of the 
study. 
 
Who has reviewed the study? 
All research in the NHS is looked at by an independent group of people, called a Research Ethics 
Committee, to protect your interests. This study has been reviewed and approved by the London Queen 
Square Research Ethics Committee (Ref No: 12/LO/1615) as well as by the Research and Development 
Department within your local NHS trust. 
Contact details of the London Queen Square Research Ethics Committee: Health Research Authority, 
HRA Head Office, Skipton House, 80 London Road, London SE1 6LH. Phone: 020 7972 2584 
 
What should I do now? 
If you are interested in taking part after reading this Information Sheet please let your care team know 
and they will pass your contact details on to a member of the research team. 
For further information about the study please contact: 
Lindsay MacDonald (Researcher), UCL School of Pharmacy. 
Phone: 020 7874 1297 
Email: l.macdonald@ucl.ac.uk 
 
Kelly Humphryes (Clinical Studies Officer) 
Phone: 01273 265921 
Email: kelly.humphryes@sussexpartnership.nhs.uk 
 
Philippa Case (Clinical Studies Officer) 
Phone 01273 265921 
Email: philippa.case@sussexpartnership.nhs.uk 
 
Thank-you for taking the time to read this information. 
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Improving Information for people with Bipolar Disorder 
(IBiD) 
 
Staff Information 
 
This study is being carried out by Researchers from the Centre for Behavioural Medicine, at UCL School 
of Pharmacy in partnership with Sussex Partnership NHS Foundation Trust. The research is being funded 
by the Research for Patient Benefit Programme, NIHR (Grant number: PB-PG-1207-15248). 
 
What is the purpose of the study? 
We are recruiting patients from wards across the Trust to take part in a trial aiming to address some of 
the outstanding information needs of patients with Bipolar Disorder. The study will run from June 2013 
until December 2013. 
The aim is find out whether providing information which is tailored or personalised to people’s 
individual needs is more helpful for people than usual care. By conducting a randomised controlled trial 
(RCT) we will be able to find out whether this approach results in any changes about how people feel 
about their diagnosis and treatment. 
A copy of the research protocol is available if you would like further information about the study. 
What will happen to participants who take part in the study? 
Everyone who agrees to take part will complete a questionnaire with a member of the research team. 
The questionnaire includes how they feel about taking medication, their satisfaction with information 
about medication and their opinions about their diagnosis. This will take approximately 45 minutes and 
will take place in a private place within the hospital environment. 
Randomisation will then be carried out independently from the Research Team or care staff. 
Those who have been randomised to receive the additional information will meet with the researcher to 
informally talk about their thoughts and opinions about their diagnosis and medications and receive 
written, tailored information. This appointment will last between one hour and one and a half hours and 
will also take place in a private place within the hospital environment. 
Everyone will be asked to complete a second questionnaire about 2 months after their previous 
appointment with a member of the research team. 
Participants will receive a payment of £20 to compensate them for their time. 
Who is eligible to take part? 
Inclusion Criteria 
Able to provide written informed consent 
Diagnosis of bipolar disorder 
Currently prescribed medication for bipolar 
disorder 
Age over 18 years 
Exclusion Criteria 
Organic Brain Syndrome 
Active suicidal ideation 
Primary diagnosis of substance misuse 
Patients considered as presenting as risk to 
others. 
 
How can you help? 
Recruitment to the study will be carried out by Clinical Studies Officers (CSO), employed by Sussex 
Partnership NHS Foundation Trust, based in the R&D Department. 
We are asking ward staff to identify patients who meet the eligibility criteria outlined above. Patients 
identified as meeting the eligibility criteria should be provided with a Participant Information Sheet 
(your ward will be provided with a supply of these). 
Those patients expressing a verbal interest will be approached, if appropriate, within 48 hours by the 
CSO. 
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The CSO will go through the information sheet with potential participants and answer any questions 
they may have. 
The researchers involved in the study will visit with you prior to the start of the study to discuss how to 
make sure that we keep any disruption to a minimum. 
 
Who has reviewed the study? 
This study has been reviewed and approved by London Queen Square Research Ethics Committee (Ref 
No: 12/LO/1615) as well as by the R&D Department within Sussex Partnership NHS Foundation Trust 
(Ref: CSP 87823). 
 
 
Who can I contact for further information? 
If you would like more information, please contact the relevant individual listed below. 
Lindsay MacDonald, 
Researcher 
Centre for Behavioural Medicine,  
UCL School of Pharmacy, 
020 7874 1297 
l.macdonald@ucl.ac.uk 
 
Sally Skipper, 
MHRN Clinical Studies Officer, 
Sussex Education Centre, 
01273 265921 
sally.skipper@sussexpartnership.nhs.uk 
 
Kelly Humphryes 
MHRN Clinical Studies Officer, 
Sussex Education Centre, 
01273 265921 
kelly.humphryes@sussexpartnership.nhs.uk 
 
Philippa Case 
MHRN Clinical Studies Officer, 
Sussex Education Centre, 
01273 265921 
philippa.case@sussexpartnership.nhs.uk 
 
 
Thank-you for taking the time to read this information sheet. 
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 Example email to ward staff to update on progress 
of the study 
 
Improving Information for people with Bipolar Disorder (IBiD) 
 
Dear colleagues, 
This is just a quick email to update you about the IBiD study currently recruiting patients with 
bipolar disorder across the Trust. 
Thank-you to all those already involved for your support and for starting to refer patients to 
the study. 
If we have not yet met as part of our visits to the sites, I hope we can arrange to speak soon 
and I can tell you about the study. 
 
Recruitment 
We have so far recruited 8 participants to the study, but just to remind you we are recruiting 
until December 2013. 
We aim to recruit at least 30 people with a bipolar diagnosis before the end of the year. 
 
An update on our team 
Just to update you, Sally Skipper has moved to a different role, so your points of contact now 
for any potential recruits are Kelly, Philippa (cc’d into email) and myself. 
 
Any new staff members in your teams? 
Please let me know if it would be useful for us to come and meet with any new members of 
staff who may have joined your teams since we started the study. I will be pleased to come 
and meet with them to discuss the study. 
 
Study documents 
Please also let me know if you would like any more copies of either the Participant Information 
sheets or Staff information sheets and I will bring or send copies to you. 
 
Please feel free to forward this email around your teams as you feel appropriate. 
 
Once again, many thanks for helping us with this study. 
Please do not hesitate to get in touch with us about anything relating to the IBiD study or if 
you have any patients who might be interested in participating. 
 
Best wishes, 
 
Lindsay 
(IBiD study coordinator) 
(on behalf of the IBiD team; Lindsay MacDonald, Kelly Humphryes & Philippa Case) 
 
Lindsay MacDonald 
Follow CBM on twitter @CBM_UCLSoP 
Centre for Behavioural Medicine,  
UCL School of Pharmacy, Mezzanine Floor, BMA House, 
Tavistock Square, London WC1H 9JP 
Direct line: + 44 (0) 207 874 1297 
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 IBiD study consent form 
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 IBiD randomisation process 
 
First 10 participants are allocated using a random number table (Kirkwood, Medical Statistics; pg 485, 
Column 6, first 10 rows). 
 
Coin toss used to allocate even numbers (Heads) for IG and odd numbers (Tails) for CG. 
 
After first 10 participants, use minimisation to balance by age group and gender (Ref Clinical trials A 
practical guide to design, analysis and reporting). 
 
Pt ID Gender DoB Age 
Treatment 
allocation 
 F Removed 59 IG 
 F  74 IG 
 F  31 CG 
 F  34 CG 
 M  56 CG 
 F  45 CG 
 F  37 CG 
 M  61 IG 
 M  55 IG 
 M  39 IG 
 
Participant  
F 
62 
 
 IG CG  
M 3 1 
10 
F 2 4 
18-30 0 0 
10 31-45 1 4 
46+ 4 1 
 
 
IG=6 
CG=5 
=CG 
 
Participant  
F 
47 
 
 IG CG  
M 3 1 
11 
F 2 5 
18-30 0 0 
11 31-45 1 4 
46+ 4 2 
 
IG=6 
CG=7 
=IG 
 
Participant  
M 
54 
 
 
 IG CG  
M 3 1 
12 
F 3 5 
18-30 0 0 
12 31-45 1 4 
46+ 5 2 
 
IG=8 
CG=3 
=CG 
 
Participant  
F 
64 
 
 IG CG  
M 3 2 
13 
F 3 5 
18-30 0 0 
13 31-45 1 4 
46+ 5 3 
 
IG=8, CG=8 
Balanced groups, simple 
randomisation to 
determine allocation (coin 
toss). 
Heads (IG) Tails (CG) 
Tails 
=CG 
Participant  
F 
47 
 
 
 IG CG  
M 3 2 
14 
F 3 6 
18-30 0 0 
14 31-45 1 4 
46+ 5 4 
 
IG=8 
CG=10 
=IG 
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Participant  
F 
55 
 
 IG CG  
M 3 2 
15 
F 4 6 
18-30 0 0 
15 31-45 1 4 
46+ 6 4 
 
IG=10, CG=10 
Balanced groups, simple 
randomisation to 
determine allocation (coin 
toss). 
Heads (IG) Tails (CG) 
Heads 
=IG 
Participant  
F 
46 
 
 IG CG  
M 3 2 
16 
F 5 6 
18-30 0 0 
16 31-45 1 4 
46+ 7 4 
 
IG=12 
CG=10 
=CG 
 
Participant  
F 
65 
 
 IG CG  
M 3 2 
17 
F 5 7 
18-30 0 0 
17 31-45 1 4 
46+ 7 5 
 
IG=12, CG=12 
Balanced groups, simple 
randomisation to 
determine allocation (coin 
toss). 
Heads (IG) Tails (CG) 
Tails 
=CG 
Participant  
F 
54 
 
 IG CG  
M 3 2 
18 
F 5 8 
18-30 0 0 
18 31-45 1 4 
46+ 7 6 
 
IC=12 
CG=14 
=IG 
 
Participant  
M 
48 
 
 IG CG  
M 3 2 
19 
F 6 8 
18-30 0 0 
19 31-45 1 4 
46+ 8 6 
 
IC=11 
CG=8 
=CG 
 
Participant  
F 
66 
 
 
 IG CG  
M 3 3 
20 
F 6 8 
18-30 0 0 
20 31-45 1 4 
46+ 8 7 
 
IG=14 
CG=15 
=IG 
 
Participant  
F 
65 
 
 
 IG CG  
M 3 3 
21 
F 7 8 
18-30 0 0 
21 31-45 1 4 
46+ 9 7 
 
IG=16 
CG=15 
=CG 
 
Participant  
M 
54 
 
 IG CG  
M 3 3 
22 
F 7 9 
18-30 0 0 
22 31-45 1 4 
46+ 9 8 
 
IG=12 
CG=11 
=CG 
 
Participant  
F 
36 
 
 IG CG  
M 3 4 
23 
F 7 9 
18-30 0 0 
23 31-45 1 4 
46+ 9 9 
 
IG=8 
CG=13 
=IG 
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Participant  
M 
51 
 
 IG CG  
M 3 4 
24 
F 8 9 
18-30 0 0 
24 31-45 2 4 
46+ 9 9 
 
IG=12 
CG=13 
=IG 
Participant  
F 
39 
 
 IG CG  
M 4 4 
25 
F 8 9 
18-30 0 0 
25 31-45 2 4 
46+ 10 9 
 
IG=10 
CG=13 
=IG 
Participant  
F 
43 
 
 IG CG  
M 4 4 
26 
F 9 9 
18-30 0 0 
26 31-45 3 4 
46+ 10 9 
 
IG=12 
CG=13 
=IG 
Participant HC28 
F 
44 
 
 IG CG  
M 4 4 
27 
F 10 9 
18-30 0 0 
27 31-45 4 4 
46+ 10 9 
 
IG=14 
CG=13 
HC28 = CG 
Participant WL29 
F 
66 
 
 IG CG  
M 4 4 
28 
F 10 10 
18-30 0 0 
28 31-45 4 5 
46+ 10 9 
 
IG=20 
CG=19 
WL29 = CG 
Participant HC30 
F 
52 
 
 IG CG  
M 4 4 
29 
F 10 11 
18-30 0 0 
29 31-45 4 5 
46+ 10 10 
 
IG=20 
CG=21 
HC30 = IG 
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 Letter to participants care coordinators 
 
 
 
Date (letter sent when pt recruited) 
 
Dear (named care coordinator), 
 
Re: Improving information for people with Bipolar Disorder REC: 12/LO/1615 
 
I am writing to inform you that (patient’s name and dob) is participating in the above study 
which is being conducted jointly by Sussex Partnership NHS Foundation Trust and researchers 
at UCL School of Pharmacy. 
 
The purpose of the study is to evaluate, through a randomised controlled trial, the impact of 
providing individually tailored information about bipolar and its treatment compared to 
treatment as usual. 
 
The study has been funded by an NHS National Institute for Health Research: Research for 
Patient Benefit programme grant (NIHR RfPB) and has received full NHS ethics approval (REC: 
12/LO/1615) and approval from Susses partnership NHS Foundation Trust Research and 
Development department (Ref CSP 87823). 
 
The study involves participants completing baseline questionnaire measures either in hospital 
or at home with a member of our team. Following this, they are allocated at random to receive 
either a written information resource alongside a tailored education session with a member of 
the research team or treatment as usual. Then after 6-8 weeks participants will complete 
follow-up questionnaires with a member of our team. 
 
For your information, we enclose a copy of the Participant Information Sheet. If you have any 
questions about the research please do not hesitate to contact either myself on 020 7874 
1297, Kelly Humphryes or Philippa Case (MHRN Clinical Studies Officers) 01273 265921. 
 
Yours sincerely 
 
 
 
Lindsay MacDonald 
Study Coordinator 
 
Enc:  Copy of the Participant Information Sheet 
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 Letter notifying TAU participants of their group 
allocation 
 
Date  
 
Dear  
Re: Improving information for people with Bipolar Disorder REC: 12/LO/1615 
You recently completed a questionnaire with a member of our research team at (insert 
hospital and ward) as part of the study named above. Thank-you for completing this 
first questionnaire. 
This letter is to let you know that you have been assigned to the usual care group for 
this study. This means that you will continue to receive the standard care and 
information from your care team. 
Half of all people in the study will receive usual care and the other half will receive new 
written tailored information. This type of study is called a randomised controlled trial 
(RCT) and is the best way of researching new approaches to treatment to find out 
which are the best ones. To find out we need to compare the different approaches. We 
put people into groups and use a different approach with each one. The results in the 
two groups are compared. To try to make sure the groups are the same to start with, 
patients are put into groups at random (by chance). 
You have been randomly allocated to the usual care group. Although you will not be 
receiving the new approach you will still be making an important contribution to our 
research project by taking part. 
Everyone in both groups will be asked to complete a second questionnaire about 2 
months after their first appointment with the researcher. This should take no longer 
than about 30 minutes and will take place in a location convenient for your, for 
example in your home or where your care team work. 
You will receive £20 to compensate for your time in taking part in the study. 
Your help with this study is very much appreciated. 
If you have any questions about this study, please contact me at 020 7874 1297 or by 
e-mail l.macdonald@ucl.ac.uk , or you can write to me at the address below. 
Yours sincerely, 
 
Lindsay MacDonald 
Study Coordinator 
 424 
 IBiD intervention tailoring 
Bipolar: A question of balance 
Intervention content tailoring 
Correct order  
Bipolar 
Bipolar beliefs 
Stigma 
Taking control 
Medications meanings 
Medication – necessity 
Medication – concerns 
Medication – practical 
Self-monitoring 
Working with health professionals 
 
Gets section 
Does not automatically receive section 
 
Page Tailoring Detail EA01 WL02 WM08 EB09 CO10 WM12 
Title page         
How we hope this 
booklet can help you 
        
Understanding bipolar (2 
pages) 
        
Mood mapping         
Is there a cause of 
bipolar? (2 pages) 
        
A long journey to 
diagnosis 
Making sense of the 
diagnosis: Does taking 
medication mean I have 
to accept I am ill? (2 
pages) 
        
Will I always have 
bipolar? 
Acute beliefs IPQB_2 3 (acute) 10 (chronic belief) 0 (acute) 10 (chronic 
belief) 
10 (chronic belief) 10 (chronic belief) 
‘There’s such a lot of 
stigma about giving 
yourself a label’ (2 pages) 
      No stigma beliefs  
Taking control         
Medications prescribed 
for bipolar 
        
 425 
Making an Informed 
choice about medications 
prescribed for bipolar 
        
Your thoughts and 
feelings about taking 
medication (3 pages) 
        
I don’t feel ill, so why 
should I continue to take 
my medication? 
Illness identity 
Necessity 
beliefs 
IPQ_9 
BMQ necessity 
items 
0 (does not agree 
with diagnosis) 
Average 2 
10 (full 
agreement with 
diagnosis) 
Average 4 
0 (does not agree 
with diagnosis) 
Low necessity beliefs 
10 (full 
agreement 
 
10 (full 
agreement with 
diagnosis) 
High necessity 
beliefs 
10 (full agreement 
with diagnosis) 
High necessity 
beliefs 
I don’t feel like the 
medication is working 
Necessity 
beliefs 
BMQ 
IPQ_4 treatment 
control 
Average 2 Average 4 Low necessity beliefs Strong  
treatment 
control 
High necessity 
beliefs 
IPQ_4 = 10 
treatment 
extremely 
helpful. 
High necessity 
beliefs 
IPQ_4 = 10 
treatment extremely 
helpful. 
Medication changes: Why 
does the medication I am 
given keep changing? 
        
I’ve been on the same 
medication for years, do I 
need to change? 
        
I’m worried about the 
side-effects from these 
medicines (3 pages) 
Side-effect 
concerns 
BMQ_C6 
BMQ_C11 
All disagree or SD 
 
All disagree or SD  All agree or SA Numerous 
moderate side-
effects 
 
But disagree for 
BMQ items 
Numerous 
moderate side-
effects 
Only agree for 
Diazepam 
(But reports multiple 
symptoms of 
moderate to severe)  
I sometimes worry about 
whether there might be 
long-term effects of 
taking these medicines. 
LT effects 
concern 
BMQ 
M1_BMQ_C2 
 
Strongly 
Disagree 
Disagree 
Disagree 
Disagree 
Disagree 
Agree 
Strongly 
Disagree 
 
Disagree Uncertain/ 
Agree 
Agree for 
Valproate 
SA/A for Lithium & 
Diazepam 
I sometimes worry that I 
might become addicted 
to or dependent on the 
medicines I’m taking. 
Dependence 
concern 
BMQ 
M1_BMQ_C5 
M1_BMQ_C8 
All disagree or SD All disagree or SD Uncertain Concerns about 
dependence 
Agree for 
Valproate 
Only agree for 
Diazepam 
 
I dislike the way these 
medicines make me feel 
Med effects 
concerns 
M1_BMQ_C10 
M1_BMQ_C11 
C10 & C11 All 
disagree or SD 
Uncertain 
Disagree 
Disagree 
 
C11 all disagree 
Agree and SA Uncertain C10 & C11 All 
disagree or SD 
Agree/ Uncertain for 
Diazepam 
 
Taking medication is an 
unwelcome reminder of 
my condition 
Reminder 
concerns 
BMQ 
M1_BMQ_C9 
All disagree or SD All disagree or SD  Uncertain Agree 2/3 All disagree or SD Only agree for 
Diazepam 
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I tend to hide the fact 
that I am taking these 
medicines from other 
people 
Hiding concerns BMQ 
M1_BMQ_C7 All disagree or 
SD 
All disagree or SD Disagree All disagree All disagree or SD All SD 
Taking these medicines 
affects my daily life 
Disruption 
Concerns 
BMQ 
M1_BMQ_C4 
All disagree or SD All disagree or SD Strongly agree All disagree Strongly agree for 
2/3 meds 
Only agree for 
Diazepam 
 
Alcohol, bipolar and your 
medication 
SIMS SIMS_12 None needed About right About right About right None needed About right 
‘Sometimes I find it 
difficult to take my 
medication’ (3 pages) 
BMQ – practical 
barriers 
   Practical barriers Sometimes 
forget to take 
one med 
(MARS) 
No practical 
barriers reported 
No practical barriers 
reported 
What should I do if I am 
having any problems and 
who should I contact in 
an emergency? 
        
Monitoring your 
symptoms and looking 
after yourself (2 pages) 
        
Getting the most from 
your consultations (2 
pages) 
        
Useful resources         
 
Page Tailoring Detail HC15 HC16 CO21 HM24 
Title page       
How we hope this booklet can 
help you 
      
Understanding bipolar (2 pages)       
Mood mapping       
Is there a cause of bipolar? (2 
pages) 
      
A long journey to diagnosis 
Making sense of the diagnosis: 
Does taking medication mean I 
have to accept I am ill? (2 
pages) 
      
Will I always have bipolar? Acute beliefs IPQB_2 Response 10 Response ‘6’ Response 8 but ‘very 
unsure about bipolar 
as was previously 
schizophrenia’. 
Response 10, but 
answering for 
situation as no 
understanding of 
bipolar. 
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‘There’s such a lot of stigma 
about giving yourself a label’ (2 
pages) 
  Stigma beliefs strong No stigma beliefs No stigma beliefs 1.86 
Taking control       
Medications prescribed for 
bipolar 
      
Making an Informed choice 
about medications prescribed 
for bipolar 
      
Your thoughts and feelings 
about taking medication (3 
pages) 
      
I don’t feel ill, so why should I 
continue to take my 
medication? 
Illness identity 
Necessity beliefs 
IPQ_9 
BMQ necessity items 
Necessity mixed Response ‘9’ 
High necessity beliefs  
Response ‘9’ 
High necessity beliefs 
Low necessity beliefs 
and no understanding 
of bipolar 
I don’t feel like the medication 
is working 
Necessity beliefs BMQ 
IPQ_4 treatment 
control 
Necessity mixed 
6 for IPQ control 
Good treatment 
control 
High necessity beliefs 
Good treatment 
control (9) 
High necessity beliefs 
Low necessity beliefs 
and low treatment 
control 
Medication changes: Why does 
the medication I am given keep 
changing? 
      
I’ve been on the same 
medication for years, do I need 
to change? 
      
I’m worried about the side-
effects from these medicines (3 
pages) 
Side-effect 
concerns 
BMQ_C6 
BMQ_C11 
BMQ few concerns 
but many in SAQ 
No side effect 
concerns 
Or SAQ reporrted 
BMQ few concerns 
but some severe in 
SAQ 
Agree for Olanzapine 
and many side effects 
in SAQ 
I sometimes worry about 
whether there might be long-
term effects of taking these 
medicines. 
LT effects concern BMQ 
M1_BMQ_C2 
 
Agree No LT effect concerns No LT effect concerns Agree 
I sometimes worry that I might 
become addicted to or 
dependent on the medicines 
I’m taking. 
Dependence 
concern 
BMQ 
M1_BMQ_C5 
M1_BMQ_C8 
Agree Disagree Disagree Agree for Zopiclone 
I dislike the way these 
medicines make me feel 
Med effects 
concerns 
M1_BMQ_C10 
M1_BMQ_C11 
Disagree Disagree Disagree Uncertain for 
Olanzapine 
Taking medication is an 
unwelcome reminder of my 
condition 
Reminder 
concerns 
BMQ 
M1_BMQ_C9 
Agree Disagree Disagree Agree for Olanzapine 
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I tend to hide the fact that I am 
taking these medicines from 
other people 
Hiding concerns BMQ 
M1_BMQ_C7 
Agree 
Disagree Disagree Agree for 
Olanzapine 
Taking these medicines affects 
my daily life 
Disruption 
Concerns 
BMQ 
M1_BMQ_C4 
Disagree Disagree Disagree Agree for Olanzapine 
Alcohol, bipolar and your 
medication 
SIMS SIMS_12 Too little None receieved About right None received 
‘Sometimes I find it difficult to 
take my medication’ (3 pages) 
BMQ – practical 
barriers 
 Sometimes difficulty 
in remembering 
Sometimes difficulty 
in remembering 
No practical barriers 
reported, MARS full 
compliance 
Some practical 
difficulties 
What should I do if I am having 
any problems and who should I 
contact in an emergency? 
      
Monitoring your symptoms and 
looking after yourself (2 pages) 
      
Getting the most from your 
consultations (2 pages) 
      
Useful resources       
Completing your own mood 
chart (4 pages) 
      
 
Page Tailoring Detail WM25 HC26 WR27 HC30  
Title page        
How we hope this booklet 
can help you 
       
Understanding bipolar (2 
pages) 
       
Mood mapping        
Is there a cause of bipolar? 
(2 pages) 
       
A long journey to diagnosis 
Making sense of the 
diagnosis: Does taking 
medication mean I have to 
accept I am ill? (2 pages) 
       
Will I always have bipolar? Acute beliefs IPQB_2 Response 10 Response 10 Response 10 Response 10  
‘There’s such a lot of stigma 
about giving yourself a 
label’ (2 pages) 
  2.03 2.39  2.89 2.10  
Taking control        
Medications prescribed for 
bipolar 
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Making an Informed choice 
about medications 
prescribed for bipolar 
       
Your thoughts and feelings 
about taking medication (3 
pages) 
       
I don’t feel ill, so why 
should I continue to take 
my medication? 
Illness identity 
Necessity 
beliefs 
IPQ_9 
BMQ necessity 
items 
Low necessity 
beliefs 
Good 
understanding 
Low necessity 
beliefs 
Low understanding 
of bipolar 
High necessity 
beliefs 
Full agreement 
with diagnosis 
Uncertain 
necessity for 
Olanzepine, 
Venlafaxin, 
Mirtazepine 
Agreement with 
diagnosis 
6 for 
understanding. 
 
I don’t feel like the 
medication is working 
Necessity 
beliefs 
BMQ 
IPQ_4 treatment 
control 
Low necessity 
beliefs and 5 
treatment control 
Low necessity 
beliefs, 8 for 
control 
High necessity 
beliefs 
10 for treatment 
control 
Uncertain 
necessity beliefs, 8 
for treatment 
control 
 
Medication changes: Why 
does the medication I am 
given keep changing? 
       
I’ve been on the same 
medication for years, do I 
need to change? 
       
I’m worried about the side-
effects from these 
medicines (3 pages) 
Side-effect 
concerns 
BMQ_C6 
BMQ_C11 
Agree 
Some severe side-
effects 
Side effects from 
Halperidol/ 
Mild moderate in 
SAQ 
Side effects from 
Lithium, 
Quetiapine, 
Clonazepam 
SAQ – many 
severe. 
SE for Olanzepine 
& mirtazepine. 
Some moderate SE 
on SAQ. 
 
I sometimes worry about 
whether there might be 
long-term effects of taking 
these medicines. 
LT effects 
concern 
BMQ 
M1_BMQ_C2 
 
Strongly agree Agree Valproate & 
Halperidol 
Agree for Lithium, 
Clonazepam 
 
Agree for 
Olanzepine, 
Venlafaxin, 
Mirtazepine 
 
I sometimes worry that I 
might become addicted to 
or dependent on the 
medicines I’m taking. 
Dependence 
concern 
BMQ 
M1_BMQ_C5 
M1_BMQ_C8 
Strongly agree Disagree for all Agree for 
Lorazepam, 
Zolpidem & 
Clonazepam 
Agree for 
Olanzepine, 
Venlafaxin, 
Mirtazepine 
 
I dislike the way these 
medicines make me feel 
Med effects 
concerns 
M1_BMQ_C10 
M1_BMQ_C11 
Strongly agree Agree Halperidol Agree Quetiapine, 
Lorazepam, 
Agree for 
Mirtazepine 
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Zolpidem, 
Clonazepam 
Taking medication is an 
unwelcome reminder of my 
condition 
Reminder 
concerns 
BMQ 
M1_BMQ_C9 
Disagree Agree Halperidol Disagree for all Disagree for all  
I tend to hide the fact that I 
am taking these medicines 
from other people 
Hiding concerns BMQ 
M1_BMQ_C7 
Agree Disagree for all Agree for 
Lorazepam only 
Disagree for all  
Taking these medicines 
affects my daily life 
Disruption 
Concerns 
BMQ 
M1_BMQ_C4 
Strongly agree Disagree for all Disagree for all Agree for 
Venlafaxin, 
Mirtazepine 
 
Alcohol, bipolar and your 
medication 
SIMS SIMS_12 About right Too little None needed About right  
‘Sometimes I find it difficult 
to take my medication’ (3 
pages) 
BMQ – practical 
barriers 
 No practical 
barriers reported, 
MARS full 
compliance 
Sometimes 
difficulty in 
remembering 
Sometimes forget 
Valproate 
Sometimes 
difficulty in 
remembering 
 
Sometimes 
difficulty in 
remembering 
Sometimes forget 
all meds 
 
What should I do if I am 
having any problems and 
who should I contact in an 
emergency? 
       
Monitoring your symptoms 
and looking after yourself 
(2 pages) 
       
Getting the most from your 
consultations (2 pages) 
       
Useful resources        
Completing your own mood 
chart (4 pages) 
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 Example of Patient Information Sheets for 
medications 
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 COREQ Checklist for Chapter 7 
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 Confirmation of ethical approval for IBiD 
qualitative evaluation 
 
 
 436 
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 IBiD qualitative evaluation Patient Information 
Sheet 
 
 
 
Improving Information for people with Bipolar Disorder (IBiD) 
Your views about the study 
Participant Information Sheet 
Invitation 
Thank-you for taking part in the study, we are very grateful for your time. 
We would like to invite you to take part in one final thing. We are interested to hear your views of what 
it was like to take part in the study. 
Before you decide whether or not to take part it is important for you to understand why we are asking 
this and what it will involve. Please take time to read this information carefully. A member of our team 
can go through the information with you and answer any questions you may have. 
 
What is the purpose of this part of the study? 
This part of the study will help us to identify how we can improve the design of future studies like this. 
We would like to make sure that people are able to take part without too much inconvenience and that 
being part of the study fits in with their lives. 
Because this is a new study, being carried out for the first time, it is important to know how people have 
found the experience and what they thought of any information they have been given. 
 
Why have I been chosen? 
You have been chosen because you have taken part in the main research study. We are inviting 
everyone who has taken part in the study to participate in this follow-up interview. 
 
Do I have to take part? 
It is up to you to decide whether or not to take part. If you do decide to take part you will be given this 
information sheet to keep and be asked to sign a consent form. If you decide to take part you are still 
free to change your mind at any time and without giving a reason. A decision not to take part, or a 
decision to withdraw at any time, will not affect the care that you receive. 
 
What will happen to me if I take part? 
If you are interested in taking part after reading this Information Sheet please contact us using the 
contact details at the end of this information sheet. 
If you decide to take part, we will arrange a convenient time to carry out the interview. The interview 
will take place over the telephone or in a location convenient for you, and you will be asked about your 
experience of taking part in the study. We will ask for your permission to audio-tape the interview so we 
have an accurate record. Only the research team will listen back to the recording. This should take no 
more than 30 minutes. 
Will my taking part in the interview be kept confidential? 
Yes. All the information you give during the interview will be confidential and only the research team 
will have access to your responses. All information you provide will be stored securely. The notes from 
your interview will not have your name on them, (a number will be used instead) so it will not be 
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possible for people to match any information to you personally. The study complies with data protection 
laws. 
 
What are the possible benefits of taking part? 
By taking part in the interview you will help us to find out about people’s experience of the study and 
you will help us learn if this approach is helpful. 
 
What are the possible disadvantages of taking part? 
It is unlikely that there are any risks or disadvantages of taking part.  
 
Who is organising and funding this study? 
This study is being led by Professor Rob Horne, Professor of Behavioural Medicine at UCL School of 
Pharmacy in collaboration with Sussex Partnership NHS Foundation Trust. The research is being funded 
by the Research for Patient Benefit Programme, National Institute for Health Research. The study is part 
of a PhD being undertaken by Miss Lindsay MacDonald. 
 
Who has reviewed the study? 
All research in the NHS is looked at by an independent group of people, called a Research Ethics 
Committee, to protect your interests. This study has been reviewed and approved by the London Queen 
Square Research Ethics Committee (Ref No: 12/LO/1615) as well as by the Research and Development 
Department within your local NHS trust. Contact details of the London Queen Square Research Ethics 
Committee: Health Research Authority, HRA Head Office, Skipton House, 80 London Road, London SE1 
6LH. Phone: 020 7972 2584 
 
What should I do now? 
If you are interested in taking part in the interview after reading this Information Sheet please contact 
me using the details below. 
 
Lindsay MacDonald (Researcher), UCL School of Pharmacy. 
Phone: 020 7874 1297 
Email: l.macdonald@ucl.ac.uk 
Address: Dept. of Practice and Policy, UCL School of Pharmacy 
Mezzanine Floor, BMA House, Tavistock Square 
London WC1H 9JP 
 
Thank-you for taking the time to read this information 
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 IBiD qualitative evaluation consent form 
 
 
Centre number: 
Participant Identification Number: 
 
Improving Information for people with Bipolar Disorder 
Your views about the study 
 
CONSENT FORM 
Name of Researcher leading the study: Professor Rob Horne 
Contact Researcher: Lindsay MacDonald 
 
Please 
initial box 
1. I confirm that I have read and understand the participant information 
sheet dated, 02/08/13 (Version 1) for the above study. I have had the 
opportunity to consider the information, ask questions and have had 
these answered satisfactorily. 
 
 
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical care 
or legal rights being affected. 
 
 
3. I agree to my interview being audio-taped for the purposes of the study 
and any personal information will be removed.  
4. I understand that in the event that I disclose information which may 
indicate new risk to myself or others, the researcher will be obliged to 
follow Trust risk procedures that may require release of my personal 
data. 
 
5. I agree to take part in the interview.  
 
............................................ ..................... .......................................... 
Name of participant Date Signature 
 
............................................ ................... .......................................... 
Name of researcher Date Signature 
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 Semi-structured interview schedule for IBiD 
participants 
 
Semi-structured interview schedule for IBiD participants 
The interview schedule will be adapted to be appropriate to each individual participant. 
Introduce self and remind purpose of interview. 
Reiterate confidentiality 
No right or wrong answers, interested in your personal experience with the study. 
  
1 What made you decide to participate? 
 
Probe - What kind of things did you consider? 
How did you find the explanation of what would be involved? 
What did you think of the timing of the study? (ie approached whilst in hospital) 
 
2 How did you find completing the first questionnaires while you were in the hospital? 
 
Probe – length of time, arranging appointment, type of questions, timing of baseline. 
 
3 How did you feel about being assigned to the group receiving usual care/ the new information? 
 
4 Intervention group 
How did you find the session? 
 
What did you think of the booklet? (What were the most/ least useful sections?) 
 
What did you think of the exercises in the booklet? 
Did you share any of the information with anyone in your care team? 
Was there anything missing? 
Would you recommend the information to other people with a diagnosis of bipolar? 
 
How did you feel about timing of the session? 
 
 Both groups... 
What information did you receive about bipolar and medication? 
From the ward? 
From other sources? 
When did you receive the information? How do you feel it answered your questions/ addressed 
any concerns you had about medication? 
 
If any medication changes – how were any changes to the dose or type of medication you were 
taking decided on? 
 
5 How did you find completing the last questionnaires after you were discharged from hospital? 
 
Probe – length of time, arranging appointment, type of questions, timing of follow-up. 
 
6 Overall, how did you feel about being involved in the study? 
 
7 What, if anything else, would help with your understanding or getting the best from your 
medication? 
8 Is there anything else we have not already covered you would like to tell us about? 
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  Advertisement for SDM study 
 
 
 
 
Your involvement in decisions about your treatment for Bipolar Disorder 
We are conducting a survey to find out more about how involved people with a 
diagnosis of bipolar disorder are in decisions about their care and how this relates to 
how they feel about the medications they are prescribed. 
By taking part, you can enter into a prize draw to win one of 3 £50 Amazon vouchers. 
 
Who can take part? 
If you are over 18 years of age, live in the UK, have a diagnosis of bipolar disorder and 
have been prescribed medication for this, you are eligible to take part. 
 
What will taking part involve? 
We will ask you to complete some online questionnaires. These will ask for; 
 your views and experience of making decisions about your care and treatment 
 how you feel about your medications for bipolar disorder. 
It should take no more than 15 minutes to complete the survey. 
The survey is completely confidential and has received ethical approval from UCL 
Research Ethics Committee (6811/001). All information you provide will be stored 
securely in agreement with the Data Protection Act. 
 
Please click on the link below to find out more and to take part in the survey. 
https://uclpharmacy.eu.qualtrics.com/SE/?SID=SV_3e0RONc5SWdPS6h 
 
Lindsay MacDonald (PhD Researcher), UCL School of Pharmacy. 
Email: l.macdonald@ucl.ac.uk 
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 SDM study PIS and questionnaire 
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